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Preface
The abuse of amphetamines is of national concern from a public health
perspective. Review of this subject is timely and important, because the
problem of amphetamine-like drugs has recently been amplified by the
introduction of designer drugs in the illicit market. There has been an
increasing number of attempts by chemists in clandestine laboratories to
synthesize structurally altered congeners that might intensify the mood-
altering property of this class of compounds. While attention over the last
few decades has been centered on research related to amphetamine,
methamphetamine, and clinically prescribed amphetamine derivatives
including fenfluramine, recent attention has focused on a variety of
amphetamine-related designer drugs. These designer drugs include ring-
substituted derivatives of amphetamine and methamphetamine such as
3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymetham-
phetamine (MDMA “ecstasy”), respectively. MDMA has been the focus of
a great deal of recent attention, since it represents one of a number of
“designer drugs” that is being increasingly abused among certain segments
of the population, especially among college students. This popularity is
ascribed to the drugs’ mixed central nervous system (CNS) stimulant and
hallucinogenic effects. Furthermore, MDMA has been the subject of recent
scientific and legal debate, as several psychiatrists have reported that
MDMA may “enhance emotions” and “feelings of empathy” and thus serve
as an adjunct in psychotherapy. While the psychotherapeutic usefulness of
this drug remains to be determined, a great deal of research has been
carried out on the abuse liability, behavioral effects, and neurotoxic effects
of the amphetamine-related designer drugs.
A technical review meeting entitled “Pharmacology and Toxicology of
Amphetamine and Related Designer Drugs” was held at the National
Institutes of Health on August 2-4, 1988. The purpose of the technical
review was to bring together scientists who have been carrying out research
in the area to (1) summarize the research findings, (2) understand the
neuronal mechanisms through which the amphetamines produce their effects,
and (3) develop a consensus regarding future directions that may lead to
better characterization of the effects of these drugs on various physiological
parameters. An understanding of the mechanisms is critical to the
development of therapeutic approaches for the treatment of intoxication,
addiction, and adverse effects. The proceedings of this meeting are
presented in the following chapters.
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Structure-Activity Relationships of
MDMA-Like Substances
David E. Nichols and Robert Oberlender
INTRODUCTION
There is virtually no one who is involved in drug abuse research, or who
studies the properties of recreationally used drugs, that is not by now fami-
liar with 3,4-methylenedioxymethamphetamine (MDMA) (figure 1). Over
the past 4 years this substance, usually referred to in the popular press as
“Ecstasy,” has received widespread media attention, This chapter will relate
recent fmdings with respect to the potential dangers attendant on the use of
MDMA and explore its pharmacological properties.
MDMA (1)
FIGURE 1. MDMA
As the title implies, MDMA has pharmacological properties that set it apart
from other classes of drugs. This is one of the most intriguing aspects of
MDMA, largely overlooked as researchers examined the potential risks to
health of MDMA use. Basic questions of how drugs work and why some
are pleasurable and some are not are fundamental to our understanding of
why humans use drugs. Although much of the popularity of MDMA can
no doubt be attributed to curiosity following media attention, the drug itself
must have some rewarding qualities.
MDMA typifies a central problem with the substituted amphetamine-type
substances: The fact that we know so little about any of these kinds of
drugs. What does MDMA actually do? What are the psychopharmacologi-
cal properties that make it attractive for recreational use? Is it “just another
hallucinogenic amphetamine,” as some have asserted? In the following
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discussion, an attempt will be made to address some of these issues, and to
put the questions into a broader perspective.
MDMA was patented in 1914 by a German pharmaceutical firm and evalu-
ated as an appetite suppressant (Shulgin 1986). In that sense, MDMA is
not a “designer drug.” Its rediscovery in the late 1970s probably had little
to do with the fact that it was, technically speaking, a legal drug. There
were a variety of legal psychoactive drugs, many of which could probably
have been synthesized and marketed with greater economic profit than
MDMA, a substance with unremarkable quantitative potency, being only two
to three times more active on a weight basis than mescaline (Shulgin and
Nichols 1978). Nonetheless, no other substituted amphetamines with the
popularity of MDMA have appeared. The explanation seems to be that
MDMA has psychopharmacological properties that are deemed especially
rewarding to the user.
MDMA is believed to have unique psychoactive properties that clearly
distinguish it from hallucinogenic or psychostimulant phenethylamines. Not
only have MDMA users consistently reported this distinctiveness, but
subsequent studies of MDMA and similar compounds, in many laboratories.
have shown that they do not fit within the structure-activity relationships
that presently are understood to define the hallucinogenic amphetamines.
STRUCTURAL FEATURES OF MDMA
One of the structural features of MDMA that is somewhat unusual is the
fact that it is 3,4-disubstituted. Both 3,4-methylenedioxyamphetamine
(MDA) (figure 2) and MDMA possess the 3,4-methylenedioxy function, and
there apparently are no other active compounds known that fall within the
MDA (2)
FIGURE 2. MDA
substituted amphetamine class and have substituents only in the 3 and 4
positions. The largest group of substituted amphetamines with significant
haIlucinogenic potency possess either 3,4,5- or 2,4,5- trisubstitution patterns.
The parent compound MDA, although classified as a hallucinogenic amphe-
tamine and available on the illicit market for about 20 years, had gained a
reputation as the “love drug” (Weil 1976). It had been recognized for many
years by both recreational drug users and clinicians (Turek et al. 1974) that
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MDA had unique psychoactive properties that were different from hallu-
cinogens such as LSD or mescaline. While MDA in high doses appears to
be hallucinogenic or psychotomimetic, it seems not to have been used for
this effect, but rather for its effects on mood: production of a sense of
decreased anxiety and enhanced self-awareness. Even early reports
described the desire of MDA users to be with and talk to other people
(Jackson and Reed 1970). MDA is also the only substituted amphetamine
that received serious clinical study as an adjunct to psychotherapy (Yensen
et al. 1976).
A second structural feature of MDMA that distinguishes it from hallucino-
genic amphetamines is the fact that it is a secondary amine. That is, the
basic nitrogen is substituted with an N-methyl, while hallucinogenic
amphetamines are most potent as primary amines. In either 3,4,5- or
2,4,5-substituted phenethylamine derivatives, N-methylation decreases
hallucinogenic potency by up to an order of magnitude (Shulgin 1978).
When MDA is ingested, the hallucinogenic effects are long lasting, typically
10 to 12 hours, similar to the duration of LSD or mescaline. By contrast,
MDMA has a much shorter action, with perhaps a 3- to 5-hour duration of
effects. There is no evidence that typical doses of MDMA lead to hallu-
cinogenic effects in a significant proportion of users, although in high doses
hallucinogenic effects have been reported (Siegel 1986). Thus, the simple
addition of the N-methyl group limits the temporal course of the action to
less than half that of MDA and attenuates or abolishes the hallucinogenic
effects that occur with MDA itself.
A third important difference between MDMA and the hallucinogenic
amphetamines is the reversal of stereochemistry that occurs in MDMA. In
every substituted hallucinogenic amphetamine that has been studied, the
isomer with the R absolute configuration in the side chain is more potent in
animal models, in a variety of in vim assays, and in man (figure 3). The
two isomers differ in potency by a factor of 3 to 10, depending on the
assay system (Nichols and Glennon 1984). By contrast, the S isomer of
MDMA is more potent (figure 4). This was first reported in experiments
with rabbits and in clinical studies (Anderson et al. 1978), and it has
recently been confirmed in other animal models (Oberlender and Nichols
1988; Schechter 1987).
It is difficult to trivialize the significance of this argument, since the
stereospecificity of biological receptors is accepted as a basic tenet of
pharmacology. There is no rationale or experimental precedent for believing
that the 3,4-methylenedioxy substitution should do anything that would
cause the receptor(s) involved to accommodate a side chain stereochemistry
reversed from that for phenylisopropylamines with other aromatic
subtituents.
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FIGURE 3. The more active R-(-)-enantiomer of the hallucinogenic
amphetamine DOM
S-(+)-MDMA
FIGURE 4. The more active S-(+)-enantiomer of MDMA
Several studies have now clearly shown that the R enantiomer of MDA has
the hallucinogenic effects of the racemate, while the S enantiomer possesses
more potent MDMA-like properties than the R in animals models (Anderson
et al. 1978; Shulgin 1978; Glennon and Young 1984a; Nichols et al. 1982;
Nichols et al. 1986; Oberlender and Nichols 1988). Further, although
(+)-MDA appears similar to amphetamine in the drug discrimination assay
in rats (Glennon and Young 1984a), it is not generally realized that the
effects of (+)-MDA in humans qualitatively resemble those of MDMA,
rather than those of amphetamine (Shulgin, personal communication, 1985).
This is a unique situation. Both enantiomers of MDA are active, having
nearly equal quantitative potencies, but differing in qualitative effect.
N-methylation of the racemic material dramatically and selectively attenuates
the hallucinogenic effects of the R enantiomer, while essentially leaving
intact the properties of the S enantiomer.
In earlier proposals (Anderson et al. 1978), based on this stereoselectivity
for the S enantiomer of MDMA, it was suggested that, rather than having a
direct effect at serotonin receptors, perhaps MDMA was a neurotransmitter-
releasing agent, acting in a fashion similar to amphetamine, for which the S
enantiomer is also more active than the R enantiomer. A subsequent study
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in our laboratory indicated that the S isomers of MDA and MDMA were
indeed potent releasers of [³H]serotonin from prelabeled rat brain
synaptosomes (Nichols et al. 1982). Recently, it was repotted that MDA
and MDMA were potent releasers of serotonin from superfused hippocampal
slices prelabeled with [³H]serotonin (Johnson et al. 1986). In all studies to
date, whether of release of monoamines from synaptosomes or brain slices,
or of the inhibiting of monoamine reuptake into synaptosomes (Steele
et al. 1987), the S enantiomer of MDMA is either equipotent to the R
isomer or more potent.
THE ENTACTOGENS
As a consequence of these and other studies that have indicated that
MDMA has a pharmacology different from the hallucinogenic amphet-
amines, and in view of the reports by certain psychiatrists (Greer and
Tolbert 1986; Wolfson 1986) that MDMA could facilitate the process of
psychotherapy, it was hypothesized that MDMA and related compounds
represent a new pharmacological class, with as yet unexplored potential as
psychiatric drugs (Nichols 1986; Nichols et al. 1986). This class of drugs
has been called entactogens. Recently, efforts have been directed toward
understanding the mechanism of action of MDMA and related compounds
and testing the hypothesis that entactogens are a novel pharmacological
class, distinct both from hallucinogenic agents and from central stimulants
such as amphetamine or cocaine.
Important support for this hypothesis came from the discovery that the
alpha-ethyl homolog of MDMA, MBDB (figure 5) possessed MDMA-like
S-(+)-MBDB (3)
FIGURE 5. The S-(+)-enantiomer of the alpha-ethyl homologue of MDMA,
MBDB
properties in man and in the drug-discrimination paradigm in rats (Nichols
et al. 1986; Oberlender and Nichols 1988). It was known that homologa-
tion of the alpha-methyl of the hallucinogenic amphetamines completely
abolished hallucinogenic activity (Standridge et al. 1976). For example, the
alpha-ethyl homolog of R-DOM, BL-3912A (figure 6) was evaluated by a
major pharmaceutical firm and found to lack hallucinogenic activity at doses
more than a hundredfold higher than those effective for DOM (Winter
1980). This additional feature of the entactogens, that the alpha-ethyl
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homologs retained activity, was a final and most powerful argument that
MDMA, and certainly MBDB, could not lit within the well-established
structure-activity relationships of the hallucinogenic amphetamines.
R-(-)-BL3912A (4)
FIGURE 6. The nonhallucinogenic alpha-ethyl homologue of DOM,
BL-3912A
STUDIES OF STRUCTURE-ACTIVITY RELATIONSHIPS
EEG Studies
Recently, Dr. W. Dimpfel has used quantitative radioelectroencephalography
in the rat to characterize the electroencephalograph (BEG) “fingerprint” of
hallucinogenic amphetamines, MDMA, and MBDB. In this technique, four
bipolar stainless steel electrodes are chronically implanted in each of four
brain regions in rats: the frontal cortex, the hippocampus, the striatum, and
the reticular formation (Dimpfel et al. 1986). The rats are freely moving;
transmission of field potentials is accomplished using a telemetric device.
The EEG is analyzed by Fourier analysis; power density spectra are
computed for periods of 4 seconds, segmented into six frequency bands, and
averaged on each channel over timeblocks of 15 minutes.
Using this method, a variety of hallucinogenic and nonhallucinogenic com-
pounds were examined. As previously reported (Spüler and Nichols 1988),
hallucinogens produce a marked increase of power in the a, frequency
(7.0 to 9.50 Hz) in the striatum. The ability to increase power in this
region of the EEG has been observed for other classes of serotoninergic
drugs, including the 5-HT1A agonists ipsapirone, gepirone, and buspirone,
and with serotonin-uptake inhibitors (Dimpfel et al. 1988). With 5-HT1A
agonists, however, an increase in power is recorded only from the frontal
cortex and hippocampus.
Doses of DOM, DOB, or DOI of 0.2, 0.1, and 0.1 mg/kg, respectively,
produced a pronounced and long-lasting increase in a, power recorded from
the striatum. By contrast, doses of (+)-MDMA and (+)-MBDB up to
1.6 mg/kg did not elicit this characteristic feature in the EEG. Thus, in this
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sensitive quantitative EEG procedure, neither MDMA nor MBDB elicited an
EEG fingerprint (four electrodes by six frequency bands per electrode) that
resembled that produced by the hallucinogenic amphetamines DOM, DOB,
DOI, or LSD. These data are consistent with the results obtained in other
models and further support the hypothesis that MDMA and MBDB are not
hallucinogenic phenethylamines.
Thus, for this class of psychoactive agent, preliminary structure-activity
relationships are being formulated. Currently, four structural features
contrast the structure-activity relationships of entactogens with those of
hallucinogenic amphetamines.
(1)
(2)
(3)
(4)
Ring substitution at only the 3,4- positions does not give active
hallucinogens, except for MDA. However, this substitution is active
for entactogenic agents.
N-methylation greatly attenuates hallucinogenic activity, but has no
significant effect on potency of entactogens. N-ethylation also seems
to allow compounds to retain entactogenic activity.
The more active stereochemistry of the entactogens is S, while that of
the hallucinogenic amphetamines is R.
Extension of the alpha-methyl to an alpha-ethyl abolishes
hallucinogenic activity, but has only a minor effect on entactogens.
Drug Discrimination Studies
At the present time these contrasts seem sufficient to distinguish between
the two drug classes. The stereochemical argument and the effects of
alpha-ethylation are extremely powerful. A significant problem with the
hypothesis remained: showing that entactogens differed from another struc-
turally related class, the central nervous system (CNS) stimulants. Several
studies have characterized MDMA as an amphetamine-like or cocaine-like
agent, based on its stimulus properties or its self-administration in primates
(Beardsley et al. 1986; Lamb and Griffiths 1987; Evans and Johanson 1986;
Kamien et al. 1986). It is well known that both amphetamine and cocaine
have powerful effects on dopamine pathways in the brain, and it seems
likely that drugs that release dopamine, or stimulate dopamine receptors,
have reinforcing properties that lead to self-administration and dependence
liability (Wise and Bozarth 1987).
It could not be anticipated that the extension of the alpha-methyl of MDMA
to an alpha-ethyl would also attenuate the effects of the compound on
dopaminergic pathways in the brain. In contrast to MDMA, MBDB has no
significant effect either on inhibition of uptake of dopamine into striatal
synaptosomes (Steele et al. 1987) or on release of dopamine from caudate
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slices (Johnson et al. 1986). In subsequent drug discrimination experiments
in rats, the dopaminergic properties of MDMA were evident, while MBDB
seemed to have a pharmacologically “cleaner” discriminative cue.
To characterize further the behavioral pharmacology of MDMA and MBDB,
extensive drug discrimination studies were carried out using rats trained to
discriminate saline from LSD, saline from (+)-amphetamine, saline from
(±)-MDMA, and saline from (+)-MBDB. Table 1 summarizes the results of
those experiments. As is the case with hallucinogens, the drug discrimina-
tion paradigm should not be considered, in strict terms, an animal model for
entactogen activity. Yet, data from these experiments can provide a good
initial behavioral evaluation of the qualitative and quantitative effects of a
variety of compounds of interest.
It is clear from these results that, in MDMA- or MBDB-trained rats, com-
plete generalization of the training cue to the typical hallucinogenic drugs
LSD, DOM, and mescaline does not occur. Furthermore, transfer of the
training stimulus does not occur to MDMA or MBDB in animals trained to
discriminate LSD from saline (Nichols et al. 1986). Although MDMA has
been shown to substitute for mescaline (Callahan and Appel 1987).
(+)-MBDB-trained rats did not recognize the mescaline cue as similar to the
training drug. These results are consistent with the conclusion that MDMA
and MBDB are not hallucinogenic, as discussed earlier.
These data clearly illustrate the enantioselectivity of the (+)-isomers of
MDA, MDMA, and MBDB in producing an MDMA-like stimulus and
underscore the fact that in vitro studies of the biochemical pharmacology of
these substances should reveal similar selectivity, once the primary
pharmacological process underlying the interoceptive cue is identified. The
data also indicate that (+)-MDA is the most potent of all the drugs tested in
MDMA- or in (+)-MBDB-trained animals. The fact that (+)-MDA does not
substitute in amphetamine-trained animals in our studies supports the
argument that the pharmacology of this enantiomer of MDA is MDMA-like
and is not like amphetamine.
Although amphetamine substitutes for MDMA in our studies, this occurs
only at doses that disrupt a significant number of animals. Furthermore, the
large ED50 for amphetamine substitution in MDMA-trained rats is certainly
not consistent with the known potency of amphetamine in measures of its
stimulant activity. That is, in man, or in animal assays of its activity as a
CNS stimulant, amphetamine is perhaps 10 times more potent than MDA or
MDMA. Thus, its large ED50 relative to that of the enantiomers of MDA
or MDMA seems to suggest strongly that the primary discriminative cue of
MDMA cannot simply be “amphetamine-like.” Although some investigators
have reported stimulus transfer with MDMA in animals trained to discrimi-
nate amphetamine from saline, in our paradigm no substitution occurred.
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TABLE 1. Results of drug discrimination transfer tests in LSD, (+)-am-
phetamine, (±)-MDMA, or (+)-MBDB-trained rats (ED50
expressed in micromoles per kilogram of body weight)
Substitution
Drug
LSD
LSD
0.025
AMP
Training Drug
MDMA
NS PS1
(+)-MBDB
PS2
DOM 0.61 NS NS NS
(+)-AMP NS 1.68 4.22 NS
(+)-MDA NS NS 1.63 1.43
(-)-MDA 2.94 NS 2.27 3.09
(+)-MDMA NS NS 1.92 1.67
(-)-MDMA NS NS 5.03 3.09
(+)-MBDB NS NS 3.67 3.28
(-)-MBDB NS NS 6.71 6.51
Cocaine NT 20.0 13.9 PS3
Mescaline 33
Fenfluramine PS4
NSb NT NS
NS NT 2.01
KEY: NS=no substitution occurred; PS=partial substitution; NT=not tested.
NOTE: Training doses: LSD tartrale 0.186 µmol/kg; (+)-amphetamine sulfate
5.43 µmol/kg; racemic MDMA.HCl 7.63 µmol/kg; and (+)-MBDB.HCI 7.19 µmol/kg.
178% at 0.372 µmol/kg; 257% at 0.186 µmol/kg; 363% at 29.42 µmol/kg; and 47l% at
4.68 µmol/kg.
SOURCES: Stolerman and D’Mello 1981; Schechler and Rosecrans 1973.
Differences in experimental design or in numbers of animals and doses
tested may account for this discrepancy. In our experiments, symmetrical
transfer did not occur between MDMA and amphetamine.
These results show that the MDMA cue is complex and may have some
similarity to amphetamine. However, suggestions that the pharmacology of
(+)-MDMA is essentially the same as that of amphetamine are clearly not
warranted by the data, This partial amphetamine-like action is believed to
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be reflective of the effect that MDMA has on dopaminergic pathways
(Johnson et al. 1986; Steele et al. 1987). Other workers have reached
similar conclusions (Gold and Koob 1988).
Similarly, self-administration of MDMA in monkeys trained to self-
administer amphetamine (Kamien et al. 1986) or in monkeys or baboons
trained to self-administer cocaine (Beardsley et al. 1986; Lamb and Griffiths
1987) probably reflects a dopaminergic component to the pharmacology of
MDMA. This would be consistent with current theories of dopamine
involvement in the mechanism of action of drugs with dependence liability
(Wise and Bozarth 1987).
In vitro studies have also shown that the alpha-ethyl congener MBDB lacks
significant effects on dopamine systems in the brain. The drug discrimina-
tion data support this idea, and amphetamine does not substitute in
(+)-MBDB-trained rats. Furthermore, while cocaine fully substitutes in
MDMA-trained rats. it produces partial substitution in (+)-MBDB-trained
rats. This is further evidence of the decreased effect of MBDB on
catecholaminergic systems. If the data have been interpreted correctly, this
might suggest that MBDB would not be self-administered in animal models
of dependence behavior, and, hence, might have low abuse potential. It has
been found, however, that (+)-MBDB produces serotonin neurotoxicity in
rats, although MBDB is somewhat less toxic than MDMA (Johnson and
Nichols, unpublished).
To summarize the data in table 1, neither MDMA nor MBDB has hallu-
cinogen-like discriminative stimulus properties. Symmetrical transfer of the
MDMA and MBDB stimulus indicates that their primary discriminative
stimulus effects are very similar. For both MDMA and MBDB, there is
enantioselectivity for the S isomer, with about a twofold eudismic ratio.
Finally, the substitution of (+)-amphetamine and cocaine in MDMA-trained
rats may indicate that MDMA has some psychostimulant-like properties,
while MBDB seems to lack this activity.
Effect of the Side Chain Alpha-Ethyl
It seemed likely that an alpha-ethyl moiety would attenuate the ability of
other phenethylamines to interact with dopaminergic systems. To test this
hypothesis, the alpha-ethyl homolog of methamphetamine was synthesized.
This compound (figure 7) was also tested in the drug discrimination
paradigm in (+)-amphetamine trained rats, and compared with (+)-metham-
phetamine. While (+)-methamphetamine was found to have an ED50 of 1.90
micromoles per kilogram (µmol/kg), the racemic alpha-ethyl homolog only
produced full substitution at high doses, and had an ED50 of 19.62 µmol/kg,
making it approximately one-tenth the potency of (+)-methamphetamine.
This confirmed our speculation, and illustrated that the alpha-ethyl group
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was effective in reducing the effect of phenethylamines on catecholamine
pathways.
FIGURE 7. The alpha-ethyl homologue of methamphetamine
Thus, for structure-activity studies of MDMA-like substances, emphasis has
been placed on the use of (+)-MBDB as the training drug, since it seems to
possess a primary psychopharmacology similar to that of MDMA, but lacks
the psychostimulant component of MDMA. That is, MBDB is pharmacolo-
gically less complex.
Table 2 is a summary of drug discrimination testing data for drugs that
completely substitute in rats trained to discriminate saline from
(+)-MBDB-HCl (1.75 mg/kg; 7.19 µmol/kg). These data are arranged in
order of decreasing relative potency.
It is clear that the (+)-isomers of MDA and MDMA are the most potent in
producing an MBDB-like cue. Furthermore, the stimulus produced by
(+)-MDA is probably unlike that produced by amphetamine, based on the
data presented in the earlier table. Thus, if the psychopharmacology of
(+)-MDA is like that of MDMA, then N-methylation has little effect on the
entactogenic properties of the molecule, but serves primarily to attenuate the
hallucinogenic activity of (-)-MDA. Nevertheless, (-)-MDA also substitutes,
and the psychopharmacology of racemic MDA might be viewed as com-
prised of the hallucinogenic and entactogenic properties of the (-)-isomer
and the entactogenic and psychostimulant properties of the (+)-isomer. This
illustrates why detailed studies of the mechanism of action of psychoactive
compounds should be done on the pure optical isomers.
But what is the effect of MBDB or MDMA? We have been attempting to
define this through the use of drug discrimination assays, with rats trained
to a variety of drugs. Through the use of appropriate agonists and antago-
nists, we may be able to define the pharmacology of MBDB. Although
there are some exceptions (e.g., fenfluramine), most of the substituted
phenethylamines described in the literature can be categorized as hallu-
cinogens or as stimulants. The psychopharmacology of MDMA perhaps
represents a third category, and it is possible that other phenethylamine and
amphetamine derivatives may possess similar pharmacology,
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TABLE 2. Compounds that completely substitute for (+)-MBDB in drug
discrimination tests in rats
Test Drug ED50(µmol/kg)
95% Confidence
Interval
S-(+)-MDA
S-(+)-MDMA
Fenfluramine
(±)-MDA
(±)-MBDB
R-(-)-MDMA
R-(-)-MDA
S-(+)-MBDB
(±)-MDMA
R-(-)-MBDB
1.43 0.9 - 2.29
1.67 0.98 - 2.86
2.01 1.30 - 3.09
2.09 1.36 - 3.21
2.92 2.17 - 3.92
3.09 1.80 - 5.32
3.09 1.88 - 5.07
3.28 2.15 - 5.01
3.35 2.35 - 4.77
6.51 4.54 - 9.34
In view of the apparent pleasurable effects of MDMA, it becomes of consi-
derable interest to understand the mechanism of action of substances with a
similar effect. Major efforts have been directed toward the study of agents
that have an effect on serotonin pathways, since that is the neurotransmitter
system that seems most implicated in the mechanism of action of MDMA.
This hypothesis is further reinforced by the observation that MDMA substi-
tutes for fenfluramine (Schechter 1986). and fenfluramine substitutes for
MBDB (Oberlender and Nichols, unpublished). The substitution data for
(+)-amphetamine and cocaine in (+)-MBDB-trained rats are also similar to
the data for substitution of these agents in fenfluramine-trained rats (White
and Appel 1981).
However, the specific serotonin uptake inhibitor fluoxetine failed to produce
an MBDB-like cue and failed to block the stimulus effects of MBDB when
it was given prior to a training dose of MBDB. Table 3 summarizes results
of fluoxetine testing in MBDB-trained rats. In other exploratory studies,
pretreatment of MDMA-trained rats with either methysergide or ketanserin
failed to block completely the MDMA-discriminative stimulus.
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Based on the modest ability of the (+)-isomers of MDMA and MBDB to
inhibit the reuptake of norepinephrine (NE) into hypothalamic synaptosomes
(Steele et al. 1987). it seemed possible that noradrenergic pathways might
be involved in the cue. In another series of drug discrimination experi-
ments designed to test this hypothesis, the specific NE uptake inhibitor
(-)-tomoxetine was tested for stimulus transfer in doses up to 10 mg/kg in
MDMA-trained rats. At 5 mg/kg, 67 percent of the animals responded on,
the drug lever. However, pretreatment with tomoxetine in six rats trained
to discriminate MDMA from saline had no effect on the discrimination of a
subsequent dose of MDMA.
TABLE 3. Results of tests for fluoxetine substitution in (+)-MBDB.HCl-
trained (1.75 mg/kg) rats
Dose of
Fluoxetine N
Percentage
Selecting
Drug Lever
7.23 µmol/kg 8 38%
14.46 µmol/kg 8 50%
29.92 µmol/kg 7 43%
At the present time, a variety of other pharmacological agents are being
tested for their ability either to antagonize or to potentiate the effect of
MDMA in these animals. There is hope that appropriate pharmacological
manipulations will eventually be found that will give useful information
about the mechanism of action for entactogens.
ANALYSIS OF STRUCTURE-ACTIVITY RELATIONSHIPS
Medicinal chemists have a distinct advantage in pursuing mechanism-of-
action studies because it is possible to synthesize a series of structurally
related congeners and measure their biological activity. A correlation
between activity and particular structural features not only helps to identify
the pharmacophore, or active moiety imbedded within the molecule, but also
may establish critical requirements or complementarity for the biological
target or receptor for the particular drug class.
When a particular behavioral pharmacology is associated with a specific
biochemical action within a series of congeners, it is likely that the
biochemistry is a functional component of the observed behavioral activity.
This is not necessarily the case if only one or a few molecules are available
for study; they may well possess ancillary biochemical pharmacology that is
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unrelated to the behavioral phenomenon being observed. However, the
larger the series of structurally diverse molecules in which the two activities
are associated, the stronger the basis for believing that a cause-effect
relationship exists.
In designing studies of the structure-activity relationships of MDMA and
related substances, there are at least three areas for structural modification.
First, the nature of the amine substituents can be varied: other N-alkyls can
be studied, or the nitrogen can be incorporated into a ring system. A
second point for structural modification is the side chain. As already
demonstrated, the alpha-methyl can be extended to an alpha-ethyl. Other
modifications of the side chain would include incorporation into a variety of
ring systems, or dialkylation. Finally, the nature and location of the
ring substituents can be modified.
N-Alkylation
A number of investigators have examined the N-ethyl congener of MDMA,
MDE (or MDEA), which has also gained popularity on the illicit market.
Braun et al. (1980) have reported that, of the N-substituted MDA deriva-
tives that were studied for analgesic action and human psychopharmacology,
only the N-methyl, N-ethyl, and N-hydroxy compounds were active. The
latter compound, the N-hydroxy, in all probability serves merely as a
prodrug for MDA, being metabolically reduced to the primary amine, as has
been observed for para-chloramphetamine (PCA) (Fuller et al. 1974). Since
the range of modification of N-substitution seems so limited, it appears
unlikely that studies of N-substituted MDA analogs will offer significant
insight into mechanism of action. However, different N-alkyl groups may
affect regional brain distribution and pharmacokinetic properties. For
example, Boja and Schechter (1987) have found that the N-ethyl analog
MDE has a much shorter biological half-life than does MDMA.
Ring Substituents
Little is presently known about requirements for particular aromatic ring
substituents enabling a compound to possess MDMA-like activity. The
3,4-ethylidenedioxy and 3,4-isopropylidenedioxy compounds (figures 8 and
9) have been examined for ability to substitute in LSD- or MDMA-trained
rats in the drug discrimination paradigm. Both compounds gave full
substitution in rats trained to either drug. Those results and comparison
data for MDA are given in table 4. Addition of steric bulk to the dioxole
ring reduces CNS activity, whether defined as LSD-like or MDMA-like.
Fenfluramine also produces a cue that is similar to both MDMA and
MBDB, in that complete substitution occurs and does so at a relatively low
dose of fenfluramine. This would seem to imply that the dioxole ring is
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FIGURE 8. The dioxole-ring methylated homologue of MDA, EDA
FIGURE 9. The dioxole-ring dimethylated homologue of MDA, IDA
not essential, and many workers have drawn comparisons between the
neurotoxicity of fenfluramine and that of MDMA. However, the psycho-
pharmacology of fenfluramine is quite different from that of MDMA.
TABLE 4. ED50 values for substitution in LSD-trained or MDMA-trained
rats, in the drug discrimination paradigm
Compound LSD ED50 (mg/kg) MDMA ED50 (mg/kg)
MDA (figure 2) 0.97 0.88
EDA (figure 8) 3.07 1.86
IDA (figure 9) 7.12 5.21
NOTE: LSD tartrate=0.08 mg/kg, IP; (±)-MDMA.HCl=1.75 mg/kg, IP.
While MDMA produces CNS stimulation and euphoria, fenfluramine is
more of a sedative and dysphoric. A detailed comparison of the
pharmacology of fenfluramine and MDMA may be necessary to understand
exactly how MDMA works.
Another study underway has begun to examine the effect of paramethoxy-
amphetamine (PMA) in MDMA-trained rats. After testing a few doses, it
appears that full substitution may occur and that the S enantiomcr of PMA
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is more potent. This result would also be consistent with a mechanism of
action for MDMA where serotonin release is important, since PMA is a
potent releasing agent of serotonin both in vitro (Tseng et al. 1978) and
in vivo (Tseng et al. 1976; Nichols et al. 1982). PMA is also a potent
releaser of NE in peripheral tissues (Cheng et al. 1974) but the blockade of
its behavioral effects by chlorimipramine (Tseng et al. 1978) suggests that
serotonin release may be important in the mechanism of action. PMA did
make a brief appearance on the illicit market in the early 1970s but was
responsible for several deaths (Cimbura 1974), and its use subsequently
declined.
One might also speculate that PCA would have an effect similar to MDMA.
Indeed, the early clinical data for PCA suggested that it possessed
antidepressant activity (Verster and Van Praag 1970). This would suggest
that the human psychopharmacology of PCA may well be closer to that of
MDMA than fenfluramine, but it is unlikely that clinical studies can be
carried out to study this.
Side-Chain Modifications
A variety of side-chain modified analogs of MDMA and MBDB have begun
to be examined. Very early studies were of the dimethyl analog,
3,4-methylenedioxyphentermine (figure 8a) and its N-methyl derivative
(figure 10). This latter compound proved to lack MDMA-like activity
(Shulgin, unpublished). Interestingly, this compound also lacked the ability
to stimulate the release of [3H]serotonin from prelabeled rat brain
synaptosomes (Nichols et al. 1982).
Recently the tetralin and indan analogs of MDA have been examined
(figures 11 to 14). It was previously shown that when hallucinogenic
amphetamine derivatives were incorporated into similar structures, the
hallucinogen-like activity in animal models was lost (Nichols et al. 1974).
Thus. one might anticipate that a similar strategy with MDMA would lead
to congeners that would lack MDA-like hallucinogenic effects. Furthermore,
by examination of the two methylenedioxy positional isomers, one could
infer the binding conformation of MDMA itself at the target site. As
shown in table 5, one positional isomer is clearly preferred for MDMA-like
activity. Furthermore, the indan derivative, figure 12, has a potency at least
comparable to that of MDMA. This series has begun to define some of the
conformational preferences of the receptor or target sites with which
MDMA interacts, at least in producing its discriminative cue.
NON NEUROTOXIC ENTACTOGENS?
Although the problem of MDMA abuse has generated great interest because
of MDMA’s potential neurotoxicity, it is possible that nonneurotoxic
entactogens can be developed. As in most areas of technology, this is a
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R = H
R=CH3
FIGURE 10. The -dimethyl homologues of MDA(a) and MDMA(b)
FIGURE 11. Nonneurotoxic tetralin analogue of MDMA
FIGURE 12. Nonneurotoxic indan analogue of MDMA
two-edged sword. A major concern might be that a nonneurotoxic entacto-
gen could become popular as a recreational drug. A major deterrent to
widespread use of MDMA should be the consideration by potential MDMA
users that there is the possibility of neurotoxicity with unknown
consequences, perhaps delayed for years before the consequences become
manifest. On the other hand, researchers must give serious attention to the
fact that any possible clinical utility for MDMA-like substances cannot be
explored until the issue of neurotoxicity is resolved. Hence, a nonneuro-
toxic MDMA congener would allow clinical testing of the assertion that
these compounds are useful adjuncts to psychotherapy.
Undoubtedly, nonneurotoxic entactogens can and will be discovered. Suffi-
cient evidence already exists to support this hypothesis. We know, for
example, from the work of Schechter (1986) that the discriminative stimulus
properties of MDMA are largely dissipated within 4 hours of drug
administration. On the other hand, Schmidt (1987) has shown that MDMA
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FIGURE 13. Tetralin analogue of MDMA that lacks MDMA-like effects
FIGURE 14. Indan analogue of MDMA that lacks MDMA-like effects
TABLE 5. Drug discrimination results: Substitution tests in
Compound
Figure 11
Figure 12
Figure 13
MDMA-trained rats
Result in MDMA-Trained Rats
CS ED50=1.29 mg/kg
CS ED50=0.59 mg/kg
PS (75% drug responding @ 1.75 mg/kg)
Figure 14 PS (67% drug responding @ 0.5 mg/kg)
KEY: (±)-MDMA.HCl, 1.75 mg/kg IP, CS=complete substitution; PS=partial substitution.
has a biphasic depleting effect on cortical serotonin, with the later phase
(more than 6 hours) associated with the long-term toxicity, a toxicity
blocked by fluoxetine. Schmidt and Taylor (1987) administered the
serotonin uptake inhibitor fluoxetine to rats 3 hours after treatment with
MDMA and were able to prevent neurotoxicity. These workers suggested
that the unique neurochemical effects of MDMA are independent of the
long-term neurotox-icity. In our own studies, cited above, we have shown
that fluoxetine does not antagonize the MDMA cue. Battaglia et al. (1988)
reported that acute MDMA treatment decreased brain serotonin and 5-HIAA
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levels, but that multiple MDMA treatments were required to decrease the
number of 5-HT uptake sites, the latter presumably a reflection of neuron
terminal degenera-tion. These studies indicate that the acute pharmacology
can be dissociated from the long-term neurotoxic effects of MDMA.
Further, it is also known from work with the neurotoxin PCA that some
structural congeners have an acute depleting effect on brain 5-HT, but lack
the long-term neurotoxicity that is characteristic of PCA (Fuller et al. 1977).
Since the psychopharmacological effects of MDMA have a relatively rapid
onset and, in rodents, are largely dissipated at a time when a serotonin
uptake inhibitor can still block neurotoxicity, it seems quite clear that
molecules can be developed that will probably possess human psychophar-
macology similar to MDMA, but will lack serotonin neurotoxicity. When
this is accomplished we can look forward to a clearer definition of the
primary pharmacology of entactogens. One would hope that, at that time,
clinical studies with such a compound would be possible, to determine
finally whether entactogens represent a new technology for psychiatry.
DISCUSSION
QUESTION: What are the criteria that you used for these newer com-
pounds in order to classify these newer drugs as either sympathomimetic or
hallucinogenic?
ANSWER: We are basically forced to deal with a variety of models. First
of all, we have LSD-trained rats, and we have used that as our general
screen for hallucinogen-like activity. If you are familiar with the drug
discrimination literature, you can get false-positives, and perhaps
Professor Glennon will correct me if I am wrong, but I am not aware of
false-negatives. There are no cases where, in the drug discrimination
paradigm, an animal has said this drug is not hallucinogenic when, in fact,
in humans it is known that it is. So my feeling with drug discrimination is
that we are detecting false-positives.
We are using I-125-labeled DOI as a radioligand and that has been shown,
particularly by Professor Glennon and his coworkers, to be a good model
for hallucinogenic activity. I think 5-HT2 agonists, in terms of biochemical
pharmacology, are the clearest indication that a compound is hallucinogenic.
We are routinely screening compounds for ability to displace I-125 DOI
from frontal cortex homogenates. As far as the CNS stimulant effects,
differentiating from psychostimulants, the present model we are using is
substitution in amphetamine-trained rats, in drug discrimination. We have
used synaptosomes and looked at their effect on dopamine release and
reuptake. But basically they are correlative models.
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And it is certainly true that these compounds could well be hallucinogenic
but fall outside what we understand the structure-activity relationships of
these compounds to be. For example, it may well be that MBDB in
humans at some dose is hallucinogenic and is acting by some mechanism
that is totally different from what we understand to be the mechanism of
mescaline, DOM, or LSD. But at the present time, based on what we
understand about structure-activity relationships, it should not be. That
remains to be seen.
COMMENT: It might be advisable to stick to more operational definitions
in talking about these compounds. One runs a risk if compounds have not
been tested in people, and to refer to a compound as hallucinogenic when it
is operative. A drug discrimination test might lead you to certain
assumptions about the drug that are not true.
RESPONSE: Generally, it is safest to say there is LSD-like activity in
drug discrimination profiles. Similarly, with these so-called entactogens, the
name we have given them, we do know that we find in the tetralins and
indans, for example, that a particular amino-indan we tested has fairly high
potency in substituting for MDMA or MBDB. But we do not know what
its effects would be in humans. There is no way to test that. Basically we
are trying to develop correlative models based on what we know from the
clinical data. But, again, it is speculative in the absence of clinical studies.
COMMENT: I would not rule out the possibility that MDMA or MDA
produces effects at serotonin-2 receptors. Some of the data that I believe
Dr. Battaglia has accumulated shows that of the 20 brain recognition sites
that we have looked at, using standard radioligand binding procedures,
MDMA has the highest affinity at serotonin-2 receptors as labeled by
tritiated DOB. But I must qualify that. If you compare MDMA to
something like DOI, it is about a hundredfold weaker. But its affinity is
still 100 nanomolar in terms of an IC50, concentration, which is still
relatively potent considering the concentrations that may be achieved in
brain at some of the doses used in animals.
RESPONSE: I have tended to think that things do not have affinity unless
we see low nanomolar affinity. I think the EEG studies are fairly revealing
in that regard. The fact that we see this increase in alpha-l power in the
striatum is a characteristic of 5-HT2 agonists. And we are clearly seeing
EEG effects at doses that are not increasing that power in the alpha-l
frequency. I tend to think that 5-HT2 agonist effects are not that important
in the action of these compounds.
COMMENT/QUESTION: I was very intrigued by your substitution data
from the drug discrimination paradigm. But my question is not unlike
Lou Seiden’s. For with substances that are characterized by tremendously
qualitatively different effects, biphasic in nature, and in many functional
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assessments, I feel it may be premature to zero in on one selected training
dose and give that a label.
I would like to know whether or not you have explored minimal discrimi-
national doses of MDMA or MBDB and whether you have contrasted them
with higher doses and have done experiments that are reminiscent of the
Appel and White type approach where different mechanisms kick in at
different dose ranges of the drug. Do we cover the relevant qualitatively
different effects with that technique and with that approach, where one is
zeroing in on one amphetamine dose and one MDMA dose?
I also have another question. When you compare release data from a slice
preparation where it is in one application with discrimination data, are you
comparing a creature that has received hundreds of injections every other
day, on the average? I do not know what your protocol looks like, but I
presume every other day is a drug and every other day is a control
condition. Here you have an acute preparation and the relationship, of
course, is quite tenuous.
ANSWER: Yes. We have looked at the lower doses of MDMA; the
1.75 mg/kg is the dose that gave us the best discriminability. We tried
initially to train with 1 mg/kg but could not. We continued to increase the
training dose by increments until we found the dose where we got reliable
discrimination. It was 1.75 mg/kg. At least in our paradigm, I do not see
how we could go much lower.
We have not explored all of the dose-response relationships. And with
respect to the nature of the cue, we have studies underway now with a
variety of serotonin agonists and antagonists, for example, fluoxetine. And
have looked at MDMA. We cannot block the cue with fluoxetine. We are
also looking at 8-hydroxy-DPAT, buspirone. PCPA pretreatment is on the
way. So there are a variety of manipulations that we have in process.
The treatments are all randomized, so a lot of them are only half finished,
and no one can say what is happening. But in terms of pinning it down, I
think that needs to be done.
We are looking at biochemical models as really pointing us in a particular
direction. They are not rigorous; I recognize that. If we focused all our
attention on drug discrimination we could do some complete studies. My
emphasis in medicinal chemistry is to explore structure-activity relationships
and synthesize tools to explore how the drugs work So we basically, more
than focusing on pharmacological rigor, have tried to find quick screens that
would point us in a direction so we could synthesize a drug to test this
hypothesis.
Ultimately, these compounds will require a good deal of pharmacological
evaluation, and we are in the early stages of that. In accordance with
21
Dr. Gibb’s hypothesis regarding dopamine involvement, we thought that
perhaps MBDB would not be neurotoxic because of a lack of effect on
dopamine. But, in fact, it is neurotoxic as well, measured by whole-brain
serotonin 5-HIAA and tritiated paroxetine binding sites. It is perhaps
two-thirds the toxicity, on a molecular weight basis, of MDMA, but it is
toxic.
A number of the studies that we have done are not completely rigorous, but
their purpose is to see whether neurotoxicity is related to the nature of the
cue. Your questions are well taken, but it has really been a choice between
economy and rigor so that we could find the chemical structure to
synthesize.
COMMENT/QUESTION: You have answered the first question, which was
on the issue of whether or not MBDB produced long-term effects on the
amine system. The second question has to do with the nature of the cue.
We have talked with people who participated in our study over the last
year. As you know, many of them have experimented with a wide variety
of psychoactive drugs, including MBDB. When asked about MBDB their
response seems to be lukewarm in terms of how it compares to subjective
effects, and whether these effects are comparable to those of MDMA. Is
that accurate?
ANSWER: When we decided to make MBDB we felt the alpha-ethyl
would attenuate hallucinogenic activity. Dr. Shulgin made that compound
because he was looking at things that had a stimulant effect. He had made
it but had not evaluated it at effective doses. After a discussion, he
evaluated it in the group of people that worked with him.
Basically, the consensus was that the psychopharmacology was similar but
that the compound lacked the ability to produce the kind of euphoria
produced by MDMA. And he reported that there were at least one or two
individuals who felt they never wanted to take the compound again.
My own bias is toward the therapeutic potential. I do not care whether
anything we develop produces euphoria or dependence potential. I think
from the point of view of a drug abuse problem or a dependence liability
that the alpha-ethyl probably does not have the reinforcing qualities and is
not as pleasurable as MDMA.
COMMENT: My question to these people would be directed toward this
quality they regard as unique for MDMA--this rush. They admit that that
is not the main reason for taking it. They do seem to be able to make that
distinction. They do not dispute the fact that they enjoy the rush from an
MDMA dose. Whatever this other quality is, they recognize it. And it is
that quality that was less apparent in MBDB than in MDMA.
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RESPONSE: I think this is an area where you would have to do detailed
double-blind crossover studies and some fairly extensive testing to map out
what the nature of that effect is.
In the drug discrimination assay we get symmetrical transfer. They seem to
be the same. And the consensus, at least from Dr. Shulgin’s group, is that
it generally has the same kind of effect. Obviously it has not become a
problem on the street. And I think if it was a very desirable compound we
might well have heard something about it.
QUESTION: Have you done any studies of the metabolism of these
compounds? As you probably know, there have been reports that MDMA
is very quickly metabolized into MDA. Have you looked at MBDB to see
if the ethyl group gets cleaved so that you essentially have an MDMA
compound after you are through?
ANSWER: There is no chemical precedent for that kind of transformation.
I really cannot think of an enzyme system that would cleave that down to
the alpha-methyl. I think the effect is due to the alpha-ethyl.
In terms of other sites of metabolism, we are looking at the metabolism in
the dioxole ring and in dealkylation. We have seen some interesting things,
but I could not comment on this right now. With respect to the alpha-
ethyl, I think that the parent compound is probably the one that is active.
QUESTION: I have two questions about your MBDB discrimination
studies. It sounds as though you are doing experiments to investigate
whether neuronal stores of serotonin are required for MBDB to be recog-
nized. You mentioned that fluoxetine did not prevent the recognition.
Does it prevent the release of serotonin in vitro? In other words. is that a
carrier-dependent release by MBDB as it is, for example, in the case of
p-toluylamphetamine?
My second question is this: You mentioned fenfluramine. I presume you
used the racemic mixture. which would mean that in the brain you would
have both R and S fenfluramine and R and S norfenfluramine present. And
since these differ widely in their effects on dopamine versus serotonin
neuronal systems, have you studied individual enantiomers of either
fenfluramine or norfenfluramine?
ANSWER: Actually we used synthesized (+)-fenfluramine. The fluoxetine
story is not clear. It does not block the discriminative cue, but other
workers have shown that it blocks the neurotoxicity. We have not looked
at it in enough detail or at any of the in vitro models to see whether it
blocks or releases serotonin.
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COMMENT: It seems as though that might be a good tool to determine
whether the discrimination really does relate to serotonin release because,
clearly, it has been shown to block the serotonin release in vivo. If it does
not block the drug discrimination it seems that it is not consistent with the
idea that that is a consequence of serotonin release.
RESPONSE: When you are in this business, you get letters from many
strange people. I received an unsolicited letter from a fellow in Geneva,
Switzerland, about a year ago, who told me that he had taken fluvoxamine,
which I believe is available clinically in Geneva, and had subsequently
taken MDMA. He said that the fluvoxamine had no effect on the action of
the MDMA. I think this is an interesting question which, at least in one
anecdotal account, suggests that there is a difference.
The biochemical followup would be interesting if it does prevent the
release. And maybe the serotonin is a red herring. But that is the only
thing we have seen consistently at this point
COMMENT [DR. SCHUSTER]: I am extremely pleased to see the sophis-
tication of the animal studies and the medicinal chemistry studies. I lament
the current lack of sophistication with regard to the available data in
humans. It is feasible, as my colleagues and others have shown, to train
drug discrimination in humans-to do as precise quantitative work there as
is done in animals. In fact, probably more precise.
As far as subjective effects are concerned, and people’s responses regarding
why they take drugs, I have to say that I have a fair degree of skepticism
that people are reporting in any way what is relevant. It may be, it may
not be. But I can assure you that the contingencies that shape verbal
behavior may be very different from the contingencies that shape the
drug-taking behavior. And as a consequence there may not be any
necessary correlation.
It is unfortunate, and this is a real deficit in this field, that we cannot do
the very human studies that I know you would all like to do and, therefore,
we rely upon whatever evidence we have to reach conclusions. But we
have to be wary of the fact that the human data are weak in comparison.
QUESTION: Have you made any attempt to antagonize the MBDB stimu-
lus with serotonin antagonists?
ANSWER: We have tried ketanserin, but it did not antagonize the
stimulus. I do not believe we have tested fluoxetine in the MBDB-trained
animals. It has only been tested in the MDMA-trained animals. We have
not found an antagonist to the cue yet.
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QUESTION: Did you measure tryptophan hydroxylase or just the
5-HT/5-HIAA depletion?
ANSWER: We used it in the 20 mg/kg twice a day for a 4-day regimen
with MDMA, and then corrected for molecular weight and used an
equimolar dose of MBDB, sacrificed the animals 2 weeks later, and then
measured. We used basically HPLC and used serotonin and 5-HIAA from
one hemisphere and then measured tritiated pyroxetine from the other
hemisphere. And we got something like 60 percent depletion of serotonin,
and the pyroxetine binding site Bmax, decreased by about 60 percent. With
MBDB it was decreased by about 40 percent. It was a clear and significant
decrease, but not quite to the extent that we had. But we have not looked
at tryptophan hydroxylase.
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Self-Injection in Baboons of
Amphetamines and Related
Designer Drugs
C.A. Sannerud, J.V. Brady, and R.R. Griffiths
INTRODUCTION
Recent controversy about the recreational abuse and potential therapeutic use
of “designer drugs” has focused attention on MDA (methylenedioxyampheta-
mine HCl) and structurally related phenylisopropylamine compounds,
including MDMA (d,l-3,4-methylenedioxymethamphetamine HCl, “ecstasy”).
These compounds are structural analogs of the psychomotor stimulant
amphetamine and the hallucinogen mescaline, and produce stimulant and/or
hallucinogenic effects (Shulgin 1978).
In humans, MDA and MDMA have been reported to produce positive mood
changes, enhanced emotional awareness, and improved interpersonal
communication (Greer and Tolbert 1986; Downing 1986; Shulgin 1986;
Peroutka et al. 1988). Because of these psychotropic effects, MDA and
MDMA have been used in psychotherapeutic situations (Naranjo et al. 1967;
Yensen et al. 1976; Grinspoon and Bakalar 1986). In addition, presumably
because of the same positive subjective effects, recreational use of MDMA
on college campuses has increased in recent years (Peroutka et al. 1988).
Recreational abuse of “designer drugs” poses a major problem. Evidence
concerning the safety of these drugs has shown that MDA and MDMA are
toxic to serotonergic neurons in rodent (Ricaurte et al. 1985; Stone et al.
1987; O’Heam et al. 1988) and primate brains (Ricaurte et al. 1988).
MDMA has also been associated with toxicity in humans. To date, there
have been five cases reported in which MDMA has contributed to death in
recreational users (Dowling et al. 1986).
Based in part on the neurotoxicity and recreational abuse, the Drug
Enforcement Administration (DEA) has placed MDA, MDMA, and other
“designer drug” analogs of stimulant/hallucinogens on Schedule I, used for
drugs with high abuse potential and no recognized therapeutic usefulness.
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Although MDA and MDMA were recently brought under legal regulation by
scheduling under the Controlled Substances Act, other derivatives of these
compounds can be synthesized easily, and these new “designer drugs” have
begun to be used recreationally. Evaluation of these substituted phenyl-
ethylamine compounds for abuse liability should require an assessment of
the reinforcing effects of the drugs and a comparison to structurally similar
compounds, to determine relative potency and structure-activity relationships
(SARs). This chapter will summarize previously published drug self-
administration research with a variety of substituted amphetamine com-
pounds, comparing the self-administration of stimulant/hallucinogenic analogs
of MDA to standard anorectic phenylethylamine compounds in baboons.
METHOD FOR ASSESSING REINFORCING EFFECTS OF DRUGS
The use of nonhuman primates to assess abuse liability of test compounds
is indicated, since there is a good correlation between the drugs that are
abused by man and those that maintain self-injection behavior in animals
(Schuster and Thompson 1969; Griffiths et al. 1980). Of the many different
types of procedures developed to determine whether a drug will maintain
self-injection, the substitution is the most common and reliable. The
procedure involves establishing self-injection using a dose of a standard
drug that is known to maintain reliable self-injection behavior. After this
behavioral baseline is stable, a dose of test drug is substituted for the
standard compound to determine whether the test drug will maintain
self-injection.
PROCEDURE
The methods and procedures used to evaluate self-injection of these
compounds were similar to those previously described by Griffiths and
colleagues (Griffiths et al. 1976; Griffiths et al. 1979). Eighteen male
baboons (Papio cynocephalus) weighing between 15 and 30 kg were used as
subjects. Each animal was adapted to either a standard restraint chair
(Findley et al. 1971) or a harness tether restrainmg system (Lukas et al.
1982). The chaired animals were housed individually in sound-attenuated
chambers. The tethered animals were housed in standard stainless steel
primate cages surrounded by a sound-attenuating, double-walled plywood
external enclosure.
An aluminum “intelligence panel” used in self-injection studies has been
previously described (Griffiths et al. 1975). Briefly, the panel containing
levers and associated stimulus lights (approximately 1 cm in diameter) was
mounted on the inside of the chamber (chaired animals) or on the rear wall
of the cage (tethered animals). A Lindsley lever (lower left of panel), a
leaf lever (lower right of panel), and a food hopper with stimulus light
(lower left of panel) were mounted on the panel. A 5x5 cm translucent
Plexiglas panel that could be transilluminated was mounted on the aluminum
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panel in the upper left comer. A speaker for delivery of white noise and
tones was mounted behind the panel. A feeder for delivering food pellets
into the food pellet tray was mounted on the top of the wooden enclosure.
Baboons were surgically prepared with chronically indwelling silastic
catheters implanted in either femoral or jugular veins under pentobarbital or
halothane anesthesia using methods described in detail by Lukas et al.
(1982). All baboons had served in studies of intravenous self-injection with
a variety of drugs. They had continuous access to water via a drinking
tube and to food pellets (as described below) and received two pieces of
fresh fruit and a multivitamin daily.
The infusion system was similar to that described by Findley et al. (1972).
The catheter was attached to a valve system that allowed slow continuous
administration (55 to 60 mL in 24 hours) heparinized saline (5 units/mL)
via a peristaltic pump to maintain catheter patency. Drug was injected into
the valve system by means of a second pump and then flushed into the
animal with 5 mL of saline from a third pump. This system necessitated a
delay of approximately 20 seconds between the onset of drug delivery and
actual injection into the vein. Drugs were delivered within a 2-minute
period.
Food was available 24 hours per day under a fixed ratio 30 (FR 30)
response schedule on the leaf lever; i.e. every thirtieth response delivered a
1 g banana-flavored food pellet and produced a brief flash of the hopper
light.
Animals were trained to self-inject cocaine (0.4 or 0.32 mg/kg/injection)
under an FR 160 response schedule on the Lindsley lever. Drug injections
were available every 3 hours and were signaled by a 5-second tone,
followed by the illumination of the jewel light over the Lindsley lever.
When the jewel light was illuminated, each response on the Lindsley lever
produced a brief feedback tone. Upon completion of the FR requirement,
the jewel light was extinguished and the 5 mL drug injection was begun,
followed by a 5 mL flush injection. Following the completion of the
injections, the 5x5 cm translucent panel was illuminated for a 1-hour period,
and the 3-hour timeout period was begun. There was no time limit for the
completion of the response requirement.
When criterion cocaine self-injection performance (six or more injections
per day for 3 consecutive days) was obtained a dose of drug or vehicle
was substituted for cocaine for 12 to 15 days. Occasional equipment
malfunction necessitated extending the period of substitution beyond
15 days. Cocaine self-injection performance was reestablished, and when
criterion performance was obtained (typically in 3 to 5 days), another dose
of drug was substituted This procedure of replacing cocaine with drug was
continued through the study of a range of drug doses and their vehicles.
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The order of exposure to different doses was either a mixed or an
ascending sequence. The drug vehicle was generally examined immediately
before or after the series of doses.
Drugs and Doses Tested. Drug solutions were prepared by dissolving the
drug in physiological saline (0.9 percent sodium chloride) and were filter
sterilized (Millipore). Drug doses (mg/kg/infusion) were calculated on the
basis of the salt. The following drug doses were tested: d -amphetamine
sulfate (0.01, 0.05, 0.1, 0.5); l-3,4-methylenedioxyamphetamine sulfate
(MDA) (0.1, 0.5, 1.0, 2.0, 5.0); 4-methoxyamphetamine hydrochloride
(PMA) (0.001, 0.01, 0.1, 0.1 1.0); 2,5-dimethyoxy-4-methylamphetamine hydro-
chloride (DOM) (0.001, 0.01, 0.1, 1.0); 2,5-dimethyoxy-4-ethylamphetamine
hydrochloride (DOET) (0.001, 0.01, 0.1, 0.32. 1.0); d,l-3,4-methylenedioxy-
methamphetamine HCl (MDMA) (0.1, 0.32, 1.0, 3.2); phentermine hydro-
chloride (0.1, 0.5, 1.0); diethylpropion hydrochloride (0.1, 0.5, 1.0, 2.0);
phenmetrazine hydrochloride (0.1, 0.5, 1.0); phendimetrazine tartrate (0.1,
0.5, 1.0, 2.0); benzphetamine hydrochloride (0.1, 0.5, 1.0, 3.0); l-ephedrine
hydrochloride (0.3, 1.0, 3.0, 10.0); clotermine hydrochloride (0.1, 1.0, 3.0,
5.0); chlorphentermine hydrochloride (0.1, 0.5, 2.5, 5.0); and fenfluramine
hydrochloride (0.02, 0.1, 0.5, 2.5).
Chemical Structures. Figure 1 shows the chemical structures for 14
phenylethylamine compounds. Nine of these compounds are used clinically
as anorectics (d-amphetamine, phentermine, diethylpropion, phenmetrazine,
phendimetrazine, clotermine, chlorphentermine, benzphetamine, and
fenfluramine). Four of these compounds are not approved for clinical use
and are reported to have hallucinogenic properties (MDA, PMA, DOM, and
DOET). The final compound (l-ephedrine) is used clinically for bronchial
muscle relaxation, cardiovascular, and mydriatic effects. Figure 2 shows the
chemical structure for MDMA, the methyl analog of MDA. MDMA is not
approved for clinical use and has been reported to produce both LSD-like
and cocaine-like effects.
RESULTS
Figure 3 presents the mean levels of self-infusion for the 14 phenylethyl-
amines shown in figure 1. Of all the drugs tested, d-amphetamine was the
most potent, maintaining levels of drug self-injection above saline levels at
doses of 0.05 and 1.0 mg/kg/mfusion. Phentermine, diethylpropion, phen-
metrazine, phendimetrazine, benzphetamine, and MDA maintained levels of
self-injection above saline at doses of 0.5 and 1.0 mg/kg/infusion. The
compounds l-ephedrine, clotermine, and chlorphentermine were the least
potent substances that maintained performance; self-injection rates were
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FIGURE 1. Chemical structure of 14 of the 15 phenylethylamines tested to
determine whether they maintain drug self-administration
SOURCE: Griffiths et al. 1979, copyright 1979, Academic Press.
above saline control levels at doses of 3.0 and 10 mg/kg/infusion for
l-ephedrine, 3.0 and 5.0 mg/kg/infusion for clortermine, and 2.5 and
5.0 mg/kg/infusion for chlorphentermine. In contrast to the other phenyl-
ethylamines tested, fenfluramine, PMA, DOM, and DOET did not maintain
self-injection at levels greater than saline at any dose tested.
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FIGURE 2. Chemical structure of MDMA
Figure 4 shows that MDMA maintained responding above vehicle level in
the three baboons tested, the highest levels of self-injection were maintained
by 0.32 or 1.0 mg/kg/injection; lower levels were maintained by 0.1 and
3.2 mg/kg/injection. During self-injection of cocaine, vehicle (saline), and
low doses of MDMA, there were no unusual changes in gross behavior of
the baboons. While self-injecting higher doses of MDMA, however, all
three baboons engaged in notably unusual behaviors. Two animals appeared
to track nonexistent visual objects (suggesting hallucinations), were unchar-
acteristically aggressive toward laboratory personnel, and engaged in
repetitive scratching/self-grooming behavior.
Similar MDMA self-injection findings have been reported in rhesus
monkeys (Beardsley et al. 1986). In three of the four animals trained to
self-administer cocaine, substitution of at least one dose of MDMA resulted
in rates of self-injection that exceeded vehicle rates; two animals self-
administered MDMA at rates higher than cocaine rates.
CORRESPONDENCE OF BEHAVIORAL EFFECTS IN HUMANS
AND ANIMALS
In a summary of the human abuse literature on anorectic phenylethylamines,
Griffiths et al. (1979) found there was a good correlation between the
results of self-administration studies in animals and information about the
subjective effects and abuse in man. Specifically, amphetamine, diethyl-
propion, and phenmetrazine have been associated with numerous clinical
case reports involving abuse, and these three compounds as well as benz-
phetamine and l-ephedrine have shown similar subjective effects in drug
abuser populations (Griffiths et al. 1979). In addition, fenfluramine was
associated with low incidence of abuse in humans and did not maintain
self-injection responding in animals. Chlorphentermine was similarly
associated with low incidence of abuse in man, but did not maintain self-
injection uniformly in animals (Griffiths et al. 1979).
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FIGURE 3. Mean number of injections per day with 14 phenylethylamines
for the last 5 days of drug or saline substitution under a
160-response T.0. 3-hour schedule of intravenous injection
NOTE: The vertical axis represents the number of injections per day. The horizontal axis
represents doses of drug (log scale). The points above “C" represent the mean of all 3-day
drug dose or saline substitution. The points above "S” represent the mean of the last 5 days
periods of cocaine HCI (0.4 mg/kg/infection) availability that immediately preceded every
obtained during saline substitution (2 saline substitutions in each of 15 animals). Vertical 
bars indicate ranges of individual animal's means. Drug data points represent the mean of 
the last 5 days during substitution of a drug dose for individual animals.
SOURCE: Griffiths et al. 1979, copyright 1979, Academic Press.
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FIGURE 4. Mean number of injections per day for the last 5 days of
MDMA and MDMA vehicle (saline) substitution under a
160-response T.O. 3-hour schedule of intravenous injection
NOTE: The  points above “C” represent the grand mean of the 3 days of concaine HCl(0.32
mg/kg/injection) availability that preceded each MDMA dose or saline substitution. The 
points above “V” represent the mean of the last 5 days obtained during vehicle substitution. 
Vertical bars indicate ranges of individual animals' means.
SIMILARITIES AMONG AND DIFFERENCES BETWEEN
PHENYLETHYLAMINE COMPOUNDS
A comparison of MDMA to d-amphetamine, MDA, and DOM can provide
an understanding of the pharmacology of MDMA and its abuse liability.
While there are differences between MDMA and amphetamine in the
subjective effects in humans (Shulgin and Nichols 1978). the similarities in
the self-injection and preclinical pharmacology profile between MDMA and
d-amphetamine suggest that MDMA has abuse liability. Both MDMA and
d-amphetamine maintain self-injection behavior above vehicle control levels,
and high doses of both drugs are associated with a cyclic pattern of self-
injection over days (Lamb and Griffiths 1987; Griffiths et al. 1976). At
doses larger than those needed to maintain self-injections, both MDMA and
d-amphetamine suppressed food intake and food-maintained behavior (Lamb
and Griffiths 1987; Griffiths et al. 1976) and produced similar changes in
gross behavior, such as tracking nonexistent visual objects and repetitive
self-grooming (Lamb and Griffiths 1987; Lamb and Griffiths, unpublished
observations). Both MDMA and amphetamine also sham discriminative
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stimulus properties with d,l-MDA or amphetamine, but not with DOM, in
rat drug-discrimination paradigms (Glennon and Young 1984a; Glennon and
Young 1984b; Glennon et al. 1983).
MDMA has both similarities to and differences from l-MDA. MDMA and
l-MDA are self-injected in baboons and share stimulus properties with MDA
in the rat drug-discrimination paradigm (Glennon and Young 1984a). In
addition, MDMA, but not l-MDA, shares discriminative stimulus properties
with amphetamine in the rat drug-discrimination paradigm (Glennon and
Young 1984a). Consistent with the reports of lesser hallucinogenic effects
of MDMA as compared to MDA or LSD (Shulgin 1978), l-MDA, but not
MDMA, shares discriminative stimulus properties with DOM in the rat
drug-discrimination paradigm (Glennon et al. 1982; Glennon et al. 1983).
Although the substituted phenylethylamine compounds that have hallucino-
genic properties in man (e.g., DOET, DOM, PMA, MDA, and MDMA) are
commonly abused by humans, only MDA and MDMA maintained self-
injection behavior in baboons. This suggests that this animal self-injection
procedure may not be useful in predicting hallucinogenic drug effects. In
addition, it suggests that the reinforcing properties of MDA and MDMA in
baboons may be unrelated to the fact that these drugs produce hallucino-
genic effects. Some phenyl-substituted phenylisopropylamines, such as
MDA, PMA, and MDMA, have pharmacological properties distinct from
those of amphetamine or DOM. Therefore, predictions about the abuse
liability of these compounds based on their similarities to or differences
from classic stimulants (such as cocaine or amphetamine) or hallucinogens
(such as LSD or DOM) may provide inappropriate results.
STRUCTURE-ACTIVITY RELATIONSHIPS AMONG
PHENYLETHYLAMINE COMPOUNDS
A comparison between the chemical structures of substituted
phenylethylamine compounds and their potency in producing behavioral
effects reveals an inverse relationship between the size of the substituent
and central activity (Braun et al. 1980). Similarly, reports of SARs among
phenylethylamine compounds have suggested that the size of the ring
substitution in general may decrease potency of the phenylethylamines for
maintenance of self-injection behavior. Research with a series of N-ethyl-
aminates substituted at the meta position of the phenyl ring has
demonstrated that the potency of these compounds, either to increase
locomotor behavior in mice (Tessel et al. 1975) or to maintain self-injection
behavior in rhesus monkeys (Tessel and Woods 1975; Tessel and Woods
1978). was inversely related to the size of the meta-substituted constituent.
These findings indicate that the failure of fenfluramine (meta-trifluromethyl-
N-ethyl-amphetamine) to maintain self-injection behavior is attributable to its
meta-trifluromethyl group.
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An examination of the SAR, comparing figures 1 and 3, also supports the
suggestion that ring substitutions may decrease potency for maintaining
self-injection behavior. The seven compounds shown in the right column of
figures 1 and 3 have substitutions on the phenyl ring; these compounds
were generally less potent in maintaining self-injection than were the
compounds in the left columns of these figures, which do not have ring
substitutions. In addition, phentermine differs structurally from both
chlorphentermine and clotermine, which have the addition of a Cl at either
the para or ortho positions of the phenyl ring; however, chlorphentermine
and clotermine appear to be less potent than phentermine in maintaining
self-injection behavior.
A similar SAR was found between side-chain substitutions and behavioral
effects of phenylethylamines. A study using a series of d-N-alkylated
amphetamines, synthesized in a series up to and including d-N-butylamphet-
amine, found that, for substitutes larger than ethyl, potency for maintaining
drug self-administration in rhesus monkeys and for disrupting milk-drinking
activity in rats of the d-N-alkylated amphetamines was inversely related to
the N-alkyl length (Woolverton et al. 1980).
The pharmacological properties of phenylethylamines that control self-
administration are complex. The effects of phenylethylamines on a variety
of pharmacological measures do not appear to predict the reinforcing effects
of these drugs, as measured by the cocaine substitution procedure in
primates. Specifically, none of the following behavioral effects of these
compounds accurately predict the results of self-administration experiments
within the phenylethylamine class (Griffiths et al. 1976; Griffiths et al.
1979): the ability to suppress food intake (Griffiths et al. 1978); the ability
to produce rate-dependent effects on schedule-controlled behavior (Harris et
al. 1977; Harris et al. 1978); the ability to produce discriminative stimulus
properties similar to amphetamine, DOM, or MDA (Glennon et al. 1982;
Glennon et al. 1983; Glennon and Young 1984a; Glennon and Young
1984b Glennon et al. 1985; Glennon et al. 1988). Self-injection testing
should remain an integral part of a continued analysis of abuse liability of
these compounds.
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Stimulus Properties of
Hallucinogenic Phenalkylamines
and Related Designer Drugs:
Formulation of Structure-Activity
Relationships
Richard A. Glennon
INTRODUCTION
The purpose of the studies with phenalkylamine derivatives is severalfold:
(1) to classify these agents by their primary effect; (2) to understand the
structure-activity relationship (SAR) for each type of activity; and (3) to
elucidate the mechanisms of action of these agents. Armed with informa-
tion on SAR, one can, theoretically make predictions about the activity of
agents yet to be synthesized; an understanding of the mechanisms of action
can aid in the development of potential antagonists that could be useful for
reversing the effects of these substances. Obviously, before one can investi-
gate SAR and mechanisms of action, it is important to have some reliable
method of classification. In the course of the studies, several different
procedures have been used to examine the actions of these agents. Perhaps
the most useful is the drug discrimination procedure. In this paradigm,
animals are trained to recognize (or discriminate) the stimulus effects of a
particular dose of a given agent; once trained, the animals can be
administered doses of a test compound (i.e., a challenge drug) to determine
if the challenge drug produces stimulus effects similar to those of the
training drug. In such tests, referred to as tests of stimulus generalization,
the animals essentially indicate whether or not a similarity exists between
the actions of a new agent and those of a reference agent. Dose:response
curves can be obtained and ED50 values determined. Thus, the procedure
provides data that are both qualitative and quantitative. Needless to say,
there are occasions when such studies produce results that are less than
straightforward and are difficult to interpret. In other words, although drug
discrimination studies provide very useful information on similarity of
effect, potency, timecourse of action, mechanism of action, activity of
metabolites, and other data, they cannot be used by themselves to charac-
terize completely the pharmacological effects of a given agent. Reviews on
the drug discrimination paradigm, particularly as it applies to the study of
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phenalkylamines, appear in the following publications: Glennon
et al. (1983), Glennon (1986), and Young and Glennon (1986).
In drug discrimination studies, groups of rats were trained to discriminate
either the stimulant phenalkylamine (+)amphetamine (AMPH) or the hallu-
cinogenic phenalkylamine 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane
(DOM) from saline. Other structurally related training drugs that have been
used include the iodo and bromo analogs of DOM, i.e., DOI and R (-)DOB,
as well as methylenedioxyamphetamine (MDA) and methylenedioxymetham-
phetamine (MDMA). Such investigations, coupled with the results of
radioligand binding studies, have permitted the classification of a number of
phenalkylamines (Glennon et al. 1983; Glennon 1986; Young and Glennon
1986) and have allowed proposal of a mechanism of action for the
hallucinogenic phenalkylamines (Glennon et al. 1986a). The present review
describes in detail some of the SARs that have been formulated on the
basis of drug discrimination studies. This discussion of results is not meant
to be comprehensive. Because species of animal, schedule of reinforcement,
presession injection intervals, doses of training drugs, and other conditions
have remained constant throughout the studies, it should be possible to
make stricter comparisons than if data were compared across different
laboratories. This SAR analysis is based, for the most part, on the results
of discrimination studies already published.
Some of the agents used in the present study have not been previously
reported in the literature. These agents were prepared in our laboratories,
and details of their synthesis will be published elsewhere. However, three
of these agents are potential metabolites of MDMA and are described here
to the extent that such information might be helpful to other investigators
studying the metabolism of MDMA. All three were isolated as their white,
crystalline hydrochloride salts, and all were analyzed correctly for carbon,
hydrogen, and nitrogen. Melting points and recrystallization solvents (in
parentheses) are provided. N-methyl-1 -(4-hydroxy-3-methoxyphenyl)-2-
aminopropane (N-Me 4-OH MMA): 210-212 °C (isopropanol/ ether); N-
methyl-1-(3-hydroxy4-methoxyphenyl)-2-aminopropane (N-Me 3-OH PMA):
164-165 °C (isopropanol); N-methyl-1-(3,4-dihydroxyphenyl-2aminopropane
(N, dimethyl dopamine or N-Me 3,4-diOH AMPH): 116-118 °C
(isopropanol/ether).
Examination of the stimulus properties of a large number of phenalkyla-
mines and related derivatives shows many can be characterized as producing
either AMPH-like stimulus effects or DOM-like stimulus effects. The
structures of some of these agents are shown in figure 1. Certain other
agents could not be reliably classified as either AMPH-like or DOM-like
because, at the highest dose tested, they either produced vehicle-appropriate
(i.e., saline-appropriate) responding or resulted in disruption of behavior.
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FIGURE 1. Chemical structures of some of the agents employed in the
present study
Representative potency data (ED50 values) are presented in tabular form;
data in these tables are given as µmol/kg so that direct potency compari-
sons can be made within a series. However, data presented in figures are
given in mg/kg for the purpose of convenience.
Various phenallcylamines were shown to produce either DOM-like or
AMPH-like stimulus effects; the structure-activity requirements for these
activities are different from the standpoints of aromatic substitution patterns,
terminal amine substituents. and optical activity. Thus, it has been possible
to formulate two distinct SARs. It should be realized, however, that
phenalkylamines need not produce only one of these two types of effects;
certain phenallcylamines can produce pharmacological effects like neither
DOM nor AMPH. Moreover, they can produce effects that are primarily
peripheral, not central, in nature (Glennon 1987a). The fact that an agent
produced DOM- or AMPH-like effects does not imply that it cannot
produce an additional effect; conversely, if an agent does not produce either
DOM- or AMPH-like stimulus effects, it is not necessarily inactive.
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DOM-LIKE STRUCTURE-ACTIVITY RELATIONSHIPS
Aromatic Substituents
Substituents on the aromatic ring play a critical role in determining
whether or not phenalkylamines possess DOM-like activity. Hallucinogenic
activity is commonly associated with methoxy-substituted derivatives
(Shulgin 1978); for this reason, much of this work has focused on these
types of agents.
Methoxy-Substituted Derivatives. Phenalkylamines lacking aromatic sub-
stituents do not produce DOM-like stimulus effects. None of the three
possible monomethoxy derivatives, 2-methoxy-(OMA), 3-methoxy-(MMA),
or 4-methoxyphenylisopropylamine (PMA), produce DOM-like effects. Of
the six dimethoxy analogs (DMAs) (i.e., 2,3-DMA, 2,4-DMA, 2,5-DMA,
2,6-DMA, 3,4-DMA, and 3,5-DMA), only the 2,4- and 2,5-dimethoxy
derivatives 2,4-DMA and 2,5-DMA, respectively, are active. These two
agents are essentially equipotent and are approximately one-tenth as potent
as DOM. For purposes of comparison, the potencies of 2,5-DMA and
DOM are 23.8 and 1.8 µmol/kg. Five trimethoxy analogs (TMAs) have
been examined: 2,3,5-TMA is approximately one-third as potent as
2,5-DMA, and 2,3,4-TMA and 3,4,5-TMA are equipotent with 2,5-DMA.
The other two, 2,4,5-TMA and 2.4.6-TMA, are about twice as potent as
2,5-DMA. None of the three possible tetramethoxy analogs has been
investigated, and the pentamethoxy analog does not produce DOM-like
stimulus effects. From these studies, it is apparent that the 2,4- and 2,5-
dimethoxy substitution pattern plays an important role; certain 2.6-dimethoxy
derivatives are also active, depending upon what substituents are present at
the 4-position.
2,5-Dimethoxy Analogs. It should come as no surprise that methoxy
groups at the 2- and 5-positions are important, when it is realized that
DOM is a 2,5-dimechoxy-substituted derivative. Data for some representa-
tive 2,5-DMA analogs are provided in table 1. Removal of either one of
the methoxy groups abolishes DOM-like stimulus effects. Introduction of a
methyl group at the 4-position of 2,5-DMA, to produce DOM, enhances
potency by more than an order of magnitude. Homologation of this alkyl
group to ethyl (DOET) and n-propyl (DOPR) produces an increase in
potency; further homologation to n-butyl (DOBU) decreases potency, and to
amyl (DOAM) results in an agent that does not produce DOM-like stimulus
effects. The relative potencies of these agents, as compared to 2,5-DMA,
are: 2,5-DMA (1)<DOM (13)<DOET (27)<DOPR (43)>DOBU (7).
Branching of this alkyl chain has varying effects. The isopropyl analog
DOIP is eight times more potent than 2.5-DMA but is only about one-fifth
as potent as its nonbranched counterpart DOPR. The tertiary butyl
derivative DOTB does not produce DOM-like effects. In fact, it has been
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TABLE 1. Results of stimulus generalization studies using racemic DOM as
a training drug
ED50
Agent Optical Isomer R4 R R' (µmol/kg)
2,5-DMA (±)
(-)
2,4,5-TMA (±)
DOM (±)
(-)
(+)
N-Me DOM (±)
( - )
-desMe DOM
DOET (±)
( - )
(+)
DOPR
DOIP (±)
DOBU
(±)
(±)
DOF (±)
D O C (±)
DOI (±)
(-)
(+)
DOB (±)
(-)
(+)
N-Pr DOB (±)
-desMe DOB
4-OH 2,5-DMA (±)
4-COOH 2,5-DMA (±)
DOTB (±)
DOAM (±)
H
H
OCH3
CH3
CH3
CH3
CH3
CH3
CH3
C2H5
C2H5
C2H5
nC3H7
iC3H7
nC4H9
F
C1
I
I
I
Br
Br
Br
Br
B r
OH
COOH
tC4H9
nC5H11
DOBZ (±) CH2-C6H5 H CH3 NSG
H
H
H
H
H
H
CH3
CH3
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
nC3H7
H
H
H
H
H
CH3 23.8
CH3
CH3
14.0
13.7
CH3
CH3 0.8
CH3
1.8
6.9
CH3 15.3
CH3 10.0
H 5.6
CH3
CH3
0.9
0.3
CH3 3.3
CH3 0 .6
CH3 2.9
CH3 3.2
CH3 5.8
CH3
CH3
1.2
1.2
CH3 0.6
CH3 2.6
CH3
CH3
0.6
0.3
CH3 2.6
CH3 13.4
H 2.2
CH3 NSG
CH3
CH3
NSG
NSG
CH3 NSG
KEY: NSg=no stimulus generalization at the highest dose tested.
NOTE: Training drug=DOMHCl (1.0 mg/kg, IP) administered 15 minutes prior to testing. In test of
stimulus generalization, a presession injection interval of 15 minutes was employed. ED50
values are given where stimulus generalization occured.
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found that DOTB acts as a partial agonist and can antagonize the stimulus
effects of DOM (Glennon 1987b).
Certain polar substituents at the 4-position of 2,5-DMA render the
compounds inactive; for example, the 4-COOH and 4-OH derivatives do not
produce DOM-like effects. On the other hand, 4-halogenated compounds
result in relatively potent derivatives. The 4-fluoro derivative DOF is
4 times more potent than 2,5-DMA. whereas the 4-chloro (DOC) and 4-iodo
(DOI) analogs are about 20 times more potent than 2,5-DMA. The most
potent halogenated derivative is the 4-bromo analog DOB, which is about
40 times as potent as 2,5-DMA.
The location as well as the nature of these substituents is important. For
example, moving the methyl group of DOM, or the bromo group of DOB,
from the 4-position to the 3-position (to produce isoDOM and isoDOB,
respectively) results in agents that do not produce DOM-like stimulus
effects. IsoDOB (or SL7161). for example, produces saline-appropriate
responding at 100 times the ED, dose of DOB.
2,4-Dimetboxy Analogs. 2,4-DMA is approximately equipotent with
2,5-DMA. Introduction of a 5-methyl or 5-bromo group, to produce
5-methyl-2,4-DMA and 5-bromo-2,4-DMA, results in active agents, but they
are not significantly more potent than 2,4-DMA itself. It seems that the
methyl and bromo substituents are tolerated at the 5-position, but they do
not produce the increase in activity seen in the 2,5-DMA series.
Terminal Amine Substituents
A primary (i.e., unsubstituted) amine appears to be optimal for DOM-like
activity. Simple N-monomethylation of DOM results in a tenfold decrease
in potency. Larger N-alkyl substituents produce an even greater decrease in
potency; for example, N-n-propyl DOB is approximately one-thirtieth as
potent as DOB itself (Glennon et al. 1986b). Using animals trained to
discriminate R (-)DQB from saline, racemic DOB is 10 times more potent
than N-monomethyl DOB, which, in turn, is 10 times more potent than
N,N-dimethyl DOB (Glennon et al. 1987). The quaternary analog
N,N,N-trimethyl DOB iodide (QDOB) is inactive.
Alpha-Methyl Group
The u-methyl group is important, but not usually necessary for activity.
For example, the desmethyl analogs of DOM and DOB are both about
one-third as potent as their parent agents. The ademethylation of
3,4,5-TMA, to produce mescaline, results in a similar (i.e., 2.5-fold)
decrease in activity. Although these desmethyl analogs produce stimulus
effects similar to those of DOM, there is some evidence that the spectrum
of effects produced by these agents, in rats and in humans, is not
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necessarily identical with that (spectrum) of their parent compounds (Shulgin
and Carter 1975; Glennon et al., in press).
Optical Isomers
Due to the presence of the a-methyl groups, these agents exist as optical
isomers. Both isomers usually produce DOM-like effects, and the R
(-)isomers constitute the eutomeric series. In this regard then, the effects of
these agents are stereoselective, but not stereospecific. In general, the R
(-)isomers are twice as potent as their racemates and about 5 to 8 times
more potent than their S (+)enantiomers. Some representative data are
provided in table 1.
AMPHETAMINE-LIKE STRUCTURE-ACTIVITY RELATIONSHIPS
Aromatic Substituents
An unsubstituted aromatic ring appears to be optimal for AMPH-like
stimulus effects. Using animals trained to discriminate 1.0 mg/kg of
(+)amphetamine sulfate from saline (ED50=1.8 µmol/kg), no aromatic-
substituted derivative has yet been found to be more potent than AMPH
itself. For example, each of the monomethoxy-substituted derivatives, i.e.,
OMA, MMA, and PMA, produce AMPH-appropriate responding but are 4
to 15 times less potent than AMPH itself (table 2). The (+)AMPH stimulus
does not generalize to any of the above-mentioned DMAs or TMAs (or, for
that matter, to any of the agents listed in table 1); however, several of these
agents (notably 2,4-DMA, 2,5-DMA, 2,4,5-TMA, 2,4,6-TMA, and
3,4,5-TMA) result in partial generalization (40 to 50 percent AMPH-
appropriate responding) suggesting that they may be capable of producing
some AMPH-like activity in addition to their DOM-like effects (Glennon
et al. 1985). The 4-OH derivative (parahydroxyamphetamine, or Paradrine),
which is the O-desmethyl analog of PMA, produces saline-appropriate
(2 percent drug-appropriate) responding at greater than 50 µmol/kg. The
N-ethyl-3-trifluoromethyl derivative of AMPH, fenfluramine, produces
saline-like effects at doses up to about 20 µmol/kg and disruption of
behavior at doses greater than or equal to 24 µmol/kg. Complete reduction
of the aromatic nucleus of AMPH does result in retention of activity,
although potency is significantly decreased; that is, propylhexedrine produces
AMPH-like stimulus effects (ED50=15.5 µmol/kg).
Terminal Amine Substituents
In contrast to what was observed for DOM-like activity, N-monomethylation
of AMPH-like agents does not decrease their AMPH-like character. Meth-
AMPH (i.e., N-monomethylamphetamine) is slightly more potent than
amphetamine; likewise, methcathinone (N-monomethylcathinone) is twice as
potent as cathinone. N-methylation of DOM-like agents does not convert
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TABLE 2. Results of stimulus generalization studies using (+)amphetamine
as a training drug
ED50
(µmol/kg)Agent Isomer X Rx R R'
Amphetamine
Methamphetamine
Phenethylamine
Cathinone
Methcathinone
N-OH AMPH
(+)N-Et AMPH
OMA
MMA
PMA
PMMA
4-OH AMPH
Fenflummine
3,4-DMA
N-Me 3,4-DMA
2,4-DMA
N-Me 2,4-DMA
2,5-DMA
N-Me 2,5-DMA
(±)
(- )
(+)
(±)
(+)
(±)
( - )
(+)
(±)
(±)
(+)
(±)
(±)
(±)
(±)
(±)
(±)
(±)
(±)
(±)
(±)
(±)
(±)
H2
H2
H2
H2
H2
H2
0
0
0
0
H2
H2
H2
H2
H2
H2
H 2
H2
H2
H2
H2
H2
H 2
H2
H
H
H
H
H
H
H
H
H
H
H
H
2-OCH3
3-OCH3
4-OCH3
4-OCH3
4-OH
3-CF3
3,4-di OCH3
3,4-di OCH3
2,4-di OCH3
2,4-di OCH3
2,5di OCH3
2,5-di OCH3
H
H
H
CH3
CH3
H
H
H
H
CH3
OH
C2H5
H
H
H
CH3
H
C2H5
H
CH3
H
CH3
H
CH3
CH3 2.6
CH3 5.3
CH3 1.8
CH3 1.5
CH3 1.2
H NSG
CH3 3.8
CH3 1.6
CH3 23.4
CH3 1.8
CH3 1.1
CH3 4.3
CH3 38.7
CH3 17.0
CH3 9.5
CH3
CH3
NSG
CH3
NSG
NSG
CH3 NSG
CH3
CH3
NSG
CH3
NSG
NSG
CH3 NSG
CH3 NSG
KEY: NSG=no stimulus generalization at the highest dose tested.
NOTE: Rats trained to dircriminate (+)amphetamine sulfate (1.0 mg/kg) from saline administered
15 minuted prior to testing.
them to AMPH-like agents; for example, see N-Me 2,4-DMA and N-Me
2,5-DMA (table 2). Homologation of the methyl to an ethyl group results
in retention of AMPH-like activity, although potency is somewhat reduced;
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for example, (+)N-Et AMPH is 2.5 times less potent than (+)AMPH itself.
Although there have been no systematic investigations of N-alkylation,
certain AMPH analogs bearing larger substituents are active. Mefenorex,
the N-(3-chloro-n-propyl) analog of AMPH, produces saline-appropriate
behavior at about 5.5 µmol/kg and disruption of behavior at 6
µmol/kg.The N-hydroxy analog of AMPH (i.e., N-OH AMPH), a metabolite of
AMPH, also produces AMPH-like effects and is about twice as potent as
AMPH (table 2).
Alpha-Methyl Group
Removal of the a-methyl group of AMPH results in phenethylamine (PEA).
PEA does not produce AMPH-like effects. Likewise, removal of the
a-methyl group of cathinone, resulting in desmethylcathinone, also results
in an agent that does not produce AMPH-like stimulus effects. Huang and
Ho (1974a) have demonstrated that pretreatment of the animals with a
monoamine oxidase inhibitor prior to administration of PEA does lead to
stimulus generalization, suggesting that the adesmethyl analogs may simply
lack protection from metabolism.
Beta-Substituents
Very few ~-substituted analogs of AMPH have been investigated.
Ephedrine, for example, produces weak AMPH-like activity (Huang and Ho
1974b). (+)Norpseudoephedrine (cathine) also produces AMPH-like stimulus
effects. The oxidized analogs of norephedrine and ephedrine, cathinone and
methcathinone, respectively, however, are potent AMPH-like agents
(table 2).
Optical Isomers
Both optical isomers of AMPH are active (Schechter 1978). In general, for
the few isomeric pairs that have been examined, the S isomers of
AMPH-like agents are slightly more potent than the racemates and about 3
times more potent than the R isomers (Young and Glennon 1986).
S(+)AMPH, for example, is 3 times more potent than R(-)AMPH (table 2);
S(-)cathinone is 2.5 times more potent than racemic cathiione, but
(unexpectedly) is nearly 15 times more potent than R(+)cathinone.
Miscellaneous Analogs
Certain agents with AMPH-related structures also produce AMPH-like
stimulus effects. Agents in which the terminal amine has been incorporated
into a cyclic structure, such as methylphenidate (Huang and Ho 1974b
D’Mello 1981), phenmetrazine, and phendimetrazine, are active. These
agents might be considered as N-alkyl substituted phefialkylamines.
Aminorex is another agent that falls into this category and is essentially
equipotent with AMPH.
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METHYLENEDIOXY-SUBSTITUTED PHENALKYLAMINES
Methylenedioxy-substituted phenalkylamines are considered separately,
because it has been shown that the parent 3,4-methylenedioxy analog of
AMPH, MDA, is capable of producing both DOM-like and AMPH-like
stimulus effects. Its ED, value in DOM-trained rats is 7.8 µmol/kg and in
(+)AMPH-trained rats, 10.6 µmol/kg. The DOM-like properties reside
primarily with the R (-)isomer (ED50=3.8 µmol/kg), whereas the AMPH-like
activity resides with the S (+)isomer (ED50=4.2 µmol/kg) (figures 2 and 3).
To this extent, 3,4-MDA is not a particularly potent agent; it is approxi-
mately one-sixth as potent as (+)AMPH and less than one-third as potent as
DOM. A positional isomer of 3,4-MDA. 2,3-MDA, produces neither DOM-
nor AMPH-like stimulus effects. The 2-methoxy analog of 3,4-MDA (i.e.,
2-methoxy 4,5-MDA or MMDA-2) produces weak DOM-like effects
(ED50=13.7 µmol/kg), but does not produce AMPH-like stimulus effects.
3,4-MDA is unique. Not only does it produce both types of effects, but it
seems to conflict with some of the above-mentioned SARs. For example,
aromatic-substituted phenalkylamines such as the 3-methoxy and 4-methoxy
derivatives MMA and PMA arc only weak AMPH-like agents, and the
3.4-dimethoxy analog 3,4-DMA (which is structurally very similar to
3,4-MDA) does not produce AMPH-like effects. The 3-OH, 4-OMe, and
the 3-OMe 4-OH analogs of amphetamine are also inactive. Thus, it is
surprising that 3,4-MDA possesses AMPH-like character. Likewise, neither
MMA, PMA, nor 3,4-DMA produce DOM-like effects; yet 3,4-MDA does.
2-Methoxy 4,5-MDA (MMDA-2) and 2,4,5-TMA share a common substitu-
tion pattern; interestingly, these agents are essentially equipotent in
producing DOM-like stimulus effects. Table 3 displays selected results.
CONTROLLED SUBSTANCE ANALOGS (“DESIGNER DRUGS”)
One application of SARs is to make predictions concerning new agents.
Assuming that the new agents are producing one of the above-mentioned
effects, it should be possible to make approximate predictions of both
activity and potency. Over the past decade, several new agents have
appeared, and their activities and/or potencies have been consistent with
these SARs. Some of these agents have been mentioned. Also encountered
were some agents that do not fit the foregoing SAR; it is probably
worthwhile considering these agents in depth. For example, PMMA, the
N-monomethyl analog of PMA, should produce AMPH-like effects with a
potency several times that of PMA itself. In fact, PMMA produces neither
AMPH-like nor DOM-like effects. The animals’ behavior, however, was
disrupted at very low doses (<1 µmol/kg) suggesting that it may produce a
central effect that is other than (or in addition to) AMPH-like or DOM-like.
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TABLE 3. Results of stimulus generalization studies with MDA analogs
H
H
H
H
OCH3
OCH3
H
H
H
H
H
H
H
H
Agent Isomer R2
ED, Values (µmol/kg)
R R' AMPH-Like DOM-Like
3,4-MDA (MDA) (±)
(-)
(+)
HPA
2-OMe 4,5-MDA (±)
N-Me 2-OMe
4,5MDA (±)
MDMA (±)
(- )
(+)
MDE (±)
(- )
(+)
MDP (±)
N-OH MDA (±)
H CH 3 10.6
H CH3 NSG
H CH3 4.2
H H NSG
H CH3 NSG
CH3 CH3 NSG
CH3 CH3
CH3 CH3
7.1
NSG
CH3 CH3 2.6
C2H5 CH3
C2H5 CH3
NSG
C2H5 CH3
NSG
NSG
C3H7 CH3 NSG
OH CH3 NSG
7.8
3.7
NSG
NSG
13.7
NSG*
NSG*
NSG*
NSG
NSG
NSG
NSG
NSG
*Partial generalization (i.e., 40 to 55 percent drug-appropriate responding, followed, at slightly higher
doses, by disruption of behavior. NSG=no stimulus generalization at the highest dose tested.
NOTE: AMPH-like rats were trained to discriminate 1.0 mg/kg of (+)amphetamine sulfate from saline;
DOM-like rats were trained to discriminate 1.0 mg/kg of DOM-HC1 from saline.
The N-monomethyl analog of 3,4-MDA is MDMA (XTC, “Ecstasy,”
“Adam”). It would be anticipated that N-monomethylation of MDA would
reduce DOM-like character by at least an order of magnitude, simuitane-
ously enhancing the AMPH-like character. Thus, the AMPH stimulus
should generalize to the racemate and to the S (+)isomer (with the latter
being the more potent, and somewhat more potent than S(+)MDA), and the
R (-)isomer might have, at best, some weak DOM-like character. Indeed,
the (+)AMPH stimulus generalizes to racemic MDMA (ED50=7.1 µmol/kg)
(figure 4) and to S(+)MDMA (ED50=2.6 µmol/kg), but not to R(-)MDMA.
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FIGURE 2. The effects of racemic 3,4-MDA (MDA) and its optical isomers
in rats trained to discriminate DOM from saline
KEY: DOM=effect produced by the training dose, 1 mg/kg. of DOM; S=effect produced by
1 mL/kg of 0.9 percent saline.
NOTE: Doses of S(+)MDA greater than 1.5 mg/kg resulted in disruption of behavior. Results not
shown for all doses evaluated. Where stimulus generalization did not occur, result of highest
nondisruptive dose of test compounds is shown; slightly higher doses produced disruption of
behavior.
More recently, others (Evans and Johanson 1986; Kamien et al. 1986) have
published similar results with racemic MDMA. The DOM stimulus does
not generalize to racemic MDMA or to either isomer. To this extent, the
results appear to be consistent with established SARs.
MDE (MDEA, “Eve”) is the N-ethyl analog of MDA. SARs would suggest
that this agent should possess little, if any, DOM-like character and that it
should be a rather weak AMPH-like agent, Interestingly, neither the
racemate (figure 4) nor either optical isomer (figure 5) produces
(+)AMPH-appropriate responding. As expected, DOM stimulus generaliza-
tion does not occur with racemic MDE or with either of its optical isomers
(figure 6). Another inconsistency is encountered with the N-hydroxy analog
of MDA (i.e., N-OH MDA). Because N-hydroxylation of AMPH has rela-
tively little effect on its stimulus properties, it was anticipated that N-OH
MDA might behave in a manner similar to that of MDA. Figure 7 shows
that N-OH MDA produces neither AMPH-like nor DOM-like stimulus
effects. It should be noted, however, that the optical isomers of N-OH
MDA have not yet been examined.
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FIGURE 3. Effect of R(-)MDA and S(+)MDA in rats trained to
discriminate S(+)AMPH from saline
KEY: AMPH=effect of the training dose. 1 mg/kg. of S(+)amphetamine sulfate; S=the effect of
1 mL/kg of 0.9 percent saline.
NOTE: Results not necessarily shown for all doses that were examined. Where stimulus
generalization did not occur, result of highest nondisruptive dose is shown; evaluation of a
slightly higher dose resulted in disruption of behavior.
At this point, the unexpected results cannot be readily explained with
PMMA, MDE, or N-OH MDA. This is particularly confounding in view of
the report that MDMA and MDE apparently produce similar psychopharma-
cological effects in humans (Braun et al. 1980). There are several possible
explanations: (1) these agents may produce effects in rats that are different
from those produced in humans; (2) these agents may produce in rats a
central effect that somehow masks or obscures AMPH-like effects that
might have otherwise been observed at higher doses had disruption of
behavior not occurred at lower doses; and (3) some of these agents might
be capable of producing a stimulus effect distinct from those produced by
either AMPH or DOM (Glennon et al. 1988). The recent results of
Oberlender and Nichols (1988) would tend to support the latter possibility.
To gain further insight into the stimulus properties of these agents, a group
of rats was trained to discriminate MDA (1.5 mg/kg) from saline. Consis-
tent with the generalization results described above, the MDA-trained
animals recognized both racemic AMPH and DOM (table 4). MDA
stimulus generalization also occurred with both isomers of MDA, with
S(+)MDA (ED50=2.4 µmol/kg) being about twice as potent as R(-)MDA
55
TABLE 4. Results of stimulus generalization studies using rats trained to
discriminate 1.5 mg/kg of racemic MDA from saline
Agent Optical Isomer
ED50
(µmol/kg)
MDA
AMPH
DOM
MDMA
3,4-DMA
2,3-MDA
Cocaine
LSD
(±)
(-)
(+)
(±)
(±)
(±)
(±)
(±)
(+)
(+)
3.0
5.5
2 .4
7.7
2.5
4.2
23.2
13.4
17.3
0.07
(ED50=5.5 µmol/kg). Because MDA produces both AMPH-like and DOM-
like stimulus effects, it would be expected that MDA-trained animals would
recognize both cocaine and LSD, this was found to be the case (Glennon
and Young 1984a). Interestingly, the MDA stimulus also generalized to
3,4-DMA and 2,3MDA, agents to which neither the AMPH or DOM
stimulus generalizes. These results suggest that MDA is indeed producing
both AMPH-like and DOM-like effects and that it may also produce some
other stimulus effect.
Next trained was a group of rats to discriminate racemic MDMA from
saline. It was found that MDMA-trained animals (MDMA, ED50=2.2
µmol/kg) recognize both S(+)MDMA (ED50=1 µmol/kg) and R(-)MDMA
(ED50=4.3 µmol/kg). Thus, both isomers of MDMA appear to be active,
with S(+)MDMA being 4 times more potent than R(-)MDMA (Glennon
et al. 1986c). More recently, Schechter (1987) has reported an enantiomeric
potency ratio of about 2, whereas Oberlender and Nichols (1988) obtained a
ratio of 2.6. All three studies agree that the S (+)isomer is the more active
isomer, and two of the three studies find that it is twice as potent as the
racemate. Schechter (1987), on the other hand, has found that the racemate
is twice as potent as the S (+)isomer.
It is probably important to note that although there may be differences
between the effects produced by MDMA and MDE, there are also signifi-
cant similarities. For example, preliminary data using MDMA-trained
animals suggest that racemic MDMA and MDE produce similar stimulus
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FIGURE 4. Effect of racemic MDMA, MDE, and MDP in animals trained
to discriminate (+)AMPH from saline
KEY: AMPH=effect of the training dose., 1 mg/kg, of S(+)amphetamine sulfate; S=the effect of
1 mL/kg of 0.9 percent saline.
NOTE: Results not necessarily shown for all doses that were examined. Where stimulus
generalization did not occur, result of highest nondisruptive dose is shown; evaluation of a
slightly higher dose resulted in disruption of behavior.
effects, with MDE being slightly less potent than MDMA. At 8.2 µmol/kg.
MDE produces stimulus effects comparable to those of 6.5 µmol/kg of
MDMA. These results are consistent with those of Boja and Schechter
(1987), who used animals trained to discriminate MDE from saline. On the
other hand, whereas both MDMA and MDE are significantly less potent
than (+)AMPH in increasing locomotor activity in mice, S(+)MDMA and
S(+)MDE are about an order of magnitude more potent than their
R (-)enantiomers, and S(+)MDMA is at least several times more potent than
S(+)MDE (Patrick and Glennon, unpublished data).
Several recent reports allay fears that some progress is being made. For
example. whereas MDA (Glennon and Young 1984b; Evans and Johanson
1986; Kamien et al. 1986). S(+)MDA (Glennon and Young 1984b), MDMA
and/or S(+)MDMA (Glennon and Young 1984b; Evans and Johanson 1986;
Kamien et al. 1986; Glennon et al. 1988) produce AMPH-like effects,
S(+)MDA produces cocaine-like effects (Broadbent et al. 1987), and
although MDMA-trained animals recognize S(+)AMPH (Oberlender and
Nichols 1988), there are additional reports that AMPH-trained animals fail
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FIGURE 5. Effect of R(-)MDE and S(+)MDE in animals trained to
discriminate (+) AMPH from saline
KEY: AMPH=effect of the training dose, 1 mg/kg, of S(+)amphetamine sulfate S=the effect of
1 mL/kg of 0.9 percent saline.
NOTE: Results not necessarily shown for all doses that were examined. Where stimulus
generalization did not occur, result of highest nondisruptive dose is shown; evaluation of a
slightly higher dose resulted in disruption of behavior. 
to recognize S(+)MDA (Broadbent et al. 1987). MDMA, S(+)MDMA. and
R(-)MDMA (Oberlender and Nichols 1988). Furthermore, Appel and
coworkers have reported in one study that LSD-trained animals recognize
both isomers of MDA (Broadbent et al. 1987) and, in another study, that
LSD-trained animals recognize R(-)MDA but not S(+)MDA, R(-)MDMA, or
S(+)MDMA (Callahan and Appel 1987). Consistent with results in DOM
animals, Nichols and coworkers (1986) have found that LSD-trained animals
recognize racemic MDA and R(-)MDA. In the latter study, half the animals
tested also recognized R(-)MDMA. and 78 percent of a group of rats
trained to discriminate MDMA from saline selected the drug-appropriate
lever when administered LSD. However, R (-)MDA, S(+)MDA, R(-)MDMA,
and S(+)MDMA all produced drug-appropriate responding in rats trained to
discriminate mescaline from saline (Callahan and Appel 1987). These
inconsistencies might be due to procedural differences, or they might be of
greater significance. It is believed that R(-)MDA produces primarily, but
not exclusively, DOM-like (or hallucinogenic) effects, and that S(+)MDA
produces primarily, but not exclusively, AMPH-like effects. N-monomethyl-
ation of MDA enhances AMPH-like character and decreases DOM-like
properties.
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FIGURE 6. Effect of MDE and its optical isomers in rats trained to
discriminate DOM from saline
KEY:
NOTE:
DOM=effect produced by the training dose, 1 mg/kg of DOM; S=effect produced by 
1 mL/kg of 0.9 percent saline.
Doses of S(+)MDA (greater than 1.5 mg/kg resulted in disruption of behavior. Results not
shown for all doses evaluated. Where stimulus generalization did not occur, result of highest
nondisruptive dose of test compounds is shown; slightly higher doses produced disruption of
behavior.
Evidence further suggests that MDMA (possibly MDA), and particularly
MDE and MDP, can produce effects that are distinct from (or that are in
addition to, but mask) AMPH-like and/or DOM-like effects.
Recent work shows that, in rodents, MDMA is metabolized, at least in part,
to MDA, and that racemic MDMA is preferentially metabolized to
S(+)MDA (Fitzgerald et al. 1987). The extent to which MDMA metabolites
might contribute to the stimulus properties of MDMA is unknown at this
time. Because S(+)MDA is capable of producing AMPH-like stimulus
effects, involvement of this metabolite might explain some of the different
results reported for MDMA (particularly if different animal species and
various presession injection intervals were employed). In contrast, certain
other potential metabolites of MDMA, such as 3-hydroxy-PMA, 4-hydroxy-
MMA, 3,4-dihydroxy-AMPH methyldopamine), N-methyl-3-hydroxy-
PMA, N-methyl-4-hydroxy-MMA, N-methyl-3,4-dihydroxy-AMPH
(N-methyl- methyldopamine) do not produce AMPH-like stimulus effects,
but may be capable of producing other, distinct types of central activity or
may somehow interfere with potential AMPH-like effects.
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FIGURE 7. Effect of N-OH AMPH and N-OH MDA in rats trained to
discriminate (+)amphetamine from saline
KEY: AMPH=effect of the training dose, 1 mg/kg. of S(+)amphetamine sulfate; S=the effect of
1 mL/kg of 0.9 percent saline.
NOTE: Results not necessarily shown for all doses that were examined. Where stimulus
generalization did not occur, result of highest nondisruptive dose is shown; evaluation of a
slightly higher dose resulted in disruption of behavior.
CONCLUSION
The drug discrimination paradigm is a powerful tool for studying centrally
acting agents of the phenalkylamine type. It has been used to classify a
large number of agents as being either AMPH-like or DOM-like, and it
allows for the formulation of SARs. Though not discussed here, drug
discrimination studies have proven invaluable in understanding the
mechanisms of action of many of these agents (Glennon et al. 1986a;
Young and Glennon 1986; Glennon 1988). The SAR can also be used to
predict the activity (AMPH-like or DOM-like) and potency of novel agents.
Two significant exceptions to established SARs have been encountered
PMMA and the MDA analogs. Findings with PMMA were wholly unex-
pected. MDA analogs probably represent a special case; because no
methylenedioxy analogs were included in the data set used to formulate the
initial SARs, it may not be wholly valid to attempt extrapolation to these
types of agents. Nevertheless, there are instances where the SARs correctly
predict the activity and potency of certain analogs (e.g., MMDA-2,
MDMA). However, other MDA analogs (i.e., N-OH MDA, MDE, MDP)
seemingly lack all regard for the established SARs. Although differences in
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AB
FIGURE 8. Phenalkylamine analogs appear to produce central stimulus
effects along AMPH-like to DOM-like continuum, depending
upon the substituent groups present
NOTE: (A.) MDA produces both types of stimulus effects. (B.) Trifurcated model is presented to
account for a possible third, as yet undefined, type of central effect. Certain phenalkylamines
may exert effects better described by the MDA/X component of this model than by either
pure AMPH-like or DOM-like action.
metabolism and distribution may account for some of the observed results,
it is entirely possible that some of these agents might also produce a unique
effect that is neither AMPH-like nor DOM-like. Future drug discrimination
studies, using the MDA analogs as training drugs, should be of immense
benefit in understanding their stimulus effects.
Phenalkylamines are capable of producing a wide variety of pharmacological
effects; prominent among the central stimulus effects produced by these
agents are AMPH-like effects and DOM-like (or DOB-like) effects. Nearly
a decade ago, the author proposed that such agents exist along an
AMPH/DOM continuum and that the nature and location of pendent substit-
uents determine where along this continuum an agent may lie (Glennon
et al. 1980). It seems likely that MDA is positioned somewhere near the
center of this continuum, because it produces both AMPH-like and
DOM-like effects. Current evidence suggests the need for a revised model
to explain the activity of MDE and MDP and the finding that 2,3-MDA and
3,4-DMA produce MDA-like, but not AMPH-like or DOM-like stimulus
61
effects. Certain of these agents may produce non-AMPH/non-DOM-like
effects (with or without a certain amount of residual AMPH-like or
DOM-like character); to account for this, a trifurcated continuum as shown
in figure 8 is proposed. Agents such as MDE and MDP may exist
somewhere along the MDA/X segment of this new model. The presence of
the methylenedioxy group may not be a prerequisite for agents to exist
along this arm of the model if, for example, agents such as PMMA can be
shown to produce effects similar to those of MDE. In contrast, the amine
substituents may play an important role. Obviously, additional studies will
be necessary to support this working model. The model, as simplistic as it
may be, accounts for the fact that certain of these agents possess some
AMPH-like or DOM-like character but, at the same time, do not seem to
follow the established SAP. The “X-like” activity (which could, in reality,
consist of several different actions) may be a consequence of direct or
indirect actions on dopamine and/or serotonin receptors (or populations of
these receptors not normally involved in the actions of AMPH or DOM) or
may represent actions at entirely different types of receptors.
DISCUSSION
COMMENT: I was surprised by the results with the N-hydroxy com-
pounds, because a number of years ago N-hydroxy-p-toluylamphetamine was
studied, and it was found that it was identical to ptoluylamphetamine in its
properties because it was actually rapidly and essentially quantitatively
converted to p-toluylamphetamine. You are finding that the N-hydroxy
analog of MDMA is not MDMA-like in its properties. These data suggest
that they certainly are not metabolized in a similar way, perhaps.
RESPONSE: I did not show that the N-hydroxy analog of MDA is not
MDMA-like. I showed that it is not amphetamine-like.
COMMENT: That makes it not MDMA-like.
RESPONSE: You can extrapolate. I have problems with those
extrapolations.
COMMENT/QUESTION: I was not using MDMA-like in the sense that
you were using it--as a substitute. I am simply saying it did not have the
pharmacologic effect that MDMA had; namely, substitution for ampheta-
mine, which obviously must mean that the N-hydroxy compound is not
converted to MDMA to the same extent at least as the p-toluylamphetamine
analog was. I would like to know if you have any information about the
metabolism of those N-hydroxy compounds.
RESPONSE/QUESTION: None whatsoever. We are looking at the
metabolism of some of the other compounds, but we have not looked at the
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N-hydroxy. Has the N-hydroxy MDA been identified as a metabolite of
MDA from the earlier studies?
ANSWER: Not that I can remember.
RESPONSE: We have not looked at that at all. But it is surprising. I
expected to see either hydroxylation or dehydroxylation, so I expected to
see similar activities. But this is what we see. If you compare the
activities on a milligram per kilogram basis, the N-hydroxy amphetamine
appears to be equipotent. However, when you look at the molecular
weights (it is a different salt), it is in fact twice as potent. I cannot explain
that.
QUESTION: With respect to the N-hydroxy MDA, have you done a
timecourse to see whether at longer times you might pick it up if it is a
metabolic induction?
ANSWER: No, we have not. It is an idea.
QUESTION: I noticed that my group is the major one that disagrees with
the amphetamine-like activity of MDMA. And when you look at the MDE
and MDP you lose that. Is it possible that this MDMA-like activity is
really an artifact? That is, that the rats are saying it seems to be
amphetamine-like but, in fact, it really is not. And when you go ahead and
put the ethyl or propyl, you do not see the amphetamine-like activity
because that simply is not what it is?
ANSWER: Obviously no one knows what the rats are thinking. My
opinion, based on what we have done so far, is that MDE and MDP may
be doing something different. We may have a third wheel on this
continuum, it may be a three-way continuum with MDA in the middle.
Maybe there is a third kind of effect that MDA is capable of producing, but
this is grossly overshadowed by its amphetamine-like or DOM-like activity.
If we start making analogs of MDA like the N-methyl, that moves it a little
off center. It still retains some amphetamine-like activity. It may, at high
doses, have DOM-like activity. We certainly do not see it. And then we
have this third type of effect if we go even farther out to the ethyl homolog
or to the types of compounds that you are making. You may have now
gotten far enough from center that these compounds no longer have the
amphetamine-like or the DOM-like character. But what we see with
MDMA is that it is amphetamine-like.
QUESTION: Where does parachloroamphetamine fit in here?
ANSWER: We have never looked at parachloroamphetamine itself.
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QUESTION: Substitution of lipophilic moieties on the phenyl ring of DOM
makes the compounds more potent. Substitution of ionic-type moieties. like
hydroxyl anions, makes them less potent. Is that a good generalization, that
making the phenyl ring more lipophilic makes the compounds more potent
in the DOM series?
ANSWER: No. There appears to be an optimal potency beyond which the
compounds are no longer active as agonists but can, in fact, act as
antagonists. So we have analogs of DOM that can antagonize the effects of
DOM, because we have passed this optimal lipophilicity. The idea of
lipophilicity at the four position is not new, and a number of investigators
have looked at this over the years with regard to hallucinogenic activity.
Recently we have been looking at it with regard to binding at 5-HT2 sites.
And we see this correlation fits very well. As we get up to a certain point
though, it stops. It appears that, in terms of discrimination and in humans,
the propyl compound appears to be optimal. Once we get beyond that,
lipophilicity continues to increase, 5-HT2 receptor affinity continues to
increase. The compounds start decreasing in potency and, in fact, they
become inactive. So it may be that some of these are partial agonists, and
ultimately we get out to antagonists of DOM. So it is not a strictly linear
relationship.
QUESTION: Is there any evidence that a common effect of amphetamine
and MDMA is mediated through a common biochemical mechanism; for
example, antagonism studies in haloperidol?
ANSWER: No, we have not done anything in that regard in terms of drug
discrimination.
QUESTION: You seemed to have looked through all of the various
substituents in your amphetamine structure, with one exception. You did
not touch the benzene ring itself. What would happen if you saturate the
benzene ring and make a saccharide derivative of amphetamine?
ANSWER: It retains amphetamine-like activity.
RESPONSE: This is what, propylhexedrine? We have looked at
propylhexedrine, and it does retain amphetamine-like activity, but it is less
potent. In rats trained to discriminate 1.5 mg/kg of racemic MDMA from
saline (ED50=0.76 mg/kg), the ED50 values for stimulus generalization to
MDE and N-OH MDA are 0.73 and 0.47 mg/kg, respectively (Glennon and
Misenheimer, unpublished observations).
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Amphetamines: Aggressive and
Social Behavior
Klaus A. Miczek and Jennifer W. Tidey
INTRODUCTION
The potential of sudden, intense acts of violence is one of the most
attention-getting facets of amphetamine action. Hippies of the 1960s
warned: “Speed kills.” At that time, reports from law enforcement
personnel, psychiatrists, and drug abusers themselves could be viewed to
indicate that “amphetamines, more than any other group of drugs, may be
related specifically to aggressive behavior” (Ellinwood 1972). Neurotoxic
effects of amphetamines and, more recently, their designer derivatives on
neurons containing dopamine and serotonin--two neurotmnsmitters of para-
mount significance in neurobiological mechanisms of aggressive, defensive,
social, and sexual behavior--have added a new dimension to the current
wave of stimulant abuse (Seiden and Vosmer 1984; Ricaurte et al. 1985).
In fact, amphetamines may be associated with extreme changes in aggres-
sive and social interactions: intense and sudden acts of aggression as well
as total withdrawal from any social intercourse. These striking, seemingly
opposite shifts in social and aggressive behavior under the influence of
amphetamines and related substances are the product of numerous pharma-
cological, behavioral, and environmental, as well as genetic determinants.
Another paradox about amphetamines and related psychomotor stimulants is
their calming effect on excessively aggressive children and adolescents
diagnosed with attention deficit disorder. The neurobiological mechanisms
for the multiple effects of amphetamines on aggressive behavior have been
most often related to those relevant to the motor-activating and motor-
arousing effects of these drugs. Yet, mechanisms of amphetamine action
specific to their effects on aggressive and social behavior have eluded a
satisfactory delineation.
AMPHETAMINES AND HUMAN AGGRESSIVE AND SOCIAL
BEHAVIOR
Case Reports and Surveys
Case reports and survey data provide a complex account of the link
between amphetamines and aggressive behavior, leading to sharply differing
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opinions on the severity and nature of the problem. As recently reviewed
(Miczek 1987), a series of clinical observations and surveys of institu-
tionalized drug abusers and delinquents point to greatly varying representa-
tion of amphetamines in these individuals during the commission of violent
and criminal behavior. For example, several descriptions of murders and
other intense violent behavior attribute these seemingly unpredictable and
drastic changes in behavior to amphetamine abuse (Ellinwood 1971;
Siomopoulos 1981). Frequently, clinical analyses suggest that chronic
amphetamine intoxication, particularly by the intravenous route, produces a
psychotic paranoid state, including frightening delusions that may result in
aggressive acts (Kramer 1969; Angrist and Gershon 1969; Ellinwood 1971;
Siomopoulos 1981).
Some surveys found sizable proportions of prison populations and juvenile
delinquents to have committed their crimes of violence while intoxicated by
amphetamines (Hemmi 1969; Simonds and Kashani 1979); conversely,
others reported rare cases and very small percentages of juvenile delinquents
and excessively hostile individuals as having abused amphetamine
(Tinklenberg and Woodrow 1974; Tinklenberg et al. 1977; Gossop and Roy
1976). The reliability of several of these surveys is compromised by the
lack of adequately matched samples in highly selected populations of insti-
tutionalized individuals. Reliability is also compromised by reliance on
notoriously variable verbal reports for the details of the dose and frequency
of amphetamine intake, as well as on the exact nature of the drug. It may
very well be that the unusual and intense violent acts are more prominent
among chronic high-dose abusers than they are among occasional ampheta-
mine abusers. This possible distinction needs to be investigated
systematically. So far, no reports have been published showing that
substituted amphetamines are linked to a high incidence of excessively
violent behavior or other offensive social behavior.
Attention Deficit Disorders
Reductions in aggressive behavior after treatment with amphetamine and
other psychomotor stimulants are seen in children and adolescents who have
been diagnosed with hyperkinesis or attention deficit disorder. There is
considerable disagreement about these diagnostic categories and about
whether the violent outbursts and uncontrolled episodes of aggressive
behavior are limited to the early developmental period or continue into
adulthood (Mendelson et al. 1971; Minde et al. 1972).
The early report by Bradley (1937) on beneficial treatment effects with
amphetamine in aggressive, destructive, irritable, and hyperactive boys was
repeatedly confirmed by double-blind, placebo-controlled studies, Significant
reductions in aggressive behavior and improvements in social interactions
were found after treatment with 10 to 40 mg/day of d- or l-amphetamine
for boys and girls, 5 to 14 years of age, who had been diagnosed as
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hyperkinetic, autistic, explosive, unsocialized, or emotionally disturbed
(Conners 1969; Conners 1972; Winsberg et al. 1972; Winsberg et al. 1974;
Arnold et al. 1973; Maletzky 1974).
Experimental Studies on Human Aggression
Earlier experimental studies on amphetamine and human behavior focused
on performance measures as well as on eating and sleep disorders. None of
these studies identified an increase in aggressive behavior as a problematic
side effect (Leventhal and Brodie 1981; Laties and Weiss 1981). As a
matter of fact, controlled studies on amphetamine and human social
behavior, acute doses of d-amphetamine (5 to 30 mg) were found to
increase socializing and speaking with no indications of aggressive acts
(Griffiths et al. 1977). However, antifatigue and endurance-enhancing
effects of amphetamines may contribute to the effects of these substances
on aggressive behavior.
In an experiment that exposes a human subject to a competitive task leading
to prize money, acute amphetamine doses (5 and 10 mg) increased aggres-
sive responses such as delivering blasts of noise or subtracting money from
the presumed competitor (Cherek et al. 1986). At the higher dose (20 mg),
the rate of aggressive behavior declined, but the rate of money-winning
responses increased, further indicating a dissociation between amphetamine
effects on aggressive and nonaggressive responses. In contrast to ampheta-
mine, acute administrations of caffeine only decreased aggressive responses,
regardless of whether the subject was strongly or moderately provoked by
loss of prize money (Cherek et al. 1983). This experimental approach to
the study of human aggressive behavior under controlled laboratory condi-
tions fulfills the demands for accurate, objective, and reliable behavioral
measures. It is unclear, however, whether or not this experimental prepara-
tion is a valid model of clinically significant problem behavior. Future
studies with hyperaggressive individuals or those prone to stimulant-induced
aggressive behavior will be needed to validate the laboratory situation.
AMPHETAMINES AND AGGRESSION IN NONHUMAN SUBJECTS
Amphetamine Aggressiveness
More than four decades ago, Chance (1946a; Chance 1946b) observed epi-
sodes of rapid running, audible vocalizations, upright postures, biting, and,
eventually, increased lethality after administration of near-toxic doses of
amphetamine (greater than 10 mg/kg) to mice that were housed in groups.
This so-called “amphetamine aggressiveness or rage,” most often studied in
laboratory rats and mice, but also in chicks, consists of fragmented agonistic
acts and postures embedded in stereotyped motor routines (Randrup and
Munkvad 1969; Hasselager et al. 1972). The phenomenon of amphetamine
aggressiveness in otherwise placid laboratory rats or mice has limited
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behavioral validity and appears to be primarily of pharmacological or
toxicological interest; like motor stereotypies, the so-called amphetamine
aggressiveness is reduced by experimental compromises of the nigrostriatal
dopamine system such as synthesis inhibitors, receptor antagonists, and
neurotoxic or electrolytic lesions in this region.
Traditional Research Methodologies
Amphetamine, cocaine, and other psychomotor stimulants have been
examined with traditional research methodologies involving isolation-induced
aggression in mice; pain-induced aggression in mice, rats, or squirrel
monkeys; brain stimulation-induced aggression in cats; or mouse killing by
rats. The results show an inconsistent mixture of increases, decreases, or
no effects. Among the most important determinants of amphetamine effects
on aggressive and defensive responses are the stimulus situation, species,
prior experience with these types of behaviors (table 1) and, most critically,
dosage and chronicity of drug exposure.
TABLE 1. Doses of amphetamines for modulating behavior
Aggression Nonaggressive
Increases Decreases Motor Activity References
Isolation-Induced Aggression in Mice
None
None
None
2.0 IP
None
2.0 IP
None
4.0 IP
None
None
None
10.0 IP
ED50 > 3 IP
5.0 IP
> 2.0 IP
4.0 IP
6.0 IP
10.0 IP
8.0 IP
8.0 IP
0.25-1 PO
5 IP
10.0 IP
ED50 3 IP
N/S
> 2.0 IP
4.0 IP
N/S
N/S
4.0, 8.0 IP
8.0 IP
> 1.0 PO
N/S
Melander 1960
DaVanzo et al. 1966
Valzelli 1967
Charpentier 1969
Le Douarec and
Broussy 1969
Welch and Welch
1969
Scott et al. 1971
Hodge and Butcher
1975
Miczek and
O’Donnell 1978
Krsiak 1979
Essman and Valzelli
1984
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TABLE 1. (Continued)
Aggression
Increases Decreases
Nonaggressive
Motor Activity References
Pain-Induced Aggression in Mice
8.4 PO None
0.1 IP None
0.5 PO None
None 5.0 PO
Pain-Induced Aggression in Rats
None 3.0 IP
0.25-1 IP 4.0 IP
1.0 IP 3.0 IP
3.48 IP N/S
None > 2.5 IP
9.3 PO
N/S
> 0.5 PO
2.5 PO
N/S
N/S
N/S
N/S
N/S
Stille et al. 1963
Kostowski 1966
Hoffmeister and
Wuttke 1969
Tedeschi et al. 1969
Lal et al. 1968
Crowley 1972
Powell et al. 1973
Mukherjee and
Pradhan 1976
Sheard 1979
Pain-Induced Aggression in Squirrel Monkeys
None
0.125-1 SC
0.125-1 SC
0.3, 1 IM
2.0 SC
2.0 SC
0.03-1 IM
> 2 SC
> 2 SC
DeWeese 1977
Hutchinson
et al. 1977
Emley and
Hutchinson 1972;
Emley and
Hutchinson 1983
Extinction-Induced Aggression in Rats
0.1 IM 0.5, 1.0 IM 0.1-1.0 IM
Brain Stimulation-Induced Aggression in Rats
None 2.0 IP 2.0 IP
Brain Stimulation-Induced Aggression in Cats
5-7.5/cat IP
None
None
10/cat IP
>4  IP
0.3, 0.8 IP
N/S
N/S
N/S
0.125-0.5 IP 1-1.5 IP N/S
0.5-3 IP N/S N/S
Miczek 1974
Panksepp 1971
Sheard 1967
Baxter 1968
MacDonnell and
Fessock 1972
Marini et al. 1979
Maeda et al. 1985
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TABLE 1. (Continued)
Aggression
Increases Decreases
Nonaggressive
Motor Activity References
Drug-Induced Aggression in Mice
l-dopa
2.0 IP N/S N/S Lal et al. 1970
Drug-Induced Aggression in Rats (Withdrawal from Opiates)
2.0 IP N/S
ca. 3-11/day PO N/S
1-4 IP N/S
2.0 IP N/S
2.0 IP N/S
2.0 IP N/S
Mouse Killing in Rats
N/S
N/S
N/S
N/S
N/S
N/S
None
None
2-15 IP 4-5 IP
ED50 1.5 IP ED50 6.6 IP
None
None
None
0.5-2 IP
ED50 0.8 IP
ED50 1.8 IP
> 2 IP
ED50 4.2 IP
1-3 IP
None 5.0 IP N/S
None
None
None
None
None
None
None
None
None
None
2, 4 IP
ED50 0.18 IP
1.5 IP
ED50 0.6 IP
0.75-3 IP
2.0 SC
2 IP
ED50 1.15 IP
0.5-2 IP
1-3 IP
1, 1.5 IP
> 0.18 IP
N/S
N/S
N/S
N/S
N/S
N/S
N/S
2-3 IP
Florea and Thor 1968
Thor 1971
Lal et al. 1971
Carlini and
Gonzalez 1972
Puri and Lal 1973
Gianutsos et al. 1975
KarLi 1958
Horovitz et al. 1965;
Horovitz et al.
1966
Kulkarni 1968
Sofia 1969
Salama and Goldberg
1970; Salama and
Goldberg 1973
Valzelli and
Bemasconi 1971
Vergnes and
Chaurand 1972
Malick 1975
Gay et al. 1975
Malick 1976
Gay and Cole 1976
Posner et al. 1976
Barr et al. 1976
Barr et al. 1977
Barr et al. 1979
Russell et al. 1983
NOTE: All doses are expressed in mg/kg; N/S=Data not specified, PO=oral injection.
SOURCE: Miczek 1987.
73
Low acute amphetamine doses enhance pain-induced aggressive/defensive
reactions in mice, rats, and squirrel monkeys (Kostowski 1966; Hoffmeister
and Wuttke 1969; Crowley 1972; Powell et al. 1973; Emley and Hutchinson
1972; Emley and Hutchinson 1983). For example, squirrel monkeys sub-
jected to electric shocks to their tails, bite a rubber hose more frequently
after being administered amphetamine (0.06 to 1.0 mg/kg, SC) (Emley and
Hutchinson 1972; Emley and Hutchinson 1983; Hutchinson et al. 1977). In
rats, these pain-induced aggressive/defensive responses increase with doses
of 0.1 to 1.0 mg/kg (Crowley 1972).
Intermediate to higher amphetamine doses routinely decreased or disrupted
isolation- and extinction-induced aggressive behavior and pain-induced
aggressive/defensive reactions in mice, rats, and squirrel monkeys while
increasing nonaggressive motor activity (Melander 1960, DaVanzo
et al. 1966, Miczek 1974; Hodge and Butcher 1975; Krsiak 1979). It may
also be mentioned that amphetamines, as well as other psychomotor stimu-
lants, reliably block mouse-killing behavior in selected laboratory rats
(Horovitz et al. 1965; Kulkami 1968; Malick 1976; Russell et al. 1983). In
this screening test for antidepressant drugs, the antimuricidal effect of
amphetamines may be considered a false positive (Howard and Pollard
1983).
This complicated pattern of amphetamine effects in the traditional models of
aggression, each relying usually on a single index, may be conveniently
interpreted to reflect how amphetamine’s effects on aggression depend on
the particular measurement technique. Yet, such conclusions are not
heuristic. More recently, an ethological approach to the study of drug
action on aggression has focused on biologically valid test situations and
detailed behavioral measurements, in an effort to gain insight into causative
and functional determinants of aggressive, defensive, submissive, and flight
behaviors (Miczek et al. 1984). In the following, an examination of the
most important pharmacological and behavioral determinants of ampheta-
mine effects on aggressive and defensive behavior in several animal species
will emphasize the lawful, systematic nature of these drug behavior inter-
actions and, at the same time, highlight their social and environmental
constraints.
BEHAVIORAL DETERMINANTS OF AMPHETAMINE EFFECTS ON
AGGRESSION
Differentiation Between Attack, Defense, Submission, and Flight
In animal species commonly used in laboratory research, social aggregation
and dispersion are achieved by agonistic behavior patterns with various acts,
postures, movements, and signals. Confrontations between a territorial
resident and an intruder, between a dominant and lower-ranking group
member, between rival males or females, between a lactating female and a
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potential threat to her offspring can be reproduced and studied under
controlled laboratory conditions. Amphetamine differentially alters attack
and threat behaviors vs. defensive and flight reactions.
In situations of social conflict, amphetamine increases the frequency of
escape and defensive responses to threats and attacks by a stimulus animal
in mice, rats, cats, rhesus monkeys, and squirrel monkeys in a dosc-
dependent manner (Hoffmeister and Wuttke 1969; Crowley et al. 1974;
Miczek and O’Donnell 1978; Miczek 1979; Schlemmer and Davis 1981;
Haber et al. 1981). Even in the absence of a distinctive behavioral stimulus
from an opponent, amphetamine induces escape and defensive responses in
mice. Krsiak considered these unprovoked defensive and escape responses
as signs of “timidity” (Krsiak 1975; Krsiak 1979; Poschlova et al. 1977).
Amphetamines decrease attack and threat behavior by dominant animals
toward lower-ranking group members, by territorial residents toward an
intruder, by lactating females defending their litter, and play fighting by
juveniles, mainly due to distortions in the perception of socially significant
signals and the disruption of integrated sequences of threat and attack
behavior (Miczek and Gold 1983; Miczek et al. 1989). Large and intense
increments in aggressive behavior after amphetamine administration may
occur suddenly in mice, rats, cats, and several primate species, under
limited conditions. Several determinants for these infrequent but important
amphetamine effects have begun to be identified, such as the base rate of
aggressive behavior before any amphetamine administration, previous
experiences with aggressive and defensive behavior, and the level of
habituation to an aggression-provoking situation.
Baseline
Studies of amphetamine effects on behavior, mainly shaped and controlled
by schedules of reinforcement, have led to the general principle of rate
dependency; low rates of behavior tend to be increased by amphetamine-like
drugs, intermediate rates are less altered, and high rates are decreased
(Dews and Wenger 1977). This principle applies only rarely to the effects
of amphetamines on aggressive behavior (Miczek and Krsiak 1979). In
isolated mice, amphetamine increased the incidence of aggressive behavior
only in those subjects that were selected for their near-zero levels during
vehicle control tests. Amphetamine decreased aggressive behavior in
animals with high rates during vehicle control tests (Krsiak 1975; Krsiak
1979). These results lend themselves to a rate-dependency interpretation.
Comparisons between separate groups of subjects, one displaying a low rate
of aggressive behavior, the other a high rate, however, are less persuasive
evidence for rate dependency of amphetamine effects than is the demon-
stration of differential drug effects on low and high rates of behavior within
the same subject.
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A minute-by-minute analysis of rates of attack behavior during either a
5- or 28-minute confrontation between a resident and an intruder shows a
high rate of aggression in the initial phase of the encounter and a gradual
decline in the later phase (figure 1). This decrement from high to low rates
FIGURE 1. Effect of d-amphetamine on the frequency of attack bites by a
male resident mouse toward a male intruder during 28-
minutes (left) or 5-minutes (right) confrontations
NOTE: The resident mouse was adminstered an acute dose of amphetamine 30 minutes before
confrontation. Frequency of attacks is minute-by-minute average.
of aggression could be due to fatigue, habituation, or changes in the
stimulus qualities of the intruder animal. Contrary to the effects of drugs
such as alcohol, there was no evidence that amphetamine increased either
the high attack rates in the early phase of the encounter or the lower rates
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of attack in the later phase (Miczek, unpublished observations). Also,
higher amphetamine doses that decreased attack behavior at the start of an
encounter did not lead to any rebound in the later phases, even during
28-minute encounters. Apparently, once an aggressive interaction has been
initiated, and the opponent reacts with defensive and flight responses,
amphetamine does not increase further the rate of aggressive behavior
within the same encounter.
Habituation
A substantial increase in aggressive behavior is seen when amphetamine is
administered to animals that are repeatedly confronting an intruder (Winslow
and Miczek 1983). Specifically, during 2-hour sessions, resident male mice
pursued, threatened, and attacked intruders 10 times, each 5-minute
encounter being separated from the next by 5 minutes. ‘The threat and
attack behavior exponentially declined over the course of the 10 consecutive
encounters; half of all aggressive behavior was displayed during the first
3 encounters, and the remaining 7 encounters were characterized by very
low levels of aggressive behavior (Winslow and Miczek 1984). It is in this
later phase of the habituation process that amphetamine more than doubled
the rate of attack behavior (figure 2). These amphetamine effects on attack
and threat behavior were dissociated from those on elements of motor
activity such as walking, rearing, or grooming, in terms of timecourse and
dose-effect curve. This pattern of effects suggests a direct action of
amphetamine on the habituation process, an elementary form of learning, in
addition to the well-known antifatigue effects of amphetamine.
Burst-Like Pattern of Aggressive Behavior
Amphetamine substantially alters the characteristic temporal pattern of
agonistic behavior (Miczek 1983; Miczek et al. 1989). Normally, epochs or
bursts of intense and frequent threat and attack behavior alternate with
periods of relative behavioral quiescence, as, for example, in confrontations
between a resident mouse and an intruder. The intervals that separate
consecutive attacks are exponentially distributed, with 70 to 80 percent of
all intervals being very short and constituting the steep portion of this
distribution; the remaining long intervals represent the gaps that separate
bursts of attacks. Amphetamine, at doses that did not alter the frequency or
duration measures of aggressive behavior, increased the size of the
aggressive bursts, and at higher doses abolished the characteristic burst
pattern (figure 3).
Sequences of aggressive behavior that are composed of characteristic acts
and postures following each other rapidly are disrupted. These disorganiz-
ing effects parallel the analysis of amphetamine effects on other intricately
patterned behaviors such as feeding, maternal care, play behavior, or
reproductive interactions. For example, amphetamine suppresses play
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FIGURE 2. Effects of d-amphetamine and methysergide on the cumulative
frequency of attack bites and sideways threats (top) and
walking duration (bottom) during the initial and later
resident-intruder confrontations
NOTE: Confrontations were in a sequence of 10 consecutive 5-minute trials. each trial seperated
from the next by a 5-minute interval.
SOURCE: Winslow and Miczek 1983.
behavior in juvenile rats, an effect that is not antagonized by dopamine or
norepinephrine receptor antagonists (Beatty et al. 1984). Similarly, maternal
care is severely disturbed in female vervet monkeys under the influence of
amphetamine (Schirring and Hecht 1979). These findings and those of
others emphasize the disintegrative effects of amphetamine on patterns of
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NOTE: Superimposed on the histograms are curves of a mixed exponential distribution and the
component distributions. The length of attack bouts is estimated from the intersection of
the component distributions. The intervals between attacks that represent the gaps between
bouts are shaded.
SOURCE: Miczek et al. 1989.
FIGURE 3. Frequency historgrms of interval length between
consecutive attack bites by a resident mouse toward an
intruder after saline control, 2.5, or 5.0 mg/kg
d-amphetamine (n=20). B. Number of interattack intervals
surviving to increasing durations from single encounters
under saline control conditions, 1.25, 2.5, and 5.0 mg/kg
d-amphetamine.
social interaction (Kjellberg and Randrup 1971; Kjellberg and Randrup
1973; Garver et al. 1975; Miczek 1981b).
PHARMACOLOGICAL DETERMINANTS
Dose
Dose-dependent biphasic effects on aggressive behavior may be seen in
several, but not all animal species and situations (Miczek and Krsiak 1979;
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Miczek 1987). The paramount importance of dosage for amphetamine
effects on aggressive and social behavior is illustrated by experiments in
male rats confronting an opponent, either in a competitive situation or as an
intruder into their homecage, showing aggression-enhancing effects at low
acute doses (Miczek 1974; Miczek 1979). On occasion, increases in
aggressive behavior after administration of low acute amphetamine doses
have also been seen in fish, mice, and selected rhesus and stumptail
macaque monkeys (Weischer 1966; Haber et al. 1981; Winslow and Miczek
1983; Smith and Byrd 1984; Kantak and Miczek 1988). A much more
consistent observation, however, is the amphetamine-related increase in
defensive, submissive, and flight reactions, which systematically increase
with dose, up to a level at which motor stereotypies begin to interfere with
the display of these behaviors (Hoffmeister and Wuttke 1969; Miczek 1974;
Miczek and O’Donnell 1978).
Ongoing experiments with methylenedioxymethamphetamine (MDMA) show
a systematic dose-dependent decrease in attack and threat behavior in mice
confronting an intruder into their homecage (Miczek et al., unpublished
observations). The decrement in aggressive behavior appears to be
behaviorally specific; it is obtained at MDMA doses (0.3, 1, 3 mg/kg) that
are lower than those necessary to decrease measures of conditioned
performance under the control of schedules of positive reinforcement.
Because of species-dependent neurotoxicity, MDMA’s effects on aggressive
behavior need to be explored in other species, including primates.
Chronicity
Tolerance or sensitization may result from repeated exposure to ampheta-
mines, depending on the interval between consecutive amphetamine admini-
strations (Segal et al. 1980; Robinson and Becker 1986). with continuous
drug exposure resulting most often in tolerance, and intermittent
administration in behavioral sensitization. Most of the evidence on the
determinants of tolerance and sensitization to amphetamine derives from
studies on the motor-activating effects of these drugs as measured in
situations promoting locomotion, circling, or stereotyped movements.
Unfortunately, only a few experimental studies have focused on the effects
of repeated amphetamine administration on aggressive and social behavior,
although it is precisely this condition that is associated with the most
troubling clinical experiences. Methamphetamine, given in daily increasing
doses. decreased aggressive behavior in seven different mouse strains and
genera, except for grasshopper mice (Richardson et al. 1972). Daily
administration of d-amphetamine or cocaine for 2 to 4 weeks to resident
mice confronting an intruder failed to shift the dose-effect function for these
drugs’ effects on any element of threat and attack behavior, while
augmenting the stereotypy-inducing effects (O’Donnell and Miczek 1980).
Slow-release amphetamine capsules, implanted subcutaneously in rats that
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lived in large all-male colonies, produced hyperactivity and social
withdrawal in the initial phase of drug exposure; after about a week a high
incidence of startle, threat, and defensive responses was seen (Ellison 1978;
Eison et al. 1978). Similar, chronically implanted amphetamine capsules in
vervet monkeys again resulted in hallucinatory-like grooming, grasping, and
head movements, and disrupted social interactions without evidence for
tolerance development (Nielsen and Lyon 1982). These progressively more
pronounced social withdrawal and motor stereotypies are also seen in groups
of macaques or marmosets that are administered amphetamine daily (Garver
et al. 1975; Ridley et al. 1979). So far, neither tolerance nor sensitization
to amphetamine’s effects on withdrawal from all social and aggressive
interactions has been seen in the very few studies that either examined
changes in the ongoing rate of these behaviors during the course of repeated
amphetamine administration or that tested for shifts in dose-effect functions
before, during, and after chronic amphetamine exposure.
The only evidence on chronic amphetamine administration and heightened
aggressiveness derives from the studies, discussed earlier, on group-housed
placid laboratory rats or mice. The behavioral validity of these phenomena
under near-toxic dosage conditions, however, needs to be resolved.
Opiate Withdrawal
Amphetamine effects on aggression are markedly modulated by opiates and
opioid peptides. Withdrawal from prolonged exposure to opiates may lead
to increased defensive and aggressive responses in mice and rats and
increased hostility in humans (Lal et al. 1971; Gossop and Roy 1976;
Kantak and Miczek 1986). Amphetamine and cocaine, as well as dopami-
nergic agonists, increase further the already high levels of defensive
responses in aggregated rats undergoing withdrawal from opiates, leading in
extreme cases to the death of the subjects (Lal et al. 1971; Puri and Lal
1973).
Locomotor-activating effects of amphetamine have previously been linked to
dopamine release (Iversen 1977), and it has been suggested that the
aggression-enhancing effects may be mediated by a similar mechanism
(Gianutsos and Lal 1976). Enhancement of aggression by treatment with a
combination of l-dopa and d-amphetamine can be blocked with the
dopamine receptor antagonist haloperidol (Lal et al. 1975); aggression
induced by challenge with amphetamine during morphine withdrawal is
blocked by either haloperidol or alpha-methyl-para-tyrosine (Lal 1975; Puri
and Lal 1973).
The dramatic heightening of aggressive behavior in morphine-withdrawn
animals may be due to dopamine receptor upregulation (Gianutsos
et al. 1975; Lal et al. 1975). Morphine and methadone inhibit dopamine
receptors in the central nervous system (CNS) suggesting possible disuse
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supersensitivity and hyperactivity of the receptor during withdrawal (Puri
and Lal 1973; Martin and Takemori 1986). Further enhancement of
morphine-withdrawal aggression by amphetamine has been interpreted to
reflect stimulation of supersensitive dopamine receptors (Puri and Lal 1973;
Kantak and Miczek 1988).
Recently, it was found that single-housed mice that had been undergoing
withdrawal for 48 hours (after removal of a subcutaneously implanted
75-mg morphine pellet) showed an elevation of attack and threat behavior
that was doubled when these mice were challenged with amphetamine,
cocaine, l-dopa, or apomorphine (figure 4) (Kantak and Miczek 1986;
FIGURE 4. The frequency of attack, threat, walking, and grooming (mean
±SEM per 5 minutes) following saline or 0.1, 0.5, 1.0, or
25 mg/kg d-amphetamine
p<0.05 compared to vehicle control.
NOTE: These doses were administered to male resident mice implanted with either placebo pellets
(open circles) or morphine pellets (solid circles) subsequently withdrawn 48 hours prior to
testing.
SOURCE: Kantak and Miczek 1988.
Kantak and Miczek 1988). Similarly, Lal et al. (1971) and Thor
et al. (1970) found that in aggregated rats, amphetamine enhances defensive
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upright postures and audible squeals most strongly about 72 hours after
termination of a chronic morphine injection schedule. Mice that have been
in withdrawal for 5 hours, however, do not show this enhancement when
challenged with amphetamine (Miczek and Tidey, unpublished observations).
This difference in the reaction to amphetamine may reflect changes in
sensitivity of dopamine receptors over time: shortly after withdrawal from
opiates, a lessened sensitivity to amphetamine’s heightening effects on
aggression is seen; later a supersensitivity emerges.
To assess this possibility, selective dopamine receptor agonists were
administered to mice 5 hours after subcutaneous morphine pellet removal
(Miczek and Mohazab 1987). Challenge with either quinpirole, a selective
D2 agonist, or SKF 38393, a selective D1 agonist, or a combination of both
did not result in heightened aggression. In fact, the studies with combined
administration of D1 and D2 agonists indicate that, in the presence of D1
receptor activation by a small dose of SKF 38393 (3.0 mg/kg), very large
doses of D2 receptor agonists are necessary to modify aggressive behavior
in these mice, suggesting a subsensitivity of D2 receptors. This particular
timecourse relates solely to the aggression-enhancing effects; the authors and
others (Bläsig et al. 1973; Lal 1975; Kantak and Miczek 1988) have noted
that different autonomic and somatic opiate withdrawal signs emerge at
earlier times after morphine pellet removal or termination of a chronic
injection schedule.
The sub- and supersensitivity to amphetamine’s aggression-modulating
effects during withdrawal from morphine depend on the time since the last
exposure to opiates; it will be intriguing to determine how the relevant
opioid and dopamine receptor populations are altered at these behaviorally
critical phases of opiate withdrawal. The display of aggressive, defensive,
and submissive behavior is accompanied by marked changes in the function-
ing of brain opioid peptides in the absence of any drug exposure (Miczek
et al. 1986); it will also be interesting to determine how amphetamine’s
effects in individuals with differential experiences with aggressive or
submissive behavior may involve alterations in brain opioid peptides and
their receptors.
ANTAGONISM OF AMPHETAMINE EFFECTS ON SOCIAL AND
AGGRESSIVE BEHAVIOR
The most consistent and potent antagonism of amphetamine effects on
increased motor activity and stereotyped movements is obtained with
antagonists at dopamine receptors of the D2 subtype (Creese et al. 1982).
This is not the case with amphetamine’s disruptive effects on social and
aggressive behavior, So far, no antagonists have been identified that reverse
amphetamine’s disruption of sexual, play, maternal, or aggressive behavior.
In many ways, this situation parallels the clinical experiences, in being
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unable to reverse the negative symptoms of both amphetamine-induced and
endogenous psychoses with classic neuroleptics (Crow 1985).
Dopamine Receptor Antagonists
Haloperidol and chlorpromazine potently decrease aggressive and social
behavior as well as many other behavioral functions in various animal
species and humans. The marked potency and long-lasting nature of the
antiaggressive effects of the neuroleptics with dopaminergic receptor-
blocking properties may be the reason why these types of drugs are most
frequently used in treating pathologically violent individuals (Itil 1981;
Leventhal and Brodie 1981; Sheard 1984; Tupin 1985). The poor
behavioral specificity of their antiaggressive effects, however, renders the
phenothiazines, butyrophenones, or thioxanthines as less than ideal choices;
this pattern of effects is already apparent in preclinical studies (Malick
1979; Miczek and Winslow 1987).
Recently, the effects of more selective dopamine receptor antagonists on
aggressive behavior were explored. In resident mice confronting an intruder
into their homecage; quinpirole (0.1 to 1.0 mg/kg) potently reduced pursuit,
threat, and attack behavior; however, it also reduced concurrent motor
activity. This pattern of effects paralleled haloperidol effects in the same
species and situation. However, the D1 receptor agonist SKF 38393 more
selectively, although less potently, decreased aggressive behavior by resident
mice, in the absence of concurrent changes in motor functions. These
studies highlight the problem of identifying a dopamine antagonist that
could be useful in the blockade of amphetamine effects, but would not
suppress behavior on its own.
Dopaminergic receptor antagonists do not antagonize the disruptive effects
of amphetamine on aggression. In squirrel monkeys, d-amphetamine
(1.0 mg/kg) disrupted agonistic and social behavior; haloperidol pretreatment
did not prevent this disruption (figure 5, right) (Miczek and Yoshimura
1982). Similarly, d-amphetamine decreased attack and threat behavior in
resident mice confronting an intruder haloperidol pretreatment failed to
reverse this disruption, but further decreased aggressive behavior in
amphetamine-treated mice (figure 5, left) (Miczek 1981a). By contrast, the
large activation of motor activity, as evidenced by increased time spent in
locomotion, was effectively antagonized by haloperidol in mice as well as
in squirrel monkeys (figures 5). Similarly, play fighting in juvenile rats is
profoundly disrupted by amphetamine, and this disruption is not reversed by
haloperidol or chlorpromazine (Beatty et al. 1984). By contrast, in those
situations where low, acute doses of amphetamine enhance aggressive
behavior, dopaminergic receptor antagonists attenuate this enhancement.
These observations suggest differential mechanisms for the aggression-
heightening effects of amphetamine as distinct from the disruptive actions
on social and aggressive behavior. The neurobiological mechanisms for
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amphetamines’ disruption of social and aggressive behavior remain to be
elucidated.
FIGURE 5. Mice: Frequency of attack bites (A.) and the duration of
walking across cage (B.) by resident male mice after admin-
istration of d-amphetamine alone (open circles), and after
pretreatment with haloperidol (0.25 mglkg, solid circles).
Squirrel monkeys: Frequency of aggressive behavior (A.)
and walking (B.) by dominant squirrel monkeys in estab-
lished social groups following administration of ampheta-
mine alone (open bars), and combined with haloperidol
(0.25, 0.5 mg/kg, IM, solid bars).
KEY: Vertical lines at each data point represent ± 1 SEM
Noradrenergic Receptor Antagonists
Antagonism of several characteristic effects of amphetamine and cocaine by
the alpha adrenergic receptor antagonist prazosin is a most recent example
of noradrenergic mechanisms in the actions of psychomotor stimulants
(Tessel and Barrett 1986). We investigated whether or not prazosin may
attenuate the disruptive effects of amphetamine on social and aggressive
behavior in mice and squirrel monkeys (Miczek, unpublished observations).
Pretreatment with prazosin (0.4 mg/kg) attenuated the disruption of attack
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bites and sideways threats in resident mice treated with higher doses of
amphetamine, but no such attenuation was found of amphetamine-disrupted
aggressive behavior by dominant squirrel monkeys after prazosin
pretreatment (figure 6). By contrast, amphetamine’s hyperactivity, measured
FIGURE 6. Left: Frequency of attack bites (A.) and duration of walking
across cage (B.) by resident male mice after administration
of d-amphetamine alone (open circles), and after pretreat-
ment with 0.4 mglkg prazosin (solid circles). Right:
Frequency of aggressive behavior (A.) and walking (B.) by
dominant squirrel monkeys in established social groups
following administration of amphetamine alone (open
circles), and after pretreatment with 0.4 mg/kg prazosin, IM
(solid circles).
KEY: Vertical lines at each data point represent ± 1 SEM.
as time spent in locomotion, was attenuated by prazosin pretreatment both
in mice and squirrel monkeys. Previously, we have observed that
pretreatment with phenoxybenzamine or propanolol did not attenuate the
suppression of aggressive behavior in amphetamine-treated resident mice
(Miczek 198la). In juvenile rats, the suppression of play fighting by
amphetamine was also not reversed by phenoxybenzamine or propranolol
(Beatty et al. 1984). Again, although the evidence is limited to a few
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receptor antagonists and to laboratory rodents, so far there is no evidence
pointing to the possible attenuation or reversal of amphetamine’s disruptive
effects on social and aggressive behavior by noradrenergic receptor
antagonists. The negative evidence from efforts to antagonize
amphetamine’s effects on aggressive behavior with noradrenergic receptor
antagonists suggests that these amphetamine effects do not involve
noradrenergic mechanisms.
Opioid Antagonists
Opioid receptor antagonists have been found to modulate brain dopamine-
mediated behavioral and cellular functions such as motor activity, drug self-
administration, and brain stimulation reward (Koob and Bloom 1988).
Naloxone has been found to attenuate the increased motor activity in rats
and guinea pigs after amphetamine administration (Holtzman 1974; Haber
et al. 1978; Hitzemann et al. 1982; Andrews and Holtzman 1987). Similar-
ly, opiate antagonists reduced the enhancement of rewarding electrical brain
stimulation by amphetamine and cocaine (Bain and Kometsky 1987), and
intracerebral injections of opiate antagonists into the nucleus accumbens
selectively blocked heroin self-administration and motor activation in rats
(Amalric and Koob 1984; Vaccarino et al. 1985). Although independent
studies have found marked changes in social, aggressive, defensive, and
submissive behavior after either opiate antagonists or psychomotor
stimulants, the potential antagonism of amphetamine effects on these
behaviors by opiate receptor antagonist has not been investigated until
recently.
In experiments with mice and squirrel monkeys, we confirmed and extended
the antagonism of amphetamine-induced motor hyperactivity by naltrexone;
at the same time, however, amphetamine’s disruption of aggressive and
social behavior was not reversed by naltrexone (Winslow and Miczek, in
press). Specifically, in mice, the resident’s attack and threat behavior
toward an intruder was even further reduced by amphetamine after
naltrexone pretreatment (figure 7). Squirrel monkeys that are dominant
within their social group exhibit significantly lower levels of aggressive
display toward other group members and initiate fewer social interactions
after amphetamine treatment; naltrexone did not block these effects. The
interactive effects of amphetamine and naltrexone on locomotor behavior are
consistent with the proposed modulation of dopamine-mediated functions by
opioids; however, the interaction between amphetamine and naltrexone on
social behavior appears to involve a different mechanism.
SUMMARY
Clinical case reports and survey data point to incidences of intense violence
in certain individuals self-administering high doses of amphetamine via the
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FIGURE 7. Left: Frequency of attack bites (A.) and duration of walking
across cage (B.) by resident male mice after administration
of d-amphetamine alone (open circles), and after pretreat-
ment with 1.0 mg/kg naltrexone (solid circles). Right:
Frequency of aggressive behavior (A.) and walking (B.) by
dominant squirrel monkeys in established social groups
following administration of amphetamine alone (open
circles), and after pretreatment with 1.0 mg/kg, IM,
naltrexone (solid circles).
KEY: Vertical lines at each data point represent ± 1 SEM. 
SOURCE: Winslow and Miczek 1988.
intravenous route. It is unclear how common this amphetamine effect is,
what circumstances promote its occurrence, and which characteristics
predispose an individual to exhibit this effect,
Amphetamine may engender a dose-dependent biphasic effect on aggressive
behavior in experimental situations, both with human and animal subjects,
as, for example, in subjects that have habituated to an aggression-provoking
stimulus. Most often, however, amphetamines disrupt social, sexual,
matemal, and aggressive behavior patterns in a dose-dependent manner;
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neither tolerance nor sensitization appears to develop to these disruptive
effects.
Amphetamine consistently enhances defensive and flight reactions in various
experimental situations and animal species. This effect appears to be
mediated by brain dopaminergic systems. So far, no dopaminergic,
noradrenergic, or opioid antagonists have been found that attenuate, reverse,
or prevent the disruptive effects of amphetamines on social and aggressive
behavior. The evidence from opioid-withdrawn subjects strongly suggests a
profound modulatory influence by opioid peptides on the aggression-altering
effects of amphetamines.
DISCUSSION
QUESTION: You know the serine compound is very potent. Have you
tried lower doses on a rate-decreasing effect of the stimulant drug?
ANSWER: I tried 0.3 and 1.0. In mice, 0.3 does not have an effect in
itself. In rats, 0.3 could be quite disruptive. So there is quite a bit of a
species difference. The range of dose is very different in mice and rats.
QUESTION: What do you think causes the aggressive decreasing effects?
Are the mice stereotyping or perseverating on some other object?
ANSWER: In the studies we did in mice, rats, and monkeys, we looked
carefully at motor changes that might intrude into the behavior and prevent
the animals from showing the behavior, not in this dose range. They are
nonoverlapping dose ranges. You have to go to higher doses to see
stereotypic and motor-activating effects.
In fact, Cherek made that point in one of the very first studies. You
cannot see further increases in monetary reinforced behavior. But you see a
decline in aggressive behavior. And that is true in other species and
humans, too. So the most significant point is that the disruptive effects are
due to the intrusion into the repertoires of other repetitive routines.
COMMENT: One of the first studies that was done with SCH compound
23390 showed that it had pronounced antiaggressive effects. This was a
Canadian study of people who were in backward, isolated conditions. It
had a fairly pronounced effect there.
I think one of the things that is confusing in the aggressive homicide
literature is the fact that at low doses, i.e., 10, 20, 30 milligrams for a
70-kilogram person, there is a calming effect. This was one of the things
that we used to see with hyperactive children. Many of those hyperactive
children were indeed aggressive-hyperactive children, and the amphetamines
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had a very pronounced effect on that. This probably represents a low-level
activity.
In really aggressive people who have taken amphetamines a long time, you
see what is called the reactive phase of aggressiveness.
Let me give you an example of this, which is particularly true in homicides.
The individual is engaged in an activity and suddenly misinterprets
something. He wakes up in the back of a car and smells poison gas and
hits someone over the head with a pipewrench. Or he is robbing a store
and someone smiles. There is a sudden impulse and he kills an individual.
If you look at the court records, you see that story repeatedly, i.e., this
reactive component. And you can see the same thing in chronic animals.
You do have to take them out to a 3- or 6-month period to see those
effects. During long-term chronic use, the dopamine at that point is
markedly depleted. We are talking about animals that have 20 or
30 percent of the original dopamine levels a month or so after they have
been given the last dose of amphetamine.
So I think we are talking about two or three different phenomena, and I
think it is very important that we make those distinctions.
RESPONSE: I left aside the hyperactivity issue because that is a literature
study in itself. It is also limited to adolescents, children, and juveniles,
although there are some reports in adults as well. But there the therapeutic
range for amphetamine is 20, 30, or 40 milligrams, and for methylphenidate
it is slightly higher, which is actually the preferred agent.
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Neurochemical Mechanisms
Involved in Behavioral Effects of
Amphetamines and Related
Designer Drugs
Lisa H. Gold, Mark A. Geyer, and George F. Koob
INTRODUCTION
The psychoactive drug 3,4-methylenedioxymethamphetamine (MDMA) has
become increasingly popular as an abused substance (Beck and Morgan
1986; Peroutka 1987). Biochemically, MDMA is thought to release
serotonin and to a lesser extent dopamine (Johnson et al. 1986; Nichols
et al. 1982; Schmidt et al. 1987), while structurally, MDMA resembles both
mescaline and amphetamine (Nichols et al. 1986; Shulgin 1978). MDMA is
the N-methylated form of 3.4-methylenedioxyamphetamine (MDA), another
substituted phenylethylamine with psychotropic properties that may have
contributed to its popular name, “the love drug.” MDA is considered to be
frankly hallucinogenic and has been found to be highly toxic to serotonergic
neurons (Ricaurte et al. 1985). Recently, long-term depletions of sero-
tonergic markers have also been observed following single and multiple
injections of MDMA in experimental animals, indicating a neurotoxic
potential similar to that associated with MDA (Mokler et al. 1987; Schmidt
1987; Stone et al. 1986).
Interestingly, some psychotherapists have been using MDMA to enhance the
psychotherapeutic process and to promote easy emotional communication in
their patients (Grinspoon and Bakalar 1986). MDMA is characterized as
evoking an altered state of consciousness with emotional and sensual
overtones (Shulgin and Nichols 1978). This state is described as a pleasant
state of introspection, a highly controllable experience that invites
intensification of feelings (Grinspoon and Bakalar 1986) and greatly
facilitates interpersonal communication (Nichols et al. 1986). Encouraged
by these properties, the advocates of MDMA-assisted therapy argue that
MDMA is a useful therapeutic tool. Unfortunately, sympathomimetic side
effects are occasionally mentioned (Barnes 1988; Grinspoon and Bakalar
1986; Shulgin and Nichols 1978), and concern over a potential to induce
arrhythmias in individuals with underlying cardiac disease has been
expressed (Dowling et al. 1987).
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To better understand the behavioral effects of MDMA, this drug and various
analogs have been tested in several behavioral procedures in animals.
Significant abuse potential for MDMA was demonstrated by animal self-
administration of MDMA (Beardsley et al. 1986, Lamb and Griffiths 1987)
and a lowering of self-stimulation thresholds by MDMA (Hubner
et al. 1988). MDMA has also been reported to generalize to amphetamine
in drug discrimination studies, indicating that MDMA may have subjective
effects similar to those of amphetamine (Evans and Johanson 1986; Kamien
et al. 1986; Oberlender and Nichols 1988). A more complex mechanism of
action has been suggested by one report of generalization to the serotonin
agonist fenfluramine (Schechter 1986) and another report that described
drug-like responding following MDMA in rats trained on mescaline
(Callahan and Appel 1987). Indeed, several authors have concluded that
MDMA may produce discriminative stimulus effects that are different from
both stimulants and hallucinogens (Glennon et al. 1988; Oberlender and
Nichols 1988).
LOCOMOTOR ACTIVITY AND PSYCHOSTIMULANT EFFECTS
Locomotor activity has historically been used as an index of psycho-
stimulant effects. Simple assessment of amount of locomotor activity can
provide the basis for anatomical as well as pharmacological analysis of the
neural substrates that mediate the behavioral expression of stimulant action.
More sophisticated behavioral measurement systems can record multiple
measures of activity and describe spatial and temporal patterning of locomo-
tion. In such systems, qualitative aspects of behavioral activation can be
evaluated by examining the entire activity profile. A comparison of the
effects of novel drugs with those produced by well-characterized substances
may lead to a better understanding of their mechanisms of action and
subjective properties.
Neural Substrates of Psychostimulant Locomotion
The neural substrates of locomotor activation produced by psychomotor
stimulants have been linked for some time to dopamine function in the
nucleus accumbens. An early finding reported that direct injection of
dopamine into the nucleus accumbens produced enhanced locomotor activity
in rats (Pijnenburg and Van Rossum 1973), and the unconditioned motor
activation produced by amphetamine was shown to be blocked by dopamine
receptor antagonists (Pijnenburg et al. 1975). Destruction of dopamine
terminals within the nucleus accumbens with 6-hydroxydopamine (6-OHDA)
was found to attenuate the locomotion produced by indirect sympathomi-
metics (Joyce and Koob 1981; Kelly et al. 1975; Kelly and Iversen 1976)
but not to disrupt the locomotor-activating properties of caffeine, scopola-
mine (Joyce and Koob 1981) (figure 1). corticotropin-releasing factor (CRF)
(Swerdlow and Koob 1985). or heroin (Vaccarino et al. 1986) (figure 2) in
rats. Thus, the locomotor stimulation produced by psychostimulant drugs
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has been hypothesized to result from release of dopamine from the
mesolimbic dopamine terminals in the region of the nucleus accumbens, but
other drugs with locomotor-activating properties may interact with other
parts of the limbic-nucleus accumbens-ventral pallidal circuitry known to be
important for psychostimulant activation (Swerdlow et al. 1984; Swerdlow
et al. 1986).
Neural Substrates of Psychostimulant Reinforcement
The locomotor-activating properties of psychomotor stimulants have been
hypothesized to be one aspect of their reinforcing properties (Mucha
FIGURE 1. Effects of amphetamine, scopolamine, caffeine, and saline on
locomotor activity in rats with 6-OHDA lesions of the
nucleus accumbens or sham-operated controls
(n=8 rats/group)
*Refers to a signficant group effect.
**Refers to a significant difference between the groups at 10 minutes postinjection, simple main effects.
KEY: Values in upper right corner of each panel represent mean ± SEM for the total activity
over the 2-hour  drug test.
SOURCE: Joyce and Koob, 1981, Copyright 1981, Springer-Verlag.
et al. 1982; Spyraki et al. 1982; Swerdlow and Koob 1984). Animals will
learn to prefer an environment previously associated with drugs that produce
hyperactivity, and pharmacological or surgical manipulations that block the
locomotor-activating properties of psychomotor stimulants block this place
preference. The nucleus accumbens, which has been demonstrated to be
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FIGURE 2. Effects of 6-OHDA lesions of the nucleus accumbens on the
locomotor response ajier SC injection of heroin (0.5 mg/kg)
or amphetamine (0.25 mg/kg)
*Significantly different from sham group. p<0.05.
NOTE: Rats were habituated to the photocell cages for 90 minutes. after which they were injected.
Inserts show the mean ± SEM total counts for 180 minutes for eight rats in the sham and
lesion group, respectively. 
SOURCE: Vaccarino et al. 1986, Copyright 1986, Pergamon Press.
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involved in a variety of the behavioral actions of stimulants and opiates,
may act as a bridge between the limbic system and the extrapyramidal
motor system, integrating limbic influences and motor activity (Mogenson
and Nielson 1984; Swerdlow et al. 1986).
The reinforcing properties of psychomotor stimulants have also been linked
to the activation of central dopamine neurons and their postsynaptic recep-
tors. When the synthesis of catecholamines is inhibited by administering
alpha-methyl-para-tyrosine, an attenuation of the subjective effects of
euphoria associated with psychomotor stimulants occurs in man (Jonsson
et al. 1971), and a blockade of the reinforcing effects of methamphetamine
occurs in animals (Pickens et al. 1968). Furthermore, low doses of dopa-
mine antagonists will increase response rates for intravenous injections of
d-amphetamine (Risner and Jones 1976; Yokel and Wise 1975; Yokel and
Wise 1976).
Noradrenergic antagonists such as phenoxybenzamine, phentolamine, and
propranolol had no effect on stimulant (amphetamine) self-administration
(DeWit and Wise 1977; Risner and Jones 1976; Yokel and Wise 1976).
Wise and coworkers hypothesized that a partial blockade of dopamine
receptors produced a partial blockade of the reinforcing effects of
d-amphetamine. Thus, animals were thought to compensate for decreases in
the magnitude of the reinforcer by increasing their self-administration
behavior. Similar results have been observed with alpha-flupenthixol
(Ettenberg et al. 1982) and many other dopamine receptor antagonists,
including haloperidol, chlorpromazine, metoclopramide, thioridazine, and
sulpiride (Roberts and Vickers 1984). Recently, the selective D-1 antagonist
SCH 23390 was shown to increase cocaine self-administration at doses that
did not impair motor function (Koob et al. 1987a), whereas spiperone, a
D-2 selective compound, produced only small increases in responding at
doses close to those that produced motor dysfunction. These results suggest
that dopamine receptor blockade, particularly D-l receptor blockade, may be
involved in the reinforcing effects of psychomotor stimulants in rats. It
should be noted, however, that the SCH 23390 compound failed to produce
this action consistently when administered intravenously to rhesus monkeys
self-administering cocaine (Woolverton 1986).
The role of dopamine in the reinforcing properties of psychomotor stimu-
lants was extended by the observations that 6-OHDA lesions of the nucleus
accumbens produce extinction-like responding and a significant and long-
lasting reduction in self-administration of cocaine and d-amphetamine over
days (Lyness et al. 1979; Roberts et al. 1977). These effects were thought
to be due largely to the depletion of dopamine, since rats pretreated with
desmethylimipramine before the nucleus accumbens lesion (to protect nore-
pinephrine neurons from destruction with the 6-OHDA) showed an identical
extinction-like response (Roberts et al. 1980). Similar results were obtained
following 6-OHDA lesions of the ventral tegmental area (Roberts and Koob
105
1982). Subsequent studies have shown that 6-OHDA lesions of the frontal
cortex (Martin-Iverson et al. 1986) and corpus striatum (Koob et al. 1987b)
do not significantly alter cocaine self-administration. Interestingly, lesions
of specific subsets of the dopamine forebrain projections have been
associated with facilitated acquisition of amphetamine self-administration
(Deminiere et al. 1984; Deminiere et al. 1988), suggesting that some
specific neuropathology within the dopamine system could sensitize
individuals to the reinforcing actions of psychostimulants.
These results, showing facilitated acquisition of psychostimulant self-
administration with lesions of subsets of the dopamine projections, empha-
size the need for other measures of reinforcement besides a continuous
reinforcement schedule. To this end, rats that had been trained to self-
administer cocaine intravenously were subjected to a progressive-ratio
procedure following 6-OHDA lesion to the nucleus accumbens or corpus
striatum. The rats with a lesion of the nucleus accumbens showed a signi-
ficant decrease in the highest ratio for which they would respond to obtain
cocaine (figure 3) (Koob et al. 1987b). Complementary results have been
obtained using a similar progressive-ratio procedure in which rats with
6-OHDA nucleus accumbens lesions increased significantly the highest ratios
for which they would self-administer apomorphine (Roberts and Vickers
1988). This motivational probe thus avoids many of the problems associ-
ated with measuring local rates of responding. For example, the rats with
6-OHDA lesions showed a decrease in cocaine self-administration while on
a continuous reinforcement schedule that superficially could be interpreted
as either a decrease or increase in the reinforcing value of cocaine. The
results in the progressive-ratio test suggest that this decrease in local rates
of responding, previously observed with lesions to the region of the nucleus
accumbens, does in fact represent a motivational deficit.
Both amphetamine and cocaine have also been reported to support intra-
cranial self-administration in the mesolimbic/mesocortical  dopaminergic
system. Rats will self-administer cocaine into the medial prefrontal cortex
(Goeders and Smith 1983). while amphetamine is self-administered into the
orbitofrontal cortex of rhesus monkeys (Phillips and Rolls 1981) and the
nucleus accumbens of rats (Hoebel et al. 1983; Monaco et al. 1981). These
data indicate that the mesolimbic/mesocortical dopaminergic system is
involved in the initiation of stimulant reinforcement processes, and this work
suggests that the region of the nucleus accumbens, more specifically the
mesolimbic dopamine system, may be an important substrate for reinforcing
properties of several psychomotor stimulant drugs.
Behavioral Profile of MDMA
Both quantitative and qualitative aspects of the behavioral profile of motor
activation produced by MDMA and methylenedioxyethylamphctamine
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FIGURE 3. Effects of 6-OHDA lesions to the nucleus accwnbens and
corpus striatum on responding for rats self-administering
cocaine
*Significantly different from sham group. p<0.05 Newman-Keuls test.
KEY:
NOTE:
H.=2 times the normal 0.75 mg/kg/injection dose; M=middle dose range,
0.75 mg/kg/injection; L=1/2 the 0.75 mg/kg/injection dose.
Top panel shows continuous reinforcement data averaged over the first 3 days postlesion
(means ± SEM). Sham, vehicle-injected (0.1 mg/mL ascorbic acid in saline) controls.
Caudate, rats receiving 8 µg  in 2 µL of 6-OHDA injected into the corpus striatum. N.
Acc rats receiving 8 µg in 2 µL of 6-OHDA injected into the nucleus accumbens. Mid-
dle panel shows the dose-effect functions for each group. Bottom panel shows the mean
rewards and mean highest ratio obtained by each group on the progressive ratio probe
SOURCE: Koob et al. 1987b. Copyright 1987, Raven Press.
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(MDE) have been characterized and, the effects of these drugs compared
with those of classic stimulants and hallucinogens (Gold et al. 1988).
Exploratory activity was monitored in eight separate behavioral pattern
monitor (BPM) chambers, each consisting of a 30.5 by 61 cm black Plexi-
glas holeboard with three floor holes, seven wall holes, and a steel
touchplate 15 cm above the floor that detected rearings against the wall
(figure 4) (Geyer et al. 1986). The frequency of photobeam breaks was
used as a general measure of motor activity, and the number and duration
of holepokes and rearings were cumulated.
FIGURE 4. Diagrammatic representation of the behavioral pattern monitor
chamber. The positions of the seven wall and three floor
holes are shown in each diagram
KEY: a. Infrared photobems are arranged in a Cartesian coordinate system on 7.6-cm centers
and are sampled five times per second
b. Sectors are equal 15-cm squares and are used to define crossovers, a measure of
horizontal locomotion.
c. Regions are unequal in size and are used primarily to define entries into the center
region and for the CV9 analysis of spatial patterns of locomotion.
SOURCE: Geyer et al. 1987. Copyright 1981. Pergamon Press.
MDMA significantly altered the behavioral activity profile of rats.
Figure 5A illustrates the timecourse of the effects of MDMA on crossovers
resolved into 30-minute blocks across the 2-hour test session. Doses of
1.25, 2.5, 5.0, and 10.0 mg/kg produced significant increases in crossovers,
which remained elevated at the end of the session at the two highest doses
studied. Interestingly, during the first 10 minutes in the chamber (10 to 20
minutes postinjection), doses of 2.5 to 10 mg/kg did not significantly
increase crossovers.
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Concomitant with this total increase in horizontal locomotion, MDMA (1.25
to 10.0 mg/kg) caused alterations in measures of investigatory behavior.
MDMA had a profound effect on the distribution of investigatory holepokes
over time. Whereas the control animals exhibited a decrease in the number
of investigatory holepokes as they habituated to the chambers during the
session, the MDMA-treated rats demonstrated an initial decrease in the
number of holepokes, followed by the tendency to increase investigatory
holepoking over time (figure 5B). Similarly, MDMA (1.25 to 10.0 mg/kg)
dramatically reduced the amount of rearing behavior measured. The amount
and duration of this suppression of rearing was related to the dose of
MDMA studied (figure 5C). Rearing in rats heated with MDMA was
markedly reduced compared to control rats during the first 30 minutes.
More descriptive measures of the animals’ behavior were provided by
cumulating entries into and time spent in each of nine unequally sized
regions, which included the center and the four comer regions (Geyer
et al. 1986). Accompanying these changes in the amount of rearing and
investigatory holepoking was an observable avoidance of the center of the
experimental chamber. Thus, a significant decrease in average duration of
center entries for the first 30 minutes was obtained following MDMA doses
of 1.25 to 10.0 mg/kg.
MDE, the N-ethyl derivative of MDA, produced a behavioral profile similar
to that described for MDMA. MDE increased the number of crossovers
measured during a 1-hour experimental session (figure 5A). A transient
decrease in the number of crossovers during the first 10 minutes in the
chambers (0:549.1, 1.0:645.7, 3.0:313.1, 10.0:284.4) was noted for MDE at
doses of 3.0 and 10.0 mg/kg. As with MDMA, the two highest doses of
MDE tested (3.0 and 10.0 mg/kg) significantly decreased the total number
of holepokes for the first 30 minutes. Rearing was also suppressed by
these doses of MDE over a similar timecourse (figures 5B and 5C). At the
10 mg/kg dose of MDE, avoidance of the center was again observed as a
significant decrease in the average duration of center entries.
For spatial pattern analyses, the data were reduced to sequences of X,Y
positions as described elsewhere (Geyer et al. 1986). These sequences were
used to produce video displays of the animal’s position, rearings, and
holepokes, which could be viewed from 1 to 20 times teal-time speed. The
transition frequency between any of five areas (two ends, center, and two
long wall areas) was calculated, as was the coefficient of variation (CV) for
the relative transition frequencies (Geyer 1982). A related but slightly
different procedure evaluated the sequence of position changes by calculat-
ing the number of occurrences of each of the 40 transitions among any of 9
specified regions. As an animal preferentially repeats certain transitions, the
CV increases, while a more random pattern produces a lower CV. T’he CV
thus reflects the extent to which the animal establishes a preferred pattern
of locomotor activity over time.
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FIGURE 5. Timecourse effects of MDMA (n=7 to 8 rats/group) and MDE
(n=9 to 12 rats/group) on A (crossovers), B (total
holepokes), and C (rearings) per 30 minutes in the BPM
p<0.05.
NOTE: Animals were injected 10 minutes before being placed in the chambers. Effects of selected
doses are shown as group means ±SEM.
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Both MDMA and MDE caused some obvious qualitative changes in the lo-
comotor patterns of rats. At moderate to high doses of MDMA, a definite
avoidance of the center of the experimental chamber was frequently seen,
and circling around the perimeter was the dominant behavior. This thigmo-
taxis is similar to that previously observed with apomorphine or scopola-
mine (Geyer et al. 1986). Although most rats had a predominant direction
of rotation, occasionally the rats reversed direction for one or more
revolutions. The impression of a disruption in locomotor patterns described
above was corroborated by a significant change in the spatial CV measure.
Both MDMA and MDE increased the spatial CV, which suggests a more
perseverative nature of locomotor patterns (table 1). In contrast, doses of
amphetamine (AMPH) that produced similar increases of horizontal
locomotion tended to induce highly varied patterns of directional changes,
which were reflected in a reduced spatial CV (Geyer et al. 1986).
Neural Substrates for the Psychostimulant Actions of MDMA
The neurochemical mechanisms for the stimulant properties of MDMA were
examined in a photocell cage apparatus following pharmacological and
neurochemical manipulations. Locomotor activity was measured in a bank
of 16 wire cages 20 cm by 25 cm by 36 cm, each cage with two horizontal
infrared beams across the long axis 2 cm above the floor. Total photocell
beam interruptions and crossovers were recorded by a computer every 10
minutes. Before the drug series, each rat was habituated to the photocell
cages overnight, and, prior to drug injection, the rats were habituated again
to the photocell cages for at least 90 minutes.
A role for serotonin in the stimulant actions of MDMA was tested by
examining the effects in rats of the serotonin antagonist methysergide on
MDMA activation (Gold and Koob 1988). The locomotor-activating proper-
ties of MDMA. amphetamine, and methysergide are seen in figure 6. Drug
doses for amphetamine and MDMA were selected to produce similar in-
creases in activity, although MDMA appears to have a longer duration of
action (Gold et al. 1988). Once the rats were habituated to the photocell
apparatus, saline injection produced only transient arousal (lasting less than
20 minutes) followed by relative inactivity (figure 6C). MDMA at
10 mg/kg produced an increase in beam interruptions that lasted for at least
2 hours (figure 6A). Methysergide (2.5, 5, 10 mg/kg) significantly
potentiated the locomotor hyperactivity produced by MDMA (10 mg/kg)
when compared to MDMA injection alone (figure 6A). This enhancement
of MDMA’s locomotor effects was evident within the first 10 minutes and
lasted for the full 2-hour session. In contrast, methysergide only slightly
and nonsignificantly increased the locomotor hyperactivity produced by
0.5 mg/kg of amphetamine (figure 6B). Methysergide alone at these doses
had no effect on locomotor activity (figure 6C).
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TABLE 1. Effects of MDMA, MDE, and AMPH on spatial CV
Dose (mg/kg) CV5 CV9
0 .485 ± .02
MDMA 1.25 .709 ± . l
MDMA 2.5 .730 ± .17
MDMA 5.0 1.063 ± .21*
MDMA 10.0 .995 ± .13*
0
MDE 1.0
MDE 3.0
MDE 10.0
0 .522 ± .04
AMPH 0.25 .379 ± .06*
AMPH 0.5 .376 ± .03*
AMPH 1.0 .373 ± .04*
AMPH 2.0 .506 ± .03
1.723 ± .02
1.737 ± .05
2.209 ± .18*
2.007 ± . l l
*p<0.05, Dunnett's t-test
NOTE: Group means ± SEM are shown: an increase in spatial CV indicates a more repetitive pattern
of movements in the BPM: a decrease indicates a more highly varied pattern.
The role of the mesolimbic dopamine system, which is known to be critical
for amphetamine-stimulated locomotion, was investigated in MDMA-treated
rats with 6-OHDA lesions of the nucleus accumbens (Gold et al., in press).
Rats received bilateral injections of 6-OHDA (8 µg/2 µl, expressed as the
free base) dissolved in saline containing ascorbic acid (0.1 mg/mL; lesion
group) or injections of saline-ascorbic acid vehicle alone (sham group).
Approximately 9 days following surgery, rats were injected with saline, and
locomotor activity was measured for 120 minutes. In one study, rats (sham:
n=8, lesion: n=8) were injected on the following day with 5 mg/kg
MDMA, 3 days later with 0.5 mg/kg AMPH, and again with saline. Loco-
motor hyperactivity produced by MDMA was attenuated in the group with
6-OHDA lesions (figure 7A). When the rats were injected with 0.5 mg/kg
AMPH, the sham-operated group showed a large increase in locomotor acti-
vity; this effect was significantly reduced in the rats with lesions.
Moreover, the hyperactivity seen in the sham rats was somewhat greater
than that usually observed following this dose of AMPH, suggesting a
cross-sensitization between MDMA and AMPH. The day after the AMPH
injections, all the rats were reinjected with saline. At this time there was
no significant difference between the sham- and lesion-operated rats.
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FIGURE 6. Locomotor activity during 120-minute test session in the
photocell cage apparatus
*Significantly different from 0 methysergide dose, Newman-Keuls test following significant ANOVA
main effect
KEY: Values in the upper right corner of each panel represent mean ±SEM for the total activity
over the 2-hour drug test.
NOTE: Following a habituation period, rats were injected with methysergide (0-10 mg/kg, SC; C)
and 2 minutes latex by (A) MDMA (10 mg/kg. SC). (B) amphetamine (0.5 mg/kg. SC).
SOURCE: Gold and Koob 1988, Copyright 1986, Pergamon Press.
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FIGURE 7. Effects of 5 mg/kg MDMA, 0.5 mg/kg AMPH, or 5 mg/kg
MDMA plus 25 mg/kg methysergide on locomotor activity
in rats with 6-OHDA or sham lesions of the nucleus
accumbens
*p<0.05.
**Significant interaction.
†p.055.
KEY: Total photobeam interruptions, measured in photocell cage apparatus, for 120-minute test
session, shown as group means ± SEM.
NOTE: A. The significant difference between sham-operated rats and those with 6-OHDA lesions
following saline injection was attributed to a reduced response to the injection procedure in
the lesion-operated group. Note that means for the two groups were almost identical
(sham=576±84, lesion=524±55) for the 90-minute habituation period preceding saline
injection. Sham group, n=8; lesion group, n=8. B. Sham group. n=8; lesion group, n=6.
SOURCE: Redrawn from Gold et al., in press.
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In an additional study, following recovery and saline injection, rats (sham:
n=8, lesion: n=8) were injected with 0.5 mg/kg AMPH on day 9 or 10 and
5 mg/kg MDMA 3 days later. On day 16 or 17 these rats received two
injections: a serotonin antagonist, 2.5 mg/kg methysergide; and 5 mg/kg
MDMA. Rats were injected with 0.5 mg/kg AMPH on the next day and,
as in previous experiments, the locomotor hyperactivity produced by AMPH
was attenuated in the group with 6-OHDA lesions (figure 7B). The
mean ± SEMs per 120 minutes for the sham and lesion groups were
1,995.9±389.3 and 906±132, respectively. In the first experiment described
above, the means for these groups were 3.111.9±421.8 and 1,176.5±248.1,
respectively. When the rats were injected with 5 mg/kg MDMA 3 days
later, the sham-operated group showed a large increase in locomotor activi-
ty; this effect was significantly reduced in the rats with lesions. The
mean ± SEMs for the sham and lesion groups were 1,368±249.5 and
754.1±107.4, respectively. These values were not different from those
described in the first experiment (sham: 1,401.3±257.8, lesion:
745.2±81.7). Therefore, a cross-sensitization from AMPH to MDMA was
not evident. On the next day, locomotor activity was measured following
injections of a serotonin antagonist and MDMA. Here, methysergide
potentiated the effects of MDMA. Both the effects of surgery and the
influence of methysergide were observed. However, a log transformation of
the data eliminated the significant interaction between the two, which
suggests that the interaction effect was due to scaling differences. Thus, the
response of both the sham rats and the rats with lesions was increased by
the serotonin antagonist.
Biochemical analyses of 6-OHDA-injected animals revealed a 93 percent
depletion of dopamine. The tissue was assayed using electrochemical
detection following separation by high-pressure liquid chromatography
(Felice et al. 1978). recorded as ng/mg protein in the nucleus accumbens
and compared to control rats with sham lesions (sham=65.5±4.4,
lesion=4.9±1.5; t(39)=23.4). A lesion was defined as complete if 75 percent
or more of the dopamine was determined to be depleted from the nucleus
accumbens compared to mean sham group values.
SUMMARY
The motor activation produced by psychomotor stimulants has been long
associated with the midbrain dopamine systems. While focused stereotyped
behavior produced by high doses of indirect sympathomimetics is blocked
by removal of dopamine terminals in the corpus striatum (Creese and
Iversen 1975), the locomotor activation produced by low doses of indirect
sympathomimetics is blocked by removal of dopamine terminals in the
region of the nucleus accumbens (Kelly et al. 1975). This dopaminergic
substrate for psychostimulant effects appears selective for the indirect
sympathomimetics in that dopamine lesions to the region of the nucleus
115
accumbens do not block caffeine, scopolamine, heroin, or CSF-induced
locomotor activation (Swerdlow and Koob 1985; Vaccarino et al. 1986).
The neurochemical sites for psychomotor stimulant reward are likely to be
the presynaptic dopamine terminals located in the region of the nucleus
accumbens, frontal cortex, and other forebrain structures that originate in the
ventral tegmental area. Note, however, that intracranial self-administration
of cocaine is elicited from the frontal cortex, but not from the nucleus
accumbens (Goeders and Smith 1983). Thus, concomitant activation of
structures other than the nucleus accumbens may be an important part of
the circuitry involved in initiation of cocaine intravenous self-administration,
as has been hypothesized for the opiates (Smith and Lane 1983; Smith
et al. 1982).
In addition, these neuropharmacological studies provide evidence to show
that, in the rat, the neural/neurochemical substrates for processing the
reinforcing and stimulant properties of psychomotor stimulants may be
similar, if not identical. Parallel manipulations using dopamine receptor
antagonists and 6-OHDA lesions produce parallel results. How far this
parallelism continues in further processing is under current investigation;
however, such an overlap brings additional impetus to earlier hypotheses
relating reinforcement and motor function (Glickman and Schiff 1967).
The motor activation produced by MDMA and MDE has similarities to
classic psychostimulants, but also some important differences. In the BPM
system, the stimulant-like properties of these drugs were reflected in
significant increases in horizontal locomotor activity measured across a wide
dose range. Interestingly, medium to high doses of MDMA or MDE
produced a transient decrease in horizontal locomotion for the first 10
minutes, followed by a sustained increase. The increase in holepokes and
rearings that typically accompanies the increase in ambulation seen with
amphetamine itself or other indirect sympathomimetics (Geyer et al. 1986)
was not observed with MDMA or MDE. Instead, initial decreases in hole-
pokes and rearings and a tendency to avoid the center were evident, a
behavioral profile that is characteristic of hallucinogenic indoleamine or
phenylethylamine derivatives (Adams and Geyer 1985a; Adams and Geyer
1985b; Geyer et al. 1979).
MDMA and MDE also produced locomotor patterns that differed signifi-
cantly from other stimulants. Previous studies in rats have demonstrated
that amphetamine-induced hyperactivity involves complex patterns of widely
distributed locomotion with frequent directional changes (Geyer et al. 1986;
Geyer et al. 1987). In contrast, similar levels of behavioral activation
produced by scopolamine or apomorphine are associated with relatively
smooth locomotor paths, in which the same movement patterns are frequent-
ly repeated. Other stimulants, such as caffeine or nicotine, increase the
amount of locomotor activity without significantly altering its pattern (Geyer
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et al. 1986). With LSD and other hallucinogens, the behavioral profile is
characterized by an increase in the diversity of locomotor patterns and a
concomitant suppression of the exploration of novel and open areas (Adams
and Geyer 1985a). When evaluated on this basis, MDMA and MDE are
similar to hallucinogens in producing an avoidance of the center. This
effect is particularly notable in light of the simultaneous increases in the
total amount of locomotor activity. Unlike LSD, however, MDMA pro-
duced a scopolamine- or apomorphine-like increase in perseverative and
thigmotactic patterns of locomotion, reflected by increases in the spatial CV
measures. The MDMA profile was also similar to that of apomorphine
insofar as both drugs reduced holepoking and rearing, behaviors that are
increased by scopolamine. However, relative to apomorphine, the MDMA-
induced rotational patterns were less strictly unidirectional, and the
reductions in investigatory responses were less complete. Rather, most
animals injected with MDMA changed directions and exhibited investigatory
responses at least occasionally, effects similar to those observed following
various doses of scopolamine (Geyer et al. 1986). Hence, the behavioral
profile engendered by MDMA and MDE appears to be unique among the
various drugs that have been so characterized to date.
Investigation of the neurochemical substrates for the psychostimulant effects
of MDMA suggests a role for the mesolimbic dopamine system. Destruc-
tion of dopamine terminal fields in the nucleus accumbens significantly
attenuated the locomotor activation produced by MDMA. A similar bloc-
kade of amphetamine-induced locomotor hyperactivity is known and was
observed following amphetamine injection in these same rats. Such results
support the hypothesis that at least one component of MDMA-induced
hyperactivity is dopamine mediated and suggest that mesolimbic dopamine
specifically is the critical substrate. In this way, MDMA resembles other
classical psychostimulants like amphetamine and cocaine. Interestingly,
evidence for functional cross-sensitization was suggested in the study in
which an injection of amphetamine followed MDMA injection.
The stimulant properties of MDMA were enhanced by the presence of a
serotonin antagonist, methysergide. Thus, following serotonin-receptor
blockade, profound locomotor hyperactivity was observed. This result can
be viewed as a disinhibition of the dopamine neurons from serotonin modu-
lation. These data are consistent with the hypothesis that MDMA acts
predominantly as a serotonin agonist with weak dopamine activity. In this
study, methysergide did not potentiate the effect of amphetamine. However,
Hollister et al. (1976) reported that methysergide potentiated locomotion
produced by 2 mg/kg amphetamine intraperitonealIy. In fact, an
enhancement of an amphetamine response after prior exposure to MDMA
has also been observed. It is possible that previous exposure to MDMA
may have resulted in neurotoxic damage to some serotonin neurons.
Depletions of serotonin and its metabolites have been repotted following
single injections of MDMA (Mokler et al. 1987; Schmidt 1987; Stone
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et al. 1986). A decrease in serotonergic tone would also result in a
disinhibition of dopamine neurons and may explain the enhanced
amphetamine response. Indeed, evidence for such a “functional lesion” has
been reported in an operant procedure in which MDMA-induced serotonin
depletion was found to potentiate its psychomotor stimulant effects (Li
et al. 1986). In the case where amphetamine was given first, followed by
MDMA, no change in responsiveness would have been expected.
The stimulation of locomotor activity by MDMA and the importance of
mesolimbic dopamine in this response reflect similarities with the prototype
phenylethylamine stimulant, amphetamine. It is important to note that these
parameters are frequently associated with rewarding aspects of drugs and
drug abuse. Additionally, the behavioral profiles of MDMA and MDE
share certain characteristics with hallucinogen-like agents. This unique
mixture of stimulus properties and neurochemical actions may contribute to
a dangerous behavioral toxicity and neurotoxic potential for drugs like
MDMA.
DISCUSSION
QUESTION: Can you get animals to self-administer cocaine into the
nucleus accumbens?
ANSWER: No, I never tried that, but the literature there is complicated, as
you know. Animals will, however, self-administer cocaine into the frontal
cortex. Amphetamine is self-administered into the nucleus accumbens.
You have to know that we take out most of the mesocorticolimbic dopa-
mine system with that lesion; we are not just taking out the nucleus
accumbens dopamine projection. I am very careful to put the region of the
nucleus accumbens on my slide.
I think the way Jim Smith and I have discussed this paradox is a follows:
He thinks that the frontal cortex has something to do with initiation of
cocaine self-administration, and I think probably the whole system may be
involved in maintaining the behavior once the animals have learned it.
QUESTION: Have you tried MDMA into the nucleus accumbens?
ANSWER: No, we haven’t tried self-administration of MDMA. I am not
sure we would get rats to switch from cocaine to MDMA.
QUESTION: Have you had the opportunity to look at the impact of
methysergide pretreatment on MDMA’s effects on exploration and rearing?
ANSWER: No, we just put that on the books. We would really like to
look in the behavioral pattern monitoring system. I predict that the lesion
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is going to block the crossovers. But I don’t know what methysergide
would block. I believe it would be incredibly interesting if it would turn
those rats into amphetamine-like rats, and they would explore and show less
thigmotaxis and more nosepokes.
QUESTION: How can you dissociate the locomotor effects from the
reinforcing effects? It has been agreed that lesions of the mesolimbic
system affect locomotor activity and shown by Eberson with respect to the
dopaminergic system. How do you know you don’t have a rat that is
motorically compromised and can’t press the lever to get the cocaine? How
can you dissociate that from the reinforcement efficacy?
ANSWER: I think the only thing I can really argue strongly is that we
have made similar lesions in rats the lever pressed for heroin, so they are
lever pressing in the exact paradigm as a reinforcer, and continue to take
heroin, although the cocaine self-administration extinguishes. I have a slide
of a rat who keeps plugging along on heroin self-administration and at the
same time every other day is tested on cocaine. The paradigm was heroin
on Monday, cocaine on Tuesday, heroin on Wednesday, cocaine on
Thursday, His cocaine self-administration was completely extinguished, yet
his heroin self-administration continued. This is one piece of evidence that
looks like a real dissociation. The animals can lever press for another
reinforcer, but they choose not to lever press for cocaine.
And the other part would be that they show locomotion with other drugs.
It is just the indirect sympathomimetics where locomotion is blocked.
It could be said that the reason they are not pressing the lever for cocaine
is that it doesn’t do anything for them. And then you get into a circuit
where it is the psychostimulant effects that produce the reinforcing effects.
COMMENT: Your data showed that, at least with that one model rat, there
was a good extinction pattern and high levels of activity. I would consider
that to be a better piece of evidence.
RESPONSE: Yes, it means that the animal is capable of moving around
for apomorphine. But then it gets subtle. In people, too, there is initially a
high level of activity to exhaust residual dopamine stores and then the
activity goes down to a very low level. The apomorphine can reinstate
some locomotion. I think the most convincing evidence is the heroin. It is
not true motor activity.
QUESTION: Do you have any explanation for sensitization within the
MDMA or the methysergide? There has been evidence of serotonergic
inhibition.
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ANSWER: I think there are two ways to look at it I would say one
reason is MDMA doesn’t look like amphetamine. Why doesn’t MDMA
look like amphetamine without any other drugs added on? The animal has
the psychedelic repertoire, whatever that is, interfering. This is what Klaus
Miczek and I were discussing. The animal perhaps has another behavioral
repertoire interfering with the expression of motor activity, and that happens
to be that the animal is hanging close to the side of the cage and for what-
ever reason, if it is LSD-like, he doesn’t want to go into the center because
it is frightening. He is hallucinating. I am speculating here. And if you
then take away that competing behavior or competing brain Gestalt of
psychedelic activity, then you are turning the drug into basically ampheta-
mine. That is one way of looking at it.
Another way of viewing it would be as levers going off. Serotonin is
inhibitory, dopamine is excitatory. That is naive, but there is evidence to
suggest that in the neurochemistry of those compounds there has been a
kind of yin and yang.
QUESTION: How do you explain MDMA sensitization for amphetamine?
ANSWER: There is evidence that even one exposure of MDMA at
10 mg/kg can cause some serotonin neurotoxicity. Dr. Seiden has shown in
DRL procedures with repeated exposure that there is more of an
amphetamine-like effect after some of the serotonin has been depleted.
QUESTION: Had you looked at that at all?
ANSWER: In terms of the biochemistry itself, no, not at all.
COMMENT: I am not sure the serotonin is inhibitory and dopamine
excitatory is all that naive. There were clinical studies published where
they showed that serotonin agonists could completely suppress the CNS
stimulant effects of amphetamine clinically in humans. So you may be
seeing the same thing. I am not sure that it has to be a psychedelic
activity superimposed. It may simply be some kind of a synergistic
attenuation.
COMMENT: Both Campbell and Harvey, in independent experiments, have
shown if you take away the serotonin input you can exacerbate the
psychomotor stimulant effects of amphetamines.
RESPONSE: Yes, and there is some recent study too that was done by
Lyness showing that if the serotonin system is destroyed, toxicity and
self-administration of amphetamines are increased. There is a lot of
evidence that some of this interaction does occur at some level, but we
don’t know where yet.
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Neuronal Actions of Amphetamine
in the Rat Brain
Philip M. Groves, Lawrence J. Ryan, Marco Diana,
Stephen J. Young, and Lisa J. Fisher
INTRODUCTION
Amphetamine and related designer drugs have widespread actions on neu-
ronal activity in the brain. This is believed to be due in part to the
enhanced release and blockade of reuptake of catecholamines (Kuczenski
1983). The sites of action of such stimulant drugs of abuse include pre-
synaptic neurons, by virtue of the action of released catecholamines on
autoreceptors (Tepper et al. 1985), and postsynaptic targets of catecholamine
axons, including neurons in the cerebral cortex, basal ganglia, cerebellum,
reticular formation, and other neuron systems of the brainstem (Groves and
Rebec 1976).
The consequences of amphetamine administration include widespread neu-
ronal pathology in the brains of experimental animals (Groves et al. 1987;
Seiden and Kleven, this volume; Gibb et al., this volume) and significant
changes in the pattern and intensity of neuronal activity throughout the
brain. One particularly useful approach to understanding the sites and
mechanisms of action underlying the behavioral effects of amphetamine has
been to record the electrophysiological consequences of amphetamines
administration in the rat brain (Groves and Rebec 1976; Groves and Tepper
1983).
EFFECTS OF AMPHETAMINE ON CATECHOLAMINERGIC
NEURONS
One of the most widely known electrophysiological actions of amphetamine
on the brain is to decrease the firing rate of dopaminergic and noradrenergic
neurons recorded in vivo from the rat brain (Bunney et al. 1973; Graham
and Aghajanian 1971). The underlying mechanisms include possible inhibi-
tion by afferent systems and by local inhibitory mechanisms involving local
release of catecholamine (Groves et al. 1975). In the case of dopaminergic
neurons, this release occurs from dendrites, whereas, in noradrenergic nuclei,
release occurs from axonal collateral innervation as well as from dendrites
(Groves et al. 1979). The effect of amphetamine on monoamine neurons is
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dose dependent. Noradrenergic neurons of the locus coeruleus are most
sensitive, with a mean dose for 50 percent inhibition of firing of 0.25
mg/kg, IV (Engberg and Svenson 1979; Ryan et al. 1985). Dopamine neu-
rons are less sensitive, requiring a mean dose of approximately 1.6 mg/kg,
IV (Bunney et al. 1973). Serotonin neurons are the least sensitive,
requiring a mean dose for 50 percent inhibition of 3.0 mg/kg, IV (Rebec
et al. 1982).
The inhibition of firing of catecholamine neurons resulting from ampheta-
mine administration is likely due to activation of somatodendritic
autoreceptors. This causes a hyperpolarization of the somatodendritic
membrane of both locus coeruleus noradrenergic and substantia nigra
dopamine neurons, probably as a consequence of an increase in potassium
conductance (Lacey et al. 1987; Williams et al. 1985).
Because the cell body is hyperpolarized by autoreceptor stimulation, it
seemed plausible that stimulation of autoreceptors located on the synaptic
endings of such neurons might similarly lead to a decrease in excitability.
Over the past several years, we have determined the excitability of the
axonal synaptic endings of single monoaminergic neurons in vivo by elec-
trical stimulation of the axon while recording the antidromic responding of
the neuron at the level of the cell body. It is now apparent that, in
addition to causing a decrease in the amount of transmitter released by each
action potential (Langer 1977), stimulation of autoreceptors located at the
terminal field results in a decrease in terminal excitability in all
monoaminergic neuron systems that have been tested (Tepper et al. 1985).
The effects of amphetamine on catecholamine terminal excitability are very
similar to the effects of direct-acting agonists. Nigrostriatal dopamine
neurons, for example, show a decrease in terminal excitability following the
systemic administration of doses of amphetamine ranging from 0.25 to
5.0 mg/kg, IV (Groves et al. 1981). Direct infusions of amphetamine into
the terminal fields also decrease excitability. A similar decrease in
excitability is seen after the administration of the direct-acting D2 agonist
apomorphine (Tepper et al. 1984) and the D1 agonist SKF 38393 (unpub-
lished data). The action of amphetamine may be blocked by dopamine
antagonists, including haloperidol, fluphenazine, and sulpiride, as well as by
pretreatment with the dopamine synthesis blocker metbylparatyrosine
(Tepper et al. 1984). These actions of amphetamine occur only in regions
of the dopamine axon containing presynaptic autoreceptors; infusions of
amphetamine into the medial forebrain bundle were without effect, whether
excitability was tested by stimulation at the terminal field or along the axon
in the medial forebrain bundle.
The activation of presynaptic autoreceptors, as revealed by changes in termi-
nal excitability, suggests that amphetamine releases dopamine at every tested
dose. This observation is consistent with recent direct demonstrations using
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dialysis, which show that amphetamine induces dopamine release in the neo-
striatum in a dose-dependent manner (Hemandez et al. 1987; Impcrato and
Di Chiara 1984). Amphetamine-induced release is opposed, to some extent,
by the action on autoreceptors of released dopamine. Activation of somato-
dendritic autoreceptors decreases dopamine neuron firing, which, in
combination with dopamine terminal autoreceptor activation, will decrease
impulse-dependent release. Thus, the net effect of amphetamine on cate-
cholamine release will be a compromise between release-inducing actions
and release-diminishing actions.
Indeed, at some doses, amphetamine may actually reduce norepinephrine
release from terminals of locus coeruleus neurons, Amphetamine is a less
potent releaser of norepinephrine than it is of dopamine, and norepinephrine
release is provoked only at high doses (Kuczenski 1983). Since locus
coeruleus neurons are very sensitive to inhibition of neuronal firing, the net
effect of amphetamine at low doses may be to reduce impulse-dependent
release enough that amphetamine overwhelms the amphetamine-induced
nonimpulse-dependent release. Huang and Maas (1981). for instance,
observed a biphasic dose effect of amphetamine on hippocampal neuron
firing, which they interpreted as indicating that amphetamine reduced
norepinephrine release at low doses. A biphasic dose effect on
amphetamine has been observed on the terminal excitability of locus
coeruleus axons in frontal cortex, which we also interpreted in this manner
(Ryan et al. 1985). Thus, amphetamine may have quite different dose-
dependent effects on noradrenergic and dopaminergic neurons.
EFFECTS OF AMPHETAMINE ON NEOSTRIATAL NEURONS IN
BEHAVING RATS
Amphetamine can alter neostriatal unit activity directly by enhancing the
release of dopamine from terminals of the midbrain dopamine projections of
the substantia nigra and, at higher doses, by increasing serotonin release in
the neostriatum. It may also indirectly alter neostriatal activity by changing
activity in systems that project into the neostriatum, including the neocortex.
thalamus, and amygdala. The net effect of amphetamine on neostriatal acti-
vity will be determined by the relative magnitudes of these various
influences.
In anesthetized rats, amphetamine causes dose-dependent changes in
neostriatal unit activity. Spontaneously active neostriatal cells are uniformly
inhibited at low (<2.0 mg/kg, IP) doses. At intermediate doses, an initial
excitation precedes the inhibition, and, at high doses (>5.0 mg/kg, IP), the
predominant effect is excitation (Groves and Rebec 1976). Regional
differences in the direction, magnitude, and duration of the response of
neurons in the neostriatum exist (Rebec and Curtis 1983).
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In contrast. initial studies of neostriatal unit activity in unanesthetized,
behaving animals suggested that neostriatal units were excited by even small
doses of amphetamine (Hansen and McKenzie 1979; Rebec and Gardiner
1985; Trulson and Jacobs 1979; Warenycia and McKenzie 1984a;
Warenycia and McKenzie 19848; Warenycia and McKenzie 1984c;
Warenycia et al. 1984; West et al. 1985). and that the firing rate did not
change with the transition between amphetamine-induced locomotion and
stereotypies (Hansen and McKenzie 1979). These studies, though. did not
report the behavioral correlates of the unit activity recorded in the predrug
period. Since the firing of neostriatal neurons can vary widely with
different behaviors, the observed changes in neuronal firing following
amphetamine could reflect solely the change in behavior produced by
amphetamine. Furthermore, in these studies, primarily spontaneously active
neurons were recorded from, either as single- or multiple-unit responses.
Since the majority of neostriatal neurons are very slowly firing, rapidly
firing neurons were undoubtedly overrepresented in these studies.
In our studies, we examined how amphetamine altered the firing of
identified neostriatal projection neurons during specific pre- and postdrug
behaviors. Neurons were identified as projection neurons by antidromic
activation from the substantia nigra, using criteria that we previously
established (Ryan et al. 1986b). Of 41 antidromically identified neostriatal
cells, only 1 fired faster than 1 Hz during any of the four behaviors that we
analyzed, namely locomotion: face washing; quiet, nonmoving waking; and
sleep. The median firing rate during locomotion was 0.02 Hz (Ryan et al.,
in press). An additional group of 24 nonantidromically activated neurons
was also studied. Most of these neurons also fired infrequently; the median
rate during locomotion was also 0.02 Hz. Indeed, with the exception of
two cells that fired over 6 Hz, the nonantidromically activated cells
resembled the antidromic cells in all respects. Many antidromic and
nonantidromic neurons showed tenfold or greater changes in rate across the
four different behaviors.
The effect of amphetamine on these neostriatal neurons was relatively
uniform. Four doses of amphetamine were tested: 0.25, 1.0, 2.5, and 5.0
mg/kg, SC. At all four doses, amphetamine reduced the firing rate of both
antidromic and nonantidromic neurons during the initial drug-induced period
of locomotion as compared to the rate during predrug locomotion (figure 1).
At the higher doses, several stages of stereotyped behaviors were seen. The
transition from amphetamine-induced locomotion to locomotion associated
with stereotyped side-to-side head movements was accompanied by a further
reduction in firing rate. In those animals in which focused stereotypy was
observed following this period of locomotion plus head movements, neurons
showed a still further reduction in firing rate (figure 2).
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FIGURE 1. Change in firing rate of both antidromically and
nonantidromically activated neostriatal neurons following
amphetamine administration in the freely moving, behaving
rat
NOTE: Firing rate during predrug locomotion compared to firing rate during initial drug-induced
locomotion shows the majority of neurons inhibited by amphetamine. Some cells fired no
action potentials either pre- or postdrug.
These effects were seen for both antidromic and nonantidromic neurons.
However, of the three most rapidly firing neurons, two showed an accelera-
tion in firing rather than a reduction, much as has been previously reported
for spontaneously active neurons (Hansen and McKenzie 1979; Rebec and
Gardiner 1985; Trulson and Jacobs 1979; Warenycia and McKenzie 1984a;
Warenycia and McKenzie 1984b Warenycia and McKenzie 1984c;
Warenycia et al. 1984; West et al. 1985). Thus, amphetamine may induce
a divergence in firing rate, exciting rapidly firing neurons and inhibiting
slowly firing neurons.
Both the degree and pattern of neostriatal activity are altered by ampheta-
mine. Since identified striatonigral projection neurons are inhibited by
amphetamine, the inhibitory control of the substantia nigra pars reticulata
may be decreased. The rapid tonic firing of these neurons may be en-
hanced, ultimately resulting in increased inhibition of the targets of the pars
reticulata, namely the ventromedial thalamus, the superior colliculus, and the
pendunculopontine (PPN) nucleus. Thus, amphetamine may cause the inhi-
bition of these structures, thereby locking in a particular behavioral pattern.
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FIGURE 2. Change in firing rate of activated neostriatal neurons, data
combined across all doses
NOTE: Amphetamine-induced inhibition of neostriatal unit firing during postdrug compared to predrug
locomotion may be clearly observed. As locomotion gives way to locomotion with
stereotyped side-to-side head movements. there is a further decline in firing rate. When
locomotion with head movements was followed by focused stereotypies. there was a still
further decrease in firing rate.
EFFECTS OF AMPHETAMINE ON TERMINAL EXCITABILITY OF
STRIATONIGRAL PROJECTION NEURONS IN BEHAVING RATS
Amphetamine may exert its effects not only by altering the firing rate of
neurons, but also by altering the coupling between action potentials and
neurotransmitter release, by acting on presynaptic terminal receptors.
Dopamine receptor activation has been shown to increase GABA release in
the substantia nigra (Reubi et al. 1977; Starr 1987). It is possible that this
modulation of GABA release occurs by dopamine acting on D1 receptors
known to reside on the presynaptic terminals of striatonigral projection
neurons (Altar and Hauser 1987; Aiso et al. 1987). If so, amphetamine
may activate these receptors by inducing the local release of dopamine
within the substantia nigra (Groves et al. 1975), and this change may be
detected by measuring the electrical excitability of the axon terminal
(Groves et al. 1981). We have recently shown that, in urethane-anesthetized
rats, local infusions of the specific D1 agonist SKF 38393 (10 µM) into the
substantia nigra decrease the electrical excitability of suiatonigral neuron
terminals (unpublished data). In contrast, amphetamine, at doses ranging
from 0.5 to 5.0 mg/kg, SC, did not alter terminal excitability in either
unanesthetized, freely moving rats (Ryan et al., in press) or in
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urethane-anesthetized rats (unpublished data). Thus, it seems unlikely that
amphetamine alters GABA release in the substantia nigra by acting at
presynaptic D1 receptors on striatonigral terminals.
EFFECTS OF AMPHETAMINE ON SUBSTANTIA NIGRA PARS
RETICULATA NEURONS IN BEHAVING RATS
The substantia nigra pars reticulata represents one of the major targets of
the neostriatum. This projection has been demonstrated anatomically
(Grofova 1979) and has been shown electrophysiologically to inhibit the
firing of its target neurons (Deniau et al. 1976). Thus, since amphetamine
inhibits the firing of neostriatal neurons, it is plausible that peripheral
administration of amphetamine could alter the tonic activity of substantia
nigra pars reticulata cells across behavioral states. It is, therefore, of some
interest to study the effects of amphetamine on the activity of pars reticulata
neurons.
In anesthetized animals, the iontophoretic application of dopamine increases
the firing of pars reticulata neurons (Matthews and German 1986; Ruffieux
and Schultz 1980; Waszczak and Walters 1983), and dopamine attenuates
the inhibitory effects of GABA, which is the transmitter used by some of
the striatonigral projection. Little is known, though, about how ampheta-
mine changes activity in this structure in freely moving animals. One
recent study by Olds (1988) suggested that the activity of nondopamine
neurons of the substantia nigra increases after amphetamine administration.
However, the behavioral mix of the 90-minute predrug period was uncon-
trolled; since, as we have observed, the firing rate of these neurons varies
widely with behavior, it is unclear whether this action reflects the effects of
amphetamine on these neurons or the behavioral activation induced by
amphetamine. We have recently begun a series of experiments to elucidate
the relationship between firing rate of pars reticulata neurons and specific
behaviors and to demonstrate how amphetamine alters these correlations.
Preliminary data suggest that the firing rate of pars reticulata neurons during
several behaviors is increased by amphetamine, compared with the same
preamphetamine behavior. The activity of a single pars reticulata neuron
during pre- and postamphetamine locomotion and face washing is shown in
figure 3.
In this cell, the tonic firing of the neuron during this behavior is increased
by amphetamine. This result is consistent with our finding that neostriatal
units projecting to the pars reticulata are inhibited by amphetarninc. The
resulting disinhibition of these nigral units may, in turn, increase their tonic
inhibitory control over their target structures, such as the deep layers of the
superior colliculis (Chevalier et al. 1985). the thalamus (Deniau and
Chevalier 1985) and the PPN. These output structures are known to affect
the motor behaviors that amphetamine influences (Di Chiara et al. 1979).
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FIGURE 3. Amphetamine increases the firing rate of a substantia nigra
pars reticulata neuron in the chronically implanted,
behaving rat
NOTE: Action potentials are represented as a pulse output from a spike-height discriminator: Each
vertical line represents one action potential. The firing rate of this neuron during similar pre-
and postdrug behaviors is increased by injection of 1.0 mg/kg, SC, amphetamine. This
increase occurs for both locomotion (from a mean of 28.3 to 39.0 spikes/sec) and face
washing (from a mean of 43.7 to 46.5 spikes/sec).
EXTRASTRIATAL EFFECTS OF AMPHETAMINE ON THE
CORTICALLY EVOKED STRIATAL RESPONSE IN
ANESTHETIZED RATS
The rat neostriatum receives massive input from the cerebral cortex and
thalamus (Chung 1979; Kemp and Powell 1971; Somogyi et al. 1981).
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Neostriatal processing may not be solely influenced by effects of ampheta-
mine on intrastriatal dopamine systems but may also be influenced by
actions within these other major afferent systems. Thus, amphetamine,
which produces, among other effects, increased firing of mesencephalic
reticular neurons (Boakes et al. 1971), depression of response in locus
coeruleus (Graham and Aghajanian 1971). and cortical desynchronization
(Arushanian and Belozertsev 1978) may have marked effects on activity
within the neostriatum. As an approach to understanding the contribution of
these extrastriatal actions on striatal functioning, the effect of amphetamine
on cortically evoked intracellular events and field potentials in the
neostriatum is being studied.
Electrical stimulation of the neocortex evokes a regular sequence of
intracellular and extracellular potentials in the neostriatum (Liles 1973; Hull
et al. 1973). In intracellular striatal recordings, single-pulse stimulation of
cortical afferents elicits an initial depolarizing postsynaptic potential (DPSP),
which is followed by
depolarization (figure 4).
a long-lasting afterhyperpolarization and a rebound
FIGURE 4. Illustration of the correspondence between components of the
cortically evoked neostriatal intracellular (top, positive up)
and field potential (bottom, negative up) response
NOTE: Time calibration: 5 milliseconds for both traces. Intracellular amplitude. calibration: 10 mV.
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A correspondence between these intracellular events and components of the
cortically evoked neostriatal field potential (Ryan et al. 1986a) have recently
been demonstrated. As shown in figure 4, the initial extracellular positive
wave Pl is associated with the intracellular DPSP. The negative wave N2,
which might reflect intrastriatal collateral inhibition, occurs during the initial
period of intracellular hyperpolarization. The later period of hyperpolariza-
tion, which has been attributed to a loss of tonic excitation from cortical
and thalamic inputs (Wilson et al. 1983). is seen to overlap with the second
extracellular positive wave P2. A late negative wave, N3, occurs in phase
with the rebound depolarization. These correspondences between intra-
cellular and extracellular events encouraged employment of the cortically
evoked field potential as an index of striatal population response to the
effects of amphetamine. Systemic amphetamine (0.5 to 5.0 mg/kg) has
been found to reduce the amplitude of Pl and dramatically decreases the
latency to N3. Interestingly, these effects appear to be due, at least in part,
to the action of amphetamine at extrastriatal sites, since they could be
mimicked by high-frequency, low-current stimulation of thalamic afferents in
the mesencephalic reticular formation (Ryan et al. 1987a). Further, these
changes in the cortically evoked neostriatal field potential following either
systemic amphetamine or high-frequency reticular stimulation were abolished
by kainic acid lesion of the medial thalamus. The pharmacological
characterization of this response supports the extrastriatal origin of these
effects of amphetamine. Dopaminergic antagonists, such as haloperidol and
fluphenazine, do not block or reverse the effects of amphetamine on wave
Pl or N3. In contrast, amphetamine’s actions are potentiated by the 2
noradrenergic autoreceptor antagonist yohimbine and are reversed by the
beta antagonists propranolol and metoprolol (Ryan et al. 1987b). In
addition, the latency to a positive wave recorded in the region of somato-
sensory cortex overlying the neostriatum and temporally coincident with the
neostriatal wave N3 is reduced by amphetamine by the same amount as is
wave N3. These temporally similar actions in neostriatum and neocortex
also indicate an extrastriatal site of action for amphetamine. To characterize
further the extrastriatal effects of amphetamine, cortically evoked neostriatal
field potentials and intracellular responses have been examined after either
local application of amphetamine or high-frequency stimulation of the reticu-
lar formation (RF) (Fisher et al. 1987). Brief, low-intensity (0.1 mA) 60
Hz stimulation of the PPN produces a depolarization of cell-resting-
membrane potential and a resulting decrease of the DPSP. This depolari-
zation is reflected in a parallel reduction of the Pl wave in the evoked field
potential. In addition, a decrease in the latency of the rebound depolariza-
tion is observed following RF stimulation, corresponding to a shift in N3 in
the extracellular response. Notably, a local infusion of amphetamine into
the PPN (10-6M, total volume 0.2 uL over 4 minutes) produces alterations in
the intracellular and extracellular evoked responses, similar to those
observed with RF stimulation (figure 5) and systemic amphetamine
administration.
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FIGURE 5. Cortically evoked intracellular (A, positive up) and field
potential (B, negative up) response in the neostriatum at
increasing times following local infusion of amphetamine
(10-6M) into the pedunculopontine reticular nucleus
NOTE: Following amphetamine, the intracellular postsynaptic potential (PSP) is reduced as is P1 in
the field potential. A reduction in the latency to and a modification in components of the
rebound potential can also be observed. Time calibration: 50 milliseconds. Intracellular
amplitude: 5 mV.
Activation of the RF presumably alters neostriatal functioning via its effects
on thalamocortical pathways. These alterations may affect striatal excitabili-
ty and timing. Results suggest that important alterations in striatal function-
ing can result from extrastriatal actions of amphetamine.
CONCLUSION
The actions of amphetamine are widespread throughout the brain.
Amphetamine’s immediate effect is to alter the release of monoamines in a
dose-dependent manner that is specific for each monoamine transmitter
neuronal system. The net effect of amphetamine on monoamine release is
complex, with some mechanisms tending to increase monoamine release
(e.g., blockade of reuptake and nonimpulsedependent release), and several
mechanisms tending to diminish release (e.g., activation of somatodendritic
and terminal autoreceptors).
It is important to consider that the behavioral outcome of amphetamine-
induced alterations in monoamine release is determined by changes induced
in postsynaptic targets of monoamine neurons. The consequences of
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amphetamine on the activity of these target cells reflects both direct actions
of monoamines and changes in the pattern and intensity of interactions of
afferents and intrinsic neurons. In the neostriatum, for instance,
amphetamine affects neostriatal cells directly by altering the release of
dopamine and serotonin, and indirectly by changing activity patterns in
cortical, thalamic, and amygdalar afferents. One of the greatest challenges
facing neuropharmacologists is to dissect these multitudinous influences to
understand how amphetamine and related designer drugs produce their
important behavioral consequences.
DISCUSSION
QUESTION: Have you looked at the globus pallidus yet?
ANSWER: We have looked at the globus pallidus in anesthetized animals,
which appears to be uniformly increased by amphetamine administration. I
might mention that Jean Walters has also looked at the globus pallidus in
the behaving animals, and it is routinely increased by amphetamine
administration.
QUESTION: Do you think that there is a similar feedback regulation
system of the reticulata part for the nigra?
ANSWER: I think that is controversial right now. Yes, I think there is a
projection system that runs from the pars reticulata to pars compacta, but
the consequences of activation of that system and how you would get
access to it are not well understood at this time.
QUESTION: Is there a parallel to the reticulata component of the striatum,
the dorsal striatum in the ventral tegmental area?
ANSWER: I wish I knew that. It certainly seems so, and we are trying to
record nucleus accumbens at this time. It seems that nucleus accumbens is
similar to neostriatum, but ventral tegmental area has a much greater
heterogeneity of nerve cells than does substantia nigra. It may be that the
nondopaminergic neurons of the ventral tegmental area are just sprinkled
through and that, of course, is the neurophysiologist’s nightmare because
you don’t know where electrodes pick up, although we think there are
neurophysiological criteria. Ultimately, that question will be amenable to
analysis. I wish I could answer it now.
QUESTION: Are the effects of amphetamine in the anesthetized
preparation confounded by the anesthetic agent?
ANSWER: I am not entirely sure, but people in my lab believe that the
effects are related to two different populations of nerve cells, that those
excited by amphetamine administration represent a different population, and
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there are only five or seven or so different types of nerve cells in the
neostriatum, with 95 percent of them in one morphological class.
But there are those in my lab who believe that the excitation is being seen
by a bias toward large cells and that they represent a large cell population
in the neostriatum. I don’t necessarily believe that. I don’t know why, in
the anesthetized animal, you can flip a nerve cell that is inhibited by
amphetamine by increasing the dose. It has been postulated that the
excitation is related to the occurrence of both the stereotyped behaviors, and
that this may be provoked at doses that produce neurotoxicity. We have
also done a number of studies looking at the neurotoxicity of amphetamine
administration in animals, most of which replicate Lou Seiden’s work.
QUESTION: Do you find a population of autoreceptors at the axonal
endings using your techniques?
ANSWER: I think it is very clear that there is a population of
autoreceptors at the axonal end, but there is no population of autoreceptors
in the axon that passes through the medial forebrain level. The antidromic
stimulation is up there, and it looks as if amphetamine and related
dopamine agonists cause a decrease in excitability of the terminal field in
the same way that they cause a decrease in excitability in the cell body.
And we believe that this fact, only recently shown by Allan North’s group,
is that they cause an increase in potassium conductance and as a
consequence hyperpolarization of the cell body.
QUESTION: Does dopamine do it?
ANSWER: Yes.
QUESTION: Whose paper is that?
ANSWER: That is Lacey et al., Allan North’s group. It was published in
the Journal of Physiology last year. It was also an abstract in the Society
2 years ago. It is the consequence of that application of the agonists,
recording intracellularly in the slice of the dopamine neuron. He gets the
same thing by virtue of application of norepinephrine agonists to noradrene-
gic slice preparation. That is a conventional way to create a hyperpolari-
zation of the cell, to increase the potassium conductance, and so forth.
This is presumably the way that much of the polarization of the cells
occurs.
QUESTION: Do you think it is necessary to have an intact cell to have
this hyperpolarization?
ANSWER: I believe very strongly that you need an intact system. Now
there are certain questions that you can answer in a slice. You deprive the
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cells of all their normal afferents and in many cases you cut their axons.
You cut the axon of the very cell you are recording, but you are unaware
that has occurred. But there are many different traumatic events that take
place when you extract the slice. The behavior of the cells is quite
abnormal if you look at it carefully.
QUESTION: If you slice the medial forebrain bundle, is there a change in
the resistance at the terminal area? Which way does it go?
ANSWER: I don’t know. There is a change at the cell body; the
resistance goes way up, and it will set itself into a repetitive firing mode,
which is quite an abnormal looking mode of firing, but the dopamine
neuron or the norepinephrine neuron or virtually any neuron in slice will go
into this bizarre repetitive mode of firing.
Still, activation of autoreceptors causes an inhibition of the activity. So,
there are certain qualitative similarities that lead us to believe that the slice
is a useful preparation for entering certain types of neuropharmacologic
questions. But as far as answering how it is that the brain works, I don’t
think the slice is going to solve it for us.
COMMENT: You were showing your reticulata cell showing an increased
activation. Some people think that they may have this feedback mechanism.
Several years ago Koob and others were postulating that this was indeed
part of an outfIow system. And if you put GABA or GABAergic drugs
into that outflow system, that you could also produce behaviors.
RESPONSE: Yes.
QUESTION: Could it be either/or?
ANSWER: Well, I don’t think it is either/or.
QUESTION: Do you think it is a feedback system?
ANSWER: I don’t think it is a feedback system per se. I think the
feedback system goes a long way. I think Steve Bunney and
George Aghajanian believe that it is a feedback system and that it routes
itself from the neostriatum through the pars reticulata and that the pars
reticulata then causes the inhibition of firing in the dopamine system. Now,
as far as feedback is concerned, I think it is much more likely. for
example, that the globus pallidus causes an inhibition of firing of the
dopamine neuron when amphetamine is injected because amphetamine
causes this dramatic increase in firing of globus pallidus, and we know
anatomically that the globus thalamus projections end up in substantia nigra
pars compacta. So it is much more likely that the globus pallidus is
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influencing the activity of the dopamine neuron by virtue of an afferent
system.
And there are others who believe that dopamine is indirectly or directly
influencing pars reticulata by virtue of being released from dendrites and
exciting the pars reticulata neuron, so that is another theoretical approach
that has not, in my opinion, been adequately tested.
QUESTION: Do you find autoreceptors in mesolimbic structures?
ANSWER: Yes, we do. As far as our evidence goes, we have tested
many hundreds of mesolimbic neurons, and there is a theory that a certain
group of mesolimbic dopamine, cortically projecting neurons lack auto-
receptors. We have studied the cortically projecting tegmental area of
dopamine neurons ad nauseam, and in our hands they look exactly the same
as the substantia nigra pars compacta. They have autoreceptors and they
are influenced by low doses of amphetamine, which we know is used in the
ventral tegmental area, operated by virtue of autoreceptor activation. They
are influenced by low doses; both the excitability at the terminal and the
excitability of the cell body are inlluenced by autoreceptor activation
through the tegmental area in the cortically projecting cells. So our
evidence does not agree with that point of view.
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Methamphetamine and Related
Drugs: Toxicity and Resulting
Behavioral Changes in Response to
Pharmacological Probes
Lewis S. Seiden and Mark S. Kleven
INTRODUCTION
Some substituted phenethylamines are toxic to certain neurons in the brain.
In view of this neurotoxicity, we will review some data relevant to this
process. First, we will review data showing that methamphetamine
(METH), a prototypic psychomotor stimulant, which has been widely used
for nonmedical purposes at doses often a good deal higher than therapeutic
doses, is neurotoxic to dopamine (DA) and serotonin (5-hydroxytryptamine
(5-HT)) systems. Second, we will examine the evidence that other
substituted phenethylamines are also neurotoxic to certain transmitter
systems. Last, we will examine the behavioral and pharmacological
consequences of neurotoxicity that result from exposure to some of these
amphetamine-related drugs.
Phenethylamines can be ring- and/or side chain-substituted, and many of
these derivatives show potent pharmacological effects (Weiner 1985). Of
phenethylamines without ring substitutions, pharmacologically active
compounds tend to be mainly psychomotor stimulants, possessing
sympathomimetic, antifatigue, and reinforcing effects in humans using the
drugs. The antifatigue and reinforcing properties are likely to be
responsible for their abuse potential. In very high doses, such as those used
by human amphetamine abusers, the amphetamine-type drugs can lead to a
psychotic state, which has paranoid delusional symptoms that are very often
indistinguishable from an acute psychotic episode seen in patients with
schizophrenia (Jonsson and Gunne 1970). Outbreaks of METH epidemics
have occurred in several countries including the USA, Sweden. and Japan
(Kramer et al. 1967; Inghe 1969; Brill and Hirose 1969).
The prototype amphetamine enhances release and blocks reuptake of DA,
norepinephrine (NE), and 5-HT and is also a monoamine oxidase inhibitor.
As a result of these effects, drugs in this class are potent indirect agonists
at monoaminergic receptors. In experimental animals, amphetamine
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stimulates locomotor activity at low doses and causes stereotypic activity at
higher doses; amphetamine also interferes with food and water consumption.
These behavioral effects are related to amphetamine’s actions on DA, NE,
and 5-HT systems (Lewander 1977; Moore 1978).
Amphetamine-related drugs such as 3,4-methylenedioxyamphetamine (MDA)
or 3,4-methylenedioxymethamphetamine (MDMA), with substitutions on the
benzene ring, tend to show hallucinogenic activity at lower doses and
psychomotor stimulation at higher doses (Climko et al. 1986). In contrast
to the behavioral effects of ring-substituted amphetamines, side-chain
analogs show psychomotor stimulation at low doses and hallucinogenic
activity at higher doses. Their abuse potential raises the question of
whether amphetamine-like drugs may have long-lasting and/or toxic effects
on the central nervous system (CNS). The data show that some of these
ring-substituted compounds have toxic effects on the DA and 5-HT systems,
whereas others seem to be toxic mainly to the 5-HT system. Also of
interest are some structure-activity relationships, the toxicity to DA and/or
5-HT fibers, and a possible mechanism by which these drugs are toxic.
Data from behavioral tests using pharmacological probes show that these
neurotransmitter systems are compromised.
NEUROTOXIC EFFECTS OF AMPHETAMINE-RELATED DRUGS
Although the symptoms produced in humans suggested that the ampheta-
mine type of drugs may engender a neurotoxic response in the CNS, there
were no signs of brain pathology until the early 1970s. Koda and Gibb
(1973) reported that 18 hours after a dosing regimen in which METH was
injected every 5 hours, the Vmax for tyrosine hydroxylase was reduced.
Seiden et al. (1975-76) reported that, in monkeys administered amphetamine
for several months and sacrificed 3 to 6 months after the last injection, the
levels of DA in the brain were reduced. This long-term reduction in brain
DA suggested but did not prove that METH was toxic to DA cells.
Neurotoxicity of METH was shown to occur in rats by virtue of the facts
that: (1) levels of DA and activity of the enzyme that is rate limiting for
DA synthesis were decreased for a long period after cessation of drug
treatment (Ricaurte et al. 1980; Ricaurte et al. 1982; Hotchkiss et al. 1979);
(2) the number of reuptake sites for DA were reduced (Ricaurte et al. 1980;
Ricaurte et al. 1982); and (3) there was shown to be neuronal degeneration
in DA-rich areas of the brain (Ricaurte et al. 1982; Ricaurte et al, 1984).
It is important to stress that these three criteria must be met before
neurotoxicity can be established. Similar effects upon 5-HT levels, reuptake
sites, and morphology must also be observed before it can be concluded
that 5-HT neurotoxicity has occurred. In this regard, multiple doses of
METH have been shown to produce long-lasting reductions in tryptophan
hydroxylase activity (Hotchkiss et al. 1979) as well as 5-HT content and
uptake sites (Ricaurte et al. 1980) in the rat brain.
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The criteria for neurotoxicity have been met for the hallucinogenic
amphetamines MDA and MDMA (table 1). Levels of 5-HT were depleted
as long as 8 weeks following a repeated administration of either MDA or
MDMA (Ricaurte et al. 1985; Schmidt et al. 1986; Schmidt 1987a; Stone
et al. 1987a; Stone et al. 1987b). Additionally, both MDA and MDMA
reduced numbers of 5-HT uptake sites (Ricaurte et al. 1985; Commins
et al. 1987; Schmidt 1987a), depressed tryptophan hydroxylase activity
(Stone et al. 1986; Schmidt and Taylor 1987) and produced signs of
neuronal degeneration (Ricaurte et al. 1985; Commins et al. 1987). It is
clear from these data that neurotoxicity is directed primarily toward the
5-HT system. Much higher doses are required to produce significant
reductions in the levels of DA or its metabolites.
TABLE 1. Effects of amphetamine-related compounds on
monoaminergic neurons
Drug
Amphetamine
Cathinone
METH
MDA
MDMA
Fenfluramine
Dethylpropion
Mazindol
P P A
Cocaine
M P H
KEY: METH=methamphetamine PPA=phenylpropanolamine; MPH=methylphenidate.
Levels Uptake Sites Fink-
D A N E 5-HT DA 5-HT Heimer
More recently, the N-ethyl analog of MDA (MDE) was examined for
possible neurotoxic effects (Stone et al. 1987a; Schmidt 1987b). In
comparison to MDA and MDMA, MDE was much less potent in causing
depletions of 5-HT 2 weeks after a multiple dose regimen (10 mg/kg every
6 hours for five consecutive intervals). This regimen also failed to reduce
tryptophan hydroxylase activity; additionally, 5-HT uptake sites were not
reduced 1 week after a single 20 mg/kg injection, unlike the reduction
found with similar doses of MDA and MDMA (Schmidt 1987b). However,
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as observed with MDA and MDMA, no effects of MDE on DA neurons
were reported in these studies.
Fenfluramine, like MDMA and MDA, is a ring-substituted amphetamine
derivative that has been found to meet all the criteria for neurotoxicity.
When administered in doses higher than 12 mg/kg/day, depletions of 5-HT
and 5-hydroxyindoleacetic acid (5-HIAA) last up to 6 months after cessation
of drug treatment (Harvey and McMaster 1975; Harvey et al. 1977;
Clineschmidt et al. 1978; Steranka and Sanders-Bush 1979; Schuster
et al. 1986; Kleven et al. 1988). Other long-lasting effects of fenfluramine
include a decrease in 5-HT uptake sites (Schuster et al. 1986) and
tryptophan hydroxylase activity (Steranka and Sanders-Bush 1979).
Previous studies have also indicated that fenfluramine produces signs of
neuronal degeneration (Harvey and McMaster 1975; Harvey and McMaster
1977; Harvey et al. 1977). Recent immunohistochemical studies also
indicated that fenfluramine produced morphological damage to 5-HT
terminal fields (Appel and De Souza 1988). Collectively, the neurochemical
and histological data support the idea that fenfluramine is neurotoxic to
5-HT.
Cathinone and phenylpropanolamine are side-chain-substituted amphetamines
that have thus far met only some of the criteria for neurotoxicity. Like
d-amphetamine, cathinone releases and, at very high concentrations, blocks
uptake of DA (Wagner et al. 1982). Similarly, cathinone mimics
d-amphetamines long-lasting toxic effects on DA levels and uptake sites
(Wagner et al. 1982). The possibility that neuronal damage occurs
following neurotoxic doses of cathinone has not been examined. Neurotoxic
effects of phenylpropanolamine are unlike those reported for other
substituted phenethylamines. When very high doses (200 mg/kg by
injection) are administered, slight decreases in frontal cortex DA have been
observed (Woolverton et al. 1986). with no effects on other monoamine
systems.
Several substituted phenethylamines, such as methylphenidate (MPH) and
mazindol, are notably lacking in toxic effects on DA or 5-HT (Wagner
et al. 1980). However, mazindol does produce a slight decrease in NE,
following repeated administration. None of the other neurotoxic
amphetamine derivatives have been found to have long-lasting effects on the
NE system. Both amphetamine and MPH are potent monoamine-releasing
agents; however, MPH appears to act primarily on a pool that does not
depend upon recent synthesis (Scheel-Kruger et al. 1977). The newly
synthesized transmitter pool seems to be required for the neumtoxicity
produced by METH, since inhibition of DA synthesis blocks the
neurotoxicity of METH (Commins and Seiden 1986; Wagner et al. 1983).
The similarities in acute neurochemical effects of cocaine and amphetamine-
like compounds raise the possibility that repeated exposure to cocaine might
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produce long-term neurotoxic changes similar to those produced by METH.
Most previous studies have examined effects of repeated doses of cocaine
within 24 hours after the last injection (Roy et al. 1978; Taylor and Ho
1976; Taylor and Ho 1977). These studies reveal that exposure to cocaine
for up to 45 days causes only small decreases in DA and/or 5-HT levels.
Longer lasting consequences of repeated exposure to cocaine have only
recently been examined (Trulson and Ulissey 1987; Trulson et al. 1986;
Trulson et al. 1987). For example, it has been reported that repeated
cocaine administration to rats reduced striatal and mesolimbic tyrosine
hydroxylase activity 60 days after the last injection (Trulson et al. 1986;
Trulson et al. 1987), a finding that suggests that prolonged exposure to
cocaine might produce long-lasting damage to DA-containing neurons. A
reduction in tyrosine hydroxylase activity for several days or weeks is
consistent with toxicity to catecholamine neurons. However, using
neurochemical methods, we have not found such evidence of neurotoxicity
(Kleven et al., in press). Repeated injections of either moderate
(20 mg/kg/day) or high doses (100 mg/kg/day) of cocaine for 10 days failed
to produce long-term reductions in the concentration of monoamines or
metabolites in any of the brain regions examined, including the striatum.
Similarly, increasing exposure to 21 days of continuous infusion of a high
dose of cocaine (100 mg/kg/day) failed to significantly deplete DA and
5-HT in the striatum or other regions examined. Higher doses of cocaine
were lethal within 4 days of exposure. Therefore, long-lasting depletions of
monoamines do not seem to occur following cocaine administration.
The data reviewed above indicate that amphetamines and a number of their
analogs are neurotoxic to DA and/or 5-HT. Although both ring- (MDA,
MDMA, MDE) and side-chain-substituted amphetamines (METH, cathinone,
mazindol) have been found to produce neurotoxicity, some differences are
apparent. First, side-chain-substituted phenethylamines are primarily toxic to
DA neurons, with effects on 5-HT appearing at higher doses. On the other
hand, ring-substituted phenythylamines are selectively toxic to 5-HT
neurons, with effects on DA evident only at much higher doses. Second,
these two classes of substituted phenethylamines may also differ in terms of
potency, either absolute or relative to other behavioral effects.
Table 2 summarizes results of neurotoxicity studies that have utilized the
same regimen of drug injections (twice daily for 4 days) and survival times
(2 weeks). In addition, the ability of these drugs to suppress milk intake in
rats is also presented. It is clear that ring-substituted amphetamines are
more potent in terms of absolute dose required to reduce amine content than
is the parent compound amphetamine. With regard to relative potency,
METH is toxic to DA and 5-HT neurons at doses that are more than
tenfold higher than doses that produce anorexia, whereas fenfluramine,
MDA, and MDMA are toxic to 5-HT neurons at doses that are only three
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TABLE 2. Relationship between behavioral and neurotoxic potency
Drug
METH
Cathinone
PPA
Dethylpropion
MDA
MDMA
Fenfluramine
Neurotoxicity*
Dose†† DA-striatum 5-HT-hippo Anorectic ED50
†
100 65% 57%
100-200 50%
1 0 0 - 2 0 0  6 4 % >100
25 67% 10.0
10 41% 2.5
20 30% 2.8
6.25 43% 5.0
1.6
3.9
*Levels of transmitter % of control.
†Reduction of intake of sweetened condensed milk during 15-minute sessions.
††mg/kg injected twice daily for 4 days, rats were sacrificed 2 weeks after the last injection.
KEY: PPA=phenylpropanolamine; no effect.
to four times higher than those needed to suppress milk-drinking activity in
rats. These data suggest that ring substitution increases neurotoxic potency
to a greater extent than increasing behavioral potency.
BEHAVIORAL EFFECTS OF NEUROTOXIC AMPHETAMINES
The most robust behavioral change that has been observed after a brief
regimen of amphetamine-related drugs is altered sensitivity to subsequent
administration of the same or a related drug. The underlying effect is not
apparent until it is unmasked by pharmacological challenge. Thus, long-
lasting behavioral effects of neurotoxic amphetamines may be more subtle
than those produced by monoamine neurotoxins such as 6-hydroxydopamine
(6-OHDA) or 5,6-dihydroxytryptamine (5,6-DHT). Perhaps this is because,
with the toxic amphetamines, levels of neurotransmitter are usually depleted
to about 50 percent of normal. Studies in which monoamine neurons are
lesioned using 6-OHDA or 5,6-DHT show behavioral deficits when levels
are depleted to 80 or 90 percent of normal. Even in these studies, the most
common finding is a change in sensitivity to pharmacological probes
(Heffner and Seiden 1979; Levine et al. 1980).
The original observation of long-term depletions of DA in the rhesus
monkey was made during a study of the development of tolerance to the
effects of daily injections of METH (Fischman and Schuster 1977). In this
study, it was found that behavioral tolerance to METH on a differential-
reinforcement-of-low-rate (DRL) task persisted long after the repeated
METH regimen. In a similar study conducted later, monkeys treated with
repeated METH showed reduced sensitivity to apomorphine and increased
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sensitivity to haloperidol (Finnegan et al. 1982). Increased sensitivity to
haloperidol and tolerance to METH’s effects on locomotor activity of rats
(Lucot et al. 1980) and a force-lever task in rhesus monkeys (Ando et al.
1985) have also been reported following a regimen of METH. Since, in
each of these studies, repeated administration of METH produced substantial
decreases of DA, tolerance to subsequent METH injections is most likely
related to selective destruction of DA terminals.
In contrast to studies in which tolerance to METH was observed, sensitivity
to the effects of MDMA on DRL performance in rats has been found to
increase as a consequence of a neurotoxic regimen of MDMA (Li et al., in
press). Acute administration of MDMA at 2, 4, and 6 mg/kg increased the
response rate and decreased the reinforcement rate of rats performing under
a DRL 72-second schedule, similar to that observed with other psychomotor
stimulants. Repeated administration of MDMA for 4 days (6 mg/kg, SC,
twice daily), to rats performing on the DRL schedule produced a shift to
the left of the MDMA dose response curve and also increased the maximal
response to MDMA at all dosages. Since levels of 5-HT but not NE or
DA were significantly depleted following the MDMA regimen, the
behavioral results suggest that 5-HT neurons normally exert an inhibitory
action upon the psychomotor stimulant effects of MDMA. Since the
psychomotor stimulant effects of amphetamines appear to be mediated
primarily by the DA system, these results provide evidence that 5-HT and
DA may represent opposing systems insofar as they play a role in DRL
schedule-controlled behavior.
It has recently been found that sensitivity to the analgesic effects of
morphine is altered in rats previously treated with a neurotoxic regimen of
MDMA (Nencini et al. 1988). Rats were injected twice a day for 4 days
with 20 mg/kg MDMA or saline, and, after 14 days, nociception was
determined by measuring reaction time to the tail immersion in heated water
(55 °C). After determining baseline reaction times, rats were randomly
assigned to four groups receiving saline or morphine (2.5, 3.55, or 5 mg/kg,
SC), and the nociceptive test was repeated at various times after drug or
saline administration. Morphine administration produced an analgesic effect
that was more potent and prolonged in MDMA- than in saline-pretreated
rats. These data indicate that morphine was more potent as a consequence
of a neurotoxic regimen of MDMA.
During evaluation of neurotoxicity produced by fenfluramine, an apparent
transitory depletion of 5-HT was observed, with recovery of levels occurring
at 16 weeks for most regions except the hippocampus. It was of interest to
examine this finding in greater detail because of previous work that had
suggested irreversible effects of the drug. Tolerance to the anorectic effects
of fenfluramine was observable 2 but not 8 weeks following a standard
4-day regimen of fenfluramine (6.25 mg/kg. twice daily). Because levels of
5-HT are apparently returning toward control values by 8 weeks in striatum
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and hypothalamus, it is possible that tolerance to fenfluramine’s anorectic
effect is due to 5-HT depletion. Thus, sensitivity to the anorectic effect
may be related to existing levels of 5-HT. Rats previously allowed to drink
sweetened condensed milk during daily 15-minute sessions were treated with
fenfluramine (6.25 mg/kg twice daily for 4 days) or saline. After 2 to 8
weeks, rats were administered fenfluramine acutely, tested for milk intake,
and sacrificed 2 hours later. Acute adminitration of fenfluramine produced
a dose-related decrease in milk intake and 5-HT levels in various brain
regions. The milk intake data indicated that tolerance to the anorectic effect
of fenfluramine occurred as a result of prior exposure to fenfluramine.
However, levels of 5-HT were also depleted 2 and, to a lesser extent,
8 weeks after the fenfluramine regimen. There was apparent tolerance to
the acute 5-HT-depleting effect of fenfluramine as a result of the 4-day
fenfluramine regimen; partial recovery of this neurochemical tolerance was
observed at 8 weeks. The results suggest that tolerance to the anorectic
effects of fenfluramine may be due to a selective depletion of 5-HT.
CONCLUSION
The results of behavioral studies reviewed are summarized in table 3. It is
clear that a neurotoxic regimen of METH produced tolerance to the effects
of subsequent injections of METH on either conditioned or unconditioned
behaviors. The regimen of METH produced long-lasting depletions of DA
in each of these studies. Similarly, repeated administration of fenfluramine
also produced decreases in 5-HT and tolerance to the anorectic effects of
fenfluramine. Repeated administration of MDMA to rats performing a DRL
schedule resulted in sensitization to the effects of MDMA. This latter
finding is interpreted as being due to the effects, MDMA on DA release, in
TABLE 3. Evidence of neurotoxin-induced behavioral changes in response
to pharmacological probes
Drug Regimen Test Effect Reference
METH 0.5-16 mg/kg/day DRL MA Fischman et al. 1977
Haloperidol
METH 1-32 mg/kg/day DRL MA Finnegan et al. 1982
Haloperidol
METH 100 mg/kg/day * 4 Locomotor MA Lucot et al. 1980
Haloperidol
METH 4-40 mg/kg/day * 4 Force Lever MA Ando et al. 1985
MDMA 6.0 mg/kg/inj * 8 DRL-40 sec MDMA
MDMA 20 mg/kg/inj * 8 Tail Flick
Li et al., in press
Morphine Nencini 1988
FEN 6.25 mg/kg/inj * 8 Milk Intake FEN Kleven et al. 1988a
Key: METH=methamphetamine; FEN=fenfluramine; =tolerance; =sensitization.
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the absence of effects on 5-HT release, as a consequence of the prolonged
depletions. Each of these studies has utilized pharmacological techniques to
unmask the behavioral deficits produced by the neurotoxic regimen of drug.
It should be noted that persisting behavioral effects of the chronic regimen
of drug, in the absence of such pharmacological challenges appear not to
have been reported. While pharmacological probes reveal an underlying
change in DA and/or 5-HT function, the nature of behavioral deficits in the
absence of drug challenge remains to be determined.
DISCUSSION
QUESTION: Have you or anyone else had the opportunity to look at the
changes in the neurochemical parameters in animals that self-administer
some of the amphetamines?
ANSWER: No, not to my knowledge. What we have done is look at what
the consequences are on self-administration from these chronic regimes.
In other words, we do not have them self-administering these toxic doses.
We have done it with some rhesus monkeys that were self-administering
methamphetamine. If you give them a regime that depletes the dopamine
and serotonin, and then see what alterations there are in self-administration,
it does go down, but we have not looked at that.
QUESTION: Do you get bigger effects on some of the behavioral
parameters after the amphetamine treatments if you pretreat the animals with
a low dose of alpha methyltyrosine during that period, during the post-
amphetamine period? In the old days, when we had a partial lesion, we
gave a low dose of AMFT, and it would reexpose the lesion. Have you
tried that?
ANSWER: No. It is a good idea, though.
QUESTION: I find the technique of challenging the animals with various
“typic” agents quite intriguing for assessment after prolonged exposure to
MDMA or amphetamine. How long do those changes last? I saw in your
slide something on the order of 2 weeks or a few days after the MDMA
treatment. If you would come back a few months later, would that
supersensitivity still exist?
ANSWER: We are not sure. We have not systematically looked at later
times; we have done so accidentally, however. Sometimes we are not ready
to do an experiment, and we have repeated the MDMA experiment, We
have also, by chance, done tests 6 weeks later, and we have gotten
essentially the same results.
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QUESTION: Is that reasonably concordant then with the depleting effects
of these treatments?
ANSWER: For MDMA, it is. It certainly would not be for fenfluramine.
But we haven’t looked functionally yet.
QUESTION: Because by 8 weeks you already see some sort of recovery?
COMMENT: I would like to show a slide because I believe the data are
interesting. It has to do with the strategy of looking for a functional
change after serotonin is lost following fenfluramine treatment.
There is a recent clinical report by Emil Coccaro and colleagues that I think
might be relevant to the kind of thing you have done in rats. They have
been looking at endocrine responses to fenfluramine in humans as a marker
of central serotonergic function. And they have observed an increase in
serum prolactin concentration, which is felt to be due to serotonin release.
They reported that, in subjects who received a second dose of fenfluramine
within 12 days after the first dose, that there was a blunted response to
serum prolactin.
There are probably a multitude of explanations, but clearly one would be a
possible persistent depletion of serotonin, the substrate whose release is
required for the acute response to prolactin.
So I think the accumulation of the additional data as you have presented in
rats and perhaps additional data like that in humans may help to clarify
whether there are functional consequences of that loss of serotonin
following fenfluramine.
RESPONSE: That is very interesting. I should mention that, for
fenfluramine, the toxic dose as for MDMA is very close to the therapeutic
dose.
I didn’t go in much detail into what the effects of different doses were, but
with fenfluramine we are getting toxicity in the range of 3, 6, and
10 mg/kg and to interfere with feeding behavior in the rat you arc dealing
with an order of 2.0 mg/kg. So there isn’t much of a window there.
Similarly, for MDMA, the neurotoxic dose range is 10, 20 mg/kg and a
human is taking approximately 2.0 mg/kg. Behaviorally effective doses are
in the neighborhood of 4, 5, and 6 mg/kg.
In contrast to methamphetamine, where we are dealing with behaviorally
effective doses that are in the range of 1 to 4 mg/kg, toxicity doses are in
the range of 50 to 100.
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So you see, according to our thinking, some of these drugs are more
dangerous because the toxic doses are so very close to the behaviorally
active therapeutic doses.
COMMENT: Just a very brief comment that originally followed up on the
idea of pharmacologic challenge. It is a very powerful technique with
which one can detect underlying or covert neurochemical deficits,
The beauty of it is not only can it uncover an otherwise unapparent deficit,
but it is a technique that can be readily applied to humans.
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Role of Dopamine in the
Neurotoxicity Induced by
Amphetamines and Related
Designer Drugs
James W. Gibb, Donna M. Stone, Michel Johnson,
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INTRODUCTION
In 1971, extensive excitement about the increasing abuse of amphetamines
piqued the authors’ interest in the effects of amphetamine and its analogs
on biogenic amine metabolism; specifically, whether the biosynthesis of
biogenic amines may be altered. In the prior year, Mandell and Morgan
(1970) reported that methamphetamine (METH) produced an increase in
adrenal tyrosine hydroxylase (TH) activity. Fibiger and McGeer (1971) also
observed that chronic treatment with METH caused an increase in TH
activity in the adrenal gland and a decrease in enzyme activity in the
neostriatum.
METHAMPHETAMINE STUDIES
METH Effects on the Dopaminergic System
In an attempt to simulate in rats the dosage regimen commonly employed
by abusers of amphetamines, METH was administered (10 or 15 mg/kg
every 6 hours; four to six doses), after which the animals were killed (Koda
and Gibb 1971: Koda and Gibb 1973). TH activity and catecholamine con-
centrations were measured in various brain regions and in the adrenal.
Neostriatal TH activity was depressed in a dose-dependent manner and
reached its nadir at 36 hours. Dopamine (DA) and norepinephrine concen-
trations were initially elevated, but then decreased in parallel with TH
activity. Adrenal TH activity was elevated. presumably because of stress
associated with the toxic doses of METH.
It was later determined whether this was a generalized response to METH
of all transmitter systems or whether it was characteristic of specific
systems. In the dosage used, METH did not affect striatal choline
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acetyltransferase or glutamic acid decarboxylase; however, tryptophan
hydroxylase (TPH) activity was dramatically decreased (Hotchkiss
et al. 1979). These observations suggested that METH selectively altered
the dopaminergic and serotonergic systems, but did not change the striatal
cholinergic or GABAergic systems.
METH Effects on the Serotonergic System
While there are significant similarities in the response of the dopaminergic
and serotonergic systems to METH, there are also qualitative and quantita-
tive differences. Decreases that occur in the serotonergic parameters are
much larger than the changes in parameters of the dopaminergic system;
moreover, the doses required to obtain the response in the serotonergic
system are lower. Furthermore, the decrease in striatal TH activity is not
observed until approximately 12 hours after METH administration, while
there is a pronounced effect in the serotonergic system within 15 to 30
minutes. (figure 1). TPH activity and serotonin (5-HT) concentrations
declined rapidly, while concentrations of 5-hydroxyindoleacetic acid
(5-HIAA) were transiently elevated after a single dose of METH; tryptophan
content was also elevated after a single dose of METH. Similar responses
occurred with p-chloroamphetamine and amphetamine (Peat et al. 1985).
Since dopaminergic fibers are confined to fewer regions of the brain, while
the serotonergic system is present in many brain areas, the effect of METH
on the brain serotonergic system is more widespread than is the dopamin-
ergic response (Hotchkiss and Gibb 1980).
When only a single dose of METH (10 mg/kg) was administered, TPH
activity returned to normal in all areas within 2 weeks after administering
the drug (Bakhit and Gibb 1981). However, with repeated administration of
METH (five doses, given every 6 hours), TPH activity in the neostriatum,
cerebral cortex, nucleus accumbens, and hippocampus recovered to some
extent but remained significantly depressed 110 days after the last dose of
the drug had been administered; neostriatal TH activity was also depressed
after 110 days.
These findings suggest that, although a single exposure to METH does not
result in permanent alteration of the serotonergic system, repeated
administrations of large doses of METH result in sustained damage. These
observations, together with the METH-induced morphological alterations
(Ricaurte et al. 1982) and the compromised uptake of DA (Wagner
et al. 1980), suggest that METH, given in repeated, large doses, is
neurotoxic to brain serotonergic and dopaminergic neurons.
Role of DA and Its Reactive Metabolites
After the response to METH had been relatively well characterized, the
mechanism responsible for the effect was still unidentified. Since DA
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FIGURE 1. Effect of acute METH on serotonergic parameters
*Significantly different from control, p<0.05 by Student's t-test.
NOTE: A single dose of METH (10 mg/kg. SC) was administered and rats were killed 3 hours later.
TPH activity and concentration of tryptophan (TRP), 5-HT. and 5-HIAA in the neostriatum
were determined; saline control values (means ± SEM): 5-HT. 0.75±0.l; 5-HIAA, 0.72± 0.06,
TRP, 5.68± 0.17 ng/mg; TPH activity, 24.5± 1.4 nmol/g tissue/hr (n=6 or more).
antagonists had previously been reported to attenuate other effects of
amphetamines (Lasagna and McCann 1957; Randrup et al. 1963; Espelin
and Done 1968), the influence of chlorpromazine or haloperidol on the
METH-induced decreases in TH activity (Buening and Gibb 1974) was
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investigated. Either drug prevented the response of TH to METH in the
neostriatum; moreover, at the dosage used, haloperidol prevented and chlor-
promazine attenuated the elevation of adrenal TH activity. More recently,
it was found that the decrease in striatal TH activity is both a D1- and
D2-mediated event (Sonsalla et al. 1986).
Whether the serotonergic responses to METH could be attenuated by DA
antagonists was next examined (Hotchkiss and Gibb 1980). Surprisingly,
haloperidol, administered concurrently, prevented the METH-induced de-
crease in neostriatal TPH activity (figure 2). Similar responses were
observed in the cerebral cortex.
FIGURE 2. Effect of HA on METH-induced decrease in neostriatal
TPH activity
*p<0.05 compared to control.
†p<0.05 vS. METH done by Student’s t-test
NOTE: METH (15 mg/kg, SC) was administered four times at 6-hour intervals and rats were killed 5
days after the first administration. HA (3 mg/kg. IP) was administered on the same schedule
(n=4 to 10).
Subsequent experiments revealed that DA is necessary for METH to cause
neurotoxicity; when DA synthesis was inhibited with -methyl-p-tyrosine
(MT), the usual decrease in striatal TH activity observed after METH was
prevented (figure 3A) (Kogan and Gibb 1979). Reinstatement of DA syn-
thesis by administering, l-dopa. which circumvents the inhibited TH step,
returned the METH-induced decreased in TH activity.
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FIGURE 3. A. Inhibition of DA synthesis on the METH-induced decrease
in neostriatal TH activity. B. Inhibition of DA synthesis on
the METH-induced &crease in neostriatal TPH activity
*p<0.05 vs. Control
†p<0.001 vs. METH alone, by Student’s t-test
NOTE: A. METH (15 mg/kg, SC) was administered four times at 6-hour intervals, and rats were
killed 5 days after the first administration. MT (60 mg/kg, lP) was administered on the same
schedule. B. METH (IS mg/kg. SC) was administered five times at 6-hour intervals, and rats
were killed 18 hours after the first administration. MT (60 mg/kg. IP), l-dopa (50 mg/kg. IP),
and RO 44602 (25 mg/kg, IP) were administered concurrently (n=4 to 10). 
More fascinating was the response of the serotonergic system to MT and
METH. When DA synthesis was interrupted by concurrent administration
of MT, TPH activity remained normal after METH; however, when DA
synthesis was reinstated by administering concurrently l-dopa, a peripheral
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dopa decarboxylase inhibitor (RO 44602). MT, and METH, the METH-
induced depression of TPH activity was again observed (figure 3B).
It was thought that additional evidence for involvement of DA in the
serotonergic response to METH could be obtained by selectively destroying
the dopaminergic input to the neostriatum with bilateral injections of the
neurotoxin 6-hydroxydopamine (6-OHDA) into the substantia nigra. METH
was then administered to determine whether the decrease of TPH activity
caused by METH would be absent in the neostriatum but present in the
other regions. 6-OHDA was injected bilaterally into the substantia nigra
11 days prior to METH administration. In the neostriatum, deprived of
dopaminergic input, there was no decrease in TPH activity. In the frontal
cortex and hippocampus, however, the METH-induced decrease in TPH
activity still occurred (Johnson et al. 1987).
In summary, three different approaches were used to examine the role of
DA in the METH response: first, blockade of DA receptors by haloperidol
or more specific DA antagonists prevented the METH-induced alteration of
the dopaminergic and serotonergic systems, suggesting that DA may be
involved in these alterations; second, when DA synthesis was inhibited, the
METH-induced changes were prevented in both monoaminergic systems;
finally, when dopaminergic input to a specific brain region was interrupted,
the METH-induced decrease in TPH activity in that brain region was selec-
tively abolished.
OTHER DRUG STUDIES
Effect of MDMA on Serotonergic and Dopaminergic Systems
In 1985, Seiden and his coworkers reported that 3,4-methylenedioxy-
amphetamine (MDA) caused a decrease in brain 5-HT and 5-HIAA concen-
trations; 5-HT uptake was also compromised (Ricaurte et al. 1985). We
compared the effects of the methylenedioxy derivatives of METH and
amphetamine on the serotonergic and dopaminergic parameters previously
demonstrated as altered by METH administration (Stone et al. 1986).
When 3,4-methylenedioxymethamphetamine (MDMA) or MDA was adminis-
tered to rats in a single dose, TPH activity was markedly depressed.
Multiple doses of MDMA or MDA resulted in a further decline in TPH
activity (figure 4). In contrast to METH, however, neither MDA nor
MDMA altered neostriatal TH activity. The decrease in TPH activity was
accompanied by a dramatic decrease in 5-HT and 5-HIAA concentrations;
these changes in TPH activity and in 5-hydroxyindole content also occurred
in other serotonergic terminal areas such as the hippocampus and cerebral
cortex. Both neostriatal DA and homovanillic acid (HVA) were initially
elevated 3 hours after a single dose of MDMA, but had returned to normal
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by 24 hours. Dihydroxyphenylacetic acid (DOPAC) concentrations were
initially decreased (15 minutes) and had recovered by 24 hours.
Subsequent experiments were designed to characterize further the response
of the serotonergic system to MDMA. When a single low dose (5 mg/kg)
of MDMA was administered, there was an initial decrease in TPH activity
and concentrations of 5-HT and 5-HIAA. These serotonergic parameters
FIGURE 4. Effect of multiple-dose drug treatment on neostriatal TH and
TPH activity
**p<0.01 vs. saline control, by Student’s t-test.
NOTE: Rats were administered five SC doses of MDA (10 mg/kg). MDMA (10 mg/kg). or METH
(15 mg/kg), one dose every 6 hours. and killed 18 hours after the last dose. Results are
presented as the means ± SEM, expressed as a percent of saline control. Control values
were: TH, 2645± 163 nmol tyrosine oxidized/g tissue/hr and TPH, 45.0± 3.5 nmol 14CO2
liberated/g tissue/hr
returned toward control and were essentially normal 2 weeks after the single
dose. If, however, higher doses of MDMA (10 mg/kg, given every 6
hours) were administered and the serotonergic parameters were monitored
for varying periods of time after discontinuing treatment, neostriatal TPH
activity and concentrations of 5-HT and 5-HIAA remained significantly
depressed for at least 110 days (figure 5) (Stone et al. 1987). The
timecourse of recovery was similar in other serotonergic terminal regions
examined.
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Role of DA in MDMA-Induced Changes in the 5-HT System
The possible role of DA in the MDMA-induced alterations of the
serotonergic system was then examined. Techniques previously used in
studying the role of DA in the METH-induced neurochemical effects were
employed. When DA synthesis was inhibited with MT, the effect of
multiple doses of MDMA on TPH activity (figure 6) and concentrations of
5-HT and 5-HIAA was attenuated. The degree of protection with MT
seemed to be a function of the size and number of doses of MDMA used
as well as a function of the serotonergic parameter that was measured.
FIGURE 5. Long-term recovery of neostriatal serotonergic parameters
after multiple doses of MDMA
*p<0.01 vs. time-matched saline, by Student’s t-test
NOTE: Rats were administered live doses of MDMA (10 mg/kg). one dose every 6 hours, and killed
at specified times thereafter. Results are the means ±  SEM (n=6 to 10). expressed as a
percent of time-matched saline-treated control.
Moreover, the early transient response to a single dose of MDMA was less
attenuated by MT than was the persisting response that occurred after
multiple doses of MDMA.
DA was then depleted by using a different drug to determine whether the
response to MDMA would be attenuated. When a single high dose of
MDMA (20 mg/kg) was administered after reserpine, MT, or MT plus
reserpine pretreatment, the usual decrease in neostriatal TPH activity
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remaining 3 days after MDMA treatment was completely prevented (figure
7). Additionally, when animals were injected with 6-OHDA bilaterally into
the substantia nigra and a single dose of MDMA (10 mg/kg) was
administered 11 days later, the acute (3 hours) MDMA-induced decline in
neostriatal, but not hippocampal or cortical, TPH activity was significantly
attenuated (figure 8).
FIGURE 6. Effect of concurrent MT on the neostriatal TPH deficit induced
by multiple doses of MDMA
**p<0.01 vs. vehicle-saline.
†p<0.05.
††p<0.01 vs. corresponding vehicle-MDMA group, by two-way ANOVA and Newman-Keuls multiple
comparisons test.
NOTE: Rats were administered multiple doses of MDMA (2.5, 5, or 10 mg/kg, SC, five doses, one
every 6 hr). Concurrent with each MDMA dose, MT (60 mg/kg) or saline vehicle was
administered IP. Rats were killed 18 hours after the last dole. Results are the means of ± SEM
(n=6 to 8). expressed as a percent of control (vehicle-saline).
It was previously demonstrated that amfonelic acid, a DA-uptake blocker,
partially prevented the METH-induced decrease in TPH activity (Schmidt
et al. 1985). Recently, effects were investigated of a specific DA-uptake
blocker, GBR 12909, on the MDMA-induced response in the serotonergic
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FIGURE 7. Effect prior DA depletion on the neostriatal TPH deficit
induced by a single high dose of MDMA
**p<0.01 vs. vehicle-saline
†p<0.05.
††p<0.01 vs. vehicle-MDMA by two-way ANOVA and Newman-Keuls multiple comparisons test.
NOTE: Rats were pretreated IP with MT (120 mg/kg. 90 min before ), reserpine (5 mg/kg. 12 hr
before) or a combination (60 mg/kg MT + 5 mg/kg reserpine, 90 min and 12 hr before,
respectiely). A single dose of MDMA (20 mg/kg) was administered after the specified time
following pretreatment, and rats killed 3 days later. Results are the means ± SEM (n=6 to 7),
expressed as a percent of control (vehicle-saline).
system. GBR 12909 (20 mg/kg) was administered 15 minutes prior to
MDMA (20 mg/kg), and rats were killed 3 days later. The DA-uptake
blocker significantly attenuated the usual MDMA-induced decrease in striatal
TPH activity (figure 9) as well as the decrease in neostriatal 5-HT and
5-HIAA content
These experiments provide evidence that DA and/or its reactive metabolites
are likely involved in MDMA-induced changes in the serotonergic system.
When DA synthesis was inhibited with MT, or when DA innervation was
interrupted by 6-OHDA lesions, the effects of MDMA were prevented or
attenuated. Depletion of DA with reserpine, or inhibition of DA uptake
with GBR 12909, also attenuated the effects of MDMA on the serotonergic
system.
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FIGURE 8. Effect of prior substantia nigral lesions on the immediate
MDMA-induced decreases in regional TPH activity
**p<0.01 vs. sham-saline.
†p<0.05.
††p<0.01 vs. sham-MDMA by two-way ANOVA and Newman-Keuls multiple comparisons test. 
NOTE: Lesions were induced bilaterally by local injection of 4 µg 6-OHDA/ 8 µL  0.1% ascorbate.
vechile/side. Control rats received sham lesions of ascorbate vehicle alone. After an 11-day 
recovery period, acute MDMA (10 mg/kg) was adminstered SC and rats killed 3 hours later.
Results are the means ± SEM, expressed as a percent of sham-saline (n=22 for sham-saline
group, n=14 for 6-OHDA-saline group, n=6 to 8 for MDMA-treated groups).  Because
6-OHDA itself significantly elevated TPH activity, values from MDMA-treated rats were
expressed as a percentage ± SEM of their respective saline-treated control mean: in the 
neostriatum, TPH activity for the 6-OHDA-MDMA group was 67.6±5.1% vs. 37.5±2.3% for
sham-MDMA, p<0.01 by Student’s t-test. When similarly expressed, no significant differences
were found between sham-MDMA and 6-OHDA-MDMA groups in the hippocampus or 
frontal cortex. 
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It is premature to define the exact mechanism by which DA is involved in
the response to METH or MDMA. It is known- that these drugs release
large quantities of DA and that DA can be readily oxidized to reactive
metabolites, which could possibly cause destruction of nerve terminals
(Graham 1978; Maker et al. 1986). Moreover, these effects could be
enhanced by inhibition of monoamine oxidase, which is known to occur
with these drugs (Susuki et al. 1980). The possibility that 6-DOHA is
formed and subsequently destroys the nerve terminals, as suggested by
Seiden and Vosmer (1984), also requires investigation.
FIGURE 9. Effect of DA-uptake inhibition on the neostriatal TPH deficit
induced by a high single dose of MDMA
**p<0.01 vs. vehicle-saline.
††p<0.01 vs. vehicle-MDMA by two-way ANOVA and Newman-Keuls multiple comparisons test.
NOTE: GBR 12909 (20 mg/kg, IP) or vehicle was administered 15 min prior to a single dose of
MDMA (20 mg/kg. SC); rats were killed 3 days later. Results are the means ± SEM (n=5 to
6). expressed as a percent of control (vehicle-saline).
172
CONCLUSIONS
Observations made over the last 18 years concerning the effects of METH
on the dopaminergic and serotonergic systems, comparisons of the mono-
aminergic responses to METH and MDMA, and the studies of the possible
role of DA and/or its reactive metabolites as mediators in the alterations
observed with these drugs provide evidence that DA is necessary for the
effects to occur. Further studies are indicated to define more precisely the
mechanism(s) responsible for the neurotoxic effects of these drugs. These
studies may help to elucidate the potential neurotoxic effects of ampheta-
mine and its related congeners in persons who ingest these agents, and may
also have important implications in understanding the etiology of
Parkinsonism and mental psychoses.
DISCUSSION
QUESTION: You have dopamine reuptake blockade, you have the SCH
23390 blocking, specifically blocking this tryptophan hydroxylase effect.
Do you have a mechanism? How would you see that interaction taking
place?
ANSWER: We have thought about that and I think one of the major
challenges we have as a group is to determine the mechanism by which this
occurs.
I think the results are compatible with the idea that Dr. Seiden has, that it
is 6-hydroxydopamine. I think that it could be a 6-hydroxydopamine or
some other reactive metabolite of dopamine that is causing the effect.
I think that probably dopamine is taken up and in some way oxidized and
therefore may cause the destruction of the nerve terminals. But there are
other possibilities as well that need to be explored to find out whether that
indeed is the case. I think the jury is still out as to the mechanism that
might occur.
COMMENT: That is the reason for mentioning the SCH 23390 being
specific for blocking it and the sulpiride is not blocking it--
RESPONSE: In the serotonergic system.
COMMENT: Right, and it wouldn’t explain a 6-hydroxydopamine
mechanism. It is fascinating that there is that D1, D2 relationship.
RESPONSE: Yes, those data are a bit confusing.
I think the fact that haloperidol and all the dopamine antagonists work
doesn’t bring much clarity to the situation. I think it muddies the water.
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But it is there, and I think it is important that we show it here so that the
total picture is presented.
COMMENT: I totally agree with the AMT. We have also found that
AMT blocks the serotonergic depletion, so we are in agreement.
Furthermore, and we haven’t reported it yet, PCPA would also be expected
to block the serotonergic depletion. It does nothing to the serotonin
toxicity. So you are right, it is somewhat of a mystery as to what is going
on.
COMMENT: You have presented some evidence that dopamine may be
involved in the neurotoxic action of methamphetamine in terms of
dopaminergic neurons, and you presented evidence suggesting that it may be
involved in not only the dopamine system but also the serotonin system.
I think one has to be very careful, and it goes back to something that
Dr. Seiden raised earlier, that if you are going to speak of the ncurotoxicity,
I really think you have to look at a wide array of neurochemical changes,
not only at 1 or 2 days but at 2, 3, or 4 weeks. Then the changes should
be correlated with morphological changes.
I have no doubt that the bearing on these data is that you have shown the
pharmacological effects on tyrosine and tryptophan hydroxylase activity. I
am not sure that I can equate those with effects on actual neurotoxicity.
The main reason for my suspicion is that in the experiment with AMT
where the effect of methamphetamine on tyrosine hydroxylase activity can
be blocked and then reinstituted by coadministering l-dopa, one would
predict that if one is really talking about neurotoxic effects, then one ought
to be able to observe the same changes 2 weeks later.
We have attempted that experiment, And while it is true that on an acute
basis we can indeed restore an effect on neurochemical parameters at a day,
that is not the case at 2 weeks. This leads me to suspect that one is really
dealing with pharmacological effects of methamphetamine, reinstitution of
these pharmacological effects with l-dopa. But that may not equate with a
neurotoxic action of the drug. I think it is important because it opens up
the issue of whether dopamine does in fact mediate a neurotoxic action of
MDMA and these other compounds rather than some acute pharmacological
effects of these drugs.
RESPONSE/QUESTION: I think that your point is well taken, but I would
ask: Have you and Dr. Seiden demonstrated your uptake blockade after 2
weeks or so as well? And then I would address the question to you or
him--have you done the Fink-Heimer work at longer periods of time?
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ANSWER: No, we haven’t done the Fink-Heimer work at the longer
periods with the blocking agents. We have done the AMT protection
experiment 2 weeks later. That seems to work on the 5-HT neurons.
QUESTION: What we really need is to do some morphological studies
with something that is very selective for those particular neurons, and I
agree with you that that is something we need to strive for. Are you doing
that at the Addiction Research Center?
ANSWER: We are trying to look at it using some of the neuroanatomical
techniques that you described in terms of localizing uptake sites.
COMMENT: Let me make something clear. We don’t need any new
techniques. The experiments are very simple; they just have to be done at
2 weeks rather than at 18 hours. And it may be that you are entirely
correct, But until those experiments are performed at longer timcpoints, I
don’t think we know if we are dealing with pharmacology or toxicology.
QUESTION: In your experiments, have you ever looked at the hippocam-
pus? It is interesting to note that there is very little dopamine in the
hippocampus. And if the theory of the necessity for dopamine is correct,
then you should not see the depletion of serotonin in the hippocampus.
ANSWER: Good point. We have looked at the hippocampus and have
found that it is protected. We think that not only dopamine is involved, but
probably other catecholamines as well. 
QUESTION: How do you imagine that both a receptor antagonist and an
uptake inhibitor would block the effects? It would seem that if dopamine is
involved, it would either be acting on a membrane receptor or inside, but
not both. I would also like to ask a more specific question. You showed
that the alpha MT protected effect could be reversed by dopa. And I think
you imagined that that was because of dopamine formation. But have you
tried dopamine agonists to see if they would antagonize either the protective
effect of alpha methyltyrosine or, particularly, the protective effect of the
dopamine antagonists to try to verify that those protective effects really
have to do with blockade of a dopamine receptor as opposed to some other
possibility?
ANSWER: That is a good question. I haven’t.
COMMENT: I think that one thing that we are not dealing with effectively
is the degeneration in the cortex, which, in our hands, is quite extensive.
Somatosensory cortical, pyramidal cells die at a very high rate with chronic
administration. It seems to me that the involvement of dopaminc in that is
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less likely, and the postulation that a 6-hydroxydopamine mechanism that
doesn’t account for the sparing that one sees in certain regions.
RESPONSE: We do have experiments in progress that will address that
cortex issue because it is one that needs to be resolved.
COMMENT: We feel that it is due to the formation of 5,6-DHT in the
cortex. These cells are indeed innervated by serotonin cells and, as a
matter of fact, we have an experiment that is being published in Brain
Research where we show that if we inject 5,6-DHT into the ventricles, we
can produce exactly the same type of degeneration in the pyramidal cells,
due to the formation of the 5,6 from the 5-hydroxytryptamine. We are
exploring the possibility of it being another catecholamine in addition to
dopamine, so I think both of those may be helpful in answering your
question.
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Acute and Long-Term
Neurochemical Effects of
Methylenedioxymethamphetamine
in the Rat
Christopher J. Schmidt
INTRODUCTION
Administration of a single dose of methylenedioxymethamphetamine
(MDMA) to rats at doses above 10 mg/kg produces a biphasic pattern of
serotonin (5-HT) depletion in the central nervous system (CNS) shown for
the cerebral cortex in figure 1. Much of the work on MDMA in our labor-
atory has involved the characterization of these two phases of transmitter
depletion following MDMA. Our results indicate that these two periods of
depletion are unique with respect to their mechanism, timecourse, and
stereochemical requirements. The acute effect of MDMA, which is maxi-
mal between 3 and 6 hours following drug administration, involves a
disruption of 5-HT synthesis coupled with an increase in transmitter turn-
over. These early effects of MDMA on the serotonergic neuron appear to
be ultimately reversible. The second phase of depletion develops several
days after the administration of MDMA and is associated with a decrease in
the number of serotonergic nerve terminals. It is the latter decrease in
transmitter concentrations that corresponds to the neurotoxic effect of
MDMA. Attempts have been made to compare these in vivo effects of
MDMA with some of its in vitro activities to gain insight into the
mechanism(s) responsible for the complex neurochemical response elicited
by this drug.
ACUTE EFFECTS
Characteristic of its amphetamine-like structure, MDMA is a potent
monoamine-releasing agent as demonstrated both in vitro (Nichols et al.
1982; Johnson et al. 1986; Schmidt et al. 1987) and in vivo (Yamamoto and
Spanos 1988). This release occurs through a carrier-mediated, Ca2+-
independent mechanism typical of the phenethylamines (Schmidt et al.
1987). Figure 2 shows the concentration-dependent, MDMA-induced trans-
mitter release from preloaded rat striatal slices superfused in vitro. From
the figure, it is apparent that MDMA behaves similarly to the selective
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serotonergic neurotoxin p-chloroamphetamine (PCA) as a releasing agent.
Both PCA and MDMA show a greater potency for [3H]5-HT release as
compared to another neurotoxic amphetamine, methamphetamine. However,
methamphetamine is a more potent releasing agent for [3H]dopamine (DA)
than either MDMA or PCA, which again appear very similar. These results
are interesting in that, in contrast to the selective serotonergic neurotoxicity
of PCA and MDMA, methamphetamine has been shown to be neurotoxic to
both dopaminergic and serotonergic neurons in the rat brain (Gibb et al.,
this volume).
FIGURE 1. Timecourse of changes in 5-HT concentrations and TPH
activity following a single dose of MDMA
NOTE: All data presented as mean ± SEM.
This similarity between MDMA and PCA is also observed in vivo in that
PCA produces both an acute and long-term depletion of 5-HT (Fuller et al.
1975; Steranka et al. 1977). Like PCA, the acute decrease in 5-HT concen-
trations produced by MDMA is associated with a decrease in the activity of
the rate-limiting enzyme for 5-HT synthesis, tryptophan hydroxylase (TPH).
The timecourse of this change in cortical enzyme activity is also shown in
figure 1. More detailed analysis of this acute effect of MDMA and kinetic
analysis of TPH activity reveals that the decrease in enzyme activity actu-
ally precedes the decline in transmitter levels and is due to a reduction in
the Vmax activity of the enzyme (Schmidt and Taylor 1987; Schmidt and
Taylor 1988). As shown for the cortex in figure 3, the decrease in 5-HT
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also follows a transient spike in the concentration of 5-HIAA before the
metabolite concentrations also begin to decline. These data indicate that an
increase in transmitter release and a decrease in TPH activity are both
required to produce the large depletion produced acutely by MDMA.
FIGURE 2. Comparison of the MDMA-, PCA-, and methamphetamine-
induced release of tritiated monoamines from superfused
striatal slices in vitro
**p<0.01
***p<0.001 compared to MDMA.
†p<0.001 compared to MDMA and p<0.02 compared to PCA.
NOTE: All data presented as mean ± SEM.
The above conclusion is supported by the results shown in figure 4. Just as
inhibitors of the 5-HT uptake carrier can antagonize MDMA-induced
[3H]5-HT release in vitro, coadministration of MDMA with an uptake inhibi-
tor such as citalopram can completely block the acute depletion of 5-HT.
Although citalopram also antagonized the MDMA-induced decrease in TPH
activity, there was still a significant loss of enzyme activity when compared
to control. This implies that if MDMA requires access to the interior of
the nerve terminals to affect TPH activity, it does not require the activity of
the uptake carrier to gain entrance. Hence, these results are consistent with
the outcome of synaptosomal uptake experiments with [3H]MDMA (Schmidt
et al. 1987), which show that MDMA is not actively concentrated by a car-
rier system. Furthermore, it is apparent that the loss of enzyme activity
alone is not sufficient to reduce 5-HT concentrations, but that release via
the carrier must occur simultaneously, to deplete the terminal once synthetic
capacity is reduced.
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FIGURE 3. Detailed timecourse of serotonergic changes in the cerebral
cortex after the administration of 10 mg/kg MDMA
*p<0.05 compared to control.
**p<0.01 compared to control.
***p<0.001 compared to control.
NOTE: All data presented as mean ±SEM.
In attempting to determine the mechanism responsible for this loss of en-
zyme activity, a number of possibilities have been examined. Direct addi-
tion of MDMA to brain homogenates was without effect on TPH activity
(Schmidt and Taylor 1987) as has been demonstrated previously for a num-
ber of amphetamine analogs, including PCA (Knapp et al. 1974). The
results of attempts to incubate P2 synaptosomes with MDMA were deemed
unreliable due to a large decrease in the activity of synaptosomal TPH upon
incubation. The activity of the control synaptosomes incubated for 2 hours
at 37 °C was consistently 40 to 50 percent of the activity measured in
unincubated synaptosomes. Although, under these conditions, MDMA
increased 5-HT release, as evidenced by a decrease in synaptosomal 5-HT
concentrations, there was no further effect on TPH activity (table 1). The
use of superfused cortical slices was found to stabilize TPH activity in pro-
longed incubations compared to synaptosomes; however, MDMA was still
without effect on enzyme activity even after exposure to concentrations as
high as 250 µM for 2 hours (Schmidt and Taylor 1988). In a final attempt
to reproduce the effect of MDMA on TPH activity in vitro, we selected a
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FIGURE 4. Effect of inhibition of the 5-HT uptake carrier by citalopram
on the MDMA-induced changes in cortical TPH activity and
5-HT concentrations 3 hours post-MDMA
***p<0.001 compared to control.
††p<0.01 compared to MDMA.
†††p<0.001 compared to MDMA.
NOTE: All data presented as mean ± SEM.
mouse mast cell line, P815, to test the effects of MDMA in a cell culture
system. These cells have been characterized as containing both 5-HT and a
high level of TPH activity. The inset of figure 5 shows this activity was
easily measured in our assay. However, as also shown in the figure,
incubation of P815s with a high concentration of MDMA (250 µM) for
18 hours had no measurable effect on TPH activity in the cells (Schmidt
and Taylor 1988).
The inability to demonstrate an effect of MDMA on TPH activity in vitro
seemed to point to a requirement for intact neuronal circuitry or in vivo
metabolism of the drug. We therefore attempted to determine if a direct
effect of MDMA in the rat CNS could be achieved by local administration
of the drug directly into the brain. The injection sites were selected to
include the most likely sites of action in the brain, Figure 6 shows enzyme
activity was not altered in the right cerebral cortex 3 hours after 300 µg of
MDMA were stereotaxically injected into the right cerebral ventricle. Corti-
cal 5-HT and 5-HIAA concentrations were also unaffected by this treatment,
as were transmitter concentrations and enzyme activity in the striatum and
hippocampus. Injections of the same dose of MDMA into the substantia
nigra and near the serotonergic cell bodies of the dorsal raphe yielded simi-
lar results (Schmidt and Taylor 1988). These injections were performed
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FIGURE 5. Lack of effect of MDMA on TPH activity in the mouse
mastocytoma cell line, P815
NOTE: Cells were incubated for 18 hours in 250 µM MDMA prior to assay. Enzyme activity was
linear with respect to time under the culture conditions used, as shown at the right. Data
presented as mean ± SEM.
under halothane to allow rapid recovery from the anesthesia and observation
of the animals. Surprisingly, there were no obvious behavioral differences
between saline- and MDMA-injected rats. In the absence of any behavioral
effect of MDMA, the results from these experiments were considered
inconclusive as evidence for or against a direct central effect of MDMA.
This prompted us to set up experiments using a constant intracerebroven-
tricular infusion of MDMA to insure that brain concentrations of the drug
were maintained for a behaviorally relevant period of time. In the
established design, conscious rats were continuously infused with either
MDMA or saline for a l-hour period, after which they were observed for
an additional 2 hours prior to sacrifice. Using this approach, doses as low
as 300 µg produced significant changes in regional TPH activity (figure 7).
The latter quantity, corresponding to a dose of approximately 1 mg/kg, was
without effect on TPH activity in any of the three brain regions examined,
when given peripherally by the subcutaneous route (Schmidt and Taylor
1988). Although this seems a high dose for direct central administration, it
is consistent with data reported by Marquardt et al. (1978) showing that
10 percent of a peripherally administered dose of methylenedioxyamphe-
tamine (MDA) was present in the rat brain within 30 minutes of injection.
Assuming that the distribution of MDA and MDMA are similar, this means
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TABLE 1. Effect of MDMA on TPH, 5-HT, and 5-HIAA
Frozen control
TPH
(nmol oxidized/mg/h)
0.530
5-HT 5-HIAA
(ng/mg) (ng/mg)
Incubated control (0.218± 0.052) (2.36 ± 0.02) (2.03 ± 0.14)
100 ± 23.9 100 ± 1.0 100 ± 6.9
1 µM MDMA 85.8 ± 7.3 49.6 ± 5.9 103 ± 12.8
10 µM MDMA 88.1 ± 2.3 25.0 ± 1.7 59.1 ± 3.9
NOTE: P2 synaptosomes were incubated in a Krebs Ringer bicarbonate buffer for 2 hours at 37 °C.
The frozen control was not incubated. Values for MDMA-treated samples are given as a 
percent of the incubated control ± SEM.
that peripheral administration of 10 mg/kg of MDMA could be expected to
yield even higher brain concentrations of the drug than were achieved with
the infusion of 300 µg over 1 hour. These results therefore indicate that
the acute effect of MDMA on TPH activity in the rat is a centrally
mediated event requiring sustained, high brain concentrations of the drug.
The lipophilicity of MDMA apparently precludes maintaining such concen-
trations when the drug is rapidly administered directly into the brain.
Although these results exclude a peripheral metabolite of MDMA as the
causative agent in its acute effect on TPH activity, they do not eliminate a
role for a central metabolite. The ultimate cause of this effect of MDMA
and related drugs therefore remains to be determined.
LONG-TERM EFFECTS
A clear differentiation of the acute and long-term effects of MDMA was
first accomplished by comparing the neurochemical effects of the optical
isomers of MDMA at 3 hours and 1 week. As shown in figure 8, either
enantiomer of MDMA produced the acute depletion of 5-HT. but only rats
treated with the (+)isomer still showed depletion 1 week later. There was
also a significant reduction in the uptake of [3H]5-HT into synaptosomes
prepared from the latter group of animals (Schmidt 1987a). Hence, the
neurotoxic effect of MDMA is primarily a property of the (+)stereoisomer,
while the acute effect of MDMA has less stringent stereochemical require-
ments. In addition, the results with (-)MDMA indicate that the acute effect
of the drug on 5-HT concentrations is not permanent, since in the absence
of neurotoxicity the depletion of the transmitter produced by (-)MDMA is
reversed by 1 week. In addition to comparing the enantiomers in vivo, their
effects on neurotransmitter release in vitro were also compared. As shown
in figure 9, (+)MDMA was more potent than (-)MDMA at releasing either
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FIGURE 6. Lack of effect of intracerebroventricular MDMA (300 µg) on
serotonergic parameters in the cerebral cortex 3 hours after
administration by bolus injection
NOTE: Data presented as mean ± SEM.
[3H]DA or [3H]5-HT, although the difference between the enantiomers was
less marked for the release of [3H]5-HT.
A comparison of the acute and long-term effects of MDMA with those of
its homologs MDA and N-ethyl-methylenedioxyamphetamine (MDE) also
contrasts the acute and neurotoxic effects of these compounds. It has pre-
viously been demonstrated that all three drugs produce the acute depletion
of 5-HT measured at 3 hours (Schmidt 1987b). However, as shown in
figure 10, if the animals are allowed to survive for 1 week after drug
administration, only MDA- and MDMA-treated rats show the reduction in
5-HT concentrations and [3H]5-HT uptake indicative of neurotoxicity.
Therefore, the depletion of 5-HT produced at 3 hours by MDE was com-
pletely reversible. These results are similar to our observations with the
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FIGURE 7. Reduction in regional TPH activity 3 hours after the start of a
1-hour intracerebroventricular infusion of MDMA (300 µg)
*p<0.05 compared to control.
**p<0.01 compared to control.
NOTE: Data presented as mean ± SEM.
(-)stereoisomer of MDMA. In vitro, the three methylenedioxy analogs were
very similar in terms of [3H]5-HT release, but differed in their potency for
releasing [3H]DA. Here, the order from most to least potent was
MDA>MDMA>MDE (figure 11).
A final experiment demonstrating the distinction between the acute and
neurotoxic effects of MDMA is shown in figure 12. In this case, the 5-HT
uptake inhibitor fluoxetine was administered at various times after MDMA,
with all animals being sacrificed 1 week later. The results are shown as a
percentage of control cortical 5-HT concentrations. Simultaneous adminis-
tration of an uptake inhibitor with MDMA completely blocked the decrease
in 5-HT concentrations measured 1 week later. However, administration of
the inhibitor 3 hours after MDMA still resulted in complete protection from
the neurotoxicity. Approximately 50 percent of the depletion could still be
blocked 6 hours after MDMA; by 12 hours, the administration of fluoxetine
no longer had any effect. Blockade of the neurotoxicity by an uptake
inhibitor 3 hours after MDMA clearly differentiates the acute and long-term
effects of MDMA, since at this point the acute depletion of 5-HT is already
at a maximum. The administration of fluoxetine to MDMA-treated animals
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FIGURE 8. Comparison of the optical enantiomers of MDMA for the acute
(3 hours) and long-term (7 days) effects on the serotonergic
system
*p<0.05 compared to saline.
***p<0.001 compared to saline.
NOTE: Data presented as mean ± SEM.
at 3 hours could be considered analogous to the administration of MDE
alone, where an acute effect on 5-HT is observed without the subsequent
development of neurotoxicity. It is also apparent from these data that a
second or later carrier-mediated event is important in the production of the
neurotoxicity of MDMA. The critical phase of activity on the part of the
carrier leading to the neurotoxic response is occurring some time between
3 and 12 hours post-MDMA.
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FIGURE 9. Comparison of the optical enantiomers of MDMA for the
release of tritiated monoamines from preloaded striatal
slices superfused in vitro
*p<0.05.
**p<0.01
***p<0.001.
NOTE: Data presented as mean ± SEM.
DISCUSSION
The results of the preceding set of experiments may identify several features
of the underlying mechanisms responsible for the acute and long-term
effects of MDMA. For example, it is apparent that the production of the
acute effect of MDMA has less stringent stereochemical requirements than
does the production of neurotoxicity. While both enantiomers of MDMA
cause the rapid depletion of transmitter concentrations as well as the depres-
sion in TPH activity (Schmidt and Taylor 1988). only the (+)stereoisomer
produces neurotoxicity at the doses used in these experiments. In a similar
manner, all three methylenedioxy compounds produce the acute interruption
of serotonin synthesis, yet only the two lower n-alkyl homologs caused the
long-term effect. Therefore, in selecting what ultimately leads to the acute
effect of the drug(s) on serotonergic neurons, those activities least
influenced by stereochemistry and affected equally by either the desmethyl
or N-ethyl homolog of MDMA would be the most likely candidates. The
lack of structural stringency characteristic of the acute effect is also
observed for the release of 5-HT in vitro. The role of carrier-mediated
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5-HT release in the acute depletion of 5-HT has already been discussed. It
may be that a rapid increase in 5-HT elicited by MDMA and its analogs is
also involved in the inactivation of TPH. In contrast to the acute effect of
MDMA on 5-HT synthesis, the reduction in 5-HT concentrations and the
uptake of [3H]5-HT measured at 1 week after drug administration is less
FIGURE 10. Comparison of the neurochemical effects of the three MDA
homologs 7 days after the administration of 20 mg/kg of
each drug to rats
**p<0.01 compared to saline.
**p<0.001 compared to saline
NOTE: Data presented as mean ± SEM.
likely to be a direct result of 5-HT release. since there is little difference in
the ability of either (+) or (-)MDMA to produce such release and virtually
no difference between the three methylenedioxy homologs. The long-term
effects of the three drugs do actually correspond to their potency for
producing DA release, however. Both the release of [3H]DA and neuro-
toxicity follow the same rank order. Similarly, in comparing the
enantiomers of MDMA, the stereochemical specificity of the neurotoxicity is
the same as that of DA release.
Based upon the above considerations, it is hypothesized that the acute effect
of MDMA and its analogs is due to a rapid and sustained increase in the
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FIGURE 11. Comparison of the three MDA homologs for the release of
tritiated monoamines from preloaded striatal slices
super-fused in vitro
*p<0.05 compared to MDE.
**p<0.01 compared to MDE.
**p<0.00l compared to MDE
†p<0.05 compared to MDMA.
†††pc<0.001 compared to MDMA.
NOTE: Data presented as mean ± SEM.
carrier-mediated release of 5-HT. In contrast, the neurotoxic effect of
MDMA and its analog, MDA, may be due to a sustained elevation in the
release of DA. In this regard, Sharp et al. (1986) have recently compared
the increase in extracellular DA and 5-HT measured by intrastriatal dialysis
after PCA administration. Their results show that the release of DA is
much more pronounced than that of 5-HT and has a much longer duration.
Extracellular DA concentrations 3 hours after injection were approximately
tenfold higher in PCA-treated (5 mg/kg) rats when compared to saline-
injected controls. In contrast, by 3 hours, extracellular 5-HT concentrations
were only two to three times greater than control. Extrapolation of these
data to MDMA suggests that, during the period in which the neurotoxicity
of MDMA is developing, i.e., 3 to 12 hours after MDMA, extracellular DA
is still abnormally elevated. Yamamoto and Spanos (1988) have recently
demonstrated that DA release after a neurotoxic dose of MDMA (10 mg/kg)
is still elevated severalfold, 3 hours after drug administration.
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Time Between Fluoxetine and
MDMA Administration
FIGURE 12. Timecourse for the antagonism of MDMA-induced neuro-
toxicity by the 5-HT uptake inhibitor fluoxetine
NOTE: The inhibitor (5 mg/kg) was administered at the indicated times after MDMA, and all animals
were sacrificed 7 days later. Data are presented as a percentage of the appropriate control
(saline or fluoxetine alone), mean ± SEM.
CONCLUSION
These studies have characterized both the acute and long-term neuro-
chemical effects of a single administration of MDMA in the rat. The acute
depletion of 5-HT concentrations results from an as yet unexplained loss of
TPH activity in the serotonergic nerve terminals, coupled with a massive
carrier-mediated efflux of transmitter. The long-term depression of 5-HT
concentrations by MDMA is due to an apparent degeneration of serotonergic
nerve terminals. In its pattern of neurochemical effects, MDMA resembles
the selective serotonergic neurotoxin PCA, which may suggest a common
mechanism. Unfortunately, the mechanism responsible for the neurotoxicity
of PCA has been difficult to elucidate in spite of the number of studies that
have addressed this issue. MDMA therefore joins a well-studied group of
amphetamine analogs including amphetamine itself, methamphetamine, PCA,
and fenfluramine, which have in common an unexplained neurotoxic effect
on monoaminergic neurons in laboratory animals. It is hoped that the
increased interest in this area generated by MDMA and its well-publicized
abuse will provide the impetus to resolve the question of amphetamine
neurotoxicity.
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DISCUSSION
QUESTION: Did you try infusion for less than 1 hour? The acute TPH
changes occur as soon as 10 or 15 minutes after single administration, so
wouldn’t you expect to see changes following a 10- or 15-minute infusion?
ANSWER: You might, but I am not absolutely sure of that because the
timecourse of the levels of the drug in brain is going to differ from those
infusion paradigms, what you get with peripheral administration of the drug.
Based on the fact that at 3 hours with a very low dose of MDMA, I saw
an effect on the enzyme and no effect on the transmitter levels, we
probably can’t pay too much attention to that timecourse and expect to see
changes that are identical to what you see in the whole animal with
peripheral administration. That is what I would imagine. The experiments
could be done, though. They are not that difficult. You just stick the
cannulas in and infuse.
QUESTION/COMMENT: Is there any information on the half-lives of the
two enantiomers of MDMA in the brain? What about the half-lives of
MDA versus MDMA versus MDE?
My point is whether differing potencies, in regard to long-term effects,
might be accountable on the basis of the duration that the compounds
persist in the brain rather than intrinsic activities involving release of one or
another neurotransmitter.
ANSWER: Yes, that is a very good possibility. The difference between
PCA and amphetamine comes down to the fact that parachlorination of that
compound makes it persist in the brain longer and you go from something
like amphetamine, which has small neurotoxic effects on serotonin, to
parachloroamphetamine, which is very neurotoxic. So your point is well
taken and that is a possibility, I think.
QUESTION: To follow up on what you said about parachloramphetamine,
I think that the importance of that metabolism is even clearer if you com-
pare 4-chloroamphetamine to 3-chloroamphetamine, where those compounds
are very different in their long-term effects, but become identical in rats
that are pretreated with drugs to block the ring hydroxylation. If you make
them equal metabolically, you make them equal in terms of their long-term
effects on serotonin. You can do that also by going to the guinea pig,
which doesn’t parahydroxylate. 3-chloroamphetamine and 4-chloroampheta-
mine are already equal metabolically and they are equal in terms of their
long-term effects, Does the same thing apply to the enantiomers of MDMA
and also the analogs of MDMA?
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ANSWER: I think that is a very good possibility. It was that sort of
thinking that convinced us we really had to do infusion experiments. The
drug has to be there for a sufficient amount of time to have these effects.
QUESTION: Did you do those experiments with PCA?
ANSWER: Elaine Sanders-Bush has done those, and the enantiomers do
differ, but the enantiomers also differ in half-life, and it is probable that the
difference in long-term toxicity is simple because of that difference in half-
life.
COMMENT: I know Larry Steranka did that comparison with ampheta-
mine, but I don’t recall the results.
COMMENT: We have looked at tritiated MDA and MDMA clearance
from brain, and we haven’t seen much of a difference over a 24-hour
period. The tritium concentrations peaked in brain at about 45 minutes,
leveled off for a few hours, and then were gone by 24 hours. There was
some indication that more MDA got into the brain than MDMA, but these
are very preliminary experiments.
QUESTION: Where is your label?
ANSWER: The label for MDA was on the ring, and that was an important
point in terms of assuring that it was not just demethylation.
QUESTION: Were you measuring label or were you measuring specific
MDMA? Were you measuring radioactivity or MDMA itself?
ANSWER: We were measuring radioactivity. So far, we have looked at
MDA. We haven’t seen much metabolism of MDA to any other
metabolite. We haven’t looked at those experiments with MDMA yet.
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Effects of MDMA and MDA on Brain
Serotonin Neurons: Evidence from
Neurochemical and Autoradio-
graphic Studies
Errol B. De Souza and George Battaglia
INTRODUCTION
The drugs 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methyl-
enedioxyamphetamine (MDA) are ring-substituted derivatives of
methamphetamine and amphetamine, respectively. These methylenedioxy-
substituted amphetamines have been reported to exhibit both stimulant and
psychotomimetic properties (Anderson et al. 1978; Braun et al. 1980;
Shulgin 1986). MDMA has received a great deal of attention recently,
since it represents one of a number of “designer drugs” that have been
increasingly abused among certain segments of the population, especially
college students. MDMA has been the subject of a recent scientific and
legal debate, as several psychiatrists have reported that MDMA may
“enhance emotions” and “feelings of empathy” and thus serve as an adjunct
in psychotherapy (Greer and Tolbert 1986). Recent data demonstrating that
MDMA is self-administered in nonhuman primates (Beardsley et al. 1986;
Lamb and Griffiths 1987) suggest that the drug may have high abuse
potential in man. These reports are particularly disturbing, as the authors
and others have recently demonstrated that MDMA is a potent neurotoxin
that appears to cause selective degeneration of brain serotonin neurons
(Battaglia et al. 1987; Battaglia et al. 1988; Commins et al. 1987; Schmidt
1986; O’Hearn et al. 1988) comparable to that reported for its structural
analog MDA (Battaglia et al. 1987; Ricaurte et al. 1985; Stone et al. 1986).
This chapter describes data on the neurotoxic effects of MDMA on brain
monoamine systems in rodents. Specifically, studies are described
examining the effects of in vivo administration of MDMA on brain
monoamine systems with respect to:
(1) the selective neurodegenerative effects on brain serotonin systems;
(2) the effects of dose and frequency of drug administration;
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(3) the potential neurochemical mechanisms involved in the neurotoxic
effects of the drug;
(4) the characteristics and timecourse of recovery following destruction of
serotonin neurons;
(5) the relative sensitivity of various animal species; and
(6) the neuroanatomical and morphological specificity of MDMA- and
MDA-induced neurotoxicity.
MARKERS OF NEUROTOXICITY
Typically, neurotoxic effects of drugs on monoamine neurons have been
assessed from reductions in brain levels of monoamines and their metabo-
lites, decreases in the maximal activity of synthetic enzymes activity, and
decreases in the active uptake carrier. In the present study, the traditional
markers described above have been used, including the measurement of the
content of monoamines and their metabolites in brain at several different
timepoints following drug administration. Since reports in the literature
have documented that MDMA and MDA can inhibit the activity of trypto-
phan hydroxylase (TPH), the rate-limiting enzyme in serotonin synthesis
(Stone et al. 1986; Stone et al. 1987). it is unclear whether MDMA-induced
reductions in the content of serotonin and its metabolite 5-hydroxyin-
doleacetic acid (5-HIAA) may be due to suppressed neurotransmission in
otherwise structurally intact serotonin neurons or may represent the
consequence of the destruction of serotonin neurons and terminals.
Since monoamine uptake sites are highly concentrated on their respective
nerve terminals (Kuhar and Aghajanian 1973), the authors’ approach has
been to use selective radioligands to directly label these uptake sites in
brain and to assess the neurodegeneration of specific monoamine neurons,
by measuring the reductions in the density of their respective uptake sites.
For example, the authors have recently reported the feasibility of using the
measurement of [3H]paroxetine-labeled serotonin uptake sites to quantify the
neurotoxic effects of MDA (Battaglia et al. 1987) and MDMA (Battaglia
et al. 1987; Battaglia et al. 1988) on serotonin neurons in homogenates of
various regions of rat brain. Visualization of MDMA- and MDA-induced
destruction of serotonin axons and terminals using antibodies directed
against serotonin (O’Hearn et al. 1988) and autoradiographic studies
demonstrating corresponding decreases in [3H]paroxetine-labeled scrotonin
uptake sites in slide-mounted brain sections of MDA-treated rats (De Souza
and Kuyatt 1987) further validate use of changes in the density of serotonin
uptake sites as an appropriate index of serotonin neurodegeneration.
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IN VIVO EFFECTS OF MDMA: NEUROCHEMICAL STUDIES
The following studies were designed to assess and quantify both the neuro
chemical and neurodegenerative effects of short-term administration of
MDMA on monoamine neurons in rat brain.
Dose Dependence
A repetitive treatment regimen (sc injections twice daily for 4 consecutive
days) of MDMA at various doses up to 20 mg/kg resulted in dose-
dependent decreases in a variety of serotonergic markers in rat frontal
cerebral cortex, including serotonin, 5-HIAA, and the density of serotonin
uptake sites at 18 hours following the last injection (figure 1). At the
lowest dose of MDMA tested (5 mg/kg), serotonin content was markedly
reduced (45 percent), while only a small (14 percent), but statistically
significant, decrease in the density of serotonin uptake sites was observed; a
small decrease in 5-HIAA content was also observed at this dose, although
this change was not statistically significant. Higher doses of MDMA (10
and 20 mg/kg) resulted in comparable reductions in 5-HIAA levels (60 to
70 percent), while the decrease in serotonin was significantly greater at
20 mg/kg (90 percent) than at 10 mg/kg (80 percent). The density of
serotonin uptake sites decreased progressively as the dose of MDMA was
increased, with a maximal reduction of 90 percent observed at 18 hours
following administration of 20 mg/kg MDMA.
In contrast, following a treatment regimen of 20 mg/kg MDMA, there were
no significant differences in the density of [3H]mazindol-labeled norepine-
phrine (NE) uptake sites (fmol/mg protein) in the frontal cerebral cortex
between saline-treated (159±17) and MDMA-treated (152±5) animals. With
respect to the dose of MDMA, serotonin levels appeared to be more readily
decreased (45 percent reduction at 5 mg/kg), while comparable reductions in
5-HIAA levels and serotonin uptake sites were noted only at 10 or 20
mg/kg MDMA. This apparent discrepancy among the three serotonergic
markers measured in the present study may relate to effects of lower doses
of MDMA on synthetic enzyme activity (i.e., TPH), whereas the effects of
higher doses of MDMA in reducing all three markers may relate in part to
effects on TPH activity and in part to destruction of serotonin neurons as
evidenced by decreases in serotonin uptake sites.
The Effects of Single Versus Multiple Injections of MDMA
Since repeated systemic administration of 10 mg/kg MDMA caused marked
neurodegeneration of frontal cerebral cortex serotonin neurons, the authors
chose to investigate the neurodegenerative effects of single versus multiple
injections of MDMA at this dose. As shown in figure 2, increasing the
number of injections of MDMA (10 mg/kg, sc) resulted in significant and
progressively greater reductions in serotonin and 5-HIAA content. While
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FIGURE 1. The effect of repeated systemic administration of various doses
of MDMA on the content of serotonin (5-HT) and S-HIAA
and the density of 5-HT uptake sites in rat frontal cerebral
cortex
*Significantly different from control. p<0.05.
**Significantly different from control, p<0.01.
††Significantly different from all other MDMA-treated groups. p<0.01.
†††Significantly different from all other MDMA-treated groups, p<0.001.
NOTE: Rats were administered either saline or MDMA twice a day for 4 consecutive days and
sacrificed 18 hours after the last injection. Data represent the mean SEM from three to
live rats, expressed as a percent of values in control, saline-injected rats. Control values
for 5-HT and 5-HIAA levels were 387±61 and 251±20 pg/mg tissue, respectively. The
density of 5-HT uptake sites in the frontal cerebral cortex in controls was 396±15 fmol/mg
protein. Data were analyzed by one-way ANOVA and Duncan’s multiple range test.
SOURCE: Battaglia et al. 1988.
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one injection of MDMA was without effect on any of the serotonergic
parameters examined, two doses were sufficient to elicit a significant
reduction in serotonin content. As described above, these early effects of
MDMA on serotonin content may relate to MDMA suppression of TPH
activity. A significant reduction in 5-HIAA content (approximately
34 percent) was observed only after four injections of MDMA. Marked
reductions of 84 percent and 75 percent in serotonin and 5-HIAA,
NUMBER OF INJECTIONS OF MDMA (10mg/kg)
FIGURE 2. The effects of single and multiple injections of MDMA on the
content of serotonin (5-HT) and 5-HIAA and the density of
5-HT uptake sites in rat frontal cerebral cortex
*Significantly different from control, p<0.05.
††Significantly different from all other groups, p<0.01.
†††Signiftcantly different from all other groups, p<0.001.
NOTE: Rats were injected the specified number of times with either saline or 10 mg/kg MDMA
and sacrificed 18 hours after the last injection. Data represent the mean and SEN from
three to five animals, plotted as percent of respective values for each marker in control,
saline-injected rats. Control levels of 5-HT and 5-HIAA were 475±24 and 332±24 pg/mg
tissue, respectively. The density of 5-HT uptake sites was 349±24 fmol/mg protein in
control. Data were analyzed by one-way ANOVA and Duncan’s multiple range test.
SOURCE: Battaglia et al. 1988.
200
respectively, were observed following an eight-injection regimen of
10 mg/kg MDMA; the density of [3H]paroxetine-labeled serotonin uptake
sites was also significantly decreased (approximately 64 percent) following
eight injections of MDMA at this dose. These data suggest that a longer
treatment regimen may be required for destruction of serotonin neurons,
while effects on the content of serotonin and 5-HIAA may occur following
fewer injections.
There was no change in the content of dopamine (DA) in any of the
experimental groups; however, a small, inconsistent decrease in NE content
(approximately 20 percent) was observed in all MDMA-treated rats. This
small change in NE following MDMA treatment was not accompanied by a
reduction in the density of [3H]mazindol-labeled NE uptake sites.
Species Differences
Since amphetamines have been shown to be metabolized by different
pathways in rat, mouse, and guinea pig (Caldwell 1980). studies were
carried out to investigate whether MDMA induced neurotoxicity could be
demonstrated in other species such as mouse and guinea pig. Animals in
these studies were treated twice daily for 4 consecutive days with 20 mg/kg
MDMA. and levels of serotonin, 5-HIAA, and serotonin uptake sites were
measured at 7 days following the last injection, to assess the long-term
effects of the treatment. As shown in figure 3, MDMA caused comparable
and marked decreases in serotonin and 5-HIAA content and in the density
of serotonin uptake sites in rat and guinea pig cerebral cortex, but appeared
to be without effect on any of these serotonergic markers in the mouse.
Other studies (Stone et al. 1987) have also suggested that mice are less
susceptible to the neurotoxic effects of MDMA. Similar differences in the
sensitivity to the neurotoxic effects of parachloroamphetamine on serotonin
neurons have been observed in mouse when compared to its effects in rat
and guinea pig (Fuller 1978; Kohler et al. 1978; Sanders-Bush and Steranka
1978). The differential sensitivity may be due, in part, to species-dependent
differences in the half-life of the drug (Steranka and Sanders-Bush 1978).
Active neurotoxic metabolites or metabolic intermediates of parachloro-
amphetamine have been postulated previously as being responsible for its
neurotoxic effects on serotonin neurons (Gal and Sherman 1978; Sanders-
Bush and Steranka 1978), although to date no active neurotoxic species has
been identified. Although there has been no direct demonstration of a
neurotoxic metabolite of MDMA, some preliminary data suggest that an
active metabolite of MDMA may be responsible for eliciting its ncurotoxic
effects. The authors have previously reported that, in contrast to the
marked neurodegenerative effects on brain serotonin neurons following
systemic administration of MDMA or MDA, single, direct intracerebral
injections of MDMA or MDA were without effect on cerebral cortical
serotonin neurons, as visualized using immunohistochemistry (Molliver
et al. 1986). This observation of marked species differences and sensitivity
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FIGURE 3. The effects of repealed systemic adminisration of MDMA on
content of serotonin {5-HT) and 5-HIAA, and density of
5-HT uptake sites in rat, guinea pig, and mouse frontal
cerebral cortex
**Signifiantly different from control, p<0.001.
NOTE: Animals were treated with saline or 20 mg/kg MDMA twice a day for 4 consecutive days
and sacrificed 7 days after the last injection. Data represent ± SEM of five animals
per group, expressed as percent of saline-injected control values in respective species. In
rat, guinea pig, and mouse,  control values of 5-HT were 275±41, 296±14, and 449±36
pg/mg tissue, respectively; control values of 5-HIAA were 345±40, 92±4. and 319±34
pg/mg tissue, respectively; control values of 5-HT uptake site were 397±10, 216±6, and
233±12 fmol/mg protein, respectively. Data were analyzed by Student’s t-test.
SOURCE: Battaglia et al. 1988.
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to MDMA-induced serotonin neurotoxicity would be consistent with the
hypothesis of a peripherally produced neurotoxic metabolite of MDMA.
In more recent studies, it has also demonstrated that administration of 2.5 or
10 mg/kg MDMA twice daily for 4 consecutive days resulted in neurotoxic
effects in rhesus monkeys, with decreases in the density of scrotonin uptake
sites occurring at the higher dose (Johannessen et al. 1988). The neuro-
toxic effects of MDMA observed in primates included reductions in the
content of serotonin and 5-HIAA and marked reductions in the ccrebrospinal
(CSF) concentrations of 5-HIAA levels that were observed following drug
administration. These fmdings and other reports of neurotoxic effects of
MDMA in primates (Ricaurte et al. 1988) raise serious concerns for its
potential hazard in humans.
Potential Mechanisms
Since the neurotoxic effects of drugs such as parachloroamphetamine on
serotonin neurons can be prevented by serotonin uptake blockers (Ross
1976; Sanders-Bush and Steranka 1978). the possibility that serotonin uptake
carrier protein was likewise involved in the neurotoxic effects of MDMA
was investigated. As shown in figure 4, pretreatment of rats with the
selective serotonin uptake blocker citalopram (10 ml/kg), prior to each
injection of 10 mg/kg MDMA, resulted in nearly complete protection
against the neurotoxic effects of MDMA. Citalopram-pretreated rats
exhibited only a 15 percent decrease in serotonin uptake sites. No signifi-
cant alterations in the content of serotonin and 5-HIAA were observed
following MDMA treatment, in comparison with 60 to 80 percent reductions
in the serotonergic parameters observed in rats treated with an identical dose
of MDMA alone.
The data described above demonstrate that destruction of serotonin axons by
MDMA involves the serotonin active uptake carrier and that administration
of citalopram, a selective serotonin uptake blocker, prior to administration of
MDMA, can prevent the decreases in serotonin markers elicited by MDMA
alone. These data are consistent with previous reports for other potent
serotonin neurotoxins, demonstrating that pretreatment with serotonin uptake
blockers can prevent the neurotoxic effects of parachloroamphetamine (Ross
1976; Sanders-Bush and Steranka 1978). Furthermore, it has been shown
that MDMA-induced neurotoxicity can be prevented or reversed if a sero-
tonin uptake blocker such as fluoxetine is administered no later than
12 hours after MDMA treatment (Schmidt 1986).
In previous studies, it has been observed that, in contrast to the marked
serotonin neurodegenerative effects following systemic administration of
MDMA or MDA, single, direct intracerebral injections of MDMA or MDA
are without effect on cerebral cortical serotonin neurons, as visualized using
serotonin immunocytochemistry (Molliver et al. 1986). In addition, as
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FIGURE 4. The effect of repeated systemic administration of 10 mg/kg
MDMA, MDMA plus 10 mg/kg citalopram, and MDMA plus
25 mg/kg SKF 525A on the density of serotonin (5-HT)
uptake sites in homogenates of rat frontal cerebral cortex
NOTE: Data are expressed as percent of values in control saline-treated rats and represent the mean
± SEM from four to six animals. Control levels of 5-HT uptake sites were 356±15 fmol/mg
protein.
described above, there appears to be a differential sensitivity to the neuro-
toxic effects of MDMA in different species, which metabolize amphetamines
by different pathways. These observations of marked differences in sero-
tonin neurotoxicity to-centrally versus systemically administered MDMA and
differences in various species would be consistent with the hypothesis of a
peripherally produced neurotoxic metabolite of MDMA or MDA. Since
MDMA has been reported to interact with the hepatic microsomal enzyme
cytochrome P450 (Brady et al. 1986), the authors investigated whether
inhibition of this enzyme would alter the neurotoxic effects of MDMA was
investigated. In preliminary studies, it was found that, in rats pretreated
with the cytochrome P450 enzyme inhibitor SKF 525A, 45 minutes prior to
204
each administration of MDMA, there was neither potentiation nor attenua-
tion of the neurodegeneration found following repeated administration of
10 mg/kg MDMA. As shown in figure 4, no changes in the density of
serotonin uptake sites were observed between rats treated with MDMA
alone and those treated with MDMA plus SKF 525A. Although these data
suggest that it is unlikely that the putative neurotoxic species is a
cytochrome P450-dependent metabolite of MDMA, the involvement of some
other peripheral and/or central metabolite of MDMA or the formation of an
MDMA-induced endogenous neurotoxin cannot be ruled out. Additional
studies are required to identify the mechanisms responsible for MDMA-
induced neurotoxicity.
Regeneration of Serotonin Neurons
A detailed timecourse of recovery of affected serotonin neurons was carried
out to investigate whether serotonin neurons regenerate subsequent to their
destruction following MDMA treatment. As shown in figure 5, the
timecourse of neuronal regeneration was investigated by measuring the
recovery of serotonin uptake sites and serotonin levels in rat frontal cerebral
cortex at various timepoints up to 12 months following repeated systemic
administration (i.e., twice daily sc injections for 4 days) of 20 mg/kg
MDMA. At all timepoints up to 6 months during the recovery timecourse,
the density of serotonin uptake sites was significantly below the corres-
ponding values in age-matched, saline-treated control rats. At the 6-month
timepoint, the density of serotonin uptake sites was only 75 percent of the
values of saline-treated controls, whereas by 12 months after MDMA
treatment, the density of serotonin uptake sites returned to control levels.
The shape of the recovery curve suggests that there may be a faster initial
rate of recovery of serotonin uptake sites occurring between 18 hours and
4 weeks, which is followed by a slower rate of recovery between 4 weeks
and 12 months. These data indicate that more than 6 months are required
for a complete recovery of serotonin uptake sites to control levels.
It was of interest that, in spite of the recovery of serotonin uptake sites to
control levels, the content of serotonin in the same brain region remained
markedly (40 to 50 percent) below age-matched controls for as long as
1 year after MDMA administration. It is unclear from these data whether
there is a regeneration of axons that have previously undergone degeneration
or whether the increased density of uptake sites is a consequence of
increased collateral sprouting of neurons unaffected by the drug treatment.
It is also possible that axonal regeneration and collateral sprouting arc
associated with considerably greater densities of uptake sites per neuron,
thereby making it more difficult to assess neuronal recovery from this
index. The fact that serotonin levels remain 40 to 50 percent below age-
matched controls for up to 1 year in spite of normal levels of serotonin
uptake sites indicates that, following lesion by MDMA, the serotonin
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FIGURE 5. Timecourse of recovery of (A.) serotonin (5-HT) uptake sites
and (B.) 5-HT conten in rat cerebral cortex following
repeated systemic administration of MDMA
NOTE: Rats were treated with either saline or 20 mg/kg MDMA twice a day for 4 consecutive
days, then sacrificed at various times up to 12 months after the last injection of the drug.
Saline-injected control rats were killed at each of the timepoints; data represent the mean ±
SEM of five rats per group, plotted as percent of the value of age-matched saline-injected
control rats.
SOURCE: Adapted from Battaglia et al. 1988.
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neurons that “recover” may not be functionally identical to those present in
age-matched control brains.
The persistent neurotoxic effects of MDMA on serotonin neurons is similar
to that observed following parachloroamphetamine administration, in which
marked reductions in serotonin have been observed up to 4 months after a
single injection of parachloroamphetamine (Fuller 1978; Kohler et al. 1978;
Sanders-Bush and Steranka 1978). Since neurochemical recovery of
serotonin uptake sites and serotonin content have been used, rather than
neuroanatomical indices of neuronal regeneration, it is unclear from the
present data whether there is actual regeneration of neurons that have
previously undergone axon or terminal degeneration or whether the
increased density of uptake sites is a consequence of increased collateral
sprouting of neurons unaffected by the drug treatment, It has previously
been reported that following 5,6-dihydroxytryptamine-induced axotomy,
axonal sprouting occurs within 4 to 5 days, and the appearance of new
axonal sprouts correlates with the recovery of [3H]serotonin uptake
(Bjorklund et al. 1973). Evidence from both immunocytochemical data
(O’Hearn et al. 1988) and autoradiographic studies quantifying changes in
the density and distribution of [3H]paroxetine-labeled serotonin uptake sites
(see figure 10) indicates that serotonin cell bodies appear to be insensitive
to the neurotoxic effects of repeated systemic administration of MDMA in
rats. The fact that serotonin cell bodies are unaffected by MDMA treatment
provides a mechanism by which terminal regeneration of MDMA-affected
neurons may occur in rats.
NEUROANATOMICAL AND MORPHOLOGICAL SPECIFICITY OF
THE EFFECTS OF MDMA AND MDA
The data described above clearly demonstrate the specific and marked
neurodegenerative effects of MDMA on serotonin axons and terminals in
the cerebral cortex. Two approaches have been taken to investigate whether
the effects of MDMA on brain serotonin neurons are ubiquitous or whether
the effects of MDMA show neuroanatomical specificity. The first approach
involved the measurements of various monoamines, their metabolites, and
monoamine uptake sites in homogenates of discrete areas of rat brain
following treatment with MDMA or MDA. Second, autoradiographic
techniques were used to visualize the effects of MDMA treatment on the
localization and density of [3H]paroxetine-labeled serotonin uptake sites and
[3H]mazindol-labeled NE and DA uptake sites in slide-mounted sections of
rat brain. In addition, to address further the neurochemical specificity of
the effects of MDMA on brain serotonin neurons, effects of MDMA and
MDA treatment on the content of DA, NE, and their respective mctabolites
and DA and NE uptake sites in homogenates of various brain regions will
be described. In some studies, the changes induced by the N-ethyl
derivative of MDA (MDE) have been investigated.
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Effects of MDMA on Serotonin and 5-HIAA Content and
[3H]Paroxetine-Labeled Serotonin Uptake Sites in Discrete Regions of
Rat Brain
The effects of repeated systemic administration of MDMA and MDA on
various serotonergic parameters were investigated at 2 weeks following the
last injection of the treatment regimen previously described (i.e., 20 mg/kg,
sc, twice daily for 4 days). As shown in figure 6, MDMA and MDA
produced marked decreases in the content of serotonin and 5-HIAA in
various brain regions. Both MDMA and MDA caused dramatic decreases
in 5-HIAA levels in cerebral cortex, hippocampus, striatum, and hypothala-
mus (figure 6B). In hypothalamus, the reduction in 5-HIAA levels elicited
by MDA was significantly greater (p<0.05) than that observed with MDMA
(figure 6B). When plotted as a percent of control values in the respective
brain regions, it was apparent that, while decreases in 5-HIAA content were
observed in all the brain regions examined. the reductions in cerebral cortex
and in hippocampus (40 to 60 percent) were greater than those observed in
striatum and in hypothalamus (30 to 40 percent). With respect to serotonin
levels, marked decreases were observed in cerebral cortex and hypothalamus
in both MDMA- and MDA-treated rats (figure 6A). While small decreases
were observed in hippocampal and striatal serotonin content following either
MDA or MDMA treatment, these reductions were found to be statistically
significant only in striatum (p<0.01) of MDMA-treated rats. Data calculated
as a percent of control serotonin levels in their respective brain regions
(figure 6A) indicate a more marked reduction in serotonin in cerebral cortex
(40 to 60 percent) than in hypothalamus (18 to 33 percent).
To determine whether changes in serotonin and/or 5-HIAA were a conse-
quence of long-term suppression of serotonergic function in structurally
intact neurons or whether MDMA and MDA may be affecting a neurode-
generative process in each of the brain regions, we measured the density of
serotonin uptake sites in these brain regions. Both MDMA and MDA
caused substantial reductions in the densities of [3H]paroxetine-labeled
serotonin uptake sites in all the brain regions examined. The densities of
serotonin uptake sites were calculated as a percent of the respective control
levels in cerebral cortex, hippocampus, striatum, hypothalamus, and midbrain
and are shown in figure 7. Significant reductions (all p<0.001) were
observed in cerebral cortex (60 to 70 percent), hippocampus (70 to
75 percent), striatum (50 percent), hypothalamus (40 to 50 percent) and
midbrain (50 to 60 percent). Interestingly, MDA produced a significantly
greater reduction in the density of serotonin uptake sites in cerebral cortex
than did MDMA. It has also been observed that MDE causes 40 percent
reductions in serotonin uptake sites in cerebral cortex with a comparable
treatment regimen, suggesting that this compound may be less toxic than
either MDA or MDMA. Scatchard analysis of [3H]paroxetine saturation
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FIGURE 6. Effect of repeated systemic administration of MDMA and MDA
on the concentration of (A) serotonin (5-HT) and (B)
5-HIAA in various brain regions
*Significantly different from control, p<0.05.
**Significantly different from control, p<0.01.
***Significantly different from control, p<0.001.
†Significantly different from MDMA-treated rats, p<0.05.
NOTE: Rats were injected subcutaneously twice daily for 4 days with drug (20 mg/kg) or saline
vehicle (1 mL/kg) and sacrificed 2 weeks after the last injection. 5-HT and 5-IIIAA levels
were measured using reversed phase HPLC. Data, plotted as percent of control values in
each brain region, represent the mean and SEM from four to six control and drug-treated
rats. Control values for 5-HT and 5-HIAA in each region were: cerebal cortex, 504±58
and 422±32; hippocampus, 4l0±67 and 684±89; striatum, 363±22 and 492±50; hypo-
thalamus, 1605±55 and 997±42 pg/mg tissue, respectively. Data were analyzed by one-way
ANOVA and Duncan’s multiple range test.
SOURCE: Battaglia et al. 1987.
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FIGURE 7. Effect of repeated systemic administration of MDMA and MDA
on the density of serotonin (5-HT) uptake sites in various
brain regions
***Significantly different from control. p<0.001.
†Significant difference between MDA and MDMA treatments, p<0.001.
NOTE: Rats were injected subcutaneously twice daily for 4 days with MDMA or MDA (20 mL/kg)
or saline vehicle (1 mL/kg) and sacrificed at 2 weeks a fter the last injection. Values were
determincd from saturation studies in each region except striatum and hypothalamus, where
the density of 5-HT uptake sites was assessed using a saturating concentration (0.25 nM) of
[3H]paroxetine. No significant different from control KD values (10-20 pM) were
observed in either MDMA- or MDA-treated rats. Data, plotted as percent of the 5-HT
uptake site density observed in controls in each brain region, represent the mean and SEM
from three to six rats per group. Control values were: cerebral cortex, 338±10;
hippocampus, 360±17; striatum, 344±30; hypothalamus, 775±36; and midbrain, 570±16
fmol/mg protein. Data were analyzed by one-way ANOVA and Duncan’s multiple range
test
SOURCE: Battaglia et al. 1987.
data in control and drug-treated rats indicated that, in cerebral cortex,
[3H]paroxetine binding was through a single population of binding sites as
indicated by the Hill coefficient values (1.02, 1.01, and 1.03 in control,
MDMA-. and MDA-treated rats, respectively). Furthermore, there were no
significant differences in the affimity of [3H]paroxetine for the serotonin
uptake site (i.e., KD) between control and drug-treated rats (18.8, 20.8, and
17.9 pM in control, MDMA-, and MDA-treated rats, respectively).
Differences in the sensitivity in various brain regions to the effects of
MDMA and MDA are not unique, as previous data have demonstrated
differential sensitivity to the effects of methamphetamine (Ricaurte
et al. 1980) and parachloroamphetamine (Kohler et al. 1978; Fuller 1978)
on serotonergic systems in various brain regions. Biochemical and
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histochemical data suggest that parachloroamphetamine primarily affects the
ascending serotonin systems, whereas the descending pathways are left intact
(Kohler et al. 1978; Fuller 1978).
Effects of MDA and MDMA on Catecholamine Neurons
In contrast with the marked and consistent effects of MDMA and MDA on
serotonergic systems, neither drug produced any widespread or consistent
changes in the levels of NE, DA, or their metabolites 3,4-dihydroxyphenyl-
acetic acid (DOPAC) or homovanillic acid (HVA) in the various brain
regions examined (table 1). Small changes, however, were observed in
some brain regions. Both MDMA and MDA produced statistically signifi-
cant increases in striatal DOPAC and cerebral cortical HVA content,
whereas only MDMA treatment resulted in an increase in hippocampal
DOPAC levels (table 1). Furthermore. neither MDMA nor MDA treatment
caused any significant reduction in the levels of [3H]mazindol-labeled NE
uptake sites in cerebral cortex, hippocampus, or midbrain when compared
with the respective saline-treated controls (figure 8). Although a small
reduction was noted in NE uptake sites in hippocampus, this change was
not statistically significant. Similarly, no significant decreases were
observed in the number of [3H]mazindol-labeled DA uptake sites in cerebral
cortex, hippocampus, striatum, and midbrain following treatment with MDA.
MDMA caused a statistically significant reduction (37 percent) in the
density of DA uptake sites only in midbrain.
The neurotoxic effects of MDMA and MDA appeared to be exerted prefer-
entially on serotonergic neurons, as no widespread changes in a variety of
catecholamine markers were seen after chronic administration of these drugs.
The small increases in DOPAC and/or HVA that were seen in the cerebral
cortex, hippocampus, and striatum after chronic administration of these
MDA derivatives are comparable to similar increases in DA metabolite
levels that have been previously reported following both acute (Schmidt
et al. 1986) and chronic (Stone et al. 1986) administration of MDMA and
MDA. These alterations may reflect increases in DA turnover. Because
serotonin-containing terminals are present in high concentrations in midbrain
areas (substantia nigra and ventral tegmental area) and DA cell bodies
(Steinbusch 1983). the degeneration of serotonin terminals in these regions
after MDMA or MDA treatment may be responsible for the observed
changes in DA metabolites. Despite the small effects on DA turnover,
MDMA and MDA do not appear to produce any widespread destruction of
catecholaminergic terminals, as the only significant change observed was a
reduction in DA uptake sites in midbrain after administration of MDMA.
The reasons for the decrease in DA uptake sites are not clear at present.
Preliminary immunocytochemical data indicate that there are no changes in
the density or morphology of catecholamine axons after chronic
administration of MDMA or MDA (O’Hearn et al. 1988).
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TABLE 1. Effect of repeated systemic administration of MDMA and MDA
on NE, DA, and DA metabolite levels in various regions of rat
brain
Brain Region NE
Concentration (pg/mg tissue)
DA DOPAC HVA
Cerebral Cortex
Control
MDMA
MDA
447 ± 53 59 ± 12 96 ± 14 19 ± 4
424 ± 13 72 ± 3 73 ± 5 32 ± 4*
404 ± 26 63 ± 4 94 ± 19 36 ± 5*
Hippocampus
Control
MDMA
MDA
528 ± 62 31 ± 9 39 ± 6 6 ± 2
573 ± 34 13 ± 5 65 ± 12* 15 ± 5
608 ± 46 16 ± 4 32 ± 13 8 ± 52
Striatum
Control
MDMA
MDA
ND
ND
6,091 ± 596 3,212 ± 159 788 ± 58
6,974 ± 228 3,954 ± 320* 767 ± 46
ND 6,168 ± 569 3,669 ± 189* 890 ± 48
Hypothalamus
Control 3,320 ± 209 569 ± 40
MDMA 3,052 ± 159 475 ± 38
MDA 3,577 ± 148 585 ± 67
*Significant difference from saline-treated control rats at p<0.05.
2 2 8 ± 4 3 5 4 ± 4
2 0 0 ± 3 0 5 4 ± 5
2 2 9 ± 2 6 5 8 ± 3
KEY: ND=levels below the sensitivity of the assay. Data were analyzed by one-way ANOVA
and Duncan’s multiple range test.
NOTE: NE, DA, DOPAC, and HVA measured 2 weeks after administration of 20 mg/kg MDMA
or MDA, subcutaneously. every 12 hours for 4 consecutive days. Values represent the
mean ± SEM. n=4 to 6 rats.
SOURCE: Battaglia et al. 1981.
Autoradiographic Studies on [3H]Paroxetine-Labeled Serotonin Uptake
Sites
In vitro autoradiographic studies of [3H]paroxetine-labeled serotonin uptake
sites in control and MDMA-treated brains were carried out as previously
described (De Souza and Kuyatt 1987) to assess the neuroanatomic
localization of lesions induced by MDMA. Substantial reductions in
serotonin uptake sites (50 to 100 percent decreases) were observed in all
areas of cerebral cortex as early as 18 hours after a 4-day treatment
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FIGURE 8. Effect of repealed systemic administration of MDMA and MDA
on the density of NE uptake sites in various  brain regions
NOTE: Rats were injected subcutaneously twice daily for 4 days with MDMA or MDA (20 mg/kg)
or saline vehicle (1 mL/kg) and sacrificed 2 weeks after the last injection. NE uptake sites
were measured using 6 nM [3H]mazindol in the presence of selective blockers as previously
described (Javitch et al. 1984). Data, plotted as percent of control values in each brian
region, represent the mean and SEM from six control. MDMA-, and MDA-treated animals.
Control values of NE uptake sites were: cerebral cortex. 164±6; hippocampus, 176±9;
midbrain, 157±13 fmol/mg protein.
SOURCE: Battaglia et al. 1987.
regimen (20 mg/kg MDMA twice daily); the reductions were maintained for
at least 2 weeks. As shown in table 2, cerebral cortical regions that
showed the most extensive destruction of serotonin uptake sites (i.e., more
than 90 percent) were the prefrontal (area 32), anterior cingulate (area 24).
entorhinal, and parietal cortex. Comparable decreases in serotonin uptake
sites were observed between day 0 (18 hours after last injection) and day
14 (14 days after last injection) in several regions of cerebral cortex such as
prefrontal, pyriform, frontal areas 8 and 10, entorhinal, and primary auditory
regions. In other areas of cerebral cortex, such as the sensory motor
regions, significant reductions in serotonin uptake sites were observed only
2 weeks after the treatment.
As shown in table 2 and figure 9, marked decreases in serotonin uptake
sites were observed following MDMA administration in all regions of
caudate putamen, olfactory tubercle, endopiriform nucleus, islands of Calleja,
and nucleus accumbens. Within the caudate putamen, some time-dependent
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TABLE 2. Effects of repeated systemic administration of MDMA on the
regional decreases in [3H]paroxetine-labeled serotonin
uptake sites
Brain Region Control MDMA
Cerebral Cortex
Prefrontal area 32
Cingulate area 24
Indusium griseum
Piriform
Frontal area 8
Frontal area 10
Sensorymotor
Parietal
Entorhinal
Primary auditory
Primary visual
Olfactory tubercle
Endopiriform nucleus
Islands of Calleja
2-
2
1
2
2
1+
2
l+
4
1
2+
4
3
3+
1
1
2
1
1+
l-
l-
0
1+
l-
2
2
2
1+
Basal Ganglia
Caudate putamen
dorsolateral
dorsomedial
ventrolateral
ventromedial
Nucleus accumbens
2 l-
1+ l-
3 2
2+ 1+
2 l-
Septal Area
Medial septal nucleus
Lateral septal nucleus
Amygdala basolateral nucleus
4- 3+
3 2
4- 3+
Thalamus and Epithalamus
Anteroventral nucleus
Anteromedial nucleus
Anteroventral dorsomedial nucleus
Reuniens
Lateroposterior nucleus
Posterior nucleus
Posterioventromedial nucleus
Parafascicular nucleus
Lateral geniculate body
Medial geniculate body
Lateral habenula
3-
3
3-
4+
3
1
1
2
5-
2
3
0
0
0
1
1
1
1
l+
1+
1
l-
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TABLE 2. (Continued)
2
Brain Region Control MDMA
Hypothalamus
Lateral nucleus 4 4-
Hippocampus
CA3 region
Dentate gyrus
Molecular layer
Parasubiculum
Presubiculum
2+ 1
2 1
2+ 1
3+
3 2
Midbrain
Inferior colliculus
Interpeduncular nucleus
Central gray
Superior colliculus
superficial layers
profundum
Substantia nigra
pars compacta
pars reticulata
paranigral nucleus
Ventral tegmental area
Dorsal raphe nuclei
Median raphe nuclei
3
3+
5+
3
2+
3+
3
2
2+
5+
5+
l-
3
5+
1
1
2
2+
3
2
5+
5+
Pons-Medulla
Locus coeruleus
Pontine reticular formation
5+ 5
2 2
Cerebellum (all lobules) 2 2
KEY: Relative density of [3H]paroxetine binding sites: 1=0-50 fmol/mg tissue; 2=50-150 fmol/mg
tissue; 3=150-250 fmol/mg tissue; 4=250-400 fmol/mg tissue and 5=>400 fmol/mg tissue; +
and - values indicate the upper and lower limits, respectively, of each range.
NOTE: Data are based on observations from three animals per group. Rats were injected
subcutaneously twice daily for 4 days with MDMA (20 mg/kg) or saline (1 mL/kg) (control)
and sacrificed 14 days after the last injection. Anatomical terminology is derived from
Paxinos and Watson (1982). [3H]Paroxetine binding sites were visualized by using a
saturating concentration (0.25 nM) of [3H]paroxetine. Autoradiograms of rat brain were
generated using [3H]Ultrofilm. Analysis of [3H]paroxetine-labeled serotonin uptake site
densities in the various brain regions was performed by computerized image analysis
densitometry. No correction for “grey-white” quenching of tritium was used.
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M D M A
FIGURE 9. Autoradiographic distribution of [3H]paroxetine-labeled
serotonin uptake sites in coronal sections at the level of the
caudate putamen from (A) saline-treated and (B) MDMA-
treated rats
NOTE: In these darkfield photomicrographs (tritium-sensitive Ultrofilm), autoradiographic grains (i.e.,
binding sites) appear as white spots; the tissue is not visible. The degree of nonspecific
binding defined in the presence of 2 µM citalopram was comparable for both treatments. In
(A), note the high density of serotonin uptake sites in cingulate cortex (CG), caudate putamen
(CPu), olfactory tubercle (Tu), islands of Calleja, and lateral septal nuclei (LS) in control
brains. In MDMA-treated animals (B), marked reductions were observed in most regions
except for the septal nuclei, which were relatively unaffected.
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reductions in serotonin uptake sites were observed following MDMA
treatment. For example, equivalent decreases in serotonin uptake sites were
observed between day 0 and day 14 groups in the ventrolateral region,
while in dorsolateral and dorsomedial areas a significantly greater reduction
in serotonin uptake sites was observed only at the later timepoint. Other
brain regions that were sensitive to the neurodegenerative effects of MDMA
included various thalamic nuclei and regions of hippocampus. In contrast,
the dorsal and medial septal nuclei appeared to be less sensitive to the
neurotoxic effects of MDMA as the reductions (approximately 25 percent)
in serotonin uptake sites in these brain regions were not statistically
significant. Likewise, no significant reductions were observed in the
indusium griseum, which contains primarily serotonin axons of passage.
Within midbrain structures, regions containing serotonin projections appeared
to be more dramatically affected by MDMA than those containing scrotonin
cell bodies (figure 10). For instance, in both the superficial layers of
superior colliculus and profundum, serotonin uptake sites were reduced 85
to 90 percent, while in dorsal median raphe, central grey, and the ventral
tegmental region, there was little or no change after MDMA treatment.
Likewise, serotonin projections to substantia nigra pars compacta and
reticulata were markedly affected, while no changes in serotonin uptake sites
were observed in the interpeduncular nucleus and pontine reticular formation
up to 14 days following MDMA administration.
To assess the serotonergic selectivity of the neurodegenerative effects of
MDMA in brain, additional autoradiographic studies of NE and DA uptake
sites in brain regions containing catecholamine terminals and cell bodies
were carried out. NE and DA uptake sites were labeled using [3H]mazindol
in the presence of specific blockers as previously published (Javitch
et al. 1985). With respect to NE uptake sites, no change was observed
from control levels of [3H]mazindol binding sites in midbrain regions such
as locus coeruleus, interpeduncular nucleus, substantia nigra pars compacta,
or reticulata up to 14 days following MDMA treatment. In a number of
cerebral cortical regions that receive NE projections, [3H]mazindol-labeled
NE uptake sites were not decreased 18 hours after treatment (i.e., day 0)
but rather appeared to be slightly increased at day 14. Consistent with the
minimal effects of MDMA on metabolic parameters associated with catecho-
lamine neurons, there were no changes in the density of DA uptake sites,
when compared to levels in saline-treated rats, in either cell body regions
such as substantia nigra pars compacta and reticulata or terminal regions
such as caudate putamen, nucleus accumbens, and olfactory tubercle. These
results are therefore consistent with what has been observed in neurochemi-
cal studies in brain homogenates and indicate that the neurodegenerative
effects of MDMA appear to be confined primarily to serotonergic pathways,
since this treatment regimen did not reduce the density of uptake sites
associated with catecholamine-containing neurons. Additional studies are
necessary to assess further the neuroanatomic localization of any long-term
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S A L I N E
M D M A
FIGURE 10. Autoradiographic distribution of [3H]paroxetine-labeled
serotonin uptake sites in coronal sections at the level of
midbrain in (A) saline-treated and (B) MDMA-treated rats
NOTE: In (A), note the high density of serotonin uptake sites in control brain in regions containing
serotonin projections such as entorhinal cortex, superior colliculus (sc), presubiculum and
parasubiculum, as well as cell body regions such as dorsal (DR) and median (MR) raphe and
central grey. MDMA-treated animals exhibited marked reductions in [3H]paroxetine binding
rites in presubiculum and parasubiculum, entorhinal cortex, and superior colliculus (sc), while
no changes in densities were observed in areas containing primarily serotonin perikarya such
as the raphe nuclei (DR and MR).
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compensatory changes in NE projections or other neurotransmitter recogni-
tion sites that may occur as a consequence of MDMA lesion of scrotonin
pathways.
SUMMARY AND CONCLUSIONS
The data presented in this chapter provide strong evidence, from both
neurochemical and neuroanatomical studies, demonstrating that, following in
vivo administration of a number of methylenedioxy-substituted amphetamine
derivatives, there is widespread and long-lasting degeneration of scrotonin
neurons in brain, without any major or consistent effects on catecholamine
neurons. A detailed examination of the parameters involved in the
neurotoxic and neurodegencrative effects of MDMA on brain scrotonin
neurons indicates that:
(1) the severity of the lesion by MDMA is dependent on both the dose and
frequency of drug administration;
(2) the neurodegenerative effects of MDMA can be elicited in a number of
animal species including primates;
(3) the neurodegenerative effects on brain serotonin neurons can be
prevented by the serotonin uptake blocker, suggesting a role for the
active uptake of MDMA, a neurotoxic metabolite of MDMA, or an
unidentified endogenous neurotoxin; and
(4) the neurodegenerative effects of the drug are long-lasting (up to 1 year)
with respect to neuronal recovery, while functional recovery may be
permanently impaired.
In addition, the neurochemical and autoradiographic data suggest that there
is some neuroanatomical and morphological specificity to the neurodegen-
erative effects of MDMA and MDA, as evidenced by predominant reduc-
tions in serotonin uptake sites in brain regions containing primarily
serotonin terminals, while regions containing serotonin axons of passage and
cell bodies are relatively unaffected.
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Characterization of Brain
Interactions With
Methylenedioxyamphetamine and
Methylenedioxymethamphetamine
Robert Zaczek, Stephen Hurt, Steven Culp, and
Errol B. De Souza
INTRODUCTION
Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine
(MDMA), like other amphetamine analogs, affect multiple in vitro monoa-
mine parameters. These effects include stimulation of [3H]serotonin and
[3H]dopamine release (Johnson et al. 1986) and inhibition of serotonin,
dopamine, and norepinephrine uptake (Steele et al. 1987). In addition,
recent radioligand binding studies have demonstrated interactions of MDA
and MDMA at a variety of established postsynaptic brain recognition sites,
including serotonergic, adrenergic, and cholinergic receptors (Battaglia
et al. 1988).
Several studies have identified specific sites of interaction in brain that may
mediate the actions of amphetamine and its substituted analogs. Binding
sites for [3H]amphetamine (Hauger et al. 1984) and [3H]fenfluramine
(Garattini et al. 1987) have been identified in discrete areas of rat brain.
These sites have similar characteristics in that both have high binding
capacities (amphetamine, Bmax=60 pmol/mg protein; fenfluramine, Bmax=63
pmol/g tissue), and binding to both sites is inhibited by sodium ions. To
date, two groups have studied interactions of [3H]MDMA with rat brain.
Gehlert et al. (1985) reported high affinity specific binding (Kd=99 nM,
Bmax=31 fmol/mg protein) of [
3H]MDMA to rat brain membranes. However,
a subsequent study (Wang et al. 1987) suggested that these apparent binding
sites represent [3H]MDMA association with glass fiber filter paper. The
present study reexamines the possibility of [3H]MDMA as well as [3H]MDA
association with rat brain membranes. Also characterized is the nature of
[3H]MDA association with brain membranes to evaluate the possible
importance of the binding site in mediating MDA’s neurochemical and
behavioral effects and to examine similarities between apparent [3H]MDA
binding sites and those labeled by [3H]amphetamine and [3H]fenfluramine.
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Centrifugation assays were employed in all our studies to circumvent the
problem of [3H]MDA and [3H]MDMA absorbing onto glass filters.
ASSOCIATION TO RAT BRAIN MEMBRANES
Assay for [3H]MDA and [3H]MDMA Association
Assays were performed using a crude synaptosomal preparation of rat brain.
Male Sprague-Dawley rats were sacrificed by decapitation, and brains were
immediately dissected on ice for membrane preparation. Telencephalon
containing cerebral cortex, striatum, and hippocampus was used in all
experiments except in studies examining the regional distribution of the
binding sites. Brain areas were homogenized in 20 volumes of ice-cold
0.32 M sucrose using a smooth glass homogenizer equipped with a motor-
driven teflon pestle. The homogenate was centrifuged at 800 x g for
10 minutes at 4 °C to remove large particulate material, and the supematant
was removed and centrifuged at 20,080 x g. The resultant pellet was
resuspended in 20 volumes of the original wet weight in either ice-cold
50 mM Tris-HCl buffer (pH 7.1) alone or in the same buffer containing
0.27 M sucrose. Binding assays were performed in Beckman minivials
containing either 0.9 mL of 50 mM Tris-HCl (pH 7.1) or the same buffer
containing 0.27 M sucrose. The vials also contained 2 nM [3H]MDA
(54 Ci/mmol) or [3H]MDMA (74 Ci/mmol), competing drugs at various
concentrations, and 100 µL of each of the homogenates as indicated above.
Nonspecific binding was assessed by measuring the [3H]MDA or
[3H]MDMA incorporated into boiled tissue. All incubations were performed
for 90 minutes at 4 °C: unless indicated otherwise. Assays were terminated
by centrifugation at 32,008 x g at 4 °C. The vials were removed and the
supernatant fluid discarded. The pellets were superficially washed with
ice-cold water (7 mL three times), after which the excess water was wiped
from the inside of the vial and 5.0 mL of scintillation fluid was added to
each vial. The pellets were allowed to solubilize overnight, and the vials
were assessed for radioactivity by scintillation counting. Data from
saturation isotherms were analyzed by the nonlinear curve-fitting program
LIGAND (Munson and Rodbard 1980). Protein was measured by the
method of Lowry et al. (1951).
[3H]MDA and [3H]MDMA Association to Rat Brain Membranes
Preliminary experiments to delineate the optimum conditions for [3H]MDA
and [3H]MDMA binding to rat brain membranes indicated that the best
signal-to-noise ratio was found using a crude synaptosomal preparation
incubated at 4 °C. While most experiments employed 50 mM Tris-HCl
(pH 7.1) as the incubation medium, we found that the addition of 0.27 M
sucrose to the incubation medium increased the specific binding approxi-
mately fivefold. Subsequent experiments were carried out under both
conditions. Other preliminary experiments suggested that [3H]MDA and
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[3H]MDMA interacted with multiple sites in rat brain. A low affinity
[3H]MDA binding site (apparent Kd>1.0 mM) was found to be resistant to
boiling of the synaptosomal preparation for 15 minutes. This site was
saturable, as indicated by a 30 percent inhibition of [3H]MDA binding to
boiled synaptosomes by 1.0 mM MDA and a 56 percent inhibition of the
binding by 0.1 mM of the serotonin uptake blocker paroxetine. The indica-
tion of a saturable, nonspecific binding site for [3H]MDA in boiled
membranes necessitated that we use boiled tissue to assess nonspecific
binding in all subsequent experiments.
The saturation profiles of [3H]MDA and [3H]MDMA recognition sites in rat
brain synaptosomes in the presence of 0.27 M sucrose are shown in
figure 1. Both ligands exhibited shallow saturation curves, which extended
over 4 log units from approximately 100 nM to 1.0 mM MDA, suggesting
the presence of multiple binding sites. Data from [3H]MDA saturation
experiments fit significantly (p<0.015) better to a two-site model, indicating
both high (Kd=887 nM, Bmax=23 pmol/mg protein) and low (Kd=45 µM,
Bmax=3.2 nmol/mg protein) affinity sites upon iterative nonlinear curve-
fitting analysis. Analysis of saturation data of apparent [3H]MDMA binding
in the presence of sucrose also fit significantly better to a two-site model
(p<0.02; high affinity Kd=2.9 µM, Bmax=79 pmol/mg protein; low affinity
Kd=128 µM, Bmax=7.4 nmol/mg protein).
The effect of eliminating sucrose from the incubation medium of [3H]MDA
binding assays is shown in figure 2. While the Eadee-Scatchard plot of the
data from [3H]MDA saturation experiments performed in the absence of
sucrose was linear, suggesting [3H]MDA binding to one population of sites,
the plot representing the data from experiments performed in the presence
of 0.27 M sucrose was curvilinear, consistent with [3H]MDA binding to
multiple populations of sites (see above). Nonlinear curve-fitting analysis of
the data suggested a single apparent binding site for [3H]MDA, when
incubated with synaptosomes in the absence of sucrose (Kd=2.8 µM,
Bmaxpmol/mg protein). Thus, removal of sucrose from the incubation
medium led to the elimination of low-affinity specific [3H]MDA binding.
Similar to observations of [3H]MDA binding, removal of sucrose from the
incubation medium led to a 61 percent decrease in the apparent specific
binding at 100 nM [3H]MDMA.
The affinity (Kd values) observed for [
3H]MDA and [3H]MDMA binding
were similar to the effective doses (i.e., ED50 or K1 values) of MDA and
MDMA reported for various pre- and postsynaptic monoamine markers,
such as serotonin and dopamine release (Johnson et al. 1986), monoamine
transport (Steele et al. 1987), and multiple brain, ligand binding sites
(Battaglia et al. 1988).
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FIGURE 1. Saturation of [3H]MDA and [3H]MDMA
brain synaptosomes
binding in rat
NOTE: lncreasing amounts of unlabeled MDA or MDMA were added to 1.0 mL of incubation buffer
containing 2 nM [3H]MDA or 2 nM [3H]MDMA, respectively. Experiments were performed
on tissue in the presence of 0.27 M sucrose. Data are expressed as percent of  [3H]MDA or 
[3H]MDMA bound to tissue in the absence of added nonradioactive drug. Nonspecific
binding was assessed by measuring the amount of [3H]ligand bound to boiled synaptosomes
incubated in the presence of 0.27 M sucrose.
The high capacities (i.e., Bmax value) of [
3H]MDA and [3H]MDMA binding
sites, as well as those that have been reported for [3H]amphetamine binding
sites (60 pmol/mg protein) (Hauger et al. 1984) and [3H]fenfluramine
binding sites (63 pmol/g tissue) (Garattini et al. 1987), argue against
bimolecular interactions of these drugs with monovalent protein-binding
sites. Although the mechanism by which sucrose acts to preserve low
affinity [3H]MDA binding is yet to be determined, a similar phenomenon
has been observed for [3H]amphetamine binding (Hauger et al. 1984). In
the latter study. a wash of tissue in isotonic sucrose prior to incubation was
reported to increase nearly threefold the specific binding over a wash with
50 mM Tris-HCl alone (Hauger et al. 1984).
Pharmacology of Specific [3H]MDA Binding in Rat Brain
The pharmacology of [3H]MDA binding was determined by examining the
effects of other monoamine reuptake blockers and related amphetamine
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analogs on the inhibition of [3H]MDA binding. The pattern of paroxetine,
desipramine (DMI), dimethoxymethamphetamine (DOM), and MDA inhibi-
tion of specific [3H]MDA binding is shown in figure 3. Experiments were
performed in the presence of 0.27 M sucrose using 2 nM [3H]MDA, condi-
tions under which both high- and low-affinity [3H]MDA binding sites are
labeled. Paroxetine was the most potent inhibitor (IC50= 1.6 µM) followed
by DMI (IC50= 5.9 µM), DOM (IC50 = 17 µM), and MDA (IC50 = 43 µM).
Analysis of paroxetine and DMI inhibition curves revealed Hill coefficient
values (nH) close to 1.00 (paroxetine, nH = 0.85; DMI, nH = 0.91). MDA and
DOM gave rise to much shallower inhibition curves (MDA, nH = 0.56; DOM,
nH = 0.53). providing additional evidence for the existence of multiple
apparent [3H]MDA binding sites.
FIGURE 2. Eadee-Scatchard transformation of saturation data of
[3H]MDA binding in rat brain synaptosomes
NOTE: Increasing amounts of unlabeled MDA were added to 1.0 mL of incubation buffer containing
2 nM [3H]MDA. Experiments were performed on tissue in the presence (open circles) and
absence (closed circles) of 0.27 M sucrose. Nonspecific binding was assesed by measuring
the amouut of [3H]MDA bound to boiled synaptosomes incubated in the presence of 0.27 M
sucrose.
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FIGURE 3. Inhibition of [3H]MDA incorporation into synaptosomes
NOTE: [3H]MDA binding assays were performed in 50 mM Tris-HCl (ph 7.1) containiag 0.27 M
sucrose and 2.0 nM [3H]MDA as described in the text. Results are expressed as percent
inhibition of specific [3H]MDA incorporation in the absence of inhibitors. Boiled tissue
blanks were performed at each concentration of drug.
The inhibition of [3H]MDA binding by several other related compounds is
seen in table 1. All compounds were tested at a concentration of 10 µM
under conditions that favored the labeling of the high-affinity [3H]MDA
binding site (zero sucrose, 2 nM [3H]MDA) and at 100 µM concentration
under conditions designed to favor the study of the low-affmity [3H]MDA
binding site (0.27 M sucrose, 3 µM [3H]MDA). A significant positive
correlation (r²=0.80, p<0.01) between the relative inhibition potencies of the
test drugs at the high- and low-affinity [3H]MDA binding sites was observed
upon linear regression analysis (figure 4A).
EFFECTS OF OSMOLARITY AND DETERGENTS
A possible explanation for the large capacity (i.e., high Bmax values) of
[3H]MDA binding sites and stimulation of [3H]MDA binding by isotonic
sucrose is intrasynaptosomal internalization and sequestration of [3H]MDA.
Studies of apparent chloride-dependent [3H]glutamic acid binding (Pin
et al. 1984; Zaczek et al. 1987) have demonstrated this type of phenomenon
for labeled glutamate. This possibility was examined by measuring
[3H]MDA binding in the presence of varying concentrations of sucrose and
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estimating the relative synaptosomal volume by measuring [3H]H2O
incorporation into synaptosomes in parallel experiments. As shown in
figure 5, decreasing the concentration of sucrose in the incubation medium
led to a decrease in the level of [3H]MDA binding. This contrasted with an
increase in intrasynaptic volume, as indicated by an increase in the capacity
of the synaptosomes to retain [3H]H2O. A significant negative correlation
(r2=0.84; p<0.02) was obtained when [3H]H2O incorporation was correlated
with [3H]MDA incorporation by linear regression analysis. These data argue
against a sequestration phenomenon, since the amount of [3H]MDA binding
should increase with increasing vesicular volume, if intrasynaptosomal
internalization and sequestration was occurring.
TABLE 1. Pharmacology of inhibition of [3H]MDA binding
Drug
Amphetamine
Mescaline
MDMA
N,N-DMT
PCA
DOM
Fenfluramine
Paroxetine
Desipramine
Imipramine
High-Affinity Low-Affinity
Binding Binding
47 ± 21 31 ± 13
36 ± 4 12 ± 6
48 ± 12 32 ± 3
5 9 ± 11 56 ± 20
84 ± 7 56 ± 8
70 ± 3 35 ± 8
63 ± 6 34 ± 9
100± 1 91 ± 8
96 ± 5 83 ± 9
96 ± 3 61 ± 15
NOTE: Inhibition of high-affinity [3H]MDA binding was performed in 50 mM Tris-HCl (pH 7.1) in
the presence of 2 nM [3H]MDA to preferentially label the high-affinity site. Drugs were
tested at 10 µM concentrations for inhibition of high-affinity binding. Low-affinity
[3H]MDA binding inhibition was performed in 50 mM Tris-HCl (pH 7.1) containing 0.27 M
sucrose in the presence of 3.0 µM [3H]MDA to preferentially label the low-affinity site.
Inhibition was peformed using 100 µM concentrations of the drugs tested. Values represent
percent inhibition of specific [3H]MDA binding (mean  ± SEM) performed in the absence of
inhibiting drugs. Boiled tissue was no in simultaneous assays to assess nonspecific binding.
Another approach used to examine the possible existence of [3H]MDA
sequestration into synaptosomes was to investigate the effects of the
detergents Triton X-100 and digitonin on the level of [3H]MDA
incorporation into rat brain synaptosomes (table 2). Concentrations of
detergents lower than 0.01 percent did not affect specific [3H]MDA binding.
Digitonin. at a concentration of 0.01 percent, caused a 30 percent decrease
(p<0.05) in the level of apparent [3H]MDA binding as compared to control,
and 0.01 percent Triton caused a 71 percent decrease (p<0.01). These data
provide additional evidence against intrasynaptosomal internalization and
sequestration of [3H]MDA since relatively high concentrations (0.01 percent)
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FIGURE 4. Correlation between the relative inhibitory potencies of various
drugs at high- and low-affinity [3H]MDA binding and
between drug lipophilicities and inhibition potencies of
[3H]MDA binding
NOTE: Panel A represents the relationship between the relative inhibitory potencies of various drugs
at high- and low-affinity [3H]MDA binding. Percent inhibition by test drugs of low-affinity
[3H]MDA binding is plotted vs. the inhibition of high-affinity binding. Panels B and C
represent the relation between the lipophilicity of test drugs and their ability to inhibit high
and low [3H]MDA binding, respectively. In both cases, the retention times of test drugs on
reverse-phase HPLC are plotted vs. percent inhibition of [3H]MDA binding. Pearson’s
r values and levels of significance are derived from linear regression analysis of the data.
of the detergents were required to cause significant decreases in [3H]MDA
incorporation into the tissue. Furthermore, these decreases were only
partial, which is in contrast to what is generally observed when labeled
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substances am released from a membrane-intemalized pool by pore-forming
detergents, which abruptly release the total contents of membrane-
sequestered compounds.
FIGURE 5. Effects of varying sucrose concentration on [3H]MDA and
[3H]water incorporation into rat brain synaptosomes
NOTE: Synaptosomes were prepared and incubated under standard procedures for [3H]MDA
incorporation.  The osmolarity of the incubation buffer was changed by the addition of
various concentrations of sucrose to 50 mM Ttis-HCl (pH 7.1). The incubation medium
contained either 100 nM [3H]MDA or 2 million cpm of [3H]water. After a 90-min incubation
at 4 °C, the assays were terminated and assessed for radioactivity. Bars represent the percent
change in the level of radioactive H2O (shaded bars) end [
3H]MDA (open bars) incorporated
from the respective incorporation at 0.32 M surcrose.
The results of the osmolarity and detergent experiments indicate that MDA
is not internalized into synaptosomes to any appreciable degree. In addi-
tion, the [3H]MDA binding assays were performed at 4 °C, demonstrating a
lack of dependence on physiological temperatures; this lack is characteristic
of membrane internalization phenomena. Since other investigators have
shown that [3H]MDMA is not taken up into synaptosomes by a sodium-
dependent mechanism (Wang et al. 1987), the internalization of MDA,
MDMA, and related compounds does not appear to be necessary for their
presynaptic actions to enhance the release and to inhibit the reuptake of
monoamines. Furthermore, the intraneuronal internalization of MDA or
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MDMA is not likely to be involved in the ability of these compounds to
cause serotonin terminal degeneration. The preponderance of the evidence
supports the hypothesis that the association of [3H]MDA with synaptosomes
is primarily with membrane elements.
TABLE 2. Effects of detergents on apparent [3H]MDA binding
Detergent
Weight/Vol Percent
(Percent) Control
Triton X-100 .000l 95 ± 9
.001 98 ± 8
.01 37 ± 9**
Digitonin .0001 89 ± 9
.001 85 ± 11
.01 70 ± 4*
Difference significant at p<0.05 by ANOVA and Duncan’s multiple range test.
**Difference significant at p<0.01 by ANOVA and Duncan's multiple range test.
NOTE: Synaptosomes were incubated for 90 min at 25 °C in 50 mM Tris-HCl (pH 7.1) containing
0.27 M sucrose and 100 nM [3H]MDA. Results are expressed as percent of specific
[3H]MDA binding in the absence of detergent. Results are the means ± SEM from three
seperate experiments done in duplicate.
Role of Lipophilicity in the Incorporation of [3H]MDA Into Rat
Brain Synaptosomes
Compounds that were included in the pharmacologic profile of [3H]MDA
binding were subjected to reverse-phase HPLC analysis to assess their
relative lipophilicity. Briefly, each compound (10 µg) was injected onto a
Waters Nova-Pak C18 column and eluted with a linear gradient from 95
percent buffer A:5 percent buffer B to 20 percent buffer A:80 percent
buffer B (buffer A=95 percent water, 5 percent acetonitrile, 0.1 percent
ammonium acetate; buffer B=20 percent water, 80 percent acetonitrile,
0.1 percent ammonium acetate). Detection was performed using a Waters
Model 441 UV detector at 214 nm. Figure 6 shows the reverse-phase
chromatographic elution pattern of MDA and related compounds, which are
listed in table 1. Since separation of compounds by reverse-phase chroma-
tography is based upon the aqueous/organic partition coefficients of the
substances separated, this method gives an index of the relative lipophil-
icity of various compounds. The more lipophilic a compound is, the greater
its retention time on C18 material. The retention times, in minutes, of
the compounds tested in the present study were: amphetamine, 6.93;
mescaline, 6.93; MDMA, 10.6; N,N-dimethyltryptamine (N,N-DMT), 12.1;
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FIGURE 6. Elution pattern of monoamine uptake blockers and
amphetamine analogs from reverse-phase HPLC
KEY: amph=amphetamine; mesc=mescaline; N,N-DMT=N,N-dimethyltryptamine
PCA=parachloroamphetamine; DOM=dimethoxymethamphetamine; DMI = desipramine; IMI=imipramine.
NOTE: HPLC detection of test drugs at 200 nm UV. Peak are named for the drugs they represent.
Peak identity was discerned by analyzing each drug individually and observing its retention
time and UV spectrum by photodiode array detection between 190 and 360 nm using a
Waters Model 990 PDA detector. Retention times are listed in the text.
parachloroamphetamine (PCA), 15.4; DOM, 18.8; fenfluramine, 23.4;
paroxetine. 30.9; DMI, 32.2; and imipramine, 34.7. Figure 4B and 4C
show the correlations that were found between the retention times of the
tested drugs and their levels of inhibition of high- and low-affinity
[3H]MDA binding, respectively (table 1). A significant positive correlation
(r²=0.81, p<0.01) was observed between the HPLC retention times of the
tested drugs and their respective levels of inhibition of high-affinity
[3H]MDA binding. Although a positive correlation was found between the
lipophilicity and the ability of test compounds to inhibit low-affinity
[3H]MDA binding (r²=0.56), this correlation did not reach the level of
statistical significance.
As stated earlier, the primary site of association of [3H]MDA with brain
synaptosomes is with membrane components, not with the intrasynaptic
space. While the phenolic ends of these compounds may enable them to
interact with hydrophobic environments of brain membrane components,
their polar side chains may inhibit the ability of these compounds to move
freely across the membranes, thus inhibiting internalization. The pKa of
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amphetamine is 9.9, which indicates that over 99 percent of this drug and,
most likely, its structural analogs will be ionized at pH 7.4. The ability of
these compounds to enter the brain readily, which has been ascribed to their
supposed lipophilicity, may be due to the existence of a saturable transport
process for these drugs across the blood-brain barrier (Pardridge and Connor
1973). The high capacity for MDA and MDMA incorporation into brain
membranes could be explained by their absorption into a hydrophobic
membrane environment. We have shown positive correlations between the
lipophilicity of several monoamine uptake blockers and amphetamine
analogs and their relative inhibition potencies of both high- and low-affinity
[3H]MDA binding (figure 4); however, this correlation is not perfect. For
instance, MDMA, which has a lower affinity (higher IQ for these sites of
interaction, is more lipophilic than MDA; fenfluramine, which is less potent
at inhibiting [3H]MDA binding than PCA, is more lipophilic than the latter
compound. These data suggest that there may exist some level of structural
specificity beyond lipophilicity.
REGIONAL DISTRIBUTION OF APPARENT [3H]MDA BINDING
The relative distribution of [3H]MDA incorporation into p2 preparations from
various regions of rat brain, liver, and kidney is shown in table 3.
Apparent [3H]MDA binding had a heterogeneous regional distribution in
brain, being highest in neocortex and midbrain followed by medulla-pons,
striatum, and diencephalon. Brain levels of [3H]MDA incorporation were
lowest in cerebellum, which had 50 percent fewer binding sites than
neocortex. Although [3H]MDA incorporation was detected outside the brain,
levels were much lower than those found in most of the brain structures
studied. The level of [3H]MDA binding in liver was 40 percent and that in
kidney 20 percent of that found in neocortex. The regional distribution of
[3H]MDA incorporation in the absence of sucrose had a profile similar to
that performed in the presence of 0.27 M sucrose (data not shown). There
was a significant positive correlation between the regional levels of apparent
binding studied under the two conditions (r²=0.84, p<0.61). These data,
together with those indicating a significant correlation between the relative
inhibition potencies of MDA analogs at high- and low-affinity [3H]MDA
binding, suggest an intimate relationship between the high- and low-affinity
[3H]MDA binding sites. Although there exist some differences in the
pattern of regional distribution between [3H]MDA binding found in the
present study and that of [3H]amphetamine binding found by Hauger
et al. (1984). similarities also exist. For example, the lowest level of
binding in brain for both ligands is found in the cerebellum and low levels
of binding are found for both ligands in the periphery. The differences
among the regional distributions of [3H]amphetamine, [3H]MDA, and
[3H]fenfluramine (Garattini et al. 1987) binding may be attributed to the
various membrane preparation and assay procedures used in each study.
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TABLE 3. Regional distribution of apparent [3H]MDA binding
Region
[3H]MDA Bound
(pmol/mg protein)
Neocortex 31 ± 4
Striatum 2 4 ± 3
Diencephalon 2 4 ± 5
Midbrain 29 ± 5
Medulla-Pons 2 6 ± 5
Cerebellum 15 ± 3
Liver 10 ± 1
Kidney 6 ± 2
NOTE: A p2 preparation was prepared from each dissected region and assayed for [
3H]MDA
incorporation as described in the text. Incubation was performed in 50 mM Tris-HCI
(pH 7.1) containing 0.27 M sucrose and 2.0 nM [3H]MDA. [3H]MDA incorporation into
boiled tissue served as the measure of nonspecific binding. Values are expressed as specific
[3H]MDA bound (mean ± SEM; pmol/mg protein) and are the results of three experiments
performed in triplicate.
Concentration of MDA in Brain After Systemic Administratian
To elucidate further the relevance of the high-nanomolar to low-micromolar
affinities of tbe [3H]MDA binding sites, we determined the brain concentra-
tions of MDA following systemic administration of behaviorally active doses
(20 mg/kg) of the drug to rats. Rats were injected subcutaneously with 20
mg/kg MDA containing 0.5 µCi of [3H]MDA. Rats were sacrificed at
various times after injection, and the hippocampus was removed, weighed,
and solubilized overnight in Soluene 100 (Packard). Econoflour (5 mL)
(NEN) was then added to the solution, and radioactivity was assessed by
liquid scintillation counting. To evaluate the identity of the radioactivi-
ty, rats were sacrificed 45 minutes after injection, and brains were removed
and homogenized in 0.1 M sodium acetate using a polytron (10 seconds,
position 6). After centrifugation at 30,000 x g, the supernatant fluid was
collected and 4.0 mL was applied to a C18 Sep Pak cartridge (Waters).
The cartridge was washed with 3.0 mL of water, and radioactivity was
eluted in 1.0 mL of acetonitrile containing 0.1 percent trifluoroacetic acid.
After drying the organic eluate to approximately 200 µL under nitrogen,
50 µL of the extract was injected onto a Waters Nova Pak C18 column and
eluted at 1.0 mL per minute with a linear gradient from 3 percent acetoni-
trile:97 percent 50 mM potassium phosphate buffer (pH 6.4) to 80 percent
acetonitrile: 20 percent water over 30 minutes. Eluted compounds were
detected by UV absorbance at 214 nm. Fractions (1.0 mL) of the column
eluate were collected and added to vials containing 5.0 mL of formula 963,
which were then assessed for radioactivity by scintillation counting.
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Accumulation and Clearance Findings
Figure 7A shows the timecourse of [3H]MDA accumulation and clearance
from rat brain after a subcutaneous injection. Peak concentration, which
was reached at 45 minutes, was equivalent to 165 µM (36 µg/g). To
verify the identity of the radioactivity as [3H]MDA, reverse phase chroma-
tographic analysis was performed on brain extract from a rat 45 minutes
after MDA (20 mg/kg) injection (figure 7B). Radioactivity eluted as a
single peak at 14 minutes, which coincided with a peak having a retention
time of 13.8 minutes observed by UV detection. This peak, which was not
observed in naive animals, was isochromatographic with standard MDA.
Thus, the injected material reaching the brain at 45 minutes was MDA, not
a metabolite. The level of MDA found in brain indicates that the Kd values
of MDA’s interaction with rat brain synaptosomes are within the range of
the brain concentrations of MDA reached following administration of
behaviorally active doses of the drug.
SUMMARY
Brain recognition sites have been identified for [3H]MDA and [3H]MDMA.
The dissociation constants of MDA and MDMA for these sites are similar
to the concentrations needed to affect several brain neurochemical
parameters and are in keeping with concentrations of MDA in brain
(165 µM) following administration of behaviorally active doses (20 mg/kg)
of the drug. While the characteristics of these binding sites suggest a
possible hydrophobic interaction with brain membranes, this interaction is
not without specificity, since it has a unique pharmacology and a
heterogeneous distribution in brain.
Similarities have been found between [3H]MDA binding studied in the
present report and that of apparent [3H](+)amphetamine binding studied by
Hauger et al. (1984). Both have extremely high Bmax values, are optimal in
p2 preparations, are stabilized by sucrose, and share similar patterns of
regional distribution. Measuring the specific binding of [3H]amphetamine,
[3H]fenfluramine, [3H]MDA, and related compounds under identical
conditions will be required to determine the possible relationships among
the interactions of these compounds with brain membranes. Further study is
also needed to determine the possible importance such interactions of
amphetamine and its substituted analogs may have with brain membranes in
relation to the pharmacology of these substances.
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FIGURE 7. Determination of MDA concentration in rat brain following
administration of behaviorally active doses of the drug
NOTE Panel A shows concentration of hippocampal MDA at various timer after adminitration of
20 mg/kg MDA containing 0.5 uCi of [3H]MDA. Each point represents the average MDA
concentration of four hippocampi from two animals. No regional variation was observed in
the analysis of MDA concentrations in other brain areas. Panel B shows the reverse-phase
chromatographic elution profile of radioactivity extracted from MDA-treated rats.
237
DISCUSSION
QUESTION: Do you know if there is cell activity at the site?
ANSWER: It has not been tested. We have not done much pharmacology
at all.
QUESTION: Do you know if your regional variations in this binding site
correlate at all with myelin?
ANSWER: No, I do not know offhand the concentration of myelin in
those areas. In fact, I did the profile to prove that it was not lipophilicity,
so I was not expecting that. I did not have the foresight to look at the
concentration of myelin.
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Pharmacologic Profile of Ampheta-
mine Derivatives at Various Brain
Recognition Sites: Selective
Effects on Serotonergic Systems
George Battaglia and Errol B. De Souza
INTRODUCTION
The amphetamines have found widespread use in a number of clinical
conditions, including narcolepsy, manic-depressive psychosis, orthostatic
hypotension, nasal congestion, migraine, asthma, hyperactivity, and obesity.
Although amphetamine (phenylisopropylamine) is structurally a simple
molecule, modification of the compound at the aromatic ring, side chain, or
terminal amino group can considerably change the pharmacological speci-
ficity of the resulting compound. Amphetamine itself is a potent central
nervous system (CNS) stimulant and anorectic agent, which acts primarily
by blocking catecholamine uptake and causing neurotransmitter release. The
addition of a hydroxy group on the beta carbon atom reduces both the
stimulant and anorectic effects of the compound, while addition of a second
alpha methyl group to amphetamine preferentially attenuates the CNS stimu-
lant properties. Anorectics with reduced stimulant and cardiovascular effects
can be created by insertion of groups onto the side chain, terminal amino
group, or aromatic ring. Aromatic ring substitution by a number of substit-
uents, including methoxy groups, have been shown to markedly alter the
pharmacologic specificity of the drug, from a catecholaminergic agent to
one exerting effects primarily on serotonergic systems (Loh and Tseng
1971). For example, paramethoxylation of amphetamine was found to
increase greatly the blockade of serotonin uptake and increase the release of
[3H]5-HT, while uptake and release of dopamine were found to be atten-
uated (Loh and Tseng 1971). Since a substantial amount of data have
implicated the involvement of brain serotonergic systems in the mechanism
of action of hallucinogenic agents (Downing 1964; Brawley and Duffield
1972; Freedman and Halaris 1978; Glennon and Rosecrans 1981; Glennon
1983), it would not be unexpected for a number of ring-substituted
psychotomimetic amphetamines to elicit their behavioral and/or subjective
effects via their preferential and potent interaction with central serotonin
recognition sites.
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The psychotomimetic mono- and dimethoxyamphetamines have been
reported to produce a number of subjective effects similar to those elicited
by agents such as LSD and mescaline (Shulgin et al. 1969; Snyder
et al. 1969). Indeed, some of the most potent hallucinogens have been
ring-substituted structural analogs of amphetamine. Since the actions of
psychotomimetic amphetamines may be mediated at presynaptic serotonin
recognition sites, as well as at one or more of the postsynaptic serotonin
receptor subtypes (Titeler et al. 1987). it is important to develop a relative
pharmacologic profile for these drugs at the various serotonin binding sites.
This chapter will (1) elucidate the serotonergic sites of action of various
ring-substituted psychoactive derivatives of amphetamine with an emphasis
on derivatives of 2,5-dimethoxyamphetamine (2,5-DMA); (2) describe a
detailed pharmacological profile of the newer types of psychoactive
methylenedioxy-substituted amphetamine derivatives, the so-called “designer
drugs” such as 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-
methylenedioxyamphetamine (MDA); and (3) elucidate the role of various
serotonergic brain recognition sites in mediating some of the behavioral
and/or subjective effects of these methylenedioxy derivatives of
amphetamine.
INTERACTIONS OF 2,5-DMA DERIVATIVES WITH SEROTONIN
RECEPTORS
As mentioned, aromatic ring substituents can greatly enhance the seroto-
nergic activity (Cheng and Long 1973; Cheng et al. 1974; Dyer et al. 1973;
Nair 1974) of the amphetamines. Substitution of methoxy groups in the 2,5
position and further substitution of substituents in the para position of the
phenyl ring of amphetamines markedly enhances their affinity for serotonin
receptors. The advent of the drug discrimination paradigm and its applica-
tion to the study of such hallucinogenic agents (Hirschhorn and Winter
1971; Silverman and Ho 1980; Glennon et al. 1982; Glennon 1983; Appel
et al. 1982) has greatly enhanced our understanding of the putative sites of
action of hallucinogenic agents and of the similarities among various
hallucinogenic compounds. These studies have demonstrated a significant
correlation between the potencies of numerous agents in eliciting intero
ceptive hallucinogenic cues in animals and humans (Glennon et al. 1982;
Glennon 1983). Drs. Glennon, Titeler, and their collaborators have carried
out a series of behavioral and radioligand binding studies to elucidate the
serotonin receptor subtype(s) that may be primarily responsible for the
actions of these psychoactive agents. Specifically, these studies involved a
detailed determination of the affinities of various 2,5-dimethoxy derivatives
of amphetamine at 5-HT1 and 5-HT2 serotonin receptors (table 1) using
radioligand binding techniques to directly label these sites.
The structures of some of these agents are shown in figure 1. Compounds
listed in figure 1A are either hallucinogenic in man or produce
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TABLE 1. Affinities of 2,5-DMA derivatives for 5-HT1 and 5-HT2
serotonin receptors
5-HT2 Binding
a 5-HT1 Binding
b
Ki(5-HT1)/
Agent Ki(nM) (Hill Coefficient) Ki(nM) Hill Coeficient Ki(5-HT2)
R(-)-DOI 9.9 2,290 (0.98) 230
(±)-DOI 18.9
(0.72)
(0.73)
S(+)-DOT 35 (0.66)
2,240 (0.86) 120
920 (0.73) 26
R(-)-DOM 60
63
(0.71) 3,550 (0.84)
(±)-DOB (0.80) 38,340 (0.77) 50
(±)-DOM 100 (0.71) 2,890 (0.82) 30
-demethyl DOM 110 (0.77) (0.72) 3
R(-)-DON 210 (0.75)
350
(0.79)
(0.91)
13,300 (0.85) 60
(±)-DON 300 14,100 (1.0) 45
R(-)-N-methyl DOM 260
(0.83)
4,300 (0.86) 15
(±)-N-methyl DOM 415 3,870 (0.86) 10
(±)-DOF 1,110
(±)-2,4,5-TMA 1,650
(0.76) 3,470 (0.97) 3
(0.68)
(0.77)
46,800 (0.49) 30
(±)-4-OEt2,5-DMA 2,220 35,500 15
(±)-4-Me PIA 3,360 (0.89) 14,800
(0.83)
(0.96)
(±)-2 ,5-DMA 5,200 (0.85) 1,020 (0.75)
4
< 1
(±)-PMA 33,600 (0.87) 79,400 (0.97) 2
(±)-3,4-DMA 43,300 (0.66) 64,600 (0.94) 1
NOTE: aKi values and Hill coefficients determined by competition experiments for 0.4 nM [
3H]ketanserin-labeled
5-HT2 serotonin binding sites in rat frontal cortical homogenates. Data from Shannon et al. 1984.
bKi values and Hill coefficents determined by competition experiments for 1.0 nM
[3H]LSD(+[10-3M]Ketanserin)-labeled 5-HT1 sites in rat frontal cortical homogenates. Data from Shannon
et al. 1984.
cData from Glennon et al. 1986
hallucinogen-like responding in behavioral studies, while agents listed in
figure 1B do not generalize to a hallucinogen cue. As shown in table 1,
although 2,5-DMA itself exhibits higher affinity for 5-HT1 versus 5-HT2
serotonin receptors, all of the derivatives of 2,5-DMA exhibit substantially
higher affinity for 5-HT2 serotonin binding sites and appear to interact more
selectively with this site than do tryptamine agonists such as serotonin. The
selectivity of 2,5-DMA derivatives for 5-HT2 serotonin receptors is particu-
larly marked for compounds with substituents in the para position. For
example, some of the para-halogenated compounds such as the iodinated
(DOI) and brominated (DOB) derivatives demonstrate an extremely high
affinity and degree of selectivity in their interactions with 5-HT2 serotonin
receptors.
Nearly all the derivatives of 2,5-DMA exhibited radioligand binding charac-
teristics at 5-HT2 serotonin receptors that were consistent with those of
serotonin and other tryptamine agonists. It has been demonstrated
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R' R'' R2 R4 R 5
(A) 2,5-DMA derivatives
(±)-2,5-DMA C H 3  H O C H 3  H O C H 3
(±)-2,4,5-TMA C H 3  H O C H 3  O C H 3  O C H 3
(±)-4-OEt 2,5-DMA C H 3  H O C H 3  O C 2 H 5  O C H 3
( ± ) - D O F C H 3  H O C H 3  F O C H 3
( ± ) - D O B C H 3  H O C H 3  B r O C H 3
( ± ) - D O I C H 3  H O C H 3  I O C H 3
R ( – ) - D O I C H 3  H O C H 3  I O C H 3
( ± ) - D O N C H 3  H O C H 3  N O 2 O C H 3
R ( – ) - D O N C H 3  H O C H 3  N O 2 O C H 3
( ± ) - D O M C H 3  H O C H 3  C H 3 O C H 3
R ( – ) - D O M C H 3  H O C H 3  C H 3 O C H 3
-Demethyl DOM H H O C H 3  C H 3 O C H 3
(±)-N-Methyl DOM C H 3  C H 3 OCH3 CH3 O C H 3
R(–)-N-Methyl DOM CH3 CH3 OCH3 CH3 O C H 3
(B) Non-2,5-DMA derivatives
(± ) -PMA C H 3  H H O C H 3 H
(±)-3,4-DMA C H 3  H H O C H 3  OCH3
(±)-4-Me PIA C H 3  H H CH3 H
FIGURE 1. Structures of a series of 2,5 DMA and non-2,5 DMA
derivatives
SURCE: Shannon el at. 1984.
previously that classical serotonergic agonists of the hyptamine class interact
with high- and low-affinity states of the 5-HT2 serotonin receptor (Battaglia
et al. 1984). Agonist-like properties of serotonin-related compounds were
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initially revealed by Hill coefficient (nH) values of less than one in
radioligand binding studies. Values of less than one for nH suggest inter-
action of the compound with multiple binding sites or multiple states of the
receptor. As shown in table 1, nearly all the derivatives of 2,5-DMA
exhibited nH values of less than one at 5-HT2, serotonin receptors, suggesting
an agonist-like activity at this receptor. Data from competition experiments
can be further quantitated using a computer-assisted two-site analysis pro-
gram (Munson and Rodbard 1980). Computer-assisted two-site analysis for
the interactions of a number of the 2,5-DMA derivatives with 5-HT2 seroto-
nin receptors indicates that these compounds do indeed interact with high-
and low-affinity states of 5-HT2 serotonin receptors, with the percentage of
binding sites in the high-affinity state for 2,5-DMA derivatives being
comparable to that observed for tryptamine agonists (table 2) (Battaglia
et al. 1984). The agonist high-affinity state of 5-HT2 serotonin receptors
has also been shown to be sensitive to divalent cations and guanine nucleo-
tides (Battaglia et al. 1984; Titeler et al. 1985), as previously demonstrated
for agonists interacting with receptors coupled to a guanine nucleotide regu-
latory protein. Consistent with other agonist characteristics and, as shown
in figure 2, DOI, the 4-iodo-DMA derivative, exhibited guanine nucleotide
sensitivity. This is revealed by the decrease in overall affinity (K1 value)
and increase in nH closer to one in the presence of 5’-gyanylimidodiphos-
phate (Gpp(NH)p) (figure 2). Furthermore, derivatives such as DOI, DOB,
and DOM exhibited substantially higher overall affinities (K1) and higher
affinities at the high-affinity component (KH of 5-HT2 serotonin receptors
than did a number of tryptamine agonists at this site (table 2) (Battaglia
et al. 1984; Shannon et al. 1984). With respect to stereospecificity, the R(-)
isomers of DOI and other 2,5-DMA derivatives were the more potent iso-
mers at 5-HT2 serotonin receptors, while the S(+) isomers of methoxyam-
phetamines were more potent at presynaptic serotonin recognition sites. In
the last few years, [125I]-DOI (Glennon et al. 1988) and [3H]-DOB (Titeler
et al. 1985; Lyon et al. 1987) have proven to be highly selective agonist
radiolabels for the high-affinity component of 5-HT2 serotonin receptors.
Subsequent studies investigating the affinities of these and additional
hallucinogenic phenylisopropylamines at 5-HT2  serotonin receptors have
clearly established a prominent role for 5-HT2 serotonin receptors in the
hallucinogenic process. Significant correlations were demonstrated between
the in vitro affinities of a series of amphetamine derivatives at 5-HT2
serotonin receptors and both their human hallucinogenic dose and their ED50
values in behavioral generalization to a hallucinogen cue (Glennon
et al. 1984; Titeler et al. 1988).
Although initial studies indicated that the various derivatives of 2,5-DMA
exhibited low affinity for 5-HT1 serotonin receptors (Shannon et al. 1984). it
was unclear from these studies what the affinities of the drugs were for the
respective subtypes of 5-HT1serotonin sites (i.e., 5-HT1A, 5-HTIB, and
5-HT1C receptors). In subsequent studies (Titeler et al. 1988), the affinities
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TABLE 2. Two-site analysis of the interaction of tryptamine agonists and
2,5-DMA derivatives with 5-HT2 serotonin receptors
K H KL %RH KI/KH
2,5 DMA Derivativesa
R(-)-DOI 1.5 ± 0.5
(±)-DOI 2.3 ± 1.0
R(-)-DOM 2.7 ± 1.6
(±)-DOB 2.4 ± 0.7
a-demethyl DOM 35 ± 11
R(-)-DON 68 ± 29
(±)-DON 137 ± 49
(±)-2,4,5-TMA 200 ± 60
(±)3,4-DMA 3,100 ± 950
30.0 ± 5.1
47.4 ± 16.8
190 ± 30
245 ± 90
100 ± 25
400 ± 110
900 ± 400
1,500 ± 730
6,250 ± 1,200
80,600 ± 19,000
40 ± 5 2 0
34 ± 9 21
22 ± 5 71
50 ± 9 17
19 ± 1 4 2
52 ± 2 12
55 ± 18 13
65 ± 19 11
41 ± 6 31
25 ± 5 26
Tryptamine Derivativesb
Serotonin 30 ± 3 1,173 ± 66 25 ± 4 39
5-Methoxytryptamine 130 ± 26 2,659 ± 550 45 ± 7 20
Bufotenine 96 ± 17 1,043 ± 220 35 ± 8 11
Tryptamine 302 ± 48 4,193 ± 570 15 ± 4 14
NOTE: Data were computer-analyzed with a two-site model (Munson and Rodbard 1980). KH
represents the dissociation constant of agonists clculated for the high-affinity component of
[3H]ketanserin binding. KL is the dissociation constant calculated for the low-affinity
component of [3H]ketanserin competition curves. KI/KHis the ratio of the two dissociation
. .
constants. %RHrepresents the percentage of sites in a high-form for the agonist.
SOURCE: Shannon et al. 1984; Battaglia et al. 1984.
of a comparable series of psychoactive amphetamine derivatives were
compared at 5-HT1A, 5-HT1B, and 5-HT1C serotonin receptors. As shown in
table 3, all derivatives exhibited relatively low affinities at 5-HT1A and
5-HT1B serotonin receptors but markedly higher affinities at the 5-HT1C
serotonin receptor. Although these data suggest that 5-HT1C sites may
contribute to some of the effects of these psychoactive amphetamines, the
precise role of the 5-HT1C serotonin receptors in the hallucinogenic process
or other effects of these drugs remains unclear at the present time.
PHARMACOLOGIC PROFILE OF MDMA AT VARIOUS BRAIN
RECOGNITION SITES
Psychotomimetic amphetamines such as mescaline and DOM (STP) have
experienced periods of popularity during the last two decades. In recent
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FIGURE 2. Competition curves of R(-)-DOI for [3H]ketanserin binding to
5-HT2 serotonin receptors in rat frontal cortex membranes
in the presence and absence of the guanine nucleotide
analog Gpp(NH)p
NOTE: Lines represent the best fit of the data acording to a model for tow biding sites [in the
absence of Gpp(NH)p] and a model for one binding site [in the presence of Gpp(NH)p].
SOURCE: Shannon et al. 1984
years, a new class of designer drug, the methylenedioxyamphetamine deriva-
tives, has received a great deal of attention. These compounds, which
include MDMA, MDA, and MDA’s N-ethyl derivative MDE, have been
reported to elicit both moderate “amphetamine-like” stimulant and weak
“LSD-like” hallucinogenic effects.
To elucidate the brain recognition sites through which MDMA might elicit
its various behavioral, psychotomimetic, and neurotoxic effects. an extensive
in vitro pharmacologic screening of MDMA was carried out at various brain
neurotransmitter receptors and recognition sites. The relative potencies of
MDMA at the various brain recognition sites were assessed from competi-
tion data in which affinities (Ki values) were determined using the nonlinear
curve-fitting program LIGAND (Munson and Rodbard 1980). Details of the
assay conditions and affinities of MDMA at the various recognition sites are
reported in table 4. The pharmacologic profile of MDMA demonstrates a
broad range of affinities of the drug for various brain recognition sites
(Battaglia et al. 1988a). MDMA had the highest affinity for serotonin
uptake sites (<1 µM) with lower but comparable affinities at 5-HT2
serotonin, adrenergic, M-1 muscarinic cholinergic and H-1 histamine
receptors (Ki values < 5µM). The rank order of affinities of MDMA at
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TABLE 3. Affinities of 2,5-DMA derivatives at 5-HT1 serotonin receptor
subtypes
Agent 5-HT1B 5-HT1C5-HT1A
R(-)-DOB
DOI
DOB
DOPR
R (-)-DOM
DOET
DOM
S(+)-DOB
DOBU
2,4,5-TMA
MEM
2,5-DMA
2,4-DMA
3,4,5-TMA
2,332 ± 188
2,355 ± 77
3,770 ± 188
2,849 ± 170
4,004 ± 107
3,930 ± 115
5,122 ± 140
4,041 ± 156
4,178 ± 165
>10,000
>l0,000
1,131 ± 55
>10,000
>10,000
683 ± 46
1,261 ± 105
831 ± 37
2,330 ± 101
1,840 ± 172
2,451 ± 226
2,063 ± 112
883 ± 49
1,211 ± 86
>10,000
>10,000
8,435 ± 668
>10,000
>10,000
47 ± 10
30 ± 4
69 ± 16
14 ± 1
94 ± 17
101 ± 20
193 ± 20
81 ± 7
2 6 ± 5
2,666 ± 76
2,278 ± 90
1,217 ± 89
3,152 ± 83
5,710 ± 150
NOTE: The 5-HT1A, 5-HT1B, and 5-HT1C receptors were labeled with ‘H-OH-DPAT, ‘H-5-HT, and ‘H-
mesulergine respectively.
SOURCE: Titeler et al. 1988.
various brain receptors and uptake sites were as follows: serotonin uptake
> adrenergic = 5-HT2 serotonin = M-1 muscarinic = H-1 histamine >
norepinephrine uptake = M-2 muscarinic = -adrenergic = -adrenergic >
dopamine uptake = 5-HT1 serotonin >> D-2 dopamine > D-1 dopamine.
MDMA exhibited negligible affinities (>500 µM) at mu, delta, and kappa
opioid, central-type benzodiazepine, and corticotropin-releasing factor
receptors, as well as at choline uptake sites and at calcium channels.
Although not shown here, the affinities of MDA were comparable (< two-
fold difference) to those of MDMA at each of the respective brain recogni-
tion sites investigated. In general, the affinities of MDMA at the receptor
sites investigated could be classified as high-, moderate-, and low-affinity
interactions. These are summarized in table 5. MDMA appears to be most
potent at a number of serotonin recognition sites as well as adrenergic
and M-l muscarinic receptors with affinity constants (K1 values) in the high
nanomolar to low micromolar range. Affinities of MDMA in the micromo-
lar range at the various recognition sites appear to be pharmacologically
relevant, since similar brain concentrations of the drug have been detected
in rats following systemic administration of a single dose of MDMA (20
mg/kg), which elicits behavioral as well as neurotoxic effects (Zaczek et al.,
unpublished observation).
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TABLE 4. Pharmacologic profile of MDMA at various brain
recognition sites
Brain Recognition Affinity Brain Assay Time,
Site Ki(µM) Radioligand/Displacer Region Tempeature Buffer
Uptake Sites
Serotonin 0.61 ± .05
Norepinephrine 15.8 ± 1.7
Dopamine 24.4 ± 1.9
Choline >500
Adrenergic Receptors
18.4 ± 1.2
3.6 ± 0.8
191 ± 21
Dopamine Receptior
D-1 148 ± 14
D-2 95 ± 15
Serotonin Receptors
5-HT1 23 ± 1.5
5-HT2 5.1 ± 0.3
Cholinergic Receptors
M-1 muscarinic 5.8 ± 0.3
M-2 muscarinic 15.1 ± 0.1
0.55nM[3H]paroxetinel 1
1µM citalopram
4.OnM[3H]mazindol/ 1
0.3µM desipramine
1.0nM[3H]GBR 12935/ 2
1µM mazindol
10nM[3H]hemicholinium-3/ 2
10µM hemicholinium-3
120 min, A
Rm T
90 min,
4 °C
A
60 min, A
Rm T
30 min, B
25 °C
0.5nM[3H]prazosin/ 1
10µM phentolamine
0.5nM[3H]para-aminocloni- 1
dine/10µM phentolamine
0.5nM[3H]dihydroalprenalol/ 1
1µM propranalol
30 min,
37 °C
30 min,
37 °C
30 min,
37 °C
0.2nM[3H]SCH 23390/ 2 30 min,
0.1µM flupenthixol 37 °C
0.2nM[3H]spiperone/ 2 30 min,
1µM (+)butaclamol 37 °C
2.5nM[3H]serotonin/ 1
10µM serotonin
0.4nM[3H]ketanserin/ 1
0.5µM cinanserin
30 min,
37 °C
30 min,
37 °C
0.1nM[3H](-)QNB/ 1
1µM atropone
0.1nM[3H](-)QNB/ 3
1µM atropine
90 min,
Rm T
90 min,
Rm T
2nM[3H]dihydromorphine/ 4
1µM levallorphan
4nM[3H]D-ala2-D-leu5- 4
enkephalin (30nM morphine)/
1µM levallorphan
1.6nM[3H]ethylketazocine 4
(30nM morphine + 100nM
D-ala2-D-leu5-enkephalin)/
1µM levallorphan
45 min,
25 °C
45 min,
25 °C
45 min,
25 °C
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C
C
C
C
C
C
D
D
E
E
E
Opioid Receptors
Mu >500
Delta >500
Kappa >500
TABLE 4. (Continued)
Bran Recongnition Affinity Brain Assay Time,
Site KI(µM) Radioligand/Displacer Region Temperature Buffer
Other Sites
H-1 histamine
Receptors
Benzodiazepin
receptors
Corticotropin-
releasing factors
(CFR) receptors
Calcium channels
5.7 ± 2.4 2nM[3H]mepyramine/
1µM doxepin
>500 0.2nM[3H]flunitrazepam/
1µM clonazepam
>500 0.1nM125I-Tyr°-rat CRF/
1µM ovine CCRF
>500 0.2nM[
3H]nitredipine/
0.1µM nifedipine
1 60 min, F
Rm T
1 60 min, G
Rm T
5 120 min, H
Rm T
1 60 min, G
Rm T
KEY: Assay buffers: A = 50 mM TRIS-HCl, 120 mM NaCl, 5 mM KCl (pH 7.4 at Rm T); B = 50 mM glycylglycine,
200 nM NaCl (pH 7.8 at 25 °); C = 50 mM TRIS-HCl, 10 mM MSO4, 0.5 mM K3HDTA (pH 7.4 aat 37 °C); D =
50 nM TRIS-HCl, 10 mM MGSO4 (pH 7.7 at Rm T) E = 0.17 M TRIS HCl (pH 7.6 at 25 °C); G = 50 mM TRIS-
HCl (pH 7.7 at Rm T); F = 50 nM Na+K+ phospate (pH 7.4 at Rm T); H = 50 mM TRIS-CHl, 10 mM MgCl2, 2
mM EGTA 0.1% bovine serum albumin, 0.1 mM bacitracin sprotinin (100 KIU/mL) (pH 7.2 at 22 °C). Brain
regions: 1 = frontal contex; 2 = striatum; 3 = brain stem; 4 = whole brain; and 5 = olfactory bulb.
NOTE: Data represent the mean ± SEM from three to five competition curves at each of the sites. Ki values were
determined using the nonlinear least-sqares curve-fitting program LIGAND.
SOURCE: Battaglis et al. 1988.
TABLE 5. Relative potencies of MDMA at various brain recognition sites
High Affinity Moderate Affinity Low Affinity
(0.6 to 6µM) (10 to 100 µM) (< 100 µM)
Serotonin uptake sites
5-HT2 serotonin receptors
sites
-adrenergic receptors
Norepinephrine uptake sites
Dopamine uptake sites
5-HT1 serotonin receptors
D-1 dopamine
receptors
Choline uptake
Mu, delta, and
kappa opioid
receptors
M-1 muscarinic receptors adrenergic receptors Benzodiaepine
receptors
D-2 dopamine
receptors
As shown in table 6, we have compared the affinities of a series of
methylenedioxy derivatives with those of the parent compounds (ampheta-
mine and methamphetamine) at some of the recognition sites in brain at
which MDMA exhibited the highest affinities. These comparative studies
indicate that addition of the methylenedioxy substituent in the 3,4 position
increases their affinity at serotonin uptake, 5-HT2 serotonin, and M-1
muscarinic receptors, while the unsubstituted parent compounds appear to be
more potent at adrenergic receptors.
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TABLE 6. Relative potencies of amphetamine derivatives at selected brain
recognition sites
Compound 5-HT Uptake 5-HT2 Serotonin adrenergic M-1Muscarinic
MDMA 1.0
MDA 1.8
MDE 0.4
Amphetamine 4.8
Meth- 3.4
amphetamine
1.0
0.5
3.5
2.6
2.4
1.0
0.5
3.3
0.09
0.61
1.0
1.4
1.8
4.8
3.6
NOTE: Comparison of the affinities (K1 values) of amphetamine derivates at serotonin(5-HT)
uptake sites, 5-HT2serotonin, adrenergic, and M-1 muscarinic receptors with respect to
the affinity of MDMA at these sites. Values smaller or larger than 1.0 indicate affinities
higher or lower, respectively, than those of MDMA. 
SOURCE: Battaglia et al. 1988a.
Interestingly, the anxiolytic-like effects of MDMA do not appear to be
mediated through agonist actions at benzodiazepine receptors or antagonist
effects at corticotropin-releasing factor receptors as evidenced by the low
affinity of MDMA (>500 µM) at each of these receptors. In addition, the
reinforcing, analgesic, and mood-altering properties of the drug do not
appear to be mediated through interactions with any of the opioid receptor
subtypes, since MDMA has relatively low affinities for these receptors.
INTERACTIONS OF MDMA WITH SEROTONIN RECOGNITION
SITES
The previous data suggest that a number of the behavioral, psychotomime-
tic, and neurochemical effects of MDMA and other methylenedioxy
derivatives of amphetamine may be explained by interactions of MDMA at
multiple serotonin recognition sites in brain. MDMA may alter serotonergic
transmission in brain through direct actions at postsynaptic as well as
presynaptic serotonin recognition sites. As mentioned above, a number of
hallucinogenic phenylisopropylamine derivatives exhibit potent agonist-like
activity at brain 5-HT2 serotonin receptors (Shannon et al. 1984) and the in
vitro affinities of these hallucinogens at 5-HT2 serotonin receptors signifi-
cantly correlate with both their behavioral potencies in animals in
generalization to other hallucinogens and with their human hallucinogenic
potencies (Glennon et al. 1984; Titeler et al. 1988). Similar to previous
observations for other ring-substituted amphetamines such as the derivatives
at 2,5-DMA, we found that MDMA and other methylenedioxy derivatives of
amphetamine also exhibited high-affinity agonist-like binding characteristics
at 5-HT2 serotonin receptors. The stereospecificity observed for methylene
dioxy derivatives at 5-HT2 receptors was consistent with that observed for
other hallucinogenic compounds at this receptor (Lyon et al. 1986; Battaglia
250
et al. 1986). In addition, it was reported that MDMA interactions with the
high-affinity state of 5-HT2 serotonin receptors were sensitive to the effects
of guanine nucleotides, similar to that observed for serotonin and other
classical tryptamine agonists at this site (Battaglia et al. 1984) (figure 3).
While the overall apparent affinity (K1 value) of MDMA for [
3H]ketanserin-
labeled 5-HT2 serotonin receptors is in the low micromolar range, the
authors have observed that the interactions of MDMA and other methylene-
dioxyamphetamines with the high-affinity state of 5-HT2 serotonin receptors
labeled directly by [3H]DGB (Lyon et al. 1987) are much more potent
(K1<300 nM). Since this high-affinity component of 5-HT2 serotonin
receptors represents the most potent site of action for MDMA in brain, it is
likely that some of the “mood-altering” effects of MDMA may be mediated
by direct agonist actions at 5-HT2 serotonin receptors. A recent study
demonstrating that the serotonin receptor antagonist methysergide can
potentiate the MDMA-induced increases in locomotor activity (Gold and
Koob 1988) further supports the claim for direct actions of MDMA at
postsynaptic 5-HT2 serotonin receptors. A comparison of the relative
affinities of MDMA and MDA at postsynaptic 5-HT2 serotonin receptors
with those of other ring-substituted amphetamine hallucinogens suggests that
MDMA and MDA would be much weaker hallucinogens at this site than
would compounds such as DOM (STP) or DOI. This is not surprising, as
the methylenedioxy class of designer drugs has been reported to have
unique and subtle mood-enhancing subjective effects, rather than having the
more vivid and disorienting sensations commonly attributed to very potent
hallucinogens such as DOM or LSD.
In addition to the actions of MDMA and other derivatives at 5-HT2
serotonin receptors. some of the effects on serotonergic systems could be
mediated via 5-HT1A receptors, at which MDMA has a moderate affinity.
Direct agonist effects at this site might contribute to the mood-altering and
calming effects of the drug, since similar effects have been reported for
novel anxiolytics such as ipsaperone and buspirone, which interact with
5-HT1A serotonin receptors.
In addition to its relatively high affinity at postsynaptic 5-HT receptors,
MDMA exhibited high affinity for 5-HT uptake sites and has been shown
to increase the release of [3H]5-HT and block [3H]5-HT uptake in vitro.
These data suggest that some of the actions of MDMA may be mediated at
presynaptic binding sites. With respect to [3H]5-HT release, MDMA has
been reported to increase the release of [3H]5-HT from brain synaptosomes
(Nichols et al. 1982) and hippocampal slices (Johnson et al. 1986). With
respect to uptake blockade, MDMA has been reported to competitively
inhibit 3H-5-HT uptake in vitro (Shulgin 1986). Furthermore, the neurotoxic
effects of in vivo administration of MDMA on serotonin terminals can be
blocked by concomitant administration of the 5-HT uptake blocker citalo-
pram (Battaglia et al. 1988b; Schmidt and Taylor 1987). Additional
evidence in support of the hypothesis that MDMA produces some of its
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FIGURE 3. Competition curves of (A) serotonin and (B) MDMA for [3H]
ketanserin binding to 5-HT2 serotonin receptors in rat
frontal cortex membranes in the presence and absence of
the guanine nucleotide quanosine-5-triphosphate (GTP)
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effects through presynaptic serotonergic mechanisms is provided by data
demonstrating that MDMA can generalize to a fenfluramine cue in stimulus
discrimination studies (Schechter 1986).
Classic a-adrenergic receptor antagonists such as phentolamine have been
reported to increase the release of [3H]5-HT via effects on adrenergic
receptors (Timmermans and Van Zwieten 1982). Thus, one might speculate
that the serotonin-releasing effects of MDMA may be mediated, in part, by
high-affinity antagonist-like effects at adrenergic receptors localized to
presynaptic serotonin terminals. The relatively high affinity of MDMA at
the serotonin uptake site and adrenergic receptor may contribute, in part,
to the neurochemical, neurotoxic, and behavioral effects mediated at
presynaptic serotonin terminals.
While brain serotonin systems may play a key role in mediating some of
the effects of MDMA on analgesia and body temperature as well as in the
reported anxiolytic-like and mood-altering subjective effects of the drug,
additional neurotransmitter systems may contribute to some of the unique
subjective experiences reported for MDMA and other drugs in this class.
SUMMARY AND CONCLUSIONS
Ring-substituted psychoactive derivatives of amphetamine exhibited high
affinities for a number of serotonin recognition sites. Derivatives of
2,5-DMA exhibited preferential high affinity at 5-HT2 serotonin receptors
when compared to their relative affmities at 5-HT1 serotonin receptors.
Furthermore, 2,5-DMA derivatives exhibited agonist-like binding
characteristics at 5-HT2 serotonin receptors with the R(-) isomer being the
more potent isomer. There were significant correlations between the
in vitro affinities of 2,5-DMA derivatives at 5-HT2 serotonin receptors and
their human hallucinogenic potencies as well as with their potencies in
behavioral generalization studies, suggesting the importance of 5-HT2
serotonin receptors in mediating the hallucinogenic effects of the various
2,5-DMA derivatives.
A pharmacological profile of the methylenedioxy-substituted amphetamine
derivatives indicates that MDMA and MDA exhibited highest affinity for
serotonin uptake sites, 5-HT2 serotonin, arenergic and M-1 muscarinic
receptors. The methylenedioxy amphetamine derivatives exhibited an
inverse stereospecificity with respect to serotonin uptake sites versus
postsynaptic 5-HT receptors with the S(+) isomer being more potent at the
presynaptic recognition site, while the R(-) isomer was more potent at the
postsynaptic recognition sites. Similar to the 2,5-DMA derivatives, MDMA
and MDA exhibited agonist-like binding characteristics at 5-HT2 serotonin
receptors. Unlike 2,5-DMA derivatives, MDMA and MDA demonstrated
little selectivity for 5-HT2 versus 5HT1 subtypes of receptors. The
relatively weak hallucinogenic effects of the methylenedioxy-substituted
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amphetamine derivatives (when compared to the 2,5-DMA derivatives) may
be mediated through actions at 5-HT2 serotonin receptors. In addition, the
neurotoxic, psychotomimetic, analgesic, temperature regulation, and mood-
altering effects of MDMA and other methylenedioxy-substituted derivatives
may be mediated, in part, through their actions at other serotonin
recognition sites in brain, including serotonin uptake sites and 5-HT1A
serotonin receptors. Other behavioral. cardiovascular, and toxic effects of
MDMA and related derivatives may be mediated by actions at other central
and/or peripheral recognition sites, including muscarinic cholinergic receptors
and adrenergic receptors, for which these compounds exhibit relatively
high affinity. The precise mechanisms for the various effects of the
amphetamine derivatives remain to be determined.
DISCUSSION
QUESTION: In the absence of serotonin neurons, could MDMA still have
a direct agonist action at postsynaptic receptors or is that 5-HT?
ANSWER: Yes. From the present data, one would expect direct agonist
effects of MDMA at 5-HT2 receptors in the absence of serotonin neurons.
Based on the data that I showed you today, MDMA and other methylene
dioxy amphetamine derivatives exhibit agonist-like binding properties that
resemble those observed for 5-HT and other tryptamine agonists as well as
for other hallucinogenic amphetamines. We would expect the effects of
MDMA at 5-HT2 receptors to be somewhat weaker compared to those of
other amphetamine derivatives, since MDMA-like compounds exhibit sub-
stantially lower affinity than the 2,5-DMA derivatives at 5-HT2 sites. In
addition, unlike what we Observe with the 2,5-DMA derivatives, MDMA
and the other methylenedioxy compounds do not exhibit the preferential
affinity for 5-HT2 sites over 5-HT1 subtypes as observed for the more potent
hallucinogens. The comparable affinity of MDMA for multiple 5-HT recep-
tors may contribute to the comparatively weak hallucinogen-like properties
of this class of compounds. With respect to the second part of the
question, it would be expected that, in the presence of an intact serotonergic
system, MDMA-induced release of 5-HT via presynaptic sites of action
would also have some postsynaptic 5-HT2 receptor consequences. I inferred
that MDMA may have antagonist-like effects at alpha2 adrenergic receptors,
and this may be responsible for increased 5-HT release. However, the only
recognition site where we have tried to discern agonist versus antagonist
characteristics is at the 5-HT2 serotonin receptors.
QUESTION: Not the presynaptic?
ANSWER: No, only the postsynaptic 5-HT2 receptors.
COMMENT: It seems to me that, in the absence of the serotonin input,
the 5-HT2 serotonin receptors downregulate instead of upregulate. So if you
254
took away the serotonin input, you would expect to see a decreased
potency.
RESPONSE: Downregulation of 5-HT2 receptors, which has been observed
following treatment with antagonists, may be viewed as due to compen-
satory changes in response to tbe absence of 5-HT input. In order to assess
the hypothesis that there was modulation in the absence of serotonin, we
looked at 5-HT2 serotonin receptors following lesion with MDMA. We
chose to look at a time point 2 weeks after treatment in order to allow time
for postsynaptic receptor changes to occur. Although we did not see any
changes in the density of sites, we have not investigated whether there may
have been changes in second messenger systems coupled to these receptors.
QUESTION: Would you expect the direct effects of MDMA on the 5-HT2
receptor to have any significance in the presence of this massive 5-HT
release that it is causing?
ANSWER: When we are dealing with the effects of the methylenedioxy-
substituted derivatives on serotonergic systems, we are dealing with a
multiplicity of effects.
Our data indicate that the racemates of these compounds most likely
mediate effects on both presynaptic as well as postsynaptic 5-HT sites.
Furthermore, there is an inverse stereospecificity associated with these
actions. For example, the dextro isomers of MDMA and other drugs in this
class exhibit higher affinity than the levo isomer for the presynaptic 5-HT
uptake and also appear to be more potent in causing 5-HT release. This is
the opposite of the isomer affinities at postsynaptic receptors. The levo
isomers of MDMA-like compounds exhibit preferentially higher affinity than
the dextro isomers for both 5-HT1 and 5-HT2 serotonin receptor subtypes.
Similar stereospecificity is observed with the parent compounds, ampheta-
mine and methamphetamine, as well for the hallucinogenic 2,5-DMA deriva-
tives. While we can discern the agonist properties of these compounds at
5-HT2 receptors, it is unclear whether these drugs are acting as agonists or
antagonists at the various subtypes of 5-HT1 receptors. With respect to the
original question, if MDMA exhibits simultaneous 5-HT2 agonist and 5-HT1
antagonist activity, then one may speculate that these effects can signifi-
candy influence the fmal response, even in the presence of massive 5-HT
release by these agents.
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Effects of Amphetamine Analogs on
Central Nervous System Neuro-
peptide Systems
Glen R. Hanson, Patricia Sonsalla Anita Letter,
Kalpana M. Merchant, Michel Johnson, Lloyd Bush,
and James W. Gibb
INTRODUCTION
Substantial efforts have been devoted to elucidating the effects of ampheta-
mine analogs on central nervous system (CNS) monoaminergic pathways.
These agents enhance the activity of such neuronal systems by causing
release of their transmitter substances as well as by interfering with trans-
mitter metabolism and reuptake. However, little is known about the conse-
quences of the monoaminergic changes resulting from the administration of
these agents, i.e., the eventual effect of these drugs on transmitter systems
directly influenced by the monoaminergic pathways. Such effects are
important in transmitting the monoamine-initiated messages to those brain
regions that eventually mediate the drug-related behavioral changes. In
addition, these systems likely have important feedback functions on the
amphetamine-sensitive monoaminergic pathways. Consequently, drug-
induced changes in these feedback pathways might contribute to phenomena
such as tolerance and sensitization.
Of interest to the present work are the neuropeptide neuronal projections
associated with extrapyramidal structures and the responses of peptidergic
pathways to treatments with amphetamine analogs. These peptide systems
were selected for study because of their close association with the
mesostriatal dopaminergic neuronal circuitry, a system thought to contribute
to the locomotor and mood-altering effects of the amphetamine compounds.
For example, neurons containing substance P (SP), which originate within
the shiatum and terminate in the substantia nigra, are thought to serve an
excitatory feedback function on the mesostriatal dopamine (DA) pathway.
Thus, intranigral injections of SP cause striatal release of DA (Reid et al.
1988) and stimulate locomotion (Herrera-Marschitz et al. 1986). Nigral
administration of SP has no effect on locomotor activity in animals that
have received 6-hydroxydopamine lesions to their mesostriatal DA pathway
(Herrera-Marschitz et al. 1986).
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The interactions between neurotensin (NT) pathways and the extrapyramidal
dopaminergic system are somewhat more complex. As the vast majority of
striatal and nigral NT receptors are associated with DA neurons (Quirion et
al. 1985). NT pathways certainly contribute to the regulation of
extrapyramidal DA activity. The overall CNS pharmacology of NT has
been compared to that of neuroleptic drugs (Nemeroff 1986), while
intraventricular administration of this peptide is reported to antagonize some
of the behavioral activity of amphetamine and cocaine (Skoog et al. 1986).
Finally, dynorphin (Dyn) A1-17 is associated with striatal-nigral neurons
that, like the SP pathway, have been postulated to be part of a feedback
system to the nigral-striatal DA neurons (Herrera-Marschitz et al. 1983).
However, such a feedback role for Dyn has been questioned recently, as the
locomotor activity induced by nigral Dyn injections is not impaired by
elimination of the nigral-striatal DA pathway (HerreraMarschitx et al.
1986).
EVALUATION OF NEUROPEPTIDE RESPONSE TO
AMPHETAMINE ANALOGS
This chapter discusses the responses of these extrapyramidal neuropeptide
systems to the amphetamine analogs methamphetamine (METH), methylene
dioxyamphetamine (MDA), and methylenedioxymethamphetarnine (MDMA).
These drugs were selected for this study because they represent somewhat
diverse mechanisms of action. While all three agents are able to enhance
extrapyramidal serotonergic activity (Schmidt et al. 1987). only METH has
been characterized as a substantial stimulant of the DA system. The effects
of MDA and MDMA on extrapyramidal DA systems have not been well
elucidated. Thus, evaluating and comparing the responses of the SP, NT,
and Dyn extrapyramidal systems to these drugs will help to determine the
nature of the DA responses to METH, MDA, and MDMA administrations.
Methods
Sprague Dawley rats (180 to 220 g) were treated with METH, MDA, and
MDMA generously donated by the National Institute on Drug Abuse. Fol-
lowing drug treatments, rats were sacrificed, brains removed, and the striatal
and nigral areas dissected out. Tissue samples were rapidly frozen and
stored until analyzed. The responses of these neuropeptide systems to treat-
ments by the amphetamine analogs were assessed with radioimmunoassay
techniques by measuring drug-induced changes in the tissue content of
neuropeptidelike immunoreactivity. Highly selective and sensitive anti-
bodies were used in the detection of SP (Hanson and Loveberg 1980), NT
(Letter et al. 1987). and Dyn (Hanson et al. 1987). The mean nigral con-
tents of SP, NT, and Dyn for the control groups were 12 nanograms (ng),
595 picograms (pg), and 766 pg per mg protein, respectively. The mean
striatal contents for SP, NT, and Dyn for the control groups were
1,250,127, and 380 pg/mg protein, respectively. To characterize the
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METH-induced changes in neuropeptide levels, selective D1 (SCH 23390)
and D2 (sulpiride) dopaminergic receptor antagonists were coadministered.
The results are expressed as percent of control to facilitate comparisons;
each value represents the mean ± SEM of five to seven animals. Data
were subjected to either a Student’s r-test (figures 4 and 5) or ANOVA
analysis followed by a multiple comparisons test (figures 1, 2, and 3).
Significance was set at the .05 level.
FIGURE 1. Effects of METH on extrapyramidal SP content
*p<0.02 compared to corresponding groups. 
NOTE: METH was injected alone or  concurrently with either SCH 23390 (SCH) (0.5 mg/kg/injection)
or sulpiride (sulp) (80 mg/kg/injection).
Results
Administrations of five injections of METH (15 mg/kg/injection; 6-hour
intervals between injections) caused substantial increases in the striatal and
nigral levels of all three neuropeptides examined in rats sacrificed 18 hours
following treatment. Figures 1 to 3 present the effects of blocking the D1
and D2 dopaminergic receptors on the responses by these peptide systems
261
FIGURE 2. Effects of METH on extrapyramidal NT content
*p<0.02 compared to corresponding control.
**p<0.01 compared to the corresponding METH- and sulpride (sulp)-treated groups, and p<0.001
compared to the corresponding control.
†p<0.05 compared to the corresponding METH-treated groups.
††p<0.01 compared to the corresponding METH-treated group.
NOTE: Animals were treated as described in figure 1.
to METH treatment. Figures 4 and 5 present the responses of SP, NT, and
Dyn extrapyramidal pathways to MDMA and MDA treatments, respectively.
Following METH administration, levels of SP were elevated to 150 percent
of control in the substantia nigra and 227 percent of control in the striatum
(figure 1). Blockade of either D1 or D2 receptors totally prevented the
METH-induced rise in nigral SP content.
In rats sacrificed 18 hours following METH treatment, nigral and striatal
levels of both NT (figure 2) and Dyn (figure 3) increased dramatically, to
200 to 400 percent of respective controls. However, the effects of D1 and
D2 receptor antagonism on the METH-induced changes in these peptide
systems were somewhat different. Administration of sulpiride alone caused
an increase in striatal NT levels. METH administration in the presence of
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FIGURE 3. Effects of METH on extrapyramidal Dyn A content
*p<0.02 compared to corresponding controls.
†p<0.05 compared to the corresponding METH-treated group.
NOTE: Animals were treated as described in figure 1.
this D2 blocker resulted in increases of striatal NT content approximately
equal to the summation of the effects of the two drugs when given indi-
vidually. In contrast, the D1 antagonist, SCH 23390, had no effect alone
and substantially attenuated the METH-induced striatal changes in NT
content. The SCH 23390 compound also completely blocked the METH-
mediated elevation of nigral NT levels, while sulpiride had no effect of its
own, nor did its presence significantly influence the response of the nigral
NT system to METH treatment.
Administration of sulpiride or SCH 23390 alone did not alter the striatal or
nigral content of Dyn. Blockade of D1 receptors substantially interfered
with the METH-induced changes in both striatal and nigral Dyn levels.
Blockade of D2 receptors by sulpiride appeared to attenuate the METH-
related changes in the Dyn levels, especially in the substantia nigra, but its
interference with the METH effects was less than that of the SCH 23390
compound.
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FIGURE 4. Effects of MDMA on extrapyramidal neuropeptide contents
*p<0.05 compared to corresponding controls. 
**p<0.001 compared to corresponding controls.
NOTE: Animals were given multiple injections of MDMA (10 mg/kg/injection) and sacrificed 18
hours after treatment. Striatal and nigral content of SP, NT, and Dyn were examined
The effects of five injections of MDMA (10 mg/kg/injection) on striatal and
nigral neuropeptide content are presented in figure 4. Animals were treated
in a manner similar to that used for the METH experiments. Following
multiple MDMA administrations, the striatal levels of SP, NT, and Dyn
were elevated to 248 percent., 195 percent, and 148 percent, respectively, of
corresponding controls. Nigral content of these same peptides were
increased to 127 percent, 217 percent, and 157 percent, respectively,
compared to their controls. These effects resembled those observed with
METH treatment, Similar SP and NT responses were observed following
MDA treatment (figure 5).
CONCLUSION
These findings demonstrate that some neuropeptide systems associated with
mesostriatal dopaminergic projections are profoundly altered by treatment
with each amphetamine analog examined.Although the significance of
these drug-induced increases in striatal and nigral contents of SP, NT, and
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FIGURE 5. Effects of MDA on extrapyramidal neuropeptide contents
**p<0.01 compared to corresponding controls.
NOTE: Animals were given multiple injections of MDA (10 mg/kg/injections) and sacrificed 18 hours
after treatment. Striatal and nigral levels of SP and NT were determined.
Dyn is not yet known, it is likely that such changes reflect variations in the
activity of the associated pathways. One possible explanation is that
increases in neuropeptide tissue levels are due to decreased release of the
transmitter, which diminishes the extracellular peptide metabolism and
results in accumulation of these peptide substances. Another possible
contributing factor is a drug-related alteration in neuropeptide synthesis. For
example, Bannon et al. (1987) reported that METH administration increased
the quantity of striatal messenger RNA for the SP precursor preprotachy-
kinin. Thus, increases in peptide synthesis might contribute to increases in
peptide content caused by treatment with METH or the other amphetamine
analogs.
The dramatic responses to METH reported herein were most certainly a
consequence of drug-mediated changes in postsynaptic dopaminergic activity.
It is interesting that each neuropeptide response to METH treatment was
subtly unique. The increases in SP content cased by METH appeared to
occur primarily by activation of D2 receptors (figure 1). This conclusion is
based on previously reported findings that D2 agonists also increase nigral
SP levels, while D1 agonists actually cause a decrease in the nigral SP
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concentration (Sonsalla et al. 1984). Even so. D1 receptors appeared to play
a facilitatory role in this drug effect, as blockade of this receptor completely
prevented the METH effects. The effects of METH on the NT systems
appeared to be mediated completely by D1 receptors, as the presence of
SCH 23390 almost entirely blocked the METH-mediated changes in NT
levels, while sulpiride did not appear to interfere with the METH effects
(figure 2). Finally, these data suggest that the actions of METH on the
Dyn systems were mediated primarily by D1 receptors; even so, D2 receptors
also contributed to these effects as their blockade attenuated, although to a
lesser degree than D1 blockade, the METH-related increases in Dyn levels
(figure 3).
The present data demonstrate that the amphetamine analogs MDA and
MDMA influence the extrapyramidal neuropeptide systems in a METH-line
manner (figures 4 and 5). As already discussed, the METH effects on
these peptide systems are dopaminergically mediated, thus, it is likely that
the amphetamine designer drugs also influence SP, NT, and Dyn
extrapyramidal pathways by enhancing extrapyramidal dopaminergic activity.
In support of this conclusion, we have observed that blockade of D1
receptors with SCH 23390 completely blocks the increases in striatal NT
and Dyn induced by MDMA treatment (unpublished observation). This
finding is consistent with observations that MDMA and MDA stimulate the
release of striatal DA from tissue slices (Schmidt et al. 1987) and intact
animals (Yamamoto and Spanos 1988). In addition, Stone et al. (1986)
reported that treatments with MDA and MDMA resulted in increases in
striatal concentrations of homovanillic acid, a DA metabolite, which reflects
the extent of DA release.
While perhaps quantitatively different, each of the amphetamine analogs
examined had substantial effects on the extrapyramidal SP, NT, and Dyn
pathways. Thus. these peptide pathways likely contribute to the behavioral
effect of this group of agents in general; specifically, they might participate
in mediating the changes in locomotion or mood or the development of
psychotic disorders associated with administration of high doses of the
amphetamine analogs. More studies are necessary to identify specific
contributions ma& by each of these peptide systems to the pharmacological
profiles of these agents. In addition, these neuropeptide changes are of
interest as nemochemical markers for the effects of the amphetamine drugs
on postsynaptic dopaminergic activity and could be useful in the study of
such consequences of these drugs as tolerance and sensitization.
DISCUSSION
QUESTION: The last slide referred to postsynaptic actions of the drugs.
Do you mean postsynaptic consequences of their presynaptic actions?
266
ANSWER: Yes. We all know that the dopamine comes out The question
is: What happens after the dopamine comes out? We know that if nothing
occurred following the dopamine release as far as other transmitter systems
being influenced, them would be no behavioral effect. So downstream
systems like these peptides are probably involved in mediating those
monoaminergic messages to some other parts of the brain or playing
feedback roles and altering the way that the monoamine systems respond
So they may play roles in sensitization or tolerance by impacting on the
activity of those projections.
QUESTION: Did you mention that 6-hydroxydopamine blocks or elevates
neurotensin levels?
ANSWER: Yes, 6-hydroxydopamine by itself elevates neurotensin levels.
When you combine it with methamphetamine, you do not get any additivity.
It is just a 6-hydroxydopamine action. It is a bit complicated to interpret,
but it appears that it is still the nigral striatal dopamine pathway that is
mediating the methamphetamine effect.
QUESTlON: Have you had the opportunity to look at substance P,
possibly in the spinal cord? I am thinking about some of the work that
Dr. Seiden presented and potentially a role in analgesia.
ANSWER: We have not looked in the spinal cord at all for substance P.
Everything has been in the extrapyramidal and limbic systems.
COMMENT: Another reason why you should be looking at substance P in
the spinal cord is that, in spinal cord, substance P is cocontained in neurons
together with tyrosine hydroxylase.
RESPONSE: Right. And we have asked ourselves the question because of
the issue of coexistence, not only with substance P but with neurotensin and
probably dynorphin. Is this the reason these things are changing? Because
if they are coexisting with dopamine projections and there is some alteration
in dopamine, then maybe there is an intraneuronal action that results in the
peptide changes.
COMMENT: I was thinking about this, but I couldn’t remember if
substance P had been shown to be colocalized in the striatum.
RESPONSE: No, if there is any, it is very, very small coexistence of
substance P and tyrosine hydroxylase in the striatum. That is why we don’t
feel that that is the explanation for these changes.
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Effects of Neurotoxic Ampheta-
mines on Serotonergic Neurons:
lmmunocytochemical Studies
Mark E. Molliver, Laura A. Mamounas, and
Mary Ann Wilson
INTRODUCTION
The goal of this chapter is to review recent morphologic studies in which
current anatomic methods have been used to characterize the neurotoxic
effects of psychoactive amphetamine derivatives. Several strategies
combining anatomic with biochemical data have been employed to analyze
the effects of selected drugs in this class. These studies show that
psychoactive drugs that have selective neurotoxic effects can be useful
experimental tools to study the neural mechanisms of elusive brain functions
such as affective state control and perceptual integration.
Serotonergic neurons appear to play an important role in higher mental
functions, especially in emotional expression, and in mediating many of the
effects of psychotropic or hallucinogenic drugs. The presence of serotonin
(5-HT) in the brain was first demonstrated in the 1950s employing assay
techniques based on the action of 5-HT on smooth muscle (Twarog and
Page 1953; Amin et al. 1954). Marked regional differences in brain levels
of 5-HT were later found in the dog and cat brain using spectrophotometry
(Bogdanski et al. 1957). High 5-HT levels in limbic areas of the brain led
these authors to speculate that 5-HT may be involved in emotional
expression. The observation that the hallucinogenic drug LSD antagonized
the contractile action of 5-HT on uterine muscle led Gaddum in 1953 and
1958 to propose that 5-HT may act as a central neurotransmitter with a
specific role in cerebral function. Based on the behavioral effects of LSD,
Woolley and Shaw (1954) postulated that 5-HT may be involved in
psychiatric disorders such as schizophrenia. LSD was then shown to
decrease 5-HT turnover in the brain and increase 5-HT levels (Freedman
1961), an effect that was presumably due to inhibition of 5-HT cells in the
dorsal raphe (DR) nucleus (Aghajanian et al. 1968; Aghajanian et al. 1970).
Subsequent physiologic studies have shown that the primary effects of LSD
and of phenethylamine hallucinogens (such as mescaline or 2,5-dimethoxy-4-
methylamphetamine (DOM) are exerted at serotonergic synapses in
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forebrain (Aghajanian et al. 1970; Rasmussen and Aghajanian 1986, Trulson
et al. 1981; Jacobs 1984). Receptor binding studies have indicated that the
behavioral effects of several of these hallucinogenic drugs are blocked by
ketanserin. a 5-HT2 antagonist (Heym et al. 1984) and that the
hallucinogenic potency correlates roughly with the affinity of such
compounds for 5-HT2 binding sites (Glennon et al. 1984; Glennon 1985).
The studies cited above strongly implicate serotonergic synapses in
mediating hallucinogenic drug effects. Mom recent investigations have
supported the view that designer drugs that are substituted amphetamine
derivatives with psychotropic properties typically release 5-HT from 5-HT
axon terminals and, in some cases, may produce neurotoxic effects.
SURVEY OF SEROTONERGIC NEURONAL SYSTEMS IN THE
BRAIN
An overview of the anatomic organization of 5-HT projections in the brain
is useful as background for understanding the actions and toxicity of
psychotropic amphetamines. Important features of 5-HT neurons are the
diversity of cell types in multiple raphe nuclei and the specificity of their
organization. Serotonergic neurons, first demonstrated by the
histofluorescence method (Falck et al. 1962), are restricted to the brain
stem, where they are localized in multiple discrete clusters along the
midline, primarily within neuronal cell groups designated as the raphe nuclei
(Taber et al. 1960; Dahlstrom and Fuxe 1964). These serotonergic nuclei
extend from the midbrain to the caudal medulla and were originally
described as nine cell groups, named B1 to B9, by Dahlstrom and Fuxe
(1964). Serotonergic axon terminals have been found in widespread areas
of the forebrain (including cerebral cortex, striatum, and diencephalon)
(Fuxe 1965) and throughout the brain stem and spinal cord. A series of
studies employing small intracerebral lesions (Anden et al. 1966; Ungerstedt
1971) indicated that most 5-HT nerve terminals in the forebrain arise from
raphe nuclei in the midbrain and that the axons ascend through the lateral
hypothalamus within the medial forebrain bundle (Moore and Heller 1967;
Azmitia 1978; Conrad et al. 1974).
While most serotonergic cell bodies are located primarily in the midline
raphe of the brain stem, some 5-HT cells lie outside the boundaries of the
raphe nuclei, and not all raphe cells are serotonergic. Serotonergic axons
that innervate the forebrain arise from neurons within the mesencephalic
raphe nuclei. These cell groups are found primarily in the midbrain and
rostral pons and were originally classified as groups B6 to B9. The largest
group of serotonergic neurons is the DR nucleus (B7, DR), which lies with-
in the periaqueductal gray matter. This nucleus extends from a level just
caudal to the oculomotor nucleus down to the rostral portion of the fourth
ventricle. The DR is continuous caudally with a smaller group of 5-HT
cells (B6) that lie along the midline and the floor of the fourth ventricle.
The median raphe (MR) nucleus (also designated central superior or B8)
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lies within the central portion of the reticular formation in the midbrain
tegmentum (figure 1). The B9 cell group consists of a scattered group of
5-HT neurons that lie along the dorsal surface of the medial lemniscus in
the ventrolateral tegmentum. The other raphe nuclei, B1 to B5, contain
fewer serotonergic cells and are located along the midline in the midpons
and medulla. These more caudal cells give rise primarily to connections in
brain stem and spinal cord. Several more detailed reviews of the serotoner-
gic cells have been published recently and should be consulted for further
information (Moore 1981; Wiklund et al. 1981; Consolazione and Cuello
1982; Jacobs et al. 1984; Molliver 1987). An account of serotonergic
pathways and ascending projections in the rat has been published by
Azmitia and Segal (1978). and a map of raphe cells and projections in the
primate is presented elsewhere (Azmitia and Gannon 1986).
SEROTONERGIC INNERVATION OF CORTEX
While it has been widely believed that 5-HT along with other monoamine
(MA) neurons have diffuse and nonspecific projections, numerous pieces of
evidence indicate that 5-HT projections, although widely distributed
throughout the forebrain, have a high degree of heterogeneity, specificity,
and organization. Recent studies have shown that all cortical areas are
innervated by 5-HT axons, which form a dense terminal arborization with
striking regional differences in the laminar distribution and density of axons.
The original histofluorescence studies were limited by weak fluorescence of
5-HT and rapid fading due to photodecomposition of fluorescent molecules.
The low sensitivity of histofluorescence did not permit detection of fine
axons in the forebrain, so that the density of innervation was initially
underestimated. It was not feasible to visualize the full extent of cortical
5-HT innervation until the advent of immunocytochemistry using 5-HT
antibodies developed by Steinbusch et al. (1978). which were used to depict
the distribution of 5-HT innervation in rat brain (Steinbusch 1981). An
antibody to 5-HT produced in this laboratory was used to analyze the 5-HT
innervation pattern of cerebral cortex (Lidov et al. 1980). Lidov and
colleagues demonstrated a high density of 5-HT-containing axons throughout
the cerebral cortex of the rat with marked regional differences in the density
of axons and the laminar pattern of innervation. A high density of axons
was found in frontal cortex with a gradual decrease in more caudal areas.
In that and subsequent studies (Kosofsky 1985; Blue et al. 1988a), a distinct
laminar pattern of innervation was found in somatosensory cortex, and a
quite different pattern in the cingulate cortex, hippocampus, and dentate
gyrus, where there are distinct bands of highly varicose axons. In the
primate, the 5-HT innervation of cerebral cortex is denser and more highly
differentiated among different architectonic and functional areas (Kosofsky
et al. 1984; Morrison et al. 1982; Morrison and Foote 1986; Wilson and
Molliver 1986; Wilson et al. 1989). For example, marked differences in the
density and distribution of 5-HT axons are found in the macaque on either
side of the central sulcus, in primary motor and somatosensory cortex: while
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FIGURE 1. The locations of serotonergic cell bodies in midbrain
raphe nuclei
NOTE: The three raphe cell groups depictcd here are the source of serotonergic projections to most
parts of the forebrain.  The DR is located in the central gray matter (cg) with many cells 
between and dorsal to the medial longitudinal fasciculus (mlf). The MR is a more
scattered group of 5-HT neurons located in the central portion of the midbrain tegmentum.
A small number of cells lies in the B9 cell group along the medial lemniscus (ml) and give
rise to a small number of cortical projections. This map was prepared by Dr. L
Mamounas based on a section prepared for 5-HT immunocytochemistry.
SOURCE: Mamounas and Molliver 1988, Copyright 1988, Academic Press.
motor cortex is sparsely innervated, somatosensory cortex is characterized
by a high density of 5-HT axons extending acres most layers, with subtle
changes seen within the subdivisions of somatosensory cortex. Primary
visual cortex (Area 17) has an exceptionally dense innervation with a
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distinctive laminar distribution of 5-HT axons. In visual cortex, the density
in layer IV is particularly high but varies across sublayers, with a decrease
in laminae IVCß in the macaque (Kosofsky et al. 1984). Further primate
studies from this laboratory have revealed highly intricate, detailed
variations in innervation pattern and in the distribution of fine and beaded
axons (Wilson, in preparation; Wilson and Molliver 1989; Wilson
et al. 1989). In addition to these marked differences in innervation, subtle
differences in the laminar pattern of innervation are found between closely
related cortical areas, e.g., between the banks of the principal sulcus, the
divisions of the hippocampal formation, the anterior and posterior parts of
cingulate cortex, and among the subdivisions of somatosensory cortex
(Wilson, in preparation). The main point to be emphasized with regard to
cortical 5-HT innervation is that the characteristic regional differences may
reflect different functional influences of 5-HT neurons upon separate cortical
areas and variations in the effects of 5-HT projections upon particular
cortical cell types.
The intricacy of the 5-HT innervation of cortex is further emphasized by
differential cortical projections from the midbrain raphe nuclei. With the
development of new techniques, there has been progressive clarification of
the complex pattern of raphecortical innervation. Initial axon transport
studies suggested that the DR nucleus projects preferentially upon cerebral
neocortex and striatum while the MR innervates primarily hippocampus and
hypothalamus. Later studies using more sensitive methods demonstrated
that the projections were far more complex and that there is considerable
overlap in raphe projections to forebrain (O’Hearn and Molliver 1984; Imai
et al. 1986). Azmitia and Segal (1978) showed that the DR and MR nuclei
have direct projections to forebrain and give rise to multiple, anatomically
distinct ascending fiber bundles. The terminal distributions of the DR and
MR ascending projections converge, so that most areas of cerebral cortex
are innervated by both nuclei. with regional differences in the relative
contribution from each nucleus; evidence for differential but overlapping
raphe-cortical projections has been presented elsewhere (O’Hearn and
Molliver 1984) and summarized in a recent review (Molliver 1987).
Studies employing highly sensitive retrograde transport methods have shown
that calls within different regions of the raphe nuclei project topographically
to separate areas of cortex (Kohler and Steinbusch 1982; Jacobs et al. 1978;
O’Hearn and Molliver 1984; Waterhouse et al. 1986; Wilson and Molliver
1988). The functional significance of this complex topographic order is
indicated by evidence that individual zones of the raphe nuclei project to
functionally related parts of the brain (Kosofsky 1985; Imai et al. 1986).
Initial retrograde transport studies in the monkey reveal that there is a more
complex and intricate regional pattern of raphe-cortical projections in the
primate than in the rat (Wilson and Molliver 1988; Wilson, in preparation).
These topographic findings, although seemingly complex in detail, indicate
that the DR is heterogeneously organized and that particular zones of this
nucleus project to different cortical areas. The DR and MR nuclei have
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overlapping projections with dissimilar patterns of organization, and they
terminate predominantly in different cortical layers and upon different cell
types.
DUAL 5-HT AXON TYPES
Further evidence for the specificity of 5-HT projections, of particular
relevance to amphetamine neurotoxicity, came from anterograde transport
studies of the lectin PHA-L conducted by Kosofsky (1985). While it was
known from several previous studies that 5-HT axon morphology is hetero-
geneous, Kosofsky made the unexpected discovery that there are consistent
morphologic differences between cortical axon terminals that arise from the
DR and MR nuclei, respectively (Kosofsky and Molliver 1987). 5-HT axon
terminals arising from the MR nucleus have large, spherical varicosities
(typically 2 to 3 µm in diameter), giving these axons a characteristic beaded
appearance (figure 2). In contrast, axons that arise from the DR nucleus
FIGURE 2. A schematic representation showing the two classes of
raphe-cortical axon terminals that were identified by
anterograde axon transport
NOTE: Axons that arise from cells in the DR nucleus are extremely fine with minute pleomorphic
or fusiform varicosities. Axons from the MR nucleus have a beaded appereance
characterized by large, spherical varicosities.
SOURCE: Adapted from Kosofsky and Molliver 1987. Copyright 1987, Alan R. Liss, Inc. 
are of very fine caliber and typically have minute, pleomorphic varicosities
that are often granular or fusiform in shape. The fine axon terminals are
the most widespread and abundant type in cortex, while the beaded axons
have a more restricted and characteristic distribution. Distinctive beaded
5-HT axons have been described in other areas of forebrain, e.g., in the
entorhinal cortex (Kohler et al. 1980), in the olfactory bulb (McLean and
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Shipley 1987), and in the hippocampus (Lidov et al. 1980; Zhou and
Azmitia 1986). In addition, two corresponding morphologic axon types
were found in the cat to form mutually distinct axon systems (Mulligan and
Tork 1987; Mulligan and Tork 1988). Moreover, similar, morphologically
distinct axon types have been described in neocortex and hippocampus in
the macaque monkey (Wilson et al. 1989). Preliminary reports state that
beaded 5-HT axons may form pericellular baskets around nonpyramidal
neurons in cortex of the marmoset (Homung et al. 1987) and that similar
5-HT axons may terminate upon GABA-positive cells in the cat (Tork and
Homung 1988).
SEROTONERGIC RECEPTORS IN CORTEX
Binding sites for 5-HT are present in high density throughout the brain, and
these receptors have been the subject of recent reviews by Altar et al. 1986,
Peroutka 1988, and Sanders-Bush 1988. One of the major discoveries in
5-HT pharmacology during the past decade has been the identification of
multiple 5-HT binding sites originally classified by Peroutka and Snyder
1979 and 1981, and designated as 5-HT1 and 5-HT2 receptor types. Similar
numbers of both types are found in cerebral cortex, yet each differs in its
anatomic distribution and in the specific second messenger that is activated
(Conn and Sanders-Bush 1987). Using a new ligand for detecting 5-HT2
receptors (125I-MIL), which was developed by Dr. P. Hartig and Blue and
coworkers have compared the distribution of 5-HT axons in cortex with that
of 5-HT2 receptors. It was noted that the fine type of 5-HT axon terminals
(DR origin) was closely associated with 5-HT2 receptors, a relationship
especially evident in rat somatosensory cortex where both terminals and
receptors are extremely dense in the upper portion of layer V (Blue
et al. 1986, Blue et al. 1988b). These results raise the possibility that
5-HT2 receptors may be generally associated with fine axon terminals from
the DR and that separate 5-HT projections may form multiple and distinct
functional systems. The association of different classes of 5-HT axons with
different receptors and second messenger systems is further evidence of the
multiplicity and functional specificity of ascending 5-HT projections. The
association of fine axon terminals with 5-HT2 receptors is particularly
relevant to the action of certain psychotropic drugs, which are postulated to
act primarily at this receptor subtype (Glennon et al. 1984; Glennon and
Lucki 1988; Heym et al. 1984).
NEUROTOXICITY OF AMPHETAMINE DERIVATIVES
While neurotoxic effects of amphetamines upon MA neurons had been
reported in previous biochemical studies, a seminal paper from the
University of Chicago has stimulated a new wave of interest in the
neurotoxic effects of substituted amphetamines upon 5-HT projections.
Large doses of the ring-substituted amphetamine derivative
(±)3,4-methylenedioxyamphetamine (MDA) repeatedly administered to rats
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by subcutaneous injection produced lasting reductions in biochemical
markers for 5-HT in forebrain. Brain levels of 5-HT, levels of the
metabolite 5-hydroxyindoleacetic acid (5-HIAA), and 5-HT uptake into
synaptosomal suspensions were all substantially decreased 2 weeks after
drug treatment (Ricaurte et al. 1985). For example, 5-HT levels in striatum
and hippocampus were decreased more than 70 percent below control
values. These findings were extended and confirmed for both MDA and its
N-methyl analog 3,4-methylenedioxymethamphetamine (MDMA) by indepen-
dent investigators at Chicago, the University of Utah, and elsewhere
(Commins et al. 1987; Schmidt 1987; Stone et al. 1986; Stone et al. 1987a;
Stone et al. 1987b). The latter study from Gibb’s laboratory showed that
the effects of MDA and MDMA were highly specific for 5-HT axons and
that repeated doses produced greater than 90-percent decreases of tryptophan
hydroxylase activity in cortex. These results were interpreted as indicating
that these hallucinogenic amphetamine derivatives may cause initial release
of 5-HT followed by lasting degeneration of 5-HT projections to forebrain;
they thus appear to be similar to parachloroamphetamine (PCA) in their
action (Schmidt 1987a).
IMMUNOCYTOCHEMICAL (ICC) STUDIES OF MDA AND MDMA
TOXICITY
Based on the biochemical studies that psychotropic amphetamines act largely
upon 5-HT neurotransmission and that prolonged exposure may be toxic to
5-HT neurons, it was of interest to examine the effects of MDA and
MDMA upon the morphology of 5-HT neurons, in order to determine
whether there may be evidence for structural damage to these cells or their
processes, Consequently, an ICC study of the neurotoxic effects of MDA
and MDMA was conducted in this laboratory by E. O’Hearn, in
collaboration with Battaglia, De Souza, and Kuhar from the National
Institute on Drug Abuse (NIDA) Addiction Research Center. In previous
studies, evidence for axon degeneration was reported in the striatum
following administration of MDA or MDMA (Ricaurte et al. 1985;
Commins et al. 1987b) using the Fink-Heimer method, a silver stain for
degenerating axons. However, because of low sensitivity for 5-HT axons,
the silver-staining methods do not accurately depict the full extent or
regional distribution of degenerating 5-HT axons, nor has any other
conventional anatomic method proven satisfactory for thii purpose. Due to
their limited sensitivity, the silver stains even fail to detect forebrain axon
degeneration of MA projections following lesions of the medial forebrain
bundle (MFB) (Moore and Heller 1967). At best, variants of the silver
methods stain a small fraction of degenerating 5-HT axons, primarily in
cingulate cortex, following raphe lesions (Hedreen 1973) or in hippocampus
(Conrad et al. 1974). In order to characterize the cytotoxic effects of MDA
and MDMA, it is important to determine whether there is morphologic
evidence for degeneration of specific monoaminergic axons following drug
administration. A central goal of this study was therefore to obtain
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anatomic evidence that would establish whether or not 5-HT neurons
degenerate following exposure to these drugs. Transmitter immunocyto-
chemistry was employed for the visualization of 5-HT and catecholamine
axons in order to determine whether there is structural evidence for
degeneration, to identify the specific neuronal structures and neuronal
compartments that are damaged by the neurotoxic drugs, and to determine
the regional distribution of the effect 5-HT neurons, their axonal pathways,
and axon terminals were visualized by 5-HT immunocytochemistry using an
antibody to conjugated 5-HT, and cell bodies were examined in Nissl-
stained sections. Catecholamine axons and cell bodies were visualized using
an antibody to tyrosine hydroxylase (TH).
In initial ICC studies, animals were treated with MDA or MDMA using the
protocol described by Ricaurte et al. (1985). Adult Sprague-Dawley rats
(150 to 200 g) received subcutaneous injections of racemic MDA or
MDMA every 12 hours for 4 days. Each dose was equivalent to 20 mg/kg
of the free base. The rats were sacrificed by intracardiac aldehyde
perfusion 2 weeks after the final dose. In order to study subacute effects
for evidence of degeneration, additional rats received MDA every 12 hours
for 2 days and were sacrificed 24 hours after the last injection. Additional
experimental details are described elsewhere (O’Hearn et al. 1986; O’Hearn
et al. 1988). A series of animals treated identically and in parallel were
analyzed for changes in 5-HT levels and density of uptake sites using
paroxetine binding (Yeh et al. 1986; Battaglia et al. 1987).
The biochemical and pharmacologic results were largely in agreement with
previously reported effects of MDA and MDMA described above. The
main neurochemical results of these studies (see also Battaglia and De
Souza, this volume) confirm that, at 2 weeks after treatment, MDA and
MDMA produced marked reductions in the content of both 5-HT and its
metabolite 5-HIAA in most brain regions, with MDA causing a somewhat
more potent effect. For example, in frontal cortex, 5-HT and 5-HIAA
levels were reduced to 40 to 60 percent of control values; regional
differences are evident in that smaller reductions of approximately
30 percent were found in the hypothalamus. The density of 5-HT uptake
sites determined by paroxetine binding in homogenized tissue blocks showed
highly significant reductions in cerebral cortex (60 to 70 percent),
hippocampus (70 to 75 percent), and hypothalamus (40 to 50 percent)
(Battaglia et al. 1987). No significant changes were found in markers for
catecholamines. The above changes were closely matched by anatomic
changes found in ICC preparations, described below (O’Hearn et al. 1988).
Neurotoxicity of MDA and MDMA
It was previously shown that immunocytochemistry with an antibody
directed against 5-HT provides specific and highly sensitive visualization of
5-HT-containing cell bodies and nerve fibers throughout the central nervous
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system (CNS) (Lidov et al. 1980, Lidov and Molliver 1982; Steinbusch
1981). The results of O’Hearn et al. (1988) showed that repeated doses of
MDA or MDMA cause, at 2 weeks survival, profound loss of serotonergic
axons throughout the forebrain, especially severe in neocortex, striatum, and
thalamus (figure 3). Catecholamine innervation was unaffected, since no
differences were seen between control and treated rats using TH immuno-
cytochemistry. Both MDA and MDMA produce a similar pattern of dener-
vation in cortex and other parts of the brain, but there is a smaller
reduction in 5-HT axon density following MDMA than after MDA. There-
fore, both drugs have similar effects, but MDA is more potent at the
PCA CTRL MDA
FIGURE 3. Neurotoxic effects of psychotropic amphetamines upon 5-HT
axon terminals in rat neocortex
NOTE: Serotonin axons are visualized by 5-HT immunocytochemistry in parietal cortex. The central
panel shows the normal pattern of 5-HT innervation in a control animal. In the right panel,
there is a marked decrease in fine axon terminals 2 weeks following repeated systemic
injections of MDA (20 mg/kg). A similar loss of fine axons is seen in the left panle 2 weeks
following a single dose of PCA (10 mg/kg). Scale bar=100 µm. Darkfield photomicrograph.
If examined with high magnification brightfield microscopy, the spread axons in both treated
animals are all of the beaded type. 
same dosage. The loss of 5-HT axons exhibits regional differences in
neurotoxic effects, which are exemplified by partial sparing of 5-HT axons,
particularly evident in hippocampus (figure 4), hypothalamus, basal
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FIGURE 4. Serotonergic innervation of the dentate gyrus in rat
hippocampal formation
NOTE: Serotonin axons visualized by 5-HT immunocytochemistry in darkfield microscopy. A high
denisty of axons is seen in the control animal (central panel). Following multiple systemic
dosesof MDA (bottom panel) or two doses of PCA (top panel), most fine axon terminals 
degenerate, as seen here at 2 weeks survival. However, there is consistent sparing of beaded
axon terminals, especially marked along the inner surface of the dentate granule cell layer. 
Despite the loss of fine axons terminals, the 5-HT innervation in this area, as compared with
neocortex, appears relatively spared following administration of neurotoxic amphetamine
derivatives. Scale bar = 100 µm. 
forebrain, and much of the brain stem, except for superior colliculus, which
is markedly denervated. The forebrain denervation indicates a pronounced,
but consistently selective, loss of 5-HT axons at 2 weeks after drug
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treatment, which persists for many months. as found in later studies
(Molliver et al., in press). The persistent loss of axon terminals reflects
lasting denervation of target structures and parallels the reduction in 5-HT
uptake sites. A study of the timecourse of regeneration and the origin of
regenerating axons is currently in progress.
Axon Terminals Are Selectively Damaged
The fme morphologic detail afforded by the use of transmitter immunocyto-
chemistry has made it feasible to identify the specific cytologic compart-
ments that arc affected by these neurotoxic drugs. At the 2-week survival
times that were analyzed, intact portions of the neurons are stained by 5-HT
immunocytochemistry, while processes that have degenerated cannot be
visualized. A consistent finding was that raphe cell bodies remain normal
in density and ICC staining intensity, and that many smooth, straight,
tangentially oriented 5-HT axons remain in deep layers of cortex, in
subcortical white matter, and in basal forebrain and lateral hypothalamus.
The disappearance of fine, highly arborized axons with sparing of the
straight preterminal axons is evidence for selective vulnerability of
serotonergic axon terminals. Intense 5-HT immunoreactivity seen in dilated
axons of passage (especially in basal forebrain, in deep layers of frontal
cortex, and in MFB) is presumably due to damming up of neurotransmitter
and other axonal constituents in axon stumps secondary to ablation of the
axon terminals. The accumulation of 5-HT and other contents in pretermi-
nal axons and cell bodies indicates that these cellular compartments remain
functionally intact and that transmitter synthesis and anterograde axonal
transport are not evidently impaired. The selective destruction of axon
terminals is consistent with the large decrease in density of 5-HT uptake
sites reported by Battaglia et al. (1987).
Raphe Cell Bodies Are Spared
In Nissl-stained sections, the cell bodies in the raphe nuclei are indistin-
guishable from those in control brains. The morphology of cell bodies and
dendrites appears unremarkable, and the cells exhibit normal shape and size
and show no evidence of increased staining nor any loss of cytoplasmic
Nissl substance that would reflect chromatolysis. Moreover, Nissl-stained
sections throughout other brain regions including cortex indicate no evidence
of altered cellular morphology. Inclusion bodies in DR neurons of the
monkey that are described elsewhere (Ricaurte et al. 1988) were not seen in
raphe neurons in the rat. The lack of retrograde cytologic changes in raphe
cell bodies is somewhat surprising considering the extensive loss of fine
axon terminals. However, the sparing of cell bodies and of preterminal
axons suggests that there may be substantial potential for recovery and
regeneration of 5-HT projections. The failure to detect cytologic alterations
in raphe cell bodies may reflect technical limitations in the experimental
preparations. First, subtle cytologic changes in DR cell bodies would not
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be easily detected because these cells normally have fine, dispersed Nissl
substance and eccentric nuclei. Moreover, the use of frozen sections fixed
for immunocytochemistry does not reveal cytologic features at the highest
resolution, and subtle changes might not be visualized. Therefore, more
sensitive cytochemical methods are needed to determine whether there may
be subtle retrograde changes in the raphe neurons.
AXON DEGENERATION
One of the goals of this study was to obtain evidence that would establish
whether or not serotonergic axons are damaged or degenerate following
exposure to psychotropic drugs such as MDA or MDMA. At short survival
times (24 hours after drug administration), while there is a marked decrease
in the number of stained axons, cytopathologic changes are seen in some of
the remaining immunoreactive processes. The most frequent abnormalities
are markedly dilated axons with irregular diameter, giant varicosities, and
fragmentation of axon segments. Giant, swollen varicosities were found in
all cortical areas of treated rats but were never observed in controls. Their
diameter was at least 4 times that of the largest axonal varicosities found in
the normal brain. Moreover, the giant varicosities differ in their regional
distribution from the normal, beaded class of 5-HT axons and appear to be
newly formed structural abnormalities. Greatly swollen axonal stumps are
especially prominent in the basal forebrain and ventral to the genu of the
corpus callosum. At longer survival times, swollen axons are not found,
and the persistent loss of fibers reflects lasting denervation. Several
examples (figure 5) of swollen, fragmented axons are shown in figure 6 of
the report by O’Hearn et al. 1988.
Specific evidence for axon degeneration, especially for MA terminals, is
difficult to establish defmitively. The criteria for degeneration applied in
this chapter are based on previously documented changes in degenerating
MA axons observed by histofluorescence (Baumgarten et al. 1972;
Baumgarten et al. 1973; Bjorklund et al. 1973; Bjorkhmd and Lindvall
1979; Wiklund and Bjorklund 1980; Jonsson and Nwanze 1982). In this
study, the direct visualization of greatly swollen and fragmented nerve fibers
demonstrates that 5-HT axons are structurally damaged by exposure to
MDA and MDMA. These changes are presented as positive evidence for
acute degeneration of axon terminals. This conclusion is further supported
by the damming up of transmitter in swollen preterminal fibers that appear
after the destruction of axon terminals. The subsequent disappearance of
these damaged fibers and persistent loss of fine axon terminals reflects
lasting degeneration. A limitation of transmitter immunocytochemistry for
studying neurotoxicity is that visualization of axons depends upon retention
of the neurotransmitter. Since axons that are depleted of 5-HT cannot be
detected by this method, the present results, while providing positive
evidence for degeneration, are likely to underestimate the number of axons
that are degenerating at any one time. While not currently available, the
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FIGURE 5. Acute degeneration of 5-HT axons at 1-day survival following
four doses of MDA
NOTE: These axons exhibit cytopathologic changes, such as large, swollen varicosities, irregular
thickening, and fragmentation of fibers. Dilatations of this type are severalfold larger than
the largest 5-HT axon seen in control sections. These changes show evidence of structural
degeneration in 5-HT axons following treatment with MDA. Scale bar = 10 µm. 
SOURCE: O'Hearn et al. 1988, Copyright 1988, Oxford University Press.
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FIGURE 6. Histogram shows the nunber of retrogradely labeled neurons
in the DR and MR nuclei in PCA-treated animals and in
controls
NOTE: Retrogradely labeled cells were counted after a fluorescent dye was injected in
frontoparietal cortex. This figue shows that in rats severely denervated by PCA (right
bars) there is a 92-percent decrease in the number of labeled cells in the DR nucleus, with
no change in the member of cells labeled in the MR nucleus or B9. DR cells:
cross-hatched bars; MR/B9 cells: black bars; control animal on left; moderately denervated
rat in center, severely denervated rat on right. Treated animals received two doses of PCA
(6 mg/kg).
SOURCE: Mamounas and Molliver 1988, Copyright 1988, Academic Press.
use in future studies of a marker that is not released by the neurotoxic
drugs is likely to provide evidence of more extensive terminal degeneration.
The occurrence of drug-induced structural damage and degeneration of 5-HT
axons is further supported by the complete profile of effects produced by
psychotropic drugs such as MDA, PCA, and fenfluramine. Structural
evidence for axon damage is provided by the presence of enlarged
varicosities and swollen fragmented axons in identified 5-HT-containing
fibers at 1 to 2 days after MDA treatment. The formation of enormous,
swollen axons is even more marked after treatment with a structurally
related amphetamine derivative, fenfluramine (5.0 mg/kg) (Molliver and
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Molliver 1988; Molliver and Molliver, in press). Additional structural
evidence for axonal degeneration is summarized above and includes
Fink-Heimer-positive axons (Ricaurte et al. 1985), persistent loss of fine
axon terminals lasting many months, enlarged axon stumps with intense
immunoreactivity for 5-HT, and the loss of retrograde axonal transport to
DR cell bodies (described below). This structural evidence is accompanied
by the loss of most biochemical markers for 5-HT axon terminals (as noted
previously), including decreases in 5-HT levels, 5-HIAA, tryptophan
hydroxylase activity, and 5-HT uptake sites. Despite this constellation of
findings indicative of 5-HT axon degeneration, one may still speculate that
(however unlikely) axon terminals may remain present yet lack any
detectable properties.
DIFFERENTIAL VULNERABILITY OF 5-HT AXON TYPES
The two morphologic classes of 5-HT axons described earlier (Kosofsky and
Molliver 1987) are differentially vulnerable to the neurotoxic effects of
MDA, MDMA, and certain other neurotoxic amphetamine derivatives. The
denervation caused by MDA and MDMA is subtotal, and some 5-HT axon
terminals are consistently spared in most regions of cortex; them. is a
characteristic regional pattern of axon sparing, as noted above. The analysis
of ICC sections from MDA-treated rats using high-resolution brightfield
microscopy reveals that there is a selective loss of fine axon terminals,
which are almost completely ablated, nearly all of the spared 5-HT axon
terminals in cortex and elsewhere are of the beaded type with large
varicosities (O’Hearn et al. 1988; Mullen et al. 1987). Further analysis of
additional treated and control material shows that the spared, beaded axons
are identical in morphology and distribution to beaded axons that are found
in control animals (Mamounas et al. 1988). The differential vulnerability of
two axon types has been consistently confirmed in a series of additional
studies. The effects of MDA and MDMA were compared with those of
two other substituted amphetamines that were previously shown to cause
similar decreases in biochemical markers for 5-HT, namely PCA and
fenfluramine (Mamounas et al. 1988; Molliver and Molliver 1988; MolIiver
and Molliver, in press). Both of these compounds produced a loss of 5-HT
axon terminals that was indistinguishable from that produced by MDA or
MDMA. In a comparative study of drug effects, PCA administered as two
subcutaneous doses of 10 mg/kg produced a profound loss of 5-HT axon
terminals throughout the rat forebrain, with a regional distribution identical
to that described for MDA (Mullen et al. 1987; Mamounas et al. 1988;
Mamounas et al., in preparation; Mamounas and Molliver 1988). As with
MDA, treatment with PCA (or with fenfluramine) caused a preferential loss
of fine 5-HT axon terminals, while terminals with large, spherical
varicosities were unaffected by these drugs. The spared, beaded axons are
identical in morphology to those found in control animals, and they have
the same regional and laminar distribution. The beaded axons that are
spared are consistently found in layers II to III of parietal and occipital
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cortex, in the hippocampus where they are located in the subgranular zone
of the dentate gyrus and in the stratum lacunosum of CA1, in layer III of
lateral entorhinal cortex, in the olfactory glomeruli and in other regions
including amygdala, lateral hypothalamus, and most of brain stem (Mullen
et al. 1987; Mamounas et al. 1988; Mamounas et al., in preparation).
Beaded, relatively coarse 5-HT axons that line the ependymal surface of the
lateral ventricle, third ventricle, and aqueduct form a unique group of 5-HT
axon terminals that are also consistently spared by all of the neurotoxic
amphetamines that have been tested. A similar regional distribution of axon
loss was obtained after giving the anorexic drug fenfluramine. Repeated
doses of (±)fenfluramine at 12-hour intervals (n=4 to 8 doses) administered
subcutaneously in doses of 5, 10, or 20 mg/kg produced a persistent loss of
5-HT axons at 2-week survival times with the identical anatomic distribution
and morphologic features of spared axons seen with MDA and PCA
(Molliver and Molliver 1988; Molliver and Molliver, in press). Using three
doses at the 5-mg/kg level and shorter survival times (36 hours), 5-HT
immunocytochemistry revealed a large number of enormously swollen, frag-
mented 5-HT axons with giant varicosities that are typically over 10 times
the size of normal beaded axons. Thus, fenfluramine produces the same
pattern of axon degeneration as that seen with MDA and PCA (Molliver
and Molliver, in press). Selective neurotoxic effects of d-fenfIuramine,
similar to those found in the rat, have also been observed in cerebral cortex
of the primate (Ricaurte et al., in press). These results indicate that MDA,
MDMA, PCA, and fenfluramine, when administered in moderately large
doses, have nearly identical neurotoxic effects upon 5-HT axons. Moreover,
these studies distinguish two classes of 5-HT axons that differ in their
morphology, regional distribution, and differential vulnerability to
psychotropic drugs. In all cases, the fine axon terminals show consistent
vulnerability to the effects of these compounds, while the beaded axons
appear to be unaffected even at relatively large doses (e.g., 40 mg/kg of
PCA) (Mamounas et al. 1988; Mamounas et al., in preparation).
While the results of the ICC studies summarized above indicate that two
classes of 5-HT axons are differentially affected by particular neurotoxic
amphetamines, analogous examples of selective vulnerability to degeneration
also occur among dopamine (DA) and norepinephrine (NE) neurons in
response to different drugs. Thus, differential vulnerability of specific
subtypes of MA axons appears to be a common feature of these neuronal
systems. For example, the DA neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP), selectively damages nigro-striatal DA projections,
while sparing most DA axons that arise from the ventral tegmental area
(Langston et al. 1984; German et al. 1988). Moreover, in human cases of
Parkinson’s Disease, a selective loss of DA has been reported in the
putamen, sparing DA projections to the caudate nucleus (Kish et al. 1988).
In addition, recent studies of the neurotoxin, DSP-4, indicate that NE axons
arising from the locus coeruleus are more susceptible to this compound than
are those that arise from other NE cell groups (Lyons et al. 1989; Fritschy
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and Grzanna 1989). The above results suggest that a general principle
applying to alI types of monoaminergic neurons may be proposed for
experimental verification: at least two classes of neurons utilize each MA
transmitter, and these neuron subtypes are differentially vulnerable to
neurotoxic or cytopathologic agents. The mechanisms that determine the
differential vulnerability of particular MA cell types are currently unknown,
but are of considerable importance for further understanding of the causes
of neurotoxicity.
DIFFERENTIAL ORIGIN OF 5-HT AXONS
The differential vulnerability of fine and beaded 5-HT axons, combined with
evidence from anterograde transport that fine and beaded fibers arise from
the DR and MR nuclei. respectively, led to the proposal that axons from the
DR nucleus are selectively vulnerable to the neurotoxic effects of psycho-
tropic amphetamines, while the MR projection is resistant. The prior
anterograde transport study (Kosofsky 1985; Kosofsky and Molliver 1987)
sampled a relatively small number of neurons in the central portions of the
DR and MR nuclei and suggested a predominantly differential origin of the
two axon types. In order to determine directly whether the DR and MR
projections are differentially sensitive to psychotropic amphetamines,
L. Mamounas conducted a retrograde axonal transport study using
fluorescent dyes in animals treated with PCA and in controls. PCA is a
useful model experimental drug for the neurotoxic amphetamines, since,
when administered in a single dose. it produces the same pattern of
degeneration as MDA. Fluorescent dye was injected in the cortex and
retrogradely labeled cell bodies were mapped; only those axons that survive
PCA administration are able to take up the label and retrogradely transport
it to cell bodies of origin. Thus, by comparing the number and locations of
cortically projecting raphe neurons in control and treated animals,
identification of the nuclei of origin of drug-sensitive vs. resistant axon
terminals has been possible. The number of labeled neurons (figure 6) in
the DR nucleus of PCA-treated animals was decreased by 77 to 90 percent;
in contrast, the number of labeled neurons in the MR was unchanged
(Mamounas and Molliver 1987; Mamounas and Molliver 1988). These
results demonstrate that DR and MR projections are differentially vulnerable
to PCA, and they confii that fine axon terminals, which are highly sensi-
tive to the neurotoxic effects, arise from neurons in the DR. Moreover, the
loss of the capability for axonal transport is additional evidence in support
of axonal damage and degeneration. These results lead to the proposal that
there are dual 5-HT projections to cortex that are anatomically and func-
tionally distinct. These projections have different nuclei of origin, axon
morphology, regional distributions, and pharmacologic properties. These
findings lead to the further proposal that psychotropic amphetamines act
preferentially upon serotonergic projections from the DR nucleus and that
DR neurons may therefore be involved in the control of affective state and
perceptual integration. While the selective vulnerability of DR axons is
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likely to be of general validity, at the present time the direct demonstration
by retrograde transport showing a loss of DR projections is based solely on
studies of frontoparietal cortex after using the drug PCA. The consistent
morphology of spared axons suggests that beaded axons in other regions of
the forebrain, which are resistant to these drugs, also arise from the MR
nucleus. However, further studies combining retrograde axonal transport
from a variety of forebrain areas and treatment with MDA and/or MDMA
would be desirable to establish the generality of these findings.
EFFECTS OF MDMA IN PRIMATES
Evidence that MA neurons in the primate brain are susceptible to the toxic
effects of amphetamines was first reported following chronic methamphet-
amine treatment in rhesus monkeys (Seiden et al. 1975) before the toxicity
was characterized in rodents. Most studies of amphetamine neurotoxicity
have been conducted in rats; however, data from rodents do not always
predict the mechanism of drug action or degree of toxicity in primates. In
order to predict the potential neurotoxic effects of MDMA in humans, it is
essential to analyze the drug effects in monkeys, since there is evidence that
the metabolism of amphetamines in primates differs substantially from that
in other species (Caldwell 1976). In order to determine the sensitivity of
5-HT neurons to MDMA, Ricaurte and colleagues administered various
doses of this drug (2.5 to 5.0 mg/kg) to a series of squirrel monkeys using
subcutaneous injections, repeated twice daily for 4 days. Determination of
5-HT levels by HPLC revealed that multiple doses of MDMA produced
large depletions of 5-HT in many parts of the forebrain including neocortex,
caudate nucleus, hippocampus, and hypothalamus (Ricaurte, this volume).
At 2 weeks after the last dose, the neocortex was markedly depleted of
5-HT, with the lowest dose (2.5 mg/kg) producing a 44-percent depletion
and the highest dose (5.0 mg/kg) producing a 90-percent depletion of 5-HT
(Ricaurte et al, 1987; Ricaurte et al. 1988). Immunohistochemical
preparations from treated monkeys revealed a marked reduction in the
number of serotonergic axon terminals throughout cerebral cortex at 2
weeks survival, with the persistence of some structurally damaged
intracortical axons that were abnormally swollen (Ricaurte et al. 1988). In
addition, examination of cell bodies showed the presence of abnormal
cytoplasmic inclusion bodies in the DR nucleus. These inclusions were
periodic acid-Schiff (PAS)-positive and appeared to contain lipofuscin.
Based on the evidence that MDMA is highly toxic to serotonergic neurons
in primates, a detailed neuroanatomic analysis was conducted by
M.A. Wilson to characterize the morphology and regional distribution of
5-HT axons that are affected by MDMA in the macaque monkey. Two
weeks after treatment with MDMA (eight doses, 5 mg/kg, subcutaneous) the
density of 5-HT immunoreactive axon terminals was strikingly reduced
throughout the cerebral cortex (Wilson et al. 1987; Wilson et al. 1989). A
characteristic regional distribution of serotonergic denervation was found in
different cortical areas. For example, in somatosensory cortex, which is
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densely innervated by 5-HT axons in control animals, few 5-HT axon
terminals remain after MDMA treatment, except for beaded axons in layer
I. In other regions, there was a significant denervation, yet a subgroup of
5-HT axons consistently survives, e.g., in visual cortex, hippocampus,
dentate gyrus, and amygdala
As in the rat, the morphology of 5-HT axons in the normal primate is
heterogeneous, with both fine and beaded axon terminals intermixed. The
fine axon terminals are profoundly vulnerable to MDMA, as found in the
rat, while nearly all of the surviving axons are of the beaded type with
large spherical varicosities. The loss of 5-HT axons in monkeys is greater
than that in rats that were given a fourfold higher dose of MDMA and,
therefore, MDMA is far more neurotoxic in the primate than in the rat
(Ricaurte et al. 1988; Wilson et al. 1989). While cell bodies and
preterminal axons are stained, the morphologic changes in some 5-HT axons
and the persistent loss of fine axon terminals provide evidence that MDMA
produces axon terminal damage and degeneration in the primate cortex.
Furthermore, the selective vulnerability of fine axon terminals and the
sparing of beaded axons indicates that multiple classes of 5-HT axons can
be distinguished in primates, as in rodents. Thus, the morphologic
differences between 5-HT axons, their differential vulnerability to psycho-
tropic drugs, and characteristic regional distributions suggests that--in
primates--there may be two parallel, ascending serotonergic projections
subserving different functions. The susceptibility of fine axons to MDMA
supports the hypothesis that these axons are one of the sites of action of
this drug and am involved in the control of affective state.
The effects of MDMA in the primate indicate that the anatomic organization
and pharmacologic properties of ascending 5-HT projections in the primate
are similar to those in the rodent These studies employing relatively large,
repeated, subcutaneous doses of MDMA were not designed to analyze the
toxicity of this drug in humans, but to obtain results indicating the potential
toxicity, site of action, and biological effects of this drug on 5-HT neurons.
It should be noted that the drug administration schedule may not be com-
parable to typical human use, that humans generally take MDMA via the
oral route, and that the sensitivity of human and subhuman primates to the
effects of MDMA may not be the same. However, in view of the
extensive destruction of 5-HT axon terminals at doses that are approxi-
mately twice that commonly used for recreational purposes by humans,
MDMA may have a relatively small margin of safety, and it would be
prudent to consider this drug potentially hazardous for human use.
Therefore, if human administration of MDMA-like compounds is considered
clinically efficacious, further studies are needed to determine whether there
may be a safe dose range or if there may be related compounds with less
potential toxicity and similar beneficial effects. The studies reported here,
and in other papers in this volume, describe several methodological
approaches and well-characterized parameters to study the effects and
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neurotoxicity of new psychoactive compounds. The effects of such drugs
on pharmacologic and structural properties of 5-HT neurons in rodents are
highly predictive of the action of these drugs in primates. However, it is
clear from the above results that drug potency varies considerably among
species and must be evaluated separately in primates. The results indicate
that MDMA, combined with biochemical and immunohistochemical studies,
provides a useful experimental tool to study the activity of such drugs and
their neurotoxicity.
It would also be important to determine whether 5-HT axons are altered in
clinical dementias, since a preliminary study shows that swollen 5-HT axons
are associated with amyloid-containing plaques in aged monkeys (Kitt
et al. 1989). Since the swollen 5-HT axon terminals in Alzheimer-like
plaques are similar to degenerating axons seen after MDMA treatment, it is
possible that endogeneous or environmental toxins derived from phenethyla-
mines may play a role in the etiology of dementias. Since illicit recrea-
tional use of MDMA and related drugs may produce similar structural
damage to 5-HT axons, it is plausible that the long-term effects of such
damage might predispose susceptible individuals to degenerative disorders of
the Alzheimer’s type. Although this possibility is highly speculative,
long-term prospective followup of MDMA users for subtle psychological
changes in memory and cognitive processes are certainly warranted.
MECHANISM OF MDMA ACTION AND TOXICITY
The mechanisms by which MDMA and related drugs produce their pharma-
cologic actions and neurotoxic effects are not well understood, making it
difficult to predict what structural or metabolic differences may account for
the differential vulnerability of specific 5-HT axon types. However, new
information from several laboratories has provided insight into the
mechanisms of these drugs and indicates the importance of multidisciplinary
approaches in this area of investigation. The commonality of both
morphologic and biochemical effects of the methylenedioxy-substituted
amphetamines with fenfluramine and PCA suggests that all these compounds
may act via the same mechanism. Both in vivo and in vitro preparations
have shown that this class of compounds acts by acutely releasing serotonin
from 5-HT axon terminals in forebrain (Fuller et al. 1975a; Nichols
et al. 1982; Johnson et al. 1986; Sanders-Bush and Martin 1982; Schmidt
1987a; Trulson and Jacobs 1976). Several studies have shown that the
acute release of 5-HT is distinct from the long- term neurotoxic effects
produced by PCA or MDMA and that separate mechanisms may be
involved (Fuller et al. 1975b; Sanders-Bush et al. 1975; Schmidt 1987a);
both effects depend on a carrier-mediated mechanism. In particular, the
long-term degenerative effects can be prevented by administration of
fluoxetine or citalopram, which block the 5-HT uptake carrier (Fuller
et al. 1975b; Schmidt 1987a). The role of a carrier-mediated mechanism is
further supported by high affinity of MDMA for the 5-HT uptake site
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(Steele et al. 1987; Battaglia et al. 1988). In summary, previous
pharmacologic studies indicate that MDMA and related psychotropic
amphetamines have a multiphasic effect marked by an acute release of
5-HT, which may be reversible, followed by a chronic decrease in 5-HT
markers probably due to axon degeneration.
Morphologic studies from this laboratory provide strong support for the
multiphasic mechanism described above, and also indicate that fine axon
terminals are selectively affected. In a series of acute in vivo experiments,
a single intraperitoneal injection of PCA (10 mg/kg) or MDA (20 mg/kg)
produced a dramatic reduction in the number of 5-HT immunoreactive
axons in cortex and hippocampus of rats at survivals of 30 minutes to 4
hours following treatment (Berger et al. 1987). When administered by
itself, the 5-HT uptake inhibitor fluoxetine had no effect on the staining or
density of 5-HT axons after acute or repeated doses (Berger et al. 1987;
Berger et al., in preparation); however, fluoxetine (10 mg/kg) coadministered
with either MDA or PCA completely prevented the acute and chronic
decrease in 5-HT immunoreactive axons. The results of these and further
studies demonstrate that both MDA and PCA cause acute depeletion of 5-HT
from fine axon terminals; however, the beaded axons stain intensely and
appear unaffected (Berger et al. 1987; Mamounas et al. 1988). It is of
interest that single or repeated doses of two other ring-substituted
psychotropic amphetamines, DOM and 2,5-dimethoxy-4-ethylamphetamine
(DOET), did not produce a reduction in 5-HT levels or the staining of
5-HT axons (Berger et al. 1987), consistent with the evidence that the latter
drugs act at 5-HT2 receptors (Glennon 1985). The contrasting effects of
these several drugs led to the proposal that there are at least two classes of
psychotropic amphetamines with different sites of action: one type
exemplified by DOM or DOET acts postsynaptically at 5-HT2 receptors,
while the other type, such as PCA and MDA, acts presynaptically by a
carrier-mediated mechanism to release 5-HT from axon terminals (Berger
et al. 1987). Since PCA and MDA (but not DOM or DOET) cause degen-
eration of 5-HT axons, the ability of amphetamine derivatives to cause
massive release of 5-HT appears related to the neurotoxicity of these
compounds. The fact that fluoxetine prevents the neurotoxicity supports the
idea that the neurotoxic amphetamines act at a presynaptic site located on
5-HT axon terminals and bind to the 5-HT uptake carrier. The selective
releasing effect of psychotropic drugs such as MDA and PCA upon fine
axon terminals is relevant to the finding noted above that these terminals
appear selectively associated with 5-HT2 receptors (Blue et al. 1988b). The
release of 5-HT from this set of terminals may selectively activate 5-HT2
receptors at postsynaptic sites that are linked to activation of
phosphoinositide hydrolysis (Conn and Sanders-Bush 1987).
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IS A NEUROTOXIC METABOLITE FORMED?
Based on observed differences between the in vivo and in vitro effects of
amphetamine derivatives, several laboratories have suggested that the
neurotoxic effects may depend upon the formation of an active drug
metabolite (Sanders-Bush et al. 1972; Hotchkiss and Gibb 1980; Stone
et al. 1987b); others have suggested that a metabolite might be formed from
DA or 5-HT that is released in large quantities (Johnson et al. 1988;
Commins et al. 1987a; Stone et al. 1988). To pursue this issue, this
laboratory has employed several strategies in an effort to determine whether
the parent amphetamine derivative is itself neurotoxic.
INTRACEREBRAL DRUG ADMINISTRATION
In view of the marked neurotoxicity of systemically administered MDA,
E. O’Hearn administered MDA and/or MDMA directly into cerebral cortex
by stereotaxic microinjection (6 µg in 0.5 µl). At both long and short
survival times (3 days to 3 weeks) the 5-HT innervation density at the
injection site could not be distinguished from that in normal animals or
after saline injections (Molliver 1987; Molliver et al. 1986; O’Hearn et al.,
in preparation). These results suggested that large doses of MDA or
MDMA administered directly into the brain are not neurotoxic and that the
formation of a peripheral drug metabolite may be an essential step in
inducing neurotoxicity. However, several caveats to this interpretation are
raised, particularly that neurotoxic effects may require prolonged exposure to
the drug and these lipophilic compounds are likely to diffuse rapidly from
the injection site. To address the duration of exposure issue, U. Berger has
done a series of experiments in which PCA was continuously infused
directly into the cerebral cortex using an Alzet minipump at a rate of 10 µg
per hour for 48 hours. Following a 2-week survival period, ICC
preparations from the injection site revealed a small zone of local tissue
damage due to the implanted cannula, similar in both drug-injected and
saline control animals. However, despite continuous infusion of PCA (or
MDMA) over 2 days, the serotonergic innervation in the surrounding tissue
appeared normal, with no detectable loss of 5-HT immunoreactive staining.
In contrast, a similar injection of the neurotoxin 5,7-dihydroxytryptamine
(5,7-DHT) produced a zone of total 5-HT denervation at least 2 to 3 mm in
diameter. These chronic intracerebral microinjection experiments lend
further support to the view that the parent compound is not itself neurotoxic
(Berger 1989; Berger et al., in preparation; Molliver et al. 1986).
DRUG EFFECTS IN THE HIPPOCAMPAL SLICE PREPARATION
In order to circumvent the difficulties of maintaining known, constant drug
concentrations in the brain in vivo, the hippocampal slice preparation was
adapted to study the acute anatomic effects of psychotropic drugs. This
method was implemented in conjunction with Drs. K. Stratton and
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J. Baraban, who have experience in maintaining hippocampal slices under
in vitro conditions for electrophysiologic recording. Several experimental
paradigms have been tested with this method, showing that the hippocampal
slice preparation combined with immunocytochemistry is a useful tool for
studying in vivo and in vitro effects of psychotropic drugs. Freshly
prepared hippocampal slices are incubated in oxygenated buffer, with or
without drugs added, and are then immersion fixed and sectioned for ICC
staining. The quality and sensitivity of axonal visualization in slices is
equivalent to that in sections prepared from perfusion-fixed rats. In slices
from control rats, a high density of morphologically intact 5-HT axons is
seen in the hippocampus, with the same distribution as in conventional
sections. In order to verify the 5-HT-depleting effects of in vivo treatment,
hippocampal slices were prepared from rats that were given a single dose of
PCA (10 mg/kg) subcutaneously, and the animals were sacrificed 3 hours
later. A marked decrease of 5-HT immunoreactive axons was observed in
slices that were fixed immediately after sacrifice of PCA-treated rats. Slices
that were maintained in vitro in physiological saline showed progressive
recovery of 5-HT axon staining over 0.5 to 2 hours. However, if the
survival time of the animal after PCA treatment was extended for over 24
hours, then no recovery was seen, and the loss of 5-HT axons was
irreversible. These results provide direct immunochemical and anatomic
support for previous pharmacologic studies that showed a biphasic effect of
PCA and related amphetamine derivatives, characterized by an early phase
of 5-HT depletion that is potentially reversible during the first 24 hours
(Fuller et al. 1975a; Sanders-Bush et al. 1975; Schmidt 1987a). During this
acute phase, the fine axons are depleted of 5-HT but have not degenerated;
the terminals retain the ability to synthesize and store 5-HT if the toxic
compound dissociates, as observed in the slice incubation bath (Molliver
et al. 1988). With longer in vivo survival times (4 to 6 days after PCA)
the lack of subsequent recovery in vitro provides evidence for irreversible
axon degeneration. The timecourse of this biphasic effect closely matches
that reported by Fuller et al. (1975b) based on the use of 5-HT uptake
blockers to displace PCA in vivo.
In order to test the cytotoxic potential of PCA alone, hippocampal slices
from untreated control animals were incubated in buffer containing PCA,
over a wide range of concentrations (typically 50 µM) for 2 to 3 hours.
The incubation of slices directly in the parent compound (PCA) did not
induce 5-HT depletion, and the 5-HT innervation in these slices was indis-
tinguishable from that in control animals. Moreover, incubation of slices
from PCA-treated animals in PCA-containing buffer did not prevent the
recovery of 5-HT immunoreactive axons. The absence of 5-HT depletion
after immersion of hippocampal slices in PCA strongly supports the proposi-
tion that PCA and related drugs are not directly neurotoxic. Thus, in vivo
systemic administration of the drug appears necessary for the formation of a
neurotoxic compound, such as a metabolite of the drug or of 5-HT, which
is released.
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THE PROTECTIVE EFFECT OF 5-HT DEPLETION
To determine whether the release of endogeneous 5-HT mediates the neuro-
toxic effects of PCA in the brain, several pharmacologic regimens were
employed to deplete animals of 5-HT prior to treatment with PCA. In a
series of studies conducted by U. Berger, rats were depleted of 5-HT by
prior treatment with reserpine (2.5 mg/kg), the 5-HT synthesis inhibitor
parachlorophenylalanine (PCPA) (250 mg/kg), or a combination of both
drugs. These drugs initially produce depletion of 5-HT in brain and other
tissues (over several days) followed by recovery to normal levels over
2 weeks; after that time, normal 5-HT ICC axon staining is obtained, and
no evidence of axonal swelling or degeneration was observed. Animals
depleted of 5-HT by different regimens were subsequently treated with PCA
(10 mg/kg) and tested after 2 weeks for 5-HT neurotoxicity using both
HPLC and immunocytochemistry. This study revealed a marked protective
effect on 5-HT neurons after combined treatment with PCPA plus reserpine.
After the extensive 5-HT depletion produced by combined treatment with
both drugs, PCA produced only a small reduction in brain 5-HT levels, and
nearly all 5-HT axons in forebrain were spared. Reserpine pretreatment
alone, although producing substantially reduced brain MA levels, did not
afford significant protection against the effects of PCA. This result
indicates that depletion of 5-HT (and other biogenic amines) from vesicular
storage sites in the brain does not provide significant protection against the
neurotoxic effects of PCA, whereas more extensive depletion from brain,
platelets, and intestine by inhibition of 5-HT synthesis does prevent the
toxicity of PCA (Berger, in preparation). Since a primary pharmacological
effect of PCA is the release of 5-HT from nerve terminals and platelets,
these results suggest that the neurotoxicity of PCA is dependent upon the
presence of a releasable pool of 5-HT and is not mediated directly by the
drug or one of its metabolites. The site of the PCA-induced 5-HT release
essential for neurotoxicity is not known, although depletion of vesicular
5-HT is not itself sufficient for protection. The data suggest that an
extensive depletion of 5-HT pools is required to block the PCA-induced
toxicity. These results lead to the suggestion that the 5-HT stores in
platelets (or mast cells), the main 5-HT storage sites in the periphery, may
play a central role in the neurotoxic mechanism (Berger et al. 1989).
Therefore, it is postulated that a neurotoxic metabolite is formed from 5-HT
released by the action of PCA on platelets or on other 5-HT storage sites.
PCA is also a strong inhibitor of MA oxidase (Fuller 1966) and may
therefore facilitate the formation of an unusual neurotoxic indolamine
metabolite from peripherally released 5-HT. This metabolite, not yet
identified, may enter the brain and cause selective destruction of 5-HT
axons. This proposal is consistent with the findings from Seiden’s
laboratory that the neurotoxin 5,6-dihydroxytryptamine can be detected in
the brain following PCA administration (Commins 1987a). Moreover, since
reserpine depletes other biogenic amines, a role for catecholamines in the
toxicity of amphetamine derivatives should be considered, as proposed
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earlier (Johnson et al. 1988; Stone et al. 1988). While further investigation
is needed to determine the origin and identity of the neurotoxic compound,
the present studies indicate that exposure to the parent compound itself, e.g.,
PCA or MDA, is not sufficient to produce a lasting neurotoxic effect, nor
does it produce acute 5-HT depletion.
CONCLUSION
The present studies demonstrate the value of combining morphologic with
biochemical methods to study the neurotoxicity of psychotropic drugs upon
central 5-HT neurons and to identify the specific neurons and neuronal
compartments that are affected. There are two distinct serotonergic projec-
tions to forebrain that arise from the DR and MR nuclei, respectively, and
have different patterns of termination in cortex, morphologically distinct
axon terminals, and dissimilar pharmacologic properties. Substituted am-
phetamine derivatives PCA, MDA, MDMA, and fenfluramine have similar
profiles of neurotoxicity in the brain and all act selectively upon the fine
axon terminals that arise from the DR nucleus. Direct anatomic evidence
for structural damage to 5-HT axon terminals has been obtained after treat-
ment with MDA and with fenfluramine. These cytopathologic changes in
axons combined with the pharmacological profile of effects, which include
persistent decreases in 5-HT levels, turnover, synthesis, and uptake sites,
provide convincing evidence that these psychotropic amphetamines can
produce axon terminal degeneration. The exact mechanism of neurotoxicity
has not yet been elucidated, nor has the specific neurotoxin been identified.
Present evidence indicates that neither the parent compound alone nor a
drug metabolite produces 5-HT depletion or degeneration. Preliminary
evidence that depletion of central and peripheral 5-HT affords protection
against the effects of RCA leads to the hypothesis that a metabolite of 5-HT
released in the periphery, possibly from platelets, is essential for the
expression of amphetamine-induced neurotoxicity. The selective toxic effect
of these compounds upon one class of 5-HT axon terminals with sparing of
other 5-HT axons and of raphe cell bodies provides a setting in which
regenerative sprouting is likely to occur, a subject of ongoing investigation.
The augmented neurotoxicity of MDMA in primates raises concern about
the possible neurotoxic effects of this drug in humans. Further studies are
needed to determine whether there may be a safe range of doses for human
use of compounds in this class and whether clinically efficacious drugs
similar to MDMA but without toxic effects can be designed. Current data
also suggest that it may prove useful to explore experimentally the use of
5-HT uptake blockers such as citalopram, paroxetine, or fluoxetine to
protect against the cytotoxic effects of drug overdose. The use of selective
neurotoxic drugs in experimental studies should continue to enhance our
understanding of the complex functional organization of 5-HT projections in
the brain and the multiplicity of effects that have been ascribed to this
neurotransmitter.
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Studies of MDMA-Induced
Neurotoxicity in Nonhuman
Primates: A Basis for Evaluating
Long-Term Effects in Humans
George A. Ricaurte
INTRODUCTION
Studies of (±)3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity
in nonhuman primates are potentially of great importance to both basic
science and public health. Scientifically, such studies could shed light on
the functional role of serotonin in the primate central nervous system
(CNS). In this regard, it is pertinent to recall that it was not until the
effects of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) were explored in the monkey that its profound dopaminergic neuro-
toxic effects were noted (Chiueh et al. 1983) and then utilized to develop
the first complete animal model of Parkinson’s disease (Burns et al. 1983).
Given this precedent, it seems not unreasonable to speculate that studies of
MDMA in the primate could similarly enhance our understanding of seroto
nergic function in higher animals. From a public health perspective,
MDMA studies in monkeys are of value because they will help to define
the risk that MDMA poses to humans. Additionally, these studies could
help identify functional consequences of MDMA neurotoxicity in primates,
and thus guide the clinical assessment of MDMA-exposed individuals.
This chapter will review some recently completed studies on the long-term
effects of MDMA in nonhuman primates. The goals of these studies were
to (1) determine if the neurotoxic effects of MDMA, which have been well
documented in the rodent (see below), generalize to the primate; (2)
compare the relative sensitivity of primates and rodents to the neurotoxic
effects of MDMA; (3) ascertain if the toxic effects of MDMA in the
monkey are restricted to nerve fibers (as they are in the rat). or if they
involve cell bodies as well; (4) evaluate how closely toxic doses of MDMA
in the monkey approximate those used by humans; and (5) examine whether
5-hydroxyindoleacetic acid (5-HIAA) in the cerebrospinal fluid (CSF) can
be used to detect MDMA-induced serotonergic damage in the CNS of pri-
mates. Before presenting the results of these studies, previous results in the
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rodent will be briefly summarized, so as to put findings in the primate in
proper perspective.
PRIOR FINDINGS IN RODENTS
Bats given MDMA show prolonged reductions in the concentration of brain
serotonin (Schmidt 1987; Commins et al. 1987; Stone et al. 1986; Battaglia
et al. 1987; Mokler et al. 1987; Ricaurte et al. 1987), the number of
serotonin uptake sites (Schmidt 1987; Battaglia et al. 1987; Commins
et al. 1987), the level of 5-HIAA (Mokler et al. 1987; Stone et al. 1986),
and the activity of tryptophan hydroxylase (TPH) (Stone et al. 1986).
Correlative anatomical studies indicate that these neurochemical changes are
due to damage of serotonergic axons (O’Hearn et al. 1988). Cell bodies in
the brainstem of the rodent do not appear to be damaged by MDMA.
Serotonin-containing perikarya in the raphe nuclei of rats have a normal
cytological appearance and show no obvious reduction in number (Molliver
1987; O’Hearn et al. 1988). In guinea pigs, MDMA produces long-term
neurochemical effects similar to those in rats (Commins et al. 1987). This
is noteworthy because guinea pigs (like humans) metabolize amphetamine
primarily by side-chain deamination, whereas rats do so mainly by ring
hydroxylation (Caldwell et al. 1976). In contrast to guinea pigs and rats,
mice do not develop long-term depletions of serotonin after MDMA, even
after high doses (Stone et al. 1987). This provocative finding raises the
important question of whether other animals might not also be resistant to
MDMA’s neurotoxic effects. In this regard, monkeys are of special interest
because of their close phylogenetic relationship to humans and because they
metabolize amphetamine in a manner similar to humans (Caldwell
et al. 1976). For these reasons. as well as for those previously mentioned,
studies were undertaken to evaluate the neurotoxic potential of MDMA in
nonhuman primates.
OBSERVATIONS IN PRIMATES
Studies were performed in the squirrel monkey (Saimiri sciureus). This
primate species was selected because of its size, availability, and prior use
in neurotoxicity studies (Langston et al. 1984). Initial dose-response
determinations were carried out using the following doses of MDMA:
2.50, 3.75, and 5.00 mg/kg. Each dose of MDMA was administered
subcutaneously twice daily (at approximateIy 0800 and 1700 hours each
day) for 4 consecutive days. This particular regimen of drug administration
was employed because its prior extensive use in the rat (Commins
et al. 1987; Battaglia et al. 1987; Ricaurte et al. 1987) would permit
comparison of results in the monkey with those in the rat. Two weeks
after drug treatment, the animals were killed, the brains were removed,
dissected, and then analyzed for their regional content of serotonin,
doparnine, and noradrenaline using the method of Kilpatrick et al. (1986), as
previously described (Ricaurte et al. 1988a).
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MDMA produced a dose-related depletion of serotonin without altering the
concentration of either dopamine or norepinephrine in the monkey brain
(table 1). Even the lowest dose of MDMA produced a substantial depletion
TABLE 1. Selective dose-related depletion of serotonin in cerebral cortex
of monkeys administered MDMA 2 weeks previously
Treatment 5-HT DA NE
Saline 0.167 ± 0.015 10.4 ± 0.5 0.39 ± 0.03
MDMA - 2.50 mg/kg 0.093 ± 0.010* NT** NT
(-44%)
MDMA - 3.75 mg/kg 0.037 ± 0.013* NT NT
(-78%)
MDMA - 5.00 mg/kg 0.017 ± 0.003* 9.7 ± 0.8 0.41 ± 0.02
(-90%) (ns) (ns)
*p<0.05, determined by individual comparison to control after one-way analysis of variance showed
F value p<0.05
**NT=not tested because higher dose was without effect.
NOTE: Values in µg/g represent the mean ± SEM (n=3).
of serotonin in the cerebral cortex of the monkey (-44 percent). MDMA
also reduced the concentration of cortical 5-HIAA (table 2). Reduced levels
of serotonin and 5-HIAA were evident not only in the cerebral cortex, but
also in the caudate nucleus (-86 percent), hippocampus (-77 percent), hypo-
thalamus (-77 percent), thalamus (-84 percent), and putamen (-90 percent)
(table 3). Anatomical studies were subsequently carried out in collaboration
with Dr. Mark Molliver and Marianne Wilson of the Johns Hopkins Univer-
sity School of Medicine to determine if there was a structural basis for the
serotonin and 5-HIAA depletions induced by MDMA. These morphological
studies showed that there was a marked reduction of serotonin-immuno-
reactive axons in the monkey forebrain (figure 1). and that, at high power,
some of the remaining axons appeared swollen and misshapen (Wilson
et al. 1988). Coupled with the biochemical observations, these morpho-
logical findings suggest that MDMA produces neurochemical deficits by
damaging serotonergic axons. Further, they demonstrate that the long-term
effects of MDMA originally documented in the rodent generalize to the
primate.
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TABLE 2. Decreased concentration of 5-HIAA in the monkey brain 2 weeks
after MDMA (5 mg/kg)
N Neocortex Caudate Hippocampus Hypothalamus
Control 3 0.250 ± 0.010 0.232 ± 0.005 0.245 ± 0.006 0.897 ± 0.042
MDMA 3 0.040 ± 0.006* 0.056 ± 0.002 0.060 ± 0.001* 0.543 ± 0.084*
*p<0.05, two-tailed student's t-test.
NOTE: Values represent the mean ± standard error of the mean.
TABLE 3. Regional concentrations of serotonin in the monkey brain
2 weeks after MDMA (5 mg/kg)
Somatosensory
Cortex Caudate Putamen Hippocampus Hypothalmus Thalamus
CONTROL (n=3)
0.14 ± 0.01 0.21 ± 0.03 0.28 ± 0.02 0.13 ± 0.03 0.90 ± 0.06 0.73 ± 0.01
MDMA (n=3)
0.02 ± 0.01* 0.03 ± 0.01* 0.03 ± 0.01* 0.03 ± 0.01* 0.21 ± 0.01* 0.12 ± 0.01*
*p<0.05, two-tailed student's t-test. 
NOTE: Values represent the mean ± standard error of the mean. 
RELATIVE SENSITIVITY: PRIMATES VS. RODENTS
Next, the relative sensitivity of monkeys and rats to the serotonin-depleting
effects of MDMA was evaluated. This was done by comparing dose-
response data in these two experimental animals. In the monkey, a
2.5 mg/kg dose regimen of MDMA produced a 44 percent depletion of
serotonin (figure 2). By contrast, in the rat, a 10 to 20 mg/kg dose
regimen of MDMA was required to produce a comparable effect. Thus,
monkeys are 4 to 8 times more sensitive than rats to the serotonin-depleting
effects of MDMA. Inspection of the data in figure 2 also showed that the
dose-effect curve of MDMA in the monkey is much steeper than in the rat.
Consequently, small increments in dose cause large increases in serotonin
depletion in the monkey but not in the rat. Clearly, this could have serious
implications for humans experimenting with higher doses of MDMA, as it
suggests that the margin of safety of MDMA in primates is narrow.
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MDMA CONTROL
FIGURE 1. Marked reduction of serotonin-immunoreactive axons in the somatosensory cortex of
MDMA-treated monkey
FIGURE 2. Dose-response data in rats and monkeys administered MDMA
2 weeks previously
INVOLVEMENT OF NERVE CELL BODIES
The severity of the axonal damage caused by MDMA in the forebrain of
the monkey raised the question of whether cell bodies in this experimental
animal might also be damaged by MDMA. As noted above, cell body
damage does not occur in the rat (O’Hearn et al. 1988). However, it is to
be recalled that in the case of MPTP, it was not until it was tested in the
monkey that MPTP’s toxic effects on cell bodies were appreciated (Chiueh
et al. 1983; Langston et al. 1984). To determine if this was also the case
for MDMA, the brainstem of monkeys treated with the high dose (5 mg/kg)
regimen of the drug 2 weeks previously was examined histologically.
MDMA-treated monkeys showed no obvious cell loss in either the dorsal or
median raphe nuclei. However, there were clear cytopathologic changes in
nerve cells of the dorsal (but not median) raphe nucleus. Specifically,
nerve cells in the dorsal raphe nucleus appeared shrunken and contained
brownish-red intracytoplasmic spherical inclusions, which were acid fast in
Ziehl-Nielsen stain for lipofuscin, granular in LFB-PAS-stained sections, and
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vividly PAS positive. While the significance of these inclusions remains
unclear, their staining characteristics suggested the presence of an increased
amount of lipofuscin. More recent studies investigating the fate of these
inclusion-bearing nerve cells have suggested that they do not die, and that
their survival is associated with partial recovery of serotonin in the monkey
forebrain (Ricaurte et al. 1988c). Similar recovery of serotonin has been
noted in MDMA-treated rats (Battaglia et al. 1988). It remains to be
determined if recovery of serotonin is related to regeneration of serotonergic
axons, and if the new axons innervate their original targets or form aberrant
synaptic contacts.
RELEVANCE TO HUMANS
Clearly, much of the impetus for investigating the neurotoxic effects of
MDMA in animals has come from concern that MDMA may produce
similar toxic effects in humans. However, the extent to which findings in
animals can be extrapolated to humans has been unclear, largely for three
reasons: First, in most animal studies, MDMA has been administered
subcutaneously or intraperitoneally (Schmidt 1987; Commins et al. 1987;
Battaglia et al. 1987; Mokler et al. 1987), even though humans invariably
take the drug orally (Seymour 1986). Second, most animal studies have
used multiple doses of MDMA, and these have been given over relatively
short periods of time (Commins et al. 1987; Battaglia et al. 1987; Mokler
et al. 1987). By contrast, humans typically take single doses of MDMA,
usually weeks apart (Seymour 1986). Third, doses of MDMA tested in
animals have often far exceeded those used by humans.
In an effort to bridge the gap between studies of MDMA in animals and
human MDMA use patterns, the following studies were performed. These
studies tested the importance of dose, route, and schedule of drug
administration as determinants of MDMA neurotoxicity. In the frost
experiment, one group of monkeys received MDMA (5 mg/kg twice daily
for 4 days) subcutaneously; another group received an identical dosage
regimen of the drug orally. The animals were killed 2 weeks later, and
regional brain serotonin concentrations were determined. Monkeys given
oral MDMA showed depletions of serotonin that, depending on brain region,
ranged from one-third to two-thirds of those found in monkeys given the
drug subcutaneously (table 4). Recently, similar results have been obtained
in rhesus monkeys (Kleven et al. 1989). Taken together, the results of
these studies indicate that the oral route of administration does not afford
significant protection against the long-term effects of MDMA on serotonin
neurons.
A second study compared the effects of single versus multiple doses. One
group of monkeys received a single 5 mg/kg dose of MDMA orally;
another group received the same dose by the same route, but on a twice
daily basis for 4 days. As before, the multiple dose regimen produced a
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large depletion of serotonin in all forebrain regions examined (table 5). By
contrast, the single dose produced a depletion of serotonin only in the
thalamus and hypothalamus. In both brain regions, the depletion was
smaller than that produced by the multiple dose regimen, but achieved
statistical significance. The long-term effects of even single doses of
MDMA further attest to the high sensitivity of the primate to the serotonin-
depleting effects of MDMA. Further, they raise the question of whether
humans might be similarly affected, particularly since they take doses that
are only 2 to 3 times lower than the dose that produce an effect in the
monkey (1.7 to 2.7 vs. 5.0 mg/kg).
STUDIES OF CSF 5-HIAA
Detecting a depletion of serotonin in the brain of a living human poses a
major challenge. To date, only two methods have been attempted. The
first involve measurement of 5-HIAA in the CSF (Garelis et al. 1974; Moir
et al. 1970); the second calls for neuroendocrine challenge with various
serotonergic agents (Cowen and Anderson 1976; Heninger et al. 1984).
Unfortunately, both of these methods are indirect, and neither has been fully
validated. Accordingly, it was necessary to test the usefulness of CSF
5-HIAA as a marker of MDMA neurotoxicity in the monkey before
attempting to use it on humans.
To validate the CSF 5-HIAA method in the monkey, three monkeys were
given MDMA at a dose that produces extensive serotonergic damage
(5 mg/kg twice daily for 4 days, SC); three other age- and sex-matched
animals were given saline and served as controls. Two weeks later, all of
the animals were lightly anesthetized with ether, and 200 to 300 µL of CSF
were removed by cervical puncture. Later that same day, all animals were
killed for determination of regional CNS and CSF serotonin and 5-HIAA
levels. These measurements showed that MDMA lowered the concentration
of 5-HIAA in the CSF but not that of homovanillic acid (HVA) or
3-methoxy-4-hydroxyphenylene-glycol (MHPG) (table 6). The reduction of
CSF 5-HIAA was associated with a marked depletion of serotonin in the
CNS (table 7). The decrease in 5-HIAA in cervical CSF was smaller than
the depletion of serotonin in the forebrain (59 percent vs. 90 percent), but
greater than the depletion of serotonin in the cervical spinal cord
(45 percent vs. 59 percent) (Ricaurte et al. 1988b). Hence, cervical CSF
5-HIAA underestimates serotonin depletion in the forebrain, but overesti-
mates serotonin depletion in the cervical spinal cord. These results
indicated that while 5-HIAA in CSF does not fully reflect the depletion of
serotonin in the forebrain, it can serve as a partial indicator of serotonergic
damage induced by MDMA in the forebrain of primates.
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TABLE 4. Effect of Oral vs subcutaneous MDMA on regional brain serotonin in the primate 2 weeks later
TABLE 5. Effect of single vs multiple doses of MDMA on regional brain serotonin in the primate 2 weeks later
TABLE 6. Selective reduction in 5-HIAA in CSF of monkeys administered
MDMA 2 weeks previously
Treatment N 5-HIAA HVA MHPG
Saline 3 101 ± 7 2 5 5 ± 4 4 30 ± 4
MDMA 3 41 ± 7* 264 ± 20 40 ± 11
*p<0.05, two-tailed student's t-test.
NOTE: Values represent the mean ± SEM (expressed in µg/mg of tissue).
TABLE 7. Selective reduction in serotonin in the caudate nucleus of
monkeys administered MDMA 2 weeks previously
Treatment N
Saline 3
Serotonin
0.218 ± 0.023
Dopamine
11.6 ± 0.9
Norepinephrine
2.59 ± 0.18
MDMA 3 0.021 ± 0.005* 9.7 ± 0.2 2.84 ± 0.91
*p<0.005, two-tailed student's t -test.
NOTE: Values represent the mean ± SEM (expressed in µg/mg of tissue).
CSF 5-HIAA STUDIES IN HUMANS
In light of this, studies of CSF 5-HIAA have been initiated in a cohort of
human volunteers with a history of extensive MDMA use. Most partici-
pants in the study are individuals who have recently learned of the
neurotoxic properties of MDMA and have asked to be evaluated for
possible serotonergic damage. To qualify for the study, subjects must (1)
have used MDMA on at least 20 to 25 occasions, (2) be drug-free for at
least 2 weeks prior to participating in the study, and (3) not have a history
of neuropsychiatric illness thought to involve alterations in serotonin
metabolism. To date, 34 individuals have participated in the study. The
study is now in progress, and completion is anticipated by 1991. At this
time, it would be premature to comment on the results.
NEUROENDOCRINE STUDIES
As noted earlier, the only other method presently available for detecting
serotonergic dysfunction in living humans involves neuroendocrine challenge
with serotonin-active drugs (Cowen and Anderson 1976). One such
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neuroendocrine test is the L-tryptophan challenge test (Heninger
et al. 1984). Briefly, this test calls for intravenous administration of
L-tryptophan to human subjects with subsequent measurement of serum
prolactin concentration. A rise in serum prolactin is taken as a measure of
central serotonergic activity. Using the L-tryptophan challenge tests,
serotonergic function was recently evaluated in nine MDMA subjects in
collaboration with Drs. Price and Heninger of the Yale University School of
Medicine. L-tryptophan induced a robust rise in serum prolactin in controls
but not in MDMA subjects (figure 3). The peak change in serum prolactin
concentration and the area under the prolactin response curve were
diminished in MDMA subjects, but the difference was not statistically
signifiit (Price et al. 1989). Additional studies are now in progress to
assess the significance of these findings.
FIGURE 3. Prolactin response to IV L-tryptophan in control and
MDMA subjects (n=9)
SUMMARY AND CONCLUSION
The results of the studies reviewed here show that the neurotoxic effects of
MDMA generalize to the primate. Further, they indicate that monkeys are
considerably more sensitive than rats to the serotonin-depleting effects of
MDMA, and that the dose-response curve of MDMA in the monkey is
much steeper than in the rat. Perhaps as a consequence of this, the toxic
effects of MDMA in the monkey involve serotonergic nerve fibers as well
as cell bodies, whereas in the rat, only nerve fibers are affected. The
present studies also show that the toxic dose of MDMA in the monkey
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(5 mg/kg) closely approaches the dose typically used by humans (1.7 to
2.7 mg/kg). This finding heightens concern that MDMA may be neurotoxic
in humans, particularly since the steepness of the dose-response curve of
MDMA in the primate suggests a narrow margin of safety. Finally,
preclinical studies in monkeys have shown that CSF 5-HIAA can be used to
detect MDMA-induced serotonergic damage in the primate CNS. Studies
now underway in MDMA-exposed humans should help determine if MDMA
exerts long-term toxic effects on serotonergic neurons in the human brain.
DISCUSSION
QUESTION: How long after the administration of the MDMA in your
human subjects did you measure your parameter?
ANSWER: The request we made to the subjects was that they remain
entirely drug-free for 2 weeks. We were trying to simulate the situation
that we had in animals.
QUESTION: How long after the administration of the drug did you
measure the 5-HIAA?
ANSWER: We did not administer MDMA. We were dealing with humans
who had been previously exposed to MDMA. The request we made was
that they not take the drug for at least 2 weeks. Some subjects had not
taken the drug for over a year. Some had taken it as recently as 19 days.
QUESTION: Is there a decrease in serotonin metabolites, and does it show
any relationship to age, cumulative dose, and so forth? Did you see
anything there? You have that one person who had 42 grams. Was he any
more or any less affected?
ANSWER: We are in the midst of analyzing the data. You will remember
that the mean 5-HIAA level in control subjects is approximately 19 to 20.
In that one individual, 5-HIAA level turned out to be 14 or 13. You might
predict that he would have been the lowest one on the scale. I subsequent-
ly learned the importance of body height, and he happens to be a very
short, stocky man. So we are now in the process of reanalyzing the data,
trying to take in the appropriate variables into account. And, again, these
arc studies that have to be replicated in our own hands and extended by
others.
QUESTION: Do you see a progressive decline as a function of age, and if
you have someone who has been damaged, is there any age relationship in
this depletion?
ANSWER: No. Only one individual was 70 or 71 years old. By and
large, the individuals are younger than 40. The other side of the coin, of
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course, is does 5-HIAA really change with age in the control population?
That was one of the variables that I listed. I would emphasize that the data
for that are actually very weak. My guess is that there are no age-related
changes in 5-HIAA, at least out to 50 to 60 years of age. But that is
something we are going to have to contend with as well.
QUESTION: You showed CSF levels in monkeys after the 4-day treatment
regimen, but you also showed neurochemical data after a single oral
administration. Did you have the opportunity to look at the CSF levels
after a single oral administration?
ANSWER: No. That study was actually completed before the CSF studies.
We did not get CSF data on the animals that received the single dose
because that study was done before the CSF studies were undertaken.
COMMENT: With regard to the CSF levels, I want to emphasize that the
decreases that you get are probably a gross underestimate, as was pointed
out, Another reason is that the ventricular plexus of serotonin fibers is
completely unaffected, and that is probably a very large source. I do not
know to what extent that contributes to CSF levels of S-HT and S-HIAA,
but those fibers are in the CSF and bathing in it, and they appear to be
quite active. So they must be biasing against your seeing an effect. The
fact that you are getting such a sizable effect must mean that there is a
very profound depletion in the forebrain.
QUESTION: Does anything suggest that people who have taken these
drugs or MDMA for a period of time are subject to episodes of depressive
disorders or affective disorders?
ANSWER: Frankly, at this point, we have only anecdotal evidence. And
as Dr. Schuster mentioned yesterday, people’s responses can be very
misleading. I could cite three individuals who attribute some mood
disturbances to their prior MDMA use, but one wonders how much their
reports are based on what you want to hear.
One individual was prescient enough to realize that his depression coincided
with loss of his job so he did not know if his depression was related to
losing his job or to MDMA ingestion. I think these people are going to
need to be looked at by people who know what they are doing in terms of
analyzing depression, and that has not been done.
COMMENT: It is interesting in that letter that George Greer wrote to me
informally, off the record, that he had seen 10 patients in psychotherapy
who had been treated extensively with fenfluramine for dieting. And, after
several weeks on fenfluramine, they became very depressed, and two of
them committed suicide. So that is a very serious consideration.
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RESPONSE: Another interesting consideration is that a number of the sub-
jects have participated with the intent of helping the rest of the country see
that this is not such a harmful drug. A number of the proponents of
MDMA use the paucity of behavioral abnormalities in MDMA users to
point to the fact that literally thousands of subjects have used the drug, and
that they are not walking around like zombies; they do not appear to be
harmed.
My answer always is that no one has yet done a detailed neurobehavioral
study of these individuals and the deficit that they may have. It may be
very subtle in nature, and I am not sure that we have the methods available
to detect and quantify those deficits. The fact that these people are not
walking in with overt behavioral disturbances as the people with MPTP did.
I think, is related to the fact that, one, they may not have the kind of
neurotoxicity we are suspecting, and two, if they do, the kind of functional
consequences that you may get from serotonergic dysfunction may be much
more subtle than the kind of functional consequences you get with
dopamine dysfunction, where it is very easy to recognize the parkinsonian
patient
QUESTION: Do you have any plans to study whether it would be possible
to eliminate the large variation in dosage level and frequency and duration
since the last dose by studying fenfluramine, where patients are receiving
prescribed doses every day for finite periods of time? Perhaps one could
set up a study where you sample CSF before and after the therapy so that
you would avoid any concern about whether you had selected a group of
patients who had low 5-HIAA levels.
ANSWER: Yes, that is one of the groups that we would hope to
incorporate.
COMMENT: I am not an advocate of this view, but my colleague
Efrain Azmitia from NYU has suggested that perhaps rather than seeing
deficits, that pruning our serotonin projections now and then might be a
very advantageous and beneficial thing to do.
RESPONSE: I am not going to try to follow up on that one.
QUESTION: We are used to seeing a lot of those big beaded axons which
we, alter methamphetamine. have interpreted as damage. Do you think it is
what is left over rather than big axons that are damaged?
ANSWER: Yes. We have very carefully evaluated that question and
Dr. O’Hearn is a great skeptic who is forcing us to look at it very closely.
We are finding that the large varicosity fibers that are left are identical in
distribution, morphology, and density to those present in the normal fibers.
The damaged fibers are of a completely different nature; they are 10 times
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as big, fragmented, and very, very damaged. They can be easily
distinguished.
QUESTION: So you get both?
ANSWER: Yes.
REFERENCES
Battaglia, G.; Yeh, S.Y.; and De Souza, E.B. MDMA-induced neuro-
toxicity: Parameters of degeneration and recovery of brain serotonin
neurons. Pharmacol Biochem Behav 29:269-274, 1988.
Battaglia, G.; Yeh, S.Y.; O’Hearn, E.; Molliver. M.E.; Kuhar, M.J.; and
DeSouza, E.B. 3,4-methylenedioxymethamphetamine and 3,4-methyl-
enedioxyamphetamine destroy serotonin terminals in rat brain:
Quantification of neurodegeneration by measurement of [3H]paroxetine-
labeled serotonin uptake sites. J Pharmacol Exp Ther 242(3):911-916,
1987.
Burns, R.S.; Chieuh, C.C.; Markey, S.P.; Ebert, M.H.; Jacobowitz, D.M.;
and Kopin, I.J. A primate model of parkinsonism: Selective destruction
of dopaminergic neurons in the pars compacta of the substantia nigra by
n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.. Proc Natl Acad Sci USA
80:4546-4550, 1983.
Caldwell, J.; Dring, L.G.; and Williams, R.T. Metabolism of [14C]meth-
amphetamine in man, the guinea pig and the rat. Biochem J 129:11-21,
1976.
Chieuh, C.C.; Markey, S.P.; Burns, R.S.; Johannessen. J.N.; Jacobowitz,
D.M.; and Kopin, I.J. N-methyl-4-phenyl-1,2,3,6~tetrahydropyridine,a
parkinsonian syndrome causing agent in man and monkey, produces
different effects in the guinea pig and rat. Pharmacologist 25:131-138,
1983.
Commins, D.L.; Vosmer, G.; Virus, R.; Woolverton, W.; Schuster, C.; and
Seiden, L. Biochemical and histological evidence that methylenedioxy-
methamphetamine (MDMA) is toxic to neurons in the rat brain. J
Pharmacol Exp Ther 241:338-345, 1987.
Cowen, P.J., and Anderson, I.M. 5HT Neuroendocrinology: Changes
during depressive illness and antidepressant drug treatment. In: Deakin,
J.F.. and Freeman, H., eds. Advances in the Biology of Depression.
London: Royal College of Psychiatry, 1976.
Gads, E.; Young, S.N.; Lal, S.; and Sourkes, T.L. Monoamine
metabolites in lumbar CSF: The question of their origin in relation to
clinical studies. Brain Res 79:1-8, 1974.
Heninger, G.; Charney, D.S.; and Sternberg, D.E. Serotonergic function in
depression: Prolactin response to intravenous tryptophan in depressed
patients and healthy subjects. Arch Gen Psychiatry 41:398-402. 1984.
320
Kilpatrick, I.; Jones, M.; and Phillipson, O. A semiautomated analysis
method for catecholamines, indoleamines, and some prominent metabolites
in microdissected regions of the nervous system: An isocratic HPLC
technique employing coulometric detection and minimal sample
preparation. J Neurochem 46(6):1865-1876, 1986.
Kleven, M.S.; Woolverton, W.L.: and Seiden, L.S. Evidence that both
intragastric and subcutaneously administered MDMA produce 5HT
neurotoxicity in rhesus monkeys. Brian Res 488:121-125, 1989.
Langston, J.W.; Forno, L.S.; Rebert, C.S.; and Irwin, I. Selective nigral
toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetra-
hydropyridine (MPTP) in the squirrel monkey. Brain Res 2:390-394,
1984.
Moir, A.T.; Ashcroft, G.W.; Crawford, T.B.; Eccleston, D.; and Guldbert,
H.C. Cerebral metabolites in cerebrospinal fluid as a biochemical
approach to the brain. Brain 93:357-368, 1970.
Mokler, D.J.; Robinson, S.E.; and Rosencranx, J.A. 3,4-Methylenedioxy-
amphetamine produces long-term reductions in brain 5-hydroxytryptamine
in rats. Eur J Pharmacol 138:265-268, 1987.
Molliver, M.E. Serotonergic neural systems: What their anatomic
organization tells us about function. J Clin Psychopharmacol 7:3-23,
1987.
O’Hearn, E.G.; Battaglia, G.; De Souza, E.B.; Kuhar, M.J.; and Molliver,
ME. Methylenedioxyamphetamine (MDA) and methylenedioxymetham-
phetamine (MDMA) cause ablation of serotonergic axon terminals in
forebrain: Immunocytochemical evidence. J Neurosci 8:2788-2803, 1988.
Price, L.H.; Ricaurte, G.A.; Krystal, J.H.; and Heninger, G.R.
Neuroendocrine and mood responses to intravenous L-tryptophan in
3,4-methylenedioxymethamphetamine (MDMA) users. Arch Gen
Psychiatry 46:20-22, 1989.
Ricaurte, G.A.; Finnegan, K.T.; Nichols, D.E.; DeLanney, L.E.; Irwin, I.;
and Langston, J.W. 3,4-Methylenedioxyethylamphetamine (MDE), a novel
analog of MDMA, produces long-lasting depletion of serotonin in the rat
brain. Eur J Pharmacol 137:265-268, 1987.
Ricaurte, G.A.; DeLanney, L.E.; Irwin, I.; and Langston, J.W. Toxic effects
of 3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic
neurons in the primate: Importance of route and frequency of drug
administration. Brain Res 446:165-168, 1988a
Ricaurte, G.A.; DeLanney, L.E.; Wiener, S.G.; Irwin, I.; and Langston, J.W.
5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic
damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-
human primates. Brain Res 474:359-363. 1988b.
Ricaurte, G.A.; Forno, L.S.; Wiener, S.G.; DeLanney, L.E.; Irwin, I.; and
Langston, J.W. Effects of MDMA on central serotonergic neurons in
non-human primates: Permanent or transient? Abstr Soc Neurosci
14:558, 1988c.
321
Ricaurte, G.A.; Forno, L.S.; Wilson, M.A.; DeLanney, L.E.: Irwin. I.:
Molliver, M.E.; and Langston, J.W. MDMA selectively damages central
serotonergic neurons in the primate JAMA 260:51-55, 1988d.
Schmidt, C.J. Neurotoxicity of the psychedelic amphetamine, methyl-
enedioxymethamphetamine. J Pharmacol Exp Ther 240:l-7, 1987.
Seymour, R.B. MDMA. San Francisco, CA.: Haight Ashbury Publications,
1986.
Stone, D.M.; Hanson, G.R.; and Gibb, J.W. Differences in the central
serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice
and rats. Neuropharmacology 26:1657-1661, 1987.
Stone, D.M.; Stahl, D.S.; Hanson, G.L.: and Gibb, J.W. The effects of 3,4-
methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyam-
phetamine on monoaminergic systems in the rat brain. Eur J Pharmacol
128:41-48, 1986.
Wilson, M.A.; Ricaurte, G.A.; and Molliver, M.E. Distinct morphologic
classes of serotonergic axons in primates exhibit differential vulnerability
to the psychotropic drug 3,4-methylenedioxymethamphetamine.
Neuroscience 28:121-137, 1988.
ACKNOWLEDGMENTS
This research was supported in part by National Institute on Drug Abuse
grant number DA 05707-01.
AUTHOR
George A. Ricaurte, M.D., Ph.D.
Department of Neurology
John Hopkins University School of Medicine
Francis Scott Key Medical Center
4940 Eastern Avenue
Baltimore, MD 21224
322
Dose- and Time-Dependent Effects
of Stimulants
Everett H. Ellinwood, Jr., and Tong H. Lee
INTRODUCTION
Considerable confusion abounds in discussion of stimulant-induced toxicity,
pathology, psychopathology, and the mechanisms underlying these changes.
Although there is laboratory and clinical evidence for histochemical and
structural pathologies induced by chronic and high doses of stimulants, the
specific relationship to behavioral pathology has not been clearly
demonstrated. Clinically, the confusion originates in part from several
sources including lack of clear distinctions (1) between phases of stimulant
syndrome; (2) between the types of dosing, routes of administration, and
differential pharmacokinetic parameters for different utilization styles;
(3) between outcomes or other dependent variables; and (4) between
proposed mechanisms mediating the outcome. In basic research, the confu-
sion often results from description of a singular effect or even multiple
effects of chronic stimulant treatment without clearly delimiting the time-
frame, dosing schedule, or mutual exclusiveness of competing behavioral
effects.
Our whole task from a clinical perspective includes (1) delineation of the
patterns of behavioral pathology induced both during the active stimulant
abuse phase and the phases of withdrawal; (2) description of the sequential
profile of underlying structural and functional pathology at each of the
clinical phases; and (3) an attempt to elucidate the relationship between
(1) and (2). In addition, an understanding of the pharmacological and other
parameters sufficient and necessary for inducing components of the
stimulant syndrome is clearly needed and can be obtained only from basic
laboratory studies.
In figure 1 we have outlined phases of stimulant abuse and withdrawal;
this pattern does not depict the larger spectrum of patterns seen in stimulant
abusers. Instead, we have emphasized what is called a high-dose transition
pattern (Gawin and Ellinwood 1988), which leads to the greatest behavioral
pathology. In focusing on the high-dose transitional form, the periodic
dosing over months to years is deemphasized, as is considerable basic
research literature dealing with once or twice-a-day dosing schedules.
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Animal studies have shown that the periodic dosing regimen often leads to
behavioral augmentation or “sensitization” in animals (Post 1981).
Stimulant Use Withdrawal Phases
FIGURE 1. Phases of stimulant abuse and withdrawal seen with
high-transition pattern
PHENOMENOLOGY OF STIMULANT ABUSE
High-Transition Pattern
Initial phases in high-transition pattern are similar to those in other abuse
patterns. Typically, individuals are initially exposed to single doses of
stimulants for therapeutic (e.g., weight reduction) or other purposes
(Ellinwood 1973). Euphoria produced by single doses of stimulants before
development of tolerance are proportional to plasma levels (Fischman et al.
1976; Javaid et al. 1978). Higher levels of euphoria are achieved with
intravenous (IV) route secondary to rapid rise to a peak concentration
(figure 2, A). During the “single bolus” phase, conditioning to euphoriant
“rush” of stimulants is especially profound in individuals using a rapid route
of administration (e.g., IV or smoking). The single bolus phase is followed
by increasing doses and frequency (“dose frequency escalation” phase)
mainly secondary to a development of tolerance to euphoriant effect of
stimulants.
The high-dose transition is defined as a transition phase in which the
individual suddenly increases the doses of stimulants or switches to smoking
(e.g., cocaine “crack”) or IV route of administration (Gawin and Ellinwood
1988). This change leads to a rapid escalation of plasma levels and intense
euphoria (i.e.. rush) often with subsequent increase in dosing frequency. ln
its most severe form, the high-dose pattern is characterized by binges of
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FIGURE 2. Dose frequency escalation patterns, cocaine and amphetamine
stimulant use, in which the individual repeatedly administers high doses of
stimulant in an attempt to “chase” the euphoric state against the background
of rapidly developing acute tolerance. Each bingeing episode can last from
a few hours to days and is usually terminated by extreme physical
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exhaustion and/or exhaustion of drug supply (Gawin and Ellinwood 1988).
It is the high, sustained plasma levels that appear to lead to the greatest
pathology in both stimulant abusers and laboratory animals (Ellinwood and
Kilbey 1977). Figure 2, B through D, illustrates drug plasma levels during
the high-dose transition and bingeing phase. A severe compulsive pattern
of repeated cocaine administration is necessary to maintain sustained drug
levels during cocaine binges, whereas, because of its longer plasma half-life,
amphetamine bingeing is usually characterized by longer intervals between
injections. During this compulsive phase, severely addicted individuals
report stereotyped patterns of behavior and thiig with near exclusion of
other concerns. Possible mechanisms responsible for different phases of
high-transition pattern are summarized in figure 3 under abuse dependence.
At present. there is only speculation on these mechanisms.
During the high-dose transition, the intense euphoria associated with the
rush leads to profound conditioning of associated abuse behaviors; not only
are the injection behaviors highly conditioned to the circumstances
surrounding the injections, but the behaviors leading up to the procurement
of the drug and the preparation prior to injection are also conditioned
(Ellinwood 1973).
Aspects of Withdrawal
The clinical withdrawal period may be considered as a sequence of phases
beginning with “crash” and ending with long-term withdrawal that can only
be presented descriptively. Long-term residual effects may be noted weeks
or months afterwards. Consideration for each different phase of withdrawal
is critical in understanding and treating the evolving stages of withdrawal.
The treatment consideration in the intermediate withdrawal phase is quite
different from that in the long-term withdrawal phase (Gawin and Ellinwood
1988).
Crash, the initial phase of stimulant withdrawal, immediately follows a
bingeing episode. Initially marked depressive dysphoria, anxiety, and
agitation are noted, followed by craving for sleep over the next few hours
(Ellinwood 1973; Gawin and Ellinwood 1988). Often the individual uses a
wide variety of sedatives or anxiolytics, such as alcohol, to initiate a
sustained hypersomnia. Prolonged sleep, often lasting 24 to 36 hours, is not
unusual during this phase. Notably, addicts report minimal desire for the
abused drug during this immediate phase of withdrawal (Gawin and Kleber
1986).
As the individual recovers from the crash phase, a period of anhedonia,
dysphoria, and decreased mental and physical energy ensues (intermediate
withdrawal phase). This phase can last from several days to weeks.
Emerging from the mood and energy dysfunction, craving or high urge for
the stimulant returns, frequently leading to recidivism (Ellinwood 1973).
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FIGURE 3. Toxicity and development of dependence under single-dose,
escalated, and binge conditions
The stimulant urge-impulses are sensitive to environmental cues such as
returning home and associated multiple situational stimuli (e.g., parapher-
nalia, friends, etc.). With continued drug availability, it is not unusual to
observe repetitious cycles of bingeing with intervening crash and
intermediate withdrawal phases over a period of months. It is noted that
conditioned withdrawal responses are less pronounced than with opiates; yet,
withdrawal appears to have a phase-specific relation to the reemergence of
cue-sensitive responses that deserves further research.
With continued abstinence through the intermediate withdrawal phase, a
more natural baseline affective state returns (long-term withdrawal phase).
Although decreased in frequency and intensity, however, urges to return to
stimulant use can recur after months to years of abstinence, again frequently
triggered by environmental cues (Ellinwood 1973; Gawin and Kleber 1986).
Moreover, the individual can exhibit a “grease slide” return to previously
conditioned behavioral responses with a single “taste” of stimulants. Full
expression of the drug-induced paranoid, stereotyped thinking pattern within
minutes to hours of return to stimulant use is a well-documented long-term
sequela of high-dose stimulant abuse (Ellinwood 1973; Bell 1973). This
full expression of behavioral pathology may have originally taken weeks or
months of chronic stimulant use to evolve. These examples highlight the
latent propensity to recidivism even after long-term withdrawal from
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stimulants. A question that arises from the residual behavioral pathologies
is whether such changes are related to toxicity associated with stimulant
use. Thus, careful consideration of the acute and chronic toxicity is
warranted.
TOXICITIES ASSOCIATED WITH SINGLE DOSES
OF STIMULANTS
Peripheral Toxicities
Several types of toxicities are responsible for stimulant-related morbidity
and mortality (figure 3). Reported cardiovascular toxicities include acute
myocardial infarction, “stunned” myocardium syndrome, arrhythmias, myo-
carditis, and ruptured aorta (Cregler and Mark 1986). Significantly, a
history of underlying disease appears not to be a prerequisite. For example,
acute myocardial infarction following administration of cocaine has been
documented in patients without fixed or spastic coronary diseases or history
of cardiac symptoms (Isner et al. 1986). Interestingly, cocaine appears to
be more frequently associated with the above cardiac complications than are
amphetamines. The exact reason for this preponderance of cocaine-
associated toxicity is not clear; the significant local anesthetic effect of
cocaine may contribute to its cardiac toxicity. Alternatively, because of its
ultrashort half-life, cocaine may be more liable to overdosing with attempts
to maintain effective plasma levels.
The relative contribution of different mechanisms to stimulant-induced
cardiac toxicities is not known. Currently, sympathetic overstimulation is
thought to mediate many of these effects (Cregler and Mark 1986).
Increased oxygen demand secondary to increased heart rates and blood pres-
sure has been hypothesized to lead to myocardial infarction (especially in
patients with fixed coronary disease) and/or ventricular arrhythmias. In
patients with no history of cardiac disease, cocaine is thought to induce
acute ischemic complications via vasospasm of the coronaries (Ascher et al.
1988). In addition, Virmani et al. (1988) have reported a 20 percent
incidence of myocarditis thought to be secondary to accumulated
microvascular injuries.
One critical factor that has been neglected in considering mechanisms of
cardiac fatalities is the timeframe for various types of toxicities. For
example, a majority of cocaine-related fatalities and near fatalities reported
from emergency rooms are attributed to one or more types of cardiac
ischemic or hypertensive episodes (Isner et al. 1986). Thus, these studies
may discount the cocaine-induced arrhythmias and conduction defects as
important direct causes of fatalities. Yet, if coroner reports are used as data
sources (Virmani et al. 1988; Wetli and Wright 1979; Mittleman and Wetli
1984), there are great numbers of deaths in which pulmonary effusion and
lack of evidence for coronary occlusion, acute myocardial infarction, or
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other events tend to discount the preponderance of coronary mechanisms as
the key factor leading to death
The above discrepancy may be partly explained by studies by Kabas et al.
(1988) demonstrating that, during the first 1 to 5 minutes of large IV
cocaine dose, the His bundle-ventricular conduction time is markedly
prolonged in dogs. These results indicate that an intense but transient
conduction defect occurs almost immediately after escalation of plasma
cocaine level. Local anesthetics impair cardiac conduction by interacting
with the sodium ion channel (Starmer et al. 1984). A cardiac arrhythmia
may develop rapidly secondary to combination of the conduction defect and
cardiac irritability (due to massive cardiac stimulation by catecholamine
potentiation). Furthermore, since the local anesthetic effect is potentiated by
reduced extracellular pH (Moorman et al. 1986), acidosis due to increasing
myocardial ischemia and/or seizure activity may potentiate the arrhythmo-
genic effect, ultimately leading to a fatal cardiac arrhythmia. Precipitous
cardiac deaths, both with and without preceding seizure activities, have been
documented following IV administration of cocaine (Wetli and Wright
1979). It should be mentioned that seizures are not necessary for the
cardiac effect, and seizure threshold is above that necessary for cardiac
conduction prolongation (Kabas et al. 1988). In conclusion, many
cocaine-related sudden deaths coming directly to coroners’ attention may be
precipitated by a brief conduction defect leading to a terminal ventricular
arrhythmia.
Central Toxicity
Although the incidence of cerebrovascular accidents from stimulant usage is
low, case reports following acute intake of cocaine or amphetamines have
appeared (Cregler and Mark 1986). Persons with subclinical cerebrovascular
abnormalities such as arteriovenous malformation or cerebral aneurysm
appear to be particularly susceptible. In addition to preexisting structural
abnormalities, stimulants themselves, when abused chronically, may induce
cerebral microarteriolar pathology predisposing individuals to stroke
(Rumbaugh 1977). A sudden surge in blood pressure induced by the drug
with the background of various types of vascular abnormalities is likely to
mediate the cerebrovascular accidents. Intracranial hemorrhage should be
included in differential diagnoses for patients complaining of headaches after
stimulant use.
High doses of stimulants lead to progressive hyperthermia; death from a
gradual overdose of stimulants (e.g., those occurring in “body packers”) are
often associated with hyperpyrexia, convulsions, and cardiovascular shock
(Ellinwood 1973; Wetli and Wright 1979). Hyperpyrexia is more frequently
noted with amphetamine, perhaps due to the longer half-life of this agent,
Life-threatening hyperpyrexia usually ensues an hour or more following
large doses of stimulants and is more prevalent in relatively naive
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nontolerant users. In animals, amphetamines produce hyperthermia and
death in a dose-dependent manner (Zalis et al. 1967). Stimulants increase
body temperature by affecting both the central and peripheral temperature-
regulating mechanisms, as well as by stimulating motor activity (Ellinwood
1973).
Not only do stimulants induce hyperthermia, but elevated ambient or body
temperature itself may augment various effects of stimulants (Weihe 1973).
For example, elevated environmental temperature has been associated with
fatalities among amphetamine abusers taking their usual doses of the drug,
and exercise potentiates the toxicity, as demonstrated by fatalities among
athletes during the sixties when use of amphetamine to enhance performance
was prevalent (Ellinwood 1973). The behavioral stereotypy induced by
amphetamine is also potentiated by increased ambient temperature (Horita
and Quock 1974), as is depletion of dopamine (DA) following chronic
methamphetamine (METH) administration (Seiden and Ricaurte 1987). A
recent study shows that acute hyperthermia may attenuate adaptive
compensatory mechanisms of dopamine pathways (e.g., regulation of DA
impulse-flow) in response to methylphenidate (Lee et al. 1988). This
finding, then, suggests that the increased toxicity of stimulants under
hyperthermic conditions may be due not only to the increased temperature
per se but also to a direct impairment of the body’s ability to compensate
for stimulant toxicity.
Another modality of stimulant-induced toxicity is the induction of
generalized seizures and associated anoxia (Ellinwood 1973; Jonsson et al.
1983). As noted above, the seizure during the hyperthermic condition is
frequently associated with more gradual overdosing of stimulants, and,
indeed, status epilepticus may ensue. The complication may also result
from direct lowering of threshold by stimulants. For example, cocaine, via
its local anesthetic properties, can alter amygdala electrical activity and
produce seizures (Post et al. 1987); seizures due to local anesthetic effects,
in contrast to hyperthermia-associated seizures, appear immediately after
dosing. It should be mentioned that periods of nonfatal anoxia need to be
considered in the accumulative neuropathology associated with chronic
stimulant administration.
TOXICITIES ASSOCIATED WITH CHRONIC STIMULANT
ADMINISTRATION
Peripheral Toxicities
During the escalation and bingeing phases of stimulant abuse, higher doses
and frequency, as well as propensity for more rapid route of administration,
may lead to increased susceptibility to various medical complications. On
the other hand, development of either tolerance or sensitization to different
stimulant effects is well known (Ellinwood 1973; Post 1981) and should be
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properly assessed along with other variables already mentioned. For
example, one recent report (Avakian and Manneh 1987) demonstrated that
chronic cocaine pretreatment reduced susceptibility to epinephrine-induced
arrhythmia in rabbits, suggesting chronic abusers may become tolerant to the
arrhythmogenic effect of stimulants. It is not known whether this tolerance
indeed develops in clinical settings and, if so, whether it shows time-, abuse
pattern-, or dose-dependencies.
Central Toxicities
Effects in Laboratory Animals. As highlighted in other chapters, the
central toxicities during and after repeated stimulant bingeing may be related
to neuronal or terminal destruction and/or depletion of neurotransmitter in
the brain. In monkeys and cats, the report by Duarte-Escalante and
Ellinwood (1970) of neuronal chromatolysis associated with decreased
catecholamine histofluorescence following chronic METH intoxication has
been followed by extensive neurochemical demonstrations of damage to the
monoamine pathways by chronic stimulants (Seiden and Ricaurte 1987).
The most consistent changes have been observed in the DA systems with
more variable effects on norepinephrine (NE) and serotonergic neurons.
Given current attempts in clinical neuroscience to relate monoamine changes
to a variety of mental and movement disorders (including mood disorders
and schizophrenia), reported changes in NE and serotonin levels following
chronic stimulant administration deserve careful consideration, despite
variabilities in findings. The earlier studies by Seiden et al. (1977) are
interesting in that, in contrast to their later study using rats (Wagner et al.
1980), they demonstrated, in monkeys, 40 to 60 percent depletion of NE in
the pons-medulla, midbrain, and frontal cortex regions, both shortly and
3 to 6 months after chronic METH treatment. Molliver et al. (this volume)
also describe extensive loss of finely beaded serotonin terminal areas, yet no
loss or even an increase in serotonin in the medial and posterior raphe. In
an earlier study Duarte-Escalante and Ellinwood 1970) in cats and
monkeys, we also found increase in serotonin histofluorescence in and
around the medial raphe neurons. These findings are in sharp contrast to
more frequently reported effects of METH on brain serotonin levels, i.e., a
decrease (Seiden and Ricaurte 1987).
In addition to changes in monoamines, those in other modulators or trans-
mitters may alter the functional responsiveness following chronic stimulant
administration. For example, the marked increase in acetylcholinesterase
noted in the mesencephalon and brain stem (especially in areas containing
major catecholamine cell bodies) after chronic METH (Duarte-Escalante and
Ellinwood 1970) takes an added significance in light of recent findings that
this enzyme is, like DA, released from dendrites of DA cells in the
substantia nigra (Greenfield 1984). Functionally, the released enzyme can
inhibit DA cells firing in the compacta region. The effect of chronic
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stimulants on other substances colocalized in DA neurons, such as
cholecystokinin and cytochrome P450 reductase, has not been well studied.
The latter enzyme has been proposed to participate in a possible endogenous
formation of the neurotoxin 6-hydroxydopamine (Sasame et al. 1977); could
the same enzyme be involved in stimulant-induced neurotoxicity via a
similar mechanism as has been proposed by Seiden’s group (Seiden and
Ricaurte 1987)? Changes need to be assessed carefully in a wider spectrum
of modulators, transmitters, and their possible functional consequences.
When determining effects of chronic stimulant administration, it is essential
to distinguish specific drugs (e.g., d-amphetamine vs. METH), doses and
regimens of administration, and differential sensitivities among species as
well as the time at which measurements are made. For example, METH
causes more serotonin depletion than does d-amphetamine (Seiden and
Ricaurte 1987). Cocaine may not induce monoamine depletions (Kleven
et al. 1988), although Hitori et al. (1989) have reported a selectively
decreased binding to DA uptake sites in the prefrontal cortex. This issue
awaits further evaluation. Evidence also indicates that monoamine damage
induced by stimulants is more marked after continuous exposure (Lee and
Ellinwood 1989) or higher doses of stimulants (Seiden and Ricaurte 1987),
and this effect is perhaps more pronounced in higher animals such as the
cat and monkey (Wagner et al. 1980; Owen et al. 1981; Trulson and Crisp
1985).
One of the most critical factors determining specific changes is the time of
determination after chronic dosing. Yet this variable has not been carefully
controlled in many basic and clinical studies. For example, too frequently
in studies of neuronal damage (e.g., chromatolysis), deaths following chronic
stimulant administration is the time variable neglected. Clear demonstration
of the importance of time is provided by recent findings that the sensitivity
of DA autoreceptors undergoes a rapid change (from sub- to supersensitivi-
ty) during the first week of withdrawal (Ellinwood and Lee 1983; Lee and
Ellinwood 1989). The autoreceptor supersensitivity will be discussed
further.
Effects In Humans. Neither postmortem nor functional cerebrospinal fluid
(CSF) studies in humans provide firm evidence for similar, long-term
damages or alterations to monoaminergic neurons in chronic stimulant
abusers. In part, the lack of demonstrable neurochemical changes may well
be due to the obvious preclusion of well-controlled prospective experimenta-
tion in humans, as well as to variability in critical variables (e.g., individual
sensitivity or pattern of abuse) encountered in clinical research. Possible
relationship of the various complications of stimulant abuse including hyper-
pyrexia, seizure, anoxia, and metabolic exhaustion to neuronal chromatolysis,
terminal destruction. and monoamine and enzymatic depletion have not been
systematically explored in human autopsy cases. It should be also noted
that, under nonperturbed conditions, overt behavioral deficits are rare in
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animals depleted of monoamines with chronic stimulants (Lee and
Ellinwood 1989; Kokkinidis 1984). We need to evaluate carefully a
possible relationship between the fatigue, neurasthenia, and mood
dysfunction reported in the protracted stimulant withdrawal in humans and
an underlying neurochemical or anatomical state.
MORE ISSUES IN CHRONIC STIMULANT RESEARCH
In chronic stimulant abusers, one observes interactions among direct long-
term toxic consequences and various compensatory behavioral and physiolo-
gical mechanisms; consequently, it is necessary to evaluate multiple effects
over different phases of stimulant abuse, to sort out the contributions of
each of these mechanisms. Lack of attention to the complex interaction has
contributed to the confusion in stimulant research. Often, in basic research,
a singular mechanism for effects of chronic stimulant treatment (e.g., those
for stereotypy sensitization vs. tolerance) has been examined without consi-
deration of other concomitant changes. For example, only a few investiga-
tors have attempted to sort out the conditioned effects in assessment of
sensitization and tolerance (Post et al. 1987; Ellinwood et al. 1973). One
goal of future research should be formulation of a clear concept of how the
changes induced by chronic stimulants integrate over time and which
mechanisms are “rate limiting” in induction of different functional changes.
In addition to interaction among different mechanisms, we need to consider
that there is a competitive economy of behaviors in the animal’s repertoire,
as these behaviors undergo time-dependent changes during chronic
administration. If a single behavior, such as stimulant stereotypy, comes to
the foreground, then other behaviors, such as locomotion or grooming, have
to recede into the background, thus leading to constriction of behavioral
repertoire. The response competition of species-specific behaviors
(Ellinwood and Kilbey 1979) is rarely considered, but it may be a major
contributor to the simultaneous appearance of tolerance and sensitization
reported in many of the basic laboratory studies.
This constriction of behavioral repertoire occurs in the clinical setting.
Examples include not only the compulsive profile of drug-seeking behaviors
(with exclusion of other types of behaviors) but also compulsive ritualistic
(1) “paranoid” thinking patterns, (2) sexual behavior, and (3) cleaning,
sorting, collecting, and grooming behaviors. These are the same behaviors
that rapidly reemerge shortly after readministration of drug following a long
period of abstinence. Unfortunately, we have no clear perspective on
whether or how central toxicity is involved in the initiation, maintenance, or
reemergence of these psychopathologic changes.
Although the sequential periods of withdrawal from chronic stimulants are
an integral part of an abuse pattern, detailed studies are lacking. In this
respect, we have recently demonstrated that DA autoreceptor sensitivity
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undergoes timedependent changes during withdrawal. Thus, 7-day infusion
of amphetamine induces marked subsensitivity of both terminal and soma-
dendritic DA autoreceptors immediately following the 7-day infusion; more
important, these receptors become supersensitive over the next 7 days
(Ellinwood and Lee 1983; Lee and Ellinwood 1989). This supersensitivity
is manifested by enhanced effects of apomorphine in inhibiting cell firing
and/or DA synthesis in the nigrostriatal and mesolimbic DA pathways. We
have questioned whether the increased autoregulation may in part underlie
the characteristic lethargy and loss of mental energy observed in human
stimulant abusers during the intermediate withdrawal phase (Gawin and
Ellinwood 1988). Enhanced autoregulation may lead to a decreased ability
to “turn on” the DA transmission-regulating behavioral arousal systems.
These functional changes due to changes in autoreceptor sensitivity or other
variables could prove to be an important factor in pathogenesis and rational
treatment of chronic stimulant syndrome.
CONCLUSION
Time is an important variable in the study of the neuropathological and
psychopathological changes noted in chronic stimulant syndromes. It is
important in (1) frequency, timing, and chronicity of dosing, (2) the
evolution of neuropathology and behavioral changes over time; and
(3) evaluation of reversible and residual stages of withdrawal. Careful
delineation of the changes at each stage of the ontogeny and withdrawal of
the stimulant syndrome is warranted. As is summarized in other chapters,
there are many residual pathological changes following chronic amphetamine
stimulant dosing. The relation of neuropathology to psychopathology in the
stimulant abuse syndrome and withdrawal is tantalizing, yet essentially
unknown. This lack of understanding of the relationship certainly applies to
functional changes such as autoreceptor alterations. Whether and how the
chronic waxing and waning atypical depression seen after withdrawal is
related to the stimulant-induced central toxicities demonstrated in laboratory
studies need to be determined. Is it related to the neuronal destruction
and/or monoamine depletion in the brain, is a chronic functional state (e.g.,
DA autoreceptor supersensitivity) sufficient to facilitate this behavioral state,
or is terminal depletion and some other change a necessary covariable?
More important, can we develop a rational approach that allows the
clinician to manipulate the mechanisms to prevent relapse? The marked
variability of therapeutic agents tried for the stimulant withdrawal period
(e.g., tricyclic antidepressants, monoamine oxidase inhibitors, DA agonists,
and uptake inhibitors) attests to our lack of understanding of the rate-
limiting mechanisms involved. Understanding of the relationship between
the neuropathological and functional changes noted with the stimulant of
these syndromes may lead to a more fundamental understanding of the
development of psychopathology in the psychoses and addictions in general.
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DISCUSSION
QUESTION: What is your view of the role of the supersensitive autorecep-
tor after 7 days? Can you precipitate or replicate a psychosis?
ANSWER: No, I am not relating it to psychosis.
COMMENT/QUESTlON: I was not relating it to psychosis either. I am
trying to put it in a functional context. Have you speculated about the role
of the supersensitive autoreceptor at that point? You could speculate early
on that the subsensitivity autoreceptor favors the potentiation of the
behavioral effect. But what might happen when it becomes supersensitive?
RESPONSE: We have primarily related it to the withdrawal phase of
fatigue and lethargy. We have a system that is set to turn itself off as
rapidly as possible. What are the treatments that reverse autoreceptor
supersensitivity? Thinking ideologically, to be hit with this huge dose of
amphetamine over and over again means doing whatever must be done for
the brain to turn off that response. If you take out the more sensitive
regulation, because these receptors are now supersensitive, you immediately
turn off the impulse coupled with the release of dopamine. If you give
even a small dose of amphetamine, you now have, if you are looking at
this neuron in isolation, a terminal that is not being regulated by impulse-
coupled mechanisms. I don’t know how important that is.
COMMENT: I would favor the view that lethargy and fatigue of post-
amphetamine withdrawal during the withdrawal phase would be consistent
with the shutting off of the dopamine neuron. Still, it is hard to imagine
how that would be. First, the amphetamine-induced release is not regulated
by the autoreceptor. And, as you say, if it would be impulse related,
however weak. it would be regulated. But we do know that after a period
of amphetamine intoxication, an individual is supersensitive behaviorally.
QUESTION: Are you talking about augmentation?
ANSWER: Yes. I am talking about the influence of a subsequent dose on
an individual who has had a repetitive binge of amphetamine. At that time,
he or she is withdrawn. Then he or she comes back and you can give a
relatively low dose that will reinstitute the endstage symptoms, as was being
discussed earlier.
COMMENT: That particular phenomenon, maximum sensitization of
augmentation, is best elicited by single daily doses. We were attempting to
mimic the high-dose continuous binge phenomenon where you sustain
plasma levels (in this case, for 7 days) with an Alzet pump. You don’t see
it going the same augmentation route in that regime. In these Alzet pump
animals, at the end of 7 days, even though they are getting about a
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5 mg/kg/day dose, there is very little stereotypy. There is massive
tolerance.
I am not relating primarily the amphetamine response or the subsequent
amphetamine response to this autoreceptor phenomenon. I have tried to say
that, in the beginning, when you give a substantial dose of amphetamine,
the autoreceptors are out of the picture. I don’t think they play a part. If
you give a substantial enough dose, it wipes out the autoreceptor response.
I don’t think that we are dealing with that part of the phenomenon. I hope
we are dealing with the beginning model for this loss of mental energy, the
incapacity of the normal responses during the intermediate withdrawal
phase.
QUESTION: Have you looked at the behavioral consequence of the low
dose of apolmorphine in these particular animals?
ANSWER: Yes. In very low doses it turns off the animals. We are
talking about 50, 75 µg, IV. So they are more sensitive to turning down
locomotion, which would fit in with the hypothesis that they would turn
themselves off before they turn on.
There is no way to explain sensitization tolerance using autoreceptors.
QUESTION: Could these changes in the autoreceptors account for the
cravings for cocaine or amphetamine? If you are shutting down dopamine
activity, that may lead to the desire to return to cocaine.
ANSWER: Yes. We think that it is a neat hypothesis. In the absence of
natural reinforcement forces, craving for cocaine becomes more intense. I
think one of the things that would be important is to figure out some way
of testing it.
QUESTION: A possibility that comes to mind is from reading
Dr. Larry Stein’s work. His theory of a reward system suggests that the
cerebral cortex has basically inhibitory behavioral characteristics. And that
the reward system, when it is activated, inhibits the cerebral cortex so that
there is an inhibition of an inhibitory mechanism, thus releasing behavior.
If that is a valid concept, could that have anything to say about the
consequence of this supersensitization having behaviorally inhibitory effects?
ANSWER: I think at this point that even Larry Stein would agree that the
norepinephrine is probably not the major mediator of the reward systems. I
think that we have enough evidence to indicate that is not the case.
QUESTION: If the reward system is not being activated, for whatever
reason, is dopamine considered to be more of a neurotransmitter of the
reward system?
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ANSWER: I think there is fairly good evidence that dopamine is
substantially involved.
QUESTION: If anything was preventing a reward system from being
operative, you would, perhaps, tend to see this inhibitory effect behaviorally.
With supersensitization, do you have this kind of a consequence to beat the
reward system not being activated?
ANSWER: Well, that certainly would be one of the things we would like
to find some way of testing specifically.
COMMENT: The main point that I wanted to make is that it is very im-
portant to attempt to develop models where one is looking at least at some
sort of in vivo integrated preparation. We look at serotonin depletion. We
look at dopamine depletion. We have a variety of different mechanisms.
Again we really do not know what, at this point in time, the serotonin
depletion is doing. I think I know what it means if you deplete dopamine
beyond a certain level. But even there, it is difficult to put an exact degree
of impairment on the levels of dopamine depletion that we see in most of
these models.
I would really like to see development of models that are explant or in vivo
models, where we can see the animal in a more integrated role and look at
the corresponding in vitro events.
I don’t think we know what the rate-limiting mechanisms are for most of
the behaviors that we think we are concerned with.
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Recommendations for Future
Research on Amphetamines and
Related Designer Drugs
Ray W. Fuller
INTRODUCTION
This volume has focused on several amphetamine analogs in addition to
amphetamine and methamphetamine, especially 3,4-methylenedioxymeth-
amphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA).
Among the pharmacologic actions of these drugs, their behavioral effects in
humans and in laboratory animals have been discussed, with some attention
to electrophysiologic and electroencephalographic effects. Other functional
effects, such as effects on neuroendocrine regulation, sleep, thermoregula-
tion. and appetite and body weight have not been discussed. Consideration
of toxic effects mainly focused on neurotoxic actions that the drugs can
have on specific brain monoaminergic neurons. In relation to this action,
two other amphetamine analogs, p-chloroamphetamine and fenfluramine,
have been compared because of their similar neurotoxic actions in rats.
SOCIAL IMPLICATIONS
General concerns about abuse of amphetaminerelated drugs are similar to
concerns about other illicit or addictive drugs. Dr. G. Nahas wrote an
editorial for the Wall Street Journal arguing that “a strongly expressed
sentiment of societal disapproval” of illicit drugs is necessary for prohibitive
measures to be effective (Wall Street Journal, July 11, 1988, p. 16). He
cited examples from history to support his contention that when illicit
addictive drugs are socially accepted and easily available, they have a very
damaging effect on individuals and on a society. His examples included the
use of cannabis in the Islamic-dominated world several centuries ago, the
chewing of coca leaf in Peru, the use of opium in China at the beginning
of this century, the epidemic of amphetamine abuse in Japan in the 1950s,
and others. In some cases, there was widespread social acceptance.
Although there is acceptance of MDMA and amphetamines in only limited
segments of our society, Nahas argues there is not forceful enough
disapproval of illicit drugs in general in our society today.
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The behavioral and dependence-producing effects of some of these drugs
can be damaging to individuals, but neurotoxic damage to particular brain
neurons can result when these drugs are given to animals, including
nonhuman primates. There continue to be inadequate data about whether
such damage occurs in humans.
Patterns of Abuse of Amphetamine Analogs
The need for more accurate and precise information about human use of
MDMA and MDA was aptly stated by Dr. Gawin (this volume) and others.
There is a general perception that these drugs are widely used, especially on
college campuses, but there are relatively few hard data on the geographic
distribution of use, on the pattern(s) and frequency of use, the doses used,
and so on. For many reasons, such information is needed.
Behavioral Effects of Amphetamines: How Useful, What Mechanisms?
The behavioral effects of amphetamine, methamphetamine, MDMA, MDA,
p-chloroamphetamine, and fenfluramine are not identical. Except for the
last drug, all can cause some degree of behavioral stimulation, but exact
behavioral effects differ markedly. More complete definition of their
behavioral differences is a prerequisite to a better understanding of the
mechanism(s) of these drugs.
Apparently there are psychiatrist and nonpsychiatrist clinicians whose
experience convinces them that MDMA can have therapeutic uses, mainly
as an adjunct to psychotherapy. Despite these convictions, there appear to
be no published data to support these claims. There is an urgent need for
objective data from well-controlled, blinded clinical studies, if these claims
of therapeutic usefulness are to be taken seriously. If a bona fide use is
evident, then it may be possible to produce other drugs with the same
desirable action, lacking the toxicity inherent in MDMA.
NEUROCHEMICAL MECHANISMS
Aside from the therapeutic usefulness of MDMA, there is scientific
importance to elucidating further the mechanism(s) involved in the
seemingly unique behavioral effects of MDMA and MDA. Apparently, a
major action of these drugs is the release of serotonin and dopamine from
brain neurons, leading to enhanced serotonergic and dopaminergic input to
those neuronal systems with which they make synaptic contact. In addition,
MDMA has been shown to interact in vitro with sites including 5HT2,
5HT1A, and adrenergic receptors, among others (Battaglia, this volume).
Do those interactions occur in vivo, and does MDMA interact as an agonist
or as an antagonist at these sites? If the interactions occur in vivo, how do
they contribute to the profile of behavioral effects of MDMA? These
questions can and should be approached experimentally. Further unraveling
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of the effects of MDMA and MDA on serotonergic and dopaminergic
function is also needed. Serotonin neurons and dopamine neurons are
known to interact in many brain regions (Bosler et al. 1984; Benkirane
et al. 1987; Herve et al. 1987), so the release of dopamine may influence
serotonergic function, just as the release of serotonin may influence
dopaminergic function.
Neurotoxicity of Amphetamines
The recognition that amphetamines can be neurotoxic in brain can be traced
back to p-chloroamphetamine studies. In the middle 1960s, p-chloroamphet-
amine and p-chlorometbamphetamine were found to cause selective deple-
tion of brain serotonin (Pletscher et al. 1963; Fuller et al. 1965). The long
duration of this depletion was not appreciated until later (Sanders-Bush
et al. 1972). and it was subsequently established that the loss of serotonin
was accompanied by changes in other parameters specifically associated
with serotonin neurons, e.g., a loss in tryptophan hydroxylase, a loss in
serotonin uptake capacity, and a reduction in serotonin turnover, as well as
by histologic evidence of neurotoxicity (Puller and Snoddy 1974; Harvey
et al. 1975; Sekerke et al. 1975; Massari et al, 1978). Fenfluramine was
recognized to have similar effects on brain serotonin neuron parameters
(Harvey and McMaster 1975; Clineschmidt et al. 1978), although there has
been controversy about histologic changes (Sotelo and Zamora 1978).
During the 1970s, evidence accumulated that amphetamine and methamphet-
amine could also be neurotoxic (Ellison et al. 1978; Hotchkiss and Gibb
1980; Wagner et al. 1980). The effects of amphetamine seem mostly
limited to dopamine neurons, whereas methamphetamine affects dopamine
and serotonin neurons (Warren et al. 1984). Most recently, MDMA and
MDA have been shown to produce neurotoxicity toward brain serotonin
neurons much like that of the halogenated amphetamines (Ricaurte
et al. 1985; Stone et al. 1986).
Role of Uptake Carriers
The neurotoxic effects of all these compounds are antagonized by inhibitors
of monoamine uptake (table 1), implicating the membrane uptake carrier on
serotonin and dopamine neurons in the mechanism of neurotoxicity. In this
regard, these amphetamines are like a drug somewhat related in structure,
namely 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a
Parkinsonism-causing neurotoxic drug that has been studied intensely since
1983 (Langston and Irwin 1986). In the case of MPTP, the mechanism by
which inhibitors of the dopamine uptake carrier block the neurotoxicity
toward dopamine neurons (mainly nigrostriatal dopamine neurons) seems
clear. A metabolite of MPTP, l-methyl-4-phenylpyridinium (MPP+), has
been shown to be a substrate for the dopamine uptake carrier (Javitch
et al. 1985). Thus accumulation of MPP+, formed metabolically from
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MPTP, into dopamine neurons seems to be essential, and blockade of that
accumulation prevents the neurotoxicity. MPP+ also can be transported into
norepinephrine neurons (Javitch et al. 1985), leading to neurotoxicity toward
cortical norepinephrine neurons, an effect blocked by inhibitors of the
norepinephrine uptake carrier (Sundstrom and Jonsson 1985).
TABLE 1. Characteristics of monoaminergic neurotoxicity induced by
amphetamine and related compounds in laboratory animals
Membrane Uptake Carrier Drug Metabolite
Drug Involved in Neurotoxicity Involved in Neurotoxicity
Amphetamine Yes
Methamphetamine Yes
MDMA, MDA Yes
p-Chloroamphetamine Yes
Fenfluramine Yes
MPTP Yes Yes
The mechanism by which uptake inhibitors block the neurotoxic effects of
amphetamine, methamphetamine, MDMA, MDA, p-chloroamphetamine, and
fenfluramine is not so clear. A simple explanation (analogous to that with
MPTP) might be that these drugs are accumulated into serotonin or
dopamine neurons via the membrane uptake carrier, and that uptake
inhibitors prevent the neurotoxicity by preventing that accumulation.
However, none of these compounds have been shown to be a substrate for
dopamine or serotonin uptake carriers. Their lipophilicity leads one to
believe they would enter neurons readily without requiring active transport.
There may be, however, both entry and accumulation of these drugs. It is
conceivable that the amphetamines do enter brain monoaminergic neurons
and other cells by passive diffusion. They may in addition be accumulated
by brain monoaminergic neurons, if amphetamines are substrates for the
membrane uptake carriers. For example, p-chloroamphetamine may enter all
cells, but may be selectively concentrated in serotonin neurons, due to its
accumulation via the membrane uptake carrier. That concentration may be
required for the short-term and long-term depletion of brain serotonin, so
that inhibition of the uptake carrier blocks the depletion. No direct
evidence to support this possibility is available. Uptake of radioactive
p-chloroamphet-amine by the serotonin uptake carrier has not been shown in
vitro, although p-chloroamphetamine does have high affinity for that carrier
(Wong et al. 1973).
There has been some evidence that p-chloroamphetamine is preferentially
localized in synaptasomal fractions of brain homogenates (Wong
et al. 1972), and recently Ask and Ross (1987) have published evidence
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consistent with an accumulation of pchloroamphetamine in serotonergic
synaptosomes in vitro. They evaluated the ability of reversible inhibitors of
monoamine oxidase to be accumulated in serotonin nerve endings by the
membrane uptake carrier by comparing two conditions of serotonin
deamination: first, when the radioactive serotonin was being deaminated,
mainly inside serotonergic synaptosomes, after it was accumulated via the
uptake carrier; and second, when serotonin was being deaminated by other
synaptosomes, because its transport via the serotonin uptake carrier was
blocked. In this way, they evaluated the ability of certain reversible
inhibitors of monoamine oxidase to be themselves concentrated in seroto-
nergic synaptosomes due to their transport via the membrane uptake carrier.
Study of p-chloroamphetamine, which is a reversible inhibitor of monoamine
oxidase (Fuller 1978), did indicate accumulation within serotonergic
synaptosomes.
Further investigation of the possibility that inhibitors of the serotonin uptake
carrier protect against serotonin depletion by p-chloroamphetamine, fenflur-
amine, MDMA, MDA, and methamphetamine because they prevent the
accumulation of those drugs within serotonin nerve terminals is warranted,
but at present compelling evidence for this mechanism does not exist.
Possible Role of Dopamine Release
A second possible mechanism, supported by some existing data on metham-
phetamine and MDMA, is that these drugs release dopamine, which is then
taken up into serotonin neurons via the membrane uptake carrier, leading to
neurotoxic effects on the serotonin neurons. Inhibitors of dopamine
synthesis or of the dopamine uptake carrier, e.g., -methyltyrosine and GBR
12909, have been reported to prevent the depletion of serotonin by metham-
phetamine and by MDMA (Schmidt et al. 1985; Gibb et al., this volume).
MDMA does release dopamine both in vitro and in vivo (Yamamoto and
Spanos 1988). Dopamine can be transported into serotonergic synaptosomes
(Schmidt and Lovenberg 1985). Further investigation is needed, especially
to see if the involvement of dopamine is a general phenomenon in the
neurotoxic effects of amphetamines. We have found that potent inhibitors
of dopamine uptake, including mazindol and nomifensin, block depletion of
striatal dopamine by MPTP in mice, but do not block depletion of brain
serotonin by p-chloroamphetamine in mice.
Possible Role of an Active Metabolite of the Drug in the Neurotoxicity
of Amphetamine Analogs
The possibility that an active metabolite is involved in the neurotoxic effects
of amphetamine analogs receives limited discussion in this chapter and has
been considered previously, especially with p-chloroamphetamine (Miller
et al. 1986.) Partly because the chemical structures of these amphetamines
do not suggest ways in which they would be toxic to neurons, the
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possibility that conversion to a more reactive metabolite accounts for the
neurotoxicity has been attractive. The study of numerous analogs of
p-chloroamphetamine and other neurotoxic amphetamines has not yielded a
strong candidate for such a neurotoxic metabolite. Most potential
metabolites of p-chloroamphetamine caused less depletion of serotonin
(Fuller 1978). Although N-hydroxy-p -chloroamphetamine did deplete
serotonin, it was metabolized rapidly and almost quantitatively to
p-chloroamphetamine (Fuller et al. 1974). Inhibitors and inducers of drug
metabolism have generally failed to influence neurotoxicity of ampheta-
mines. MDA is metabolixed to a-methyldopamine (Marquardt et al. 1978;
Midha et al. 1978), a metabolite that should be considered as a possible
mediator of neurotoxicity, especially in view of the properties of dopamine
discussed below.
Involvement of a Metabolite of the Neurotransmitter in the
Neurotoxicity of Amphetamines
Also a possibility is that a product formed from one of the neurotransmit-
ters affected mediates the neurotoxic effects of amphetamines. This
possibility was suggested by Seiden and Vosmer (1984), who reported the
presence of 6-hydroxydopamine in the rat caudate nucleus after a single
injection of a high, neurotoxic dose of methamphetamine. They suggested
that 6-hydroxydopamine was formed from endogenous dopamine released by
methamphetamine and that the 6-hydroxydopamine was responsible for the
neurotoxicity to dopaminergic terminals. Other investigators have not found
6-hydroxydopamine to be present in rat striatum after amphetamine or meth-
amphetamine administration (Rollema et al. 1986).
Commins et al. (1987) have also reported the formation of 5,6-dihydroxy-
tryptamine in rat hippocampus after a single, high doses of methampheta-
mine. They suggested that the formation of 5,6-dihydroxytryptamine, a
known neurotoxic substance, may mediate the neurotoxic effects of
methamphetamine toward serotonergic nerve terminals.
Molliver (this volume) made the provocative suggestion that a metabolite of
serotonin released from blood platelets by p-chloroamphetamine may
mediate the neurotoxic effects of p-chloroamphetamine on cortical seroto-
nergic neurons in the rat. Such a possibility would be compatible with the
observations of Molliver and his colleagues (this volume) that p-chloroam-
phetamine is not effective when pumped directly into the brain or when
added to brain slices in vitro. Their demonstration that a combination of
p-chlorophenylalanine and reserpine prevented the neurotoxic effects of
p-chloroamphetamine led them to suggest that platelet serotonin stores were
involved in the neurotoxic mechanism (Berger et al., submitted for publica-
tion). This interesting idea deserves testing in various ways. Since it
would not cross the blood-brain barrier, 5,6-dihydroxytryptamine would not
346
seem to be a candidate for their hypothesized metabolite, unless the
integrity of that barrier had been lost due to the drug treatment.
Role of Dopamine Involvement in the Neurotoxicity of Amphetamines
Some data suggest that dopamine itself is involved in certain of the
neurotoxic effects. It is worth asking if dopamine might account for the
neurotoxicity of all the amphetamine analogs toward both dopaminergic and
serotonergic neurons. At least three ways in which dopamine might lead to
cytotoxicity have been suggested, First, dopamine might be converted to
6-hydroxydopamine, a known neurotoxin, as discussed above. Second,
dopamine metabolism by monoamine oxidase is known to produce hydrogen
peroxide, and excess hydrogen peroxide formation from this source might,
under some conditions, have deleterious effects on the cell (Cohen and
Mytilineou 1985). Third, dopamine itself is known to undergo auto-
oxidation analogous to, but slower than, that of 6-hydroxydopamine
(Graham et al. 1978; Graham 1984). Persistently increased intraneuronal
but extragranular concentrations of dopamine due to amphetamine-induced
release of granular stores of dopamine and protection against dopamine
oxidation by monoamine oxidase type A have been suggested as possibly
mediating the neurotoxic effects of amphetamine (Fuller and Hemrick-
Luecke 1982). Uptake of dopamine into serotonergic terminals (Schmidt
and Lovenberg 1985) might lead to destruction of serotonergic terminals
after treatment with drugs like methamphetamine and MDMA. It is not
clear why such effects should be less with amphetamine than with metham-
phetamine, yet amphetamine seems to affect dopaminergic neurons
primarily, whereas methamphetamine is neurotoxic toward serotonin neurons
as well as dopamine neurons (Hotchkiss and Gibb 1980; Ricaurte
et al. 1984). Investigation of the possible involvement of dopamine in the
different neurotoxic process is needed.
IMPLICATIONS OF NEUROTOXICITY
Functional Deficits Resulting from Amphetamine Neurotoxicity
Rats that have lost dopamine and/or serotonin terminals following treatment
with amphetamine, methamphetamine, MDMA, MDA, p-chloroamphetamine,
or fenfluramine show little in the way of overt changes in appearance or
behavior. Dr. Ricaurte (this volume) emphasized the need for more studies
in primates, since MPTP-treated mice also show little in the way of
observable functional changes, whereas MPTP-treated monkeys show marked
neurologic deficits. It may be necessary to do more detailed analysis of
specific behaviors and other functional outputs that are influenced by
dopamine and/or serotonin neurons, to detect functional deficits induced by
some neurotoxic drugs. For instance, specific behaviors such as appetite-
controlled behavior (Leibowitz and Shor-Posner 1986), muricidal behavior
(Katz 1980), and sexual behavior (Tucker and File 1983) elicited by drugs
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or environmental conditions ate known to be influenced by serotonergic
input. Careful analysis of these behaviors in rats that have received
neurotoxic doses of p-chloroamphetamine, MDMA, MDA, fenfluramine, or
methamphetamine may reveal functional deficits. Electroencephalographic
patterns, nociception, sleep, thermoregulation, and endocrine regulation are
other brain-controlled functions that are influenced by serotonergic pathways.
Careful studies of these functions, especially measuring responses elicited by
serotonergic drugs or by environmental stimuli whose actions are mediated
by serotonergic systems (insofar as that is known) may reveal functional
deficits associated with loss of serotonergic terminals. For example, we
have found that the acute increase of serum corticosterone in rats given
p-chloroamphetamine, an increase that appears to be mediated by release of
serotonin from central neurons making input to cells that release cortico-
tropin-releasing factor in the hypothalamus, is blunted in rats pretreated with
a neurotoxic dose of p-chloroamphetamine. There are few examples of
studies of this sort, in which a functional correlate of the loss in serotonin
content has been sought in rats that have received neurotoxic doses of any
of the amphetamine analogs in question. It seems important for such
studies to be done for several masons, including the goal of learning more
about physiologic functions of the serotonin and dopamine pathways that are
affected, and to suggest ways in which possible neurotoxicity in humans
might be investigated.
Does Neurotoxicity Occur in Humans
All the neurotoxic drugs discussed have been taken by human subjects.
Amphetamine and methamphetamine have a long history of therapeutic use
along with illicit misuse. To a limited extent, p-chloroamphetamine has
been used in humans as an investigational drug (Van Praag et al. 1971).
MDMA and MDA have no approved medical uses, but they appear to be
rather widely abused drugs at present. Fenfluramine continues to be
marketed as an appetite suppresant A key question, to which there is no
current answer, is whether any of these drugs produce, in humans, neuro-
toxic effects on dopamine and/or serotonin neurons in brain analogous to
those produced in rodents and in nonhuman primates (table 2). It is
remarkable that no data exist on this issue, given that the neurotoxic effects
of some of these drugs in animals have been know for more than a
decade.
There are several ways in which possible neurotoxic effects might be
studied. First, measurement of cerebrospinal fluid concentrations of
dopamine or serotonin metabolites would be a straightforward way of
assessing neurotoxicity. There are pitfalls in this approach (as outlined by
Dr. Ricaurte (this volume), such as the facts that lumbar cerebrospinal fluid
might reflect spinal cord neurochemistry more than it reflected brain
neurochemistry, and drugs like p-chloroamphetamine affect serotonin
neurons in spinal cord less than they do those in brain (Sanders-Bush
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et al. 1975). Nonetheless, fenfluramine has been shown to produce marked
decreases in 5-hydroxyindoleacetic acid concentration in the cerebrospinal
fluid during treatment (Shoulson and Chase 1975), and it would be
important to know if those concentrations return to control levels when
fenfluramine is discontinued.
TABLE 2. Nature of neurotoxic damage to brain monoaminergic neurons
Drug
Brain Monoaminergic Neurons Neurotoxicity Occurring
Showing Neurotoxic Damage in Humans
Amphetamine Dopamine
Methamphetamine Dopamine, Serotonin
MDMA, MDA Serotonin
p-Chloroamphetamine Serotonin
Fenfluramine Serotonin
MPTP Dopamine, Norepinephrine Yes
A second approach might be to measure dopamine and serotonin along with
their metabolites and other specific neuronal constituents such as tyrosine
hydroxylase and tryptophan hydroxylase or uptake carrier sites in brain
tissue obtained at autopsy. Accumulating data in this way might be a slow
and tedious process, and drug dosing history might be uncertain and
variable; nonetheless, the approach deserves consideration.
A third approach would be to measure some indicator of functional output
of dopamine and/or serotonin neurons. As mentioned previously, studies in
laboratory animals can be invaluable in defining parameters that change in
correlation with directly measurable neurotoxic effects in the brain.
Changes in serum hormones elicited by a drug whose effects are mediated
by dopamine or serotonin neurons are especially attractive possibilities, since
these changes are already being used as a means of assessing the functional
state of brain serotonergic pathways (Siever et al. 1984). In this regard, it
is intriguing that Coccaro et al. (1987) have observed recently a blunted
elevation in serum prolactin concentration elicited by fenfluramine in
psychiatric patients who had received a previous dose of fenfluramine
within a 12-day period. While there may be numerous possible explana-
tions, one could be that the first dose of fenfluramine had damaged or
destroyed a traction of the serotonin neurons from which release of
serotonin is the mechanism of prolactin elevation by fenfluramine.
A fourth approach to evaluating the intactness of dopamine and/or serotonin
neurons in human subjects who have taken one of the amphetamine analogs
might be to use a probe for labeling a constituent of those neurons in
position emission tomography scanning studies. A label for the serotonin or
dopamine uptake carrier, or a label for tryptophan hydroxylase or tyrosine
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hydroxylase, would be an ideal agent for use in studies of this sort. Such
methods are not currently available, but the possibilities for development of
methods like this seem excellent.
DISCUSSION
COMMENT: I would like to know why you thought the amphetamine
model of dopamine neurotoxicity might be more suitable or more revealing
for the study of Parkinson’s disease than the MPTP model.
RESPONSE: We do not understand all there is to know about the
mechanisms of MPTP neurotoxicity. but it seems to involve MPP+, which
is potentially cytotoxic to all cells but that attains toxic concentrations after
MPTP administration only in cells that concentrate MPP+. Dopamine
apparently is not involved in the neurotoxic effects of MPTP. I am
attracted to the idea that dopamine itself may be involved in the etiology of
Parkinson’s disease, that dopamine neurons may be at risk because of the
nature of their neurotransmitter.
If there is anything to that line of thought then I am suggesting that the
exact mechanisms involved in MPTP may not be like the mechanisms that
are involved in the &generation of those dopamine neurons in Parkinson’s
disease. And that something like amphetamine neurotoxicity might have
closer parallels to the degeneration in Parkinson’s disease. That
presupposes the way the story is going to end and obviously I don’t know
that any more than anybody else does.
I have argued in the past that looking further at amphetamine toxicity in
terms of understanding the mechanism by which those neurons die, might
be more revealing. That is not to belittle the importance of MPTP as a
model of Parkinson’s disease. Certainly in terms of effects in the MPTP-
treated monkeys, these animals are of unquestioned value. But in terms of
the mechanism by which the neurons die, that was the point that I was
questioning, whether the MPTP model would mimic as well as the
amphetamine model.
QUESTION: You mentioned the N-hydroxy parachloroamphetamine. Is it
less or more toxic than PCA?
ANSWER: The same. And the reason is that it is converted very rapidly
to PCA itself almost quantitatively.
QUESTION: If the oxidation of dopamine is proving to be toxic, are there
any natural endogenous substances or nutrients that can help prevent that?
Is it possible that perhaps ascorbic acid would keep the dopamine from
being metabolized or oxidized?
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ANSWER: I think that is an interesting possibility, since cells presumably
have some kind of cytoprotective mechanism. It is possible that in patients
predisposed to Parkinson’s disease there is some breakdown of the patients’
protective mechanisms in those neurons. That might be a reason why they
develop the disease. Fortunately, all of us don’t. I think we simply don’t
know. We should consider all possibiiities.
COMMENT: I would like to follow up with the point that Dr. Rebec,
from the University of Indiana, made here at the NIH in January. The
topic of his talk was ascorbic acid and dopamine in schizophrenia. In
experimenting with amphetamine, he was finding with individual neuron
investigation that amphetamine, in both low and high doses, was inhibitory
in some neurons. In other neurons it was inhibitory in low doses, and in
high doses it became excitatory. But in this investigation he claimed that
he was finding some substance in the brain that was counteracting the effect
of the amphetamine and, by analysis, he said it was determined to be
ascorbic acid.
Now the use of molecular psychiatry of ascorbic acid in schizophrenia by
Linus Pauling and others, where there seems to be some relationship to
dopamine neurons, and fmding that dopamine-dopaminergic neurons or
receptors are present in twice the normal amount, makes this an intriguing
area of investigation.
Dr. Rebec also said that the brains on post mortem studies of
schizophrenics tended to be mushy and to have very low levels of ascorbic
acid in their constituent tissue.
RESPONSE [FROM AUDIENCE]: We tried an opposite strategy where we
made guinea pigs scorbutic. We deprived them of their scorbic acid
contents, then exposed them to amphetamine. In those studies we found
that the ascorbutic animals were protected from some of the neurotoxicities
of the amphetamines. It is a very complex issue. It is not just a matter of
adding vitamin C or ascorbic acid and getting protection; it can work as a
double-edged sword. It can work for or against you.
QUESTION: Has anyone given an uptake blocker in the chronic state?
You showed that in the acute stage that you could get some reversal
effects. Has anyone administered an uptake blocker after chronic use of
amphetamines?
ANSWER: Even after one dose of p-chloroamphetamine, the depletion of
brain serotonin cannot be reversed at later times. You lose the reversibility
after several hours.
QUESTION: Totally lose it?
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ANSWER: Yes. So I feel very sure that in the chronic state there will
come a time when this is not reversible.
QUESTION: We have all these theories about serotonin being involved in
depression. Do you have any explanation for why depression is not seen in
humans if serotonin neurons have been damaged by these drugs?
ANSWER: I think that clearly it is possible that there is no neurotoxicity
in humans. I think all of us would like for this to be the case. And
maybe it is the case. We have talked about this a lot with fenfluramine,
and we have done studies with parachloroamphetamine in which we have
given it orally to rats at relatively low doses, but still anorectic doses, over
90 days. We have seen depletion of serotonin, but that was fully reversible
depletion. It came back when the drug was stopped. I think there may be
no neurotoxicity at the oral doses used in humans. I think that would be
great if that is the case. That would explain why there is no depression or
other kinds of symptoms. But I don’t feel comfortable about relying on the
lack of reporting of depression as real evidence that there is no
neurotoxicity. We simply need to have better data on that.
COMMENT: I think another matter to take into account is that, at least
from the experience of dopamine systems, in order to get overt behavioral
dysfunction you really need a pretty whopping lesion. In the primate, to
get the kind of Parkinsonism that people talk about in animal models, that
animal model actually turns out to be very difficult to produce in chronic
Parkinsonism. The problem is developing an animal that has 90 to
95 percent depletion of dopamine on a chronic basis. As you know, it is a
very narrow window, and it is very difficult to produce that kind of animal
preparation. So I think you have to consider the possibility that lack of
symptoms after serotonergic lesions could, perhaps, be related to the fact
that we are dealing with preparations where there is a 50, 60, 70 percent
depletion where we don’t have enough of a lesion to produce an overt
behavioral disturbance.
RESPONSE: Perhaps I can bridge the dispute by suggesting it is probably
going to vary among neuronal systems. There may be systems in which
you must have a lot of depletion to see a functional change, and there may
be others where it doesn’t take very much.
COMMENT: I would dispute it within the dopamine system itself. And I
would dispute it about Parkinson’s disease. I think that if you did a proper
neuropsychological exam that you would pick up even smaller depletion
effects. I think if you are looking for an overt complete terminal Parkinson
situation, yes, you need a 99 percent depletion. But part of the problem is
that the Parkinson situation involves not only the nigrostriatal system but
also the mesolimbic dopamine system. There are plenty of studies in rats,
and it is very easy to produce a Parkinsonian rat with a very discrete
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injection of 6-hydroxydopamine in the right place. It doesn’t require a lot
of work. I can take 2 micrograms of 6-hydroxydopamine and put it in
exactly the right location in the ventral tegmental area, and I can produce a
Parkinsonian rat that will die,
So I think you can debate that issue about 99 or 95 percent depletion. I
think that if you probe those animals with the proper pharmacological
agents and proper environmental situation, you will pick up deficits. I think
the lack of knowledge about what the serotonin systems do is the basis of
the problem here. We don’t know what the behavioral consequences of the
serotonin depletion are.
How are we going to probe a person’s gestalt? I think that was brought
out earlier. If we had proper probes we might see the effects. If we have
proper probes for exaggerating serotonergic function or proper probes for
exaggerating deficits associated with serotonergic function we would easily
pick up things. Whether that is important or not, you know it might be
good to trim our serotonin neurons slightly. Maybe we would be better off.
Maybe we would all be somewhat anxiolysed. That is another question.
But I think we have the tools in behavioral pharmacology to conduct tests
in rats that will be sensitive to serotonin depletion. And I assume that
those can be extrapolated to primates.
COMMENT: One of the problems that we have not addressed is the issue
of potential recovery and regeneration.
One of the striking aspects of this toxicity of compounds is selective
destruction terminals and the cell bodies that are left intact. Dr. De Souza
has recently reported some biochemical evidence for recovery of serotonin.
We have now found anatomic evidence for reinnervation of depleted areas
by serotonin neurons. But it is going to be a while before we figure out
whether their reinnervation is appropriate or perhaps aberrant. Do they end
up with complete recovery, do they end up with a better system than they
started with or one that malfunctions? I think that is an important area for
future study.
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